Studies in GIST with emphasis on treatment response evaluation with FDG PET. by Revheim, Mona-Elisabeth
 Studies in GIST with emphasis 
on treatment response 
evaluation with  
FDG PET 
 
 
MONA-ELISABETH REVHEIM, MD 
 
 
DEPARTMENT OF RADIOLOGY AND NUCLEAR MEDICINE 
OSLO UNIVERSITY HOSPITAL 
 
 
INSTITUTE OF CLINICAL MEDICINE 
FACULTY OF MEDICINE 
UNIVERSITY OF OSLO 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Mona-Elisabeth Revheim, 2013 
 
 
Series of dissertations submitted to the  
Faculty of Medicine, University of Oslo 
No. 1492 
 
ISBN 978-82-8264-228-6 
 
 
All rights reserved. No part of this publication may be  
reproduced or transmitted, in any form or by any means, without permission.   
 
 
 
 
 
 
 
 
Cover: Inger Sandved Anfinsen. 
Printed in Norway: AIT Oslo AS.  
 
Produced in co-operation with Akademika publishing.  
The thesis is produced by Akademika publishing merely in connection with the  
thesis defence. Kindly direct all inquiries regarding the thesis to the copyright  
holder or the unit which grants the doctorate.   
 
ϯ

ACKNOWLEDGEMENTS 
 
The work presented in this thesis was conducted at the Oslo University Hospital 
between January 2009 and September 2012. The unrestricted research grant 
received from The Norwegian Radium Hospital Research Foundation 2010 – 2012 
is gratefully acknowledged. 
 
First, I would like to thank my main supervisor, Associate Professor Therese 
Seierstad. She has been a constant presence throughout my time conducting this 
thesis and has kept me motivated, challenged and productive at all times. Her 
scientific assistance and moral support go well beyond the expectation of a PhD 
supervisor. Not only has she been a great scientific advisor, but she has also 
become a good friend. 
 
I am grateful to my co-supervisor Professor Øyvind Bruland who took the chance 
to hire me. He has the ability to balance between broad visions and realistic 
perspectives, and he has given me the tools to continue an academic career. 
Thank you for always being positive and supportive. I believe that we have 
established a very good relationship that will last and result in more quality work. 
 
I also want to acknowledge and thank Professor Jan Gunnar Fjeld and Professor 
Emeritus Kjell Rootwelt for their careful and constructive reviews. Their comments 
and suggestions have contributed to clarify certain aspects and strengthen the 
thesis. Jan Gunnar Fjeld has been both co-supervisor and an understanding boss. 
 
A special thanks to Dr. Tore Bach-Gansmo with his enthusiasm and wild ideas that 
got me interested in research. He was also the man behind the establishment of 
the human GIST xenograft used in this thesis. A special thanks also to Knut Håkon 
Hole, MD, who has given me a broader understanding of oncological imaging. 
Professor Heikki Joensuu’s experience and knowledge in oncology in general and 
GIST in particular have been invaluable. He is the man behind the “targeted” GIST 
history and I am very grateful for his contribution and for translating the findings 
from paper III into a clinical understanding. I feel lucky to have worked together 
ϰ

with Professor Arne Skretting, and I highly appreciate his willingness to share the 
great knowledge he has about imaging. 
 
I would also like to express my sincere thanks to my other co-authors Dr. Kathrine 
Røe, Professor Eirik Malinen, Bodil Bjerkehagen MD, Alexandr Kristian MSc, Hege 
Oma Ohnstad MD, Dr. Ruth Holm, Dr. Kirsten Sundby Hall, Dr. Hans Kristian 
Haugland, radiographer Edmund Reitan and Lars Julsrud MD. 
 
Without the help and willingness from chief engineer Kari Bjering (DnR), leading 
nuclear medicine technologist Randi Forfang (RH) and the nuclear medicine 
technologists at the Department of Nuclear Medicine, DnR and RH in performing 
the studies, spending extra hours performing more PET acquisitions and taking 
care of the patients, this work would not have been possible. 
 
Thanks to Ph.D-student Kjersti Johnsrud MD, for motivations and fruitful 
discussions and Dr. Trond Velde Bogsrud who walked the path before me. To all 
my colleagues at the Department of Nuclear Medicine who gave me the time to 
fulfill this thesis while their own rightful senior leave was put on hold: Thanks for 
believing in me. 
 
I also want to acknowledge and thank Senior Medical Photographer Øystein H. 
Horgmo, at the Medical Photography Section, Institute of Clinical Medicine and the 
library staff at the University of Oslo Medical Library.  
 
I am most indebted to my mother in law, Vesla Rootwelt MD. Without her big 
contributions to family logistics and true love for her grandchildren this work would 
not have been possible. “Paps”, thanks for your support and pride during many 
years of school and education – and now this. 
 
Finally, I am very grateful to Henni, Ask and Terje for their patience and love. 
 
I sincerely thank you all, 
 
Mona-Elisabeth 
ϱ

 
TABLE OF CONTENTS 

ACKNOWLEDGEMENTS........................................................................................3 
TABLE OF CONTENTS ..........................................................................................5 
ABBREVIATIONS ...................................................................................................9 
LIST OF PAPERS .................................................................................................11 
1. INTRODUCTION...............................................................................................12 
2. BACKGROUND.................................................................................................14 
2.1. GIST............................................................................................................14 
2.1.1. The history of GIST...............................................................................14 
2.1.2. Epidemiology ........................................................................................15 
2.1.3. Risk stratification...................................................................................16 
2.1.4. Molecular pathogenesis ........................................................................17 
2.1.5. Clinical presentation..............................................................................20 
2.1.6. Treatment of GIST ................................................................................20 
2.1.7. Development of resistance ...................................................................23 
2.1.8. Approaches to combat imatinib resistance ...........................................24 
2.1.9. Treatment response evaluation ............................................................25 
2.2. Imaging of GIST..........................................................................................29 
2.2.1. CT .........................................................................................................29 
2.2.2. PET.......................................................................................................30 
2.2.3. MRI .......................................................................................................38 
2.2.4. Combination of PET and CT (or MRI) ...................................................39 
2.2.5. Xenograft models..................................................................................40 
3. AIMS OF THE THESIS......................................................................................41 
4. MATERIALS AND METHODS...........................................................................42 
4.1.1. The AHAX xenograft .............................................................................43 
4.1.2. Animals .................................................................................................43 
4.1.3 Implantation ...........................................................................................43 
4.1.4. Anesthetics ...........................................................................................43 
4.1.5. TKI treatment ........................................................................................44 
4.1.6. PET examination...................................................................................44 
ϲ

4.1.7. Tumor to liver ratio ................................................................................46 
4.1.8. Gamma counter ....................................................................................46 
4.1.9. Histology and immunohistochemistry....................................................47 
4.1.10. Polymerase chain reaction (PCR) and sequencing.............................47 
4.2. Human studies ............................................................................................48 
4.2.1. Patients.................................................................................................48 
4.2.2. TKI treatment ........................................................................................48 
4.2.3. Imaging .................................................................................................48 
5. SUMMARY OF PAPERS...................................................................................50 
6. DISCUSSION....................................................................................................54 
6.1. Animal studies.............................................................................................54 
6.1.1. Xenografts ............................................................................................54 
6.1.2 Animal handling .....................................................................................55 
6.1.3. PET imaging of mice.............................................................................57 
6.1.4. Dynamic small animal PET ...................................................................58 
6.2. Human studies ............................................................................................59 
6.2.1. Patients.................................................................................................59 
6.3. Representative tissue samples ...................................................................61 
6.4. Prediction of treatment response ................................................................61 
6.4.1. Prediction of treatment response with PET...........................................61 
6.4.2. Prediction of treatment response with CT .............................................63 
6.4.3. Prediction of treatment response with DW MRI ....................................63 
6.5. FDG PET quantification ..............................................................................66 
6.5.1. SUV measurements..............................................................................66 
6.5.2. Partial volume effect or intensity diffusion.............................................69 
6.5.3. Blood glucose level ...............................................................................70 
6.5.4. Selection of ROI....................................................................................70 
6.5.5. EORTC and PERCIST criteria – application to GIST............................71 
6.5.6. Motion correction and precise co-registration between PET and CT ....73 
6.5.7. FDG ......................................................................................................74 
6.5.8. Correlation between FDG and GLUT expression in GIST ....................74 
6.6. Mutation type...............................................................................................77 
7. CONCLUSION ..................................................................................................78 
8. FUTURE PERSPECTIVES ...............................................................................80 
ϳ

8.1. Tailored PET protocols ............................................................................80 
8.2. New radiopharmaceuticals and new applications ....................................81 
8.3 Improved technology.................................................................................84 
8.4. Novel targeted therapies..........................................................................86 
8.5. Response to TKI therapy .........................................................................86 
8.6. Imaging guided personalized medicine....................................................86 
8.7. Main message .........................................................................................88 
9. REFERENCES..................................................................................................89 
10. PAPERS........................................................................................................107 

 
 


 
 
 
 
 
 
 
 
 
 
 
ϴ

 
 
 
 
 
 
 
ϵ

ABBREVIATIONS 
 
ADC  apparent diffusion coefficient 
AIC  arterial input curve 
AIF  arterial input function 
AKT   protein kinase B (PKB) 
CD117  an antigen part of the KIT receptor tyrosin kinase  
CT  computed tomography 
DW MRI diffusion weighted magnetic resonance imaging 
EORTC European Organization for Research and Treatment of Cancer 
18F  fluorine-18 
FDG  fluorine-18 (18F) labeled 2-deoxy-D-glucose 
FDG PET PET or PET/CT with FDG 
FOV  field of view 
FWHM full width half maximum  
GI  gastrointestinal 
GIST  gastrointestinal stromal tumor 
GLUT  glucose transporter 
HK  hexokinase 
HPF  high power field  
HU  Houndsfield unit 
ICC  interstitial cells of Cajal  
keV  kilo electron volt 
KIT  v-kit Hardy-Zuckerman 4 feline sarcoma viral protooncogene/c.kit 
KIT  KIT receptor tyrosin kinase 
MIP  maximum intensity projections 
MRI  magnetic resonance imaging 
NF  neurofibromatosis 
OS  overall survival 
PDGFRA platelet-derived growth factor receptor Į protooncogene 
PDGFRA platelet-derived growth factor receptor Į 
PERCIST positron emission tomography response criteria in solid tumors 
PET  positron emission tomography 
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PFS  progression-free survival 
PI3K  phosphoinositide 3-kinase  
PKC ș  protein kinase C-ș 
PMT  photo-multiplier tube 
PSF  point spread function 
RECIST response evaluation criteria in solid tumors 
ROI  region of interest 
RTK  receptor tyrosin kinase 
SCF  stem cell factor 
SUV  standardized uptake value 
SUVmax  maximum standardized uptake value 
TAC  time activity curve 
TK  tyrosine kinase 
TKI  tyrosine kinase inhibitor 
TOF  time-of-flight 
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1. INTRODUCTION  
 
Expanded knowledge of signal transduction pathways in cancers has led to new 
paradigms and development of molecular targeted therapies; gastrointestinal 
stromal tumor (GIST) being in the forefront. With an understanding of the key role 
of the receptor tyrosine kinase (RTK) KIT expression and the development of 
tyrosine kinase inhibitors (TKIs), a new era in the management of GIST began 
about a decade ago. GISTs comprise a heterogeneous entity with large variation 
in mutation status and tumor physiological variables influencing prognosis such as 
vasculature, proliferation, hypoxia and metabolism. Assessment of these 
prognostic factors prior to and early after onset of treatment may be of great value 
for implementing tailored treatment regimes. The emergence of drug-resistant 
tumor clones limits the long-term benefit of TKI in most patients and approaches to 
circumvent the development of resistance are of great clinical importance.  
 
Computer tomography (CT) is still the recommended imaging modality for 
monitoring patients with GIST. Traditionally, tumor response criteria are based on 
unidimensional tumor size changes without consideration of other treatment 
response parameters to TKIs such as tumor density, decreased vascularization 
and alteration in tumor metabolism. Functional and molecular imaging modalities 
are promising for non-invasive evaluation of treatment in GIST. Positron emission 
tomography (PET) using the glucose analog fluorine-18 (18F) labeled 2-deoxy-D-
glucose (FDG) identifies more responders than CT and at an earlier time point. 
PET can also detect secondary resistance. During the last decade, diffusion-
weighted magnetic resonance imaging (DW MRI) has been applied also for 
extracranial oncological imaging. Malignant tumors usually show high intensity on 
DW MRI because of their high cellular density limiting the motion of water 
molecules. During TKI treatment the cellular density is believed to decrease and 
thereby also the diffusion signal.  
 
A human GIST xenograft was established from a clinically imatinib-resistant tumor 
(paper I) to mimic the clinical scenario of advanced GIST. Treatment response to 
the commonly used TKIs imatinib and sunitinib were assessed by growth 
measurements, FDG PET and immunohistochemistry (papers I, II and III). In 
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
papers IV and V we explored the ability of DW MRI, FDG PET/CT and CT to 
detect early treatment responses in GIST patients receiving imatinib. 
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2. BACKGROUND  
  
2.1. GIST 
GIST is the most common sarcoma of the gastrointestinal (GI) tract (Nowain, 
2005) arising in mesenchymal components. GISTs can originate anywhere in the 
GI tract, but most tumors arise in the stomach (40 – 60%) or in the small intestine 
(25 – 30%) (DeMatteo, 2000; Miettinen, 2006). Less common sites are duodenum 
(5%), colorectum (5 –15%) and oesophagus ( 1%). Extragastrointestinal stromal 
tumors are extremely rare, but may occur in the omentum, mesentery and 
retroperitoneum (Miettinen, 2006).  
 
2.1.1. The history of GIST 
The classification and management of mesenchymal neoplasms in the GI tract has 
evolved significantly during the last 20 years. Most GI soft tissue neoplasms, 
previously classified as leiomyomas, shwannomas, leiomyoblastomas or 
leiomyosarcomas, are today classified as GISTs on the basis of identified 
molecular and immunohistological features. GISTs were originally believed to be 
derived from smooth muscle, but without complete differentiation (as seen in 
leiomyomas). Historically, most GISTs were thought to be benign due to their 
tranquil histopathological features. Long-time follow-up studies have however 
revealed that practically all GISTs have a potential for malignant behavior, also 
tumors < 2 cm (Rubin, 2000). Even small GISTs should therefore not be classified 
as benign (Fletcher, 2002b; Miettinen, 2006). The breakthrough came with the 
identification of the CD117 antigen expression in GISTs (Kindblom, 1998; Hirota, 
1998; Rubin, 2000). The other groups of neoplasms arising in the GI tract are 
usually CD117 negative (Rubin, 2000). The CD117 antigen is a part of the KIT 
transmembrane RTK and a product of the KIT protooncogene.    
 
GISTs are believed to arise from the interstitial cells of Cajal (ICC), the GI 
pacemaker cells, or in precursors of these cells (Kindblom, 1998), having features 
of smooth muscle and neuronal differentiation, and regulate peristalsis (Fletcher, 
2002b). Today, GISTs are mainly identified by their KIT immunoreactivity and 
activating mutations in KIT or platelet-derived growth factor Į (PDGFRA). 
ϭϱ

Immunohistochemically KIT-negative GISTs account for 4 – 5%, preferentially 
arising in the stomach or the omentum. 
 
The identification of oncogenic kinase mutations in GISTs and the nearly 
simultaneous discovery of TKIs revolutionized the treatment of GISTs. During the 
last century no effective drugs for advanced GISTs were available. For the first 
time, Joensuu et al reported in 2001 that the TKI imatinib resulted in durable 
effects in a patient with metastatic GIST (Joensuu, 2001). 
 
2.1.2. Epidemiology 
GIST accounts for 1 – 3% of all GI malignancies. Epidemiologic studies and 
therapeutic trials suggest an annual incidence in the range of 7 – 20 cases per 
million (Fletcher, 2002b; Nilsson, 2005; Tran, 2005). In a population of the northern 
regions of Norway, the incidence rate was reported to be close to 20 per million 
per year (Steigen, 2006). A recently published paper from the southwestern part of 
Norway found an incidence of 7.4 cases per million (Sandvik, 2011). The true 
incidence is unknown because epidemiologic data are difficult to interpret since the 
definition of GIST was based upon criteria first defined in 1990 (Tran, 2005), 
before GIST was molecularly characterized. More recent data indicate that the 
frequency of incidentally detected sub-centimeter gastric GISTs is probably higher 
(Kawanowa, 2006; Agaimy, 2007) and in a Japanese study they found microscopic 
GISTs in 35 out of 100 resected stomachs (Kawanowa, 2006).  
 
The mean age at diagnosis was 63 years in the registry of The National Cancer 
Institute’s Surveillance, Epidemiology and End Results (SEER) (Tran, 2005).  
 
The majority of GISTs are sporadic, but heritable mutations in the KIT gene occur 
and these families have a predisposition for multiple GISTs (Janeway, 2007). 
Patients with neurofibromatosis type 1 (NF1) also have a high incidence of GIST, 
but very few of them harbor mutations in the KIT or the PDGFRA genes (Mussi, 
2008). KIT is still usually overexpressed although the tumors are wild-type for KIT 
and PDGFRA. GIST in children is rare and usually connected to syndromes 
(Pappo, 2009).  
ϭϲ
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2.1.3. Risk stratification 
GISTs exhibit a wide range of malignant potentials, and criteria for identifying 
tumors with high risk for recurrence and metastases have been discussed for 
years (Fletcher, 2002b; Miettinen, 2006; Joensuu, 2008; Joensuu, 2011). For the 
planning of postoperative treatment and follow-up it is essential to have a risk 
stratification system. Tumor mitotic rate has been shown to be the strongest 
prognostic factor for relapse in operable GIST patients (Fletcher, 2002a), but 
tumor size and site have also been shown to be independent risk factors for 
recurrence free survival (RFS) (Miettinen, 2006; Rutkowski, 2007).  
 
Different risk stratifications have been developed. The National Institutes of Health 
(NIH) consensus criteria from 2001 (Fletcher, 2002b) used only tumor size and 
tumor mitotic index as risk factors. The primary site and R1 resection, being 
defined as microscopically incomplete resection and/or the presence of tumor 
rupture have later been associated with unfavorable outcome (Miettinen, 2006; 
Joensuu, 2008; Rutkowski, 2011), and Joensuu has proposed a modified 
classification system (Table 1) (Joensuu, 2008). This classification system added 
tumor site and the presence of tumor rupture to the already accepted factors.  
 
Small ( 5.0 cm) non-gastric GISTs with mitotic index > 5/50 high-power fields 
(HPF) and non-gastric intermediate size (5.1 – 10.0 cm) GISTs with mitotic index  
5 are considered high risk tumors according to Joensuu classification system 
unlike the NIH Consensus Criteria. Recently, the Joensuu classification risk 
categories were shown to be highly associated with overall survival (OS) 
(Rutkowski, 2011).  
 
Even though other prognostic factors have been identified, such as mutation type 
(Blanke, 2008a) and findings with PET/CT and MRI (Stroobants, 2003; Otomi, 
2010), none of them are yet accepted as sound risk criteria (Joensuu, 2011). 
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Table 1: Risk stratification in the proposed Joensuu classification (Joensuu 2008). 
Risk category Tumor size [cm] Mitotic index [per 50 HPF*] Primary tumor site 
Very low risk  2.0  5 Any 
Low risk 2.1 – 5.0  5 Any 
 5.0 6 – 10 Gastric Intermediate risk 
5.1 – 10.0  5 Gastric 
Any Any Tumor rupture 
> 10.0 Any Any 
Any > 10 Any 
> 5.0 > 5 Any 
 5.0 > 5 Non-gastric 
High risk 
5.1 – 10.0  5 Non-gastric 
*HPF, high power field 
 
 
2.1.4. Molecular pathogenesis 
Histologically, the appearance of GISTs is usually classified as either spindle cell 
(70%), epitheliod (20%) or mixed type (10%) (Fletcher, 2002b). Most GISTs are 
immunohistochemically positive for the RTK (95%) (Hirota, 1998). In addition, 
GISTs are immunopositive for DOG1, also known as anoctamin and protein kinase 
C-ș (PKC ș) (West, 2004).  
 
KIT is a member of the type III RTK family which also includes platelet-derived 
growth factor Į (PDGRFA) and platelet-derived growth factor ȕ (PDGRFB) among 
others. Stem cell factor and PDGFA are the natural ligands to KIT and PDGFRA, 
respectively (Rubin, 2001). 
 
About 80% of patients have gain-of-function activating mutations in the RTK gene 
KIT in regions that encode autoregulatory domains of the tyrosine kinase (TK) 
(Kindblom, 1998; Corless, 2004). These mutations occur predominantly in KIT 
exon 11 (66%) and in KIT exon 9 (12%) (Tornillo, 2006; Corless, 2011). GISTs 
with mutations in KIT exon 13 and KIT exon 17 are less common (Tornillo, 2006; 
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Corless, 2011). Activating mutations in the genes encoding PDGFRA are seen in 
approximately 8% of the patients (Hirota, 2003; Heinrich, 2003b; Corless, 2011).  
 
Spesific types of KIT mutations are associated with aggressive behavior (Singer, 
2002; Antonescu, 2003), including exon 9. In several studies KIT deletion/insertion 
mutations involving 557 and/or 558 codons of KIT exon 11 predict poor survival 
(Martin, 2005; Andersson, 2006; Martin-Broto, 2010). PDGFRA exon 18 is 
associated with better outcome (Lasota, 2006). 
 
Previous studies have shown that 10 – 14% of GISTs have no identifiable RTK 
mutations, known as wild-type GISTs (Nowain, 2005; Tornillo, 2006; Corless, 
2011). Such GISTs do not have mutation in neither KIT nor PDGFRA. However, 
their morphology is identical to GISTs harboring mutations in KIT or PDGFRA, but 
they usually express high levels of KIT per se. Wild-type GIST is a heterogeneous 
group with different oncogenic mutations. A mutation in the serine-threonine 
kinase (BRAF) is present in 13% of wild-type GISTs (Hostein, 2010). Mutations in 
the succinate dehydrogenase (SDH) complex have also recently been identified 
(Janeway, 2007). GISTs with loss-of-function mutations in SDHA have also been 
reported (Pantaleo, 2011). Furthermore, patients with NF1 can develop one or 
several GISTs (7%) (Andersson, 2005; Miettinen, 2006). Wild-type GISTs most 
often arise in the small intestine and they rarely metastasize (Andersson, 2005; 
Miettinen, 2006). 
 
Pediatric patients with GISTs account for approximately 1 – 2% of all GISTs and 
seldom harbor KIT or PDGFRA mutations. These tumors usually grow slowly but 
often metastasize (Janeway, 2007; Agaram, 2008). A special non-heritable 
pediatric type of GISTs is a combination with pulmonary chondroma and/or 
paraganglioma, known as Carney’s triad (Carney, 1999). 
 
Molecular biology studies in tumors with KIT and PDGFRA mutations show that 
these mutations activate downstream signaling pathways such as the mitogen-
activated protein kinase MAPK pathway (including RAF, MEK and MAPK) and the 
phosphoinositide 3-kinase (PI3K) and Protein Kinase B (PKB), also known as AKT 
(a serine/threonine-spesific protein kinase pathway) (Rubin, 2001; Rossi, 2006). 
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AKT activation through PI3K affects the regulation of cell cycle and has anti-
apoptotic effects (Corless, 2011) (Figure 1).  
 
 
 
 
 
Figure 1: Simplified ongogenic signaling in KIT and PDGFRA mutant GIST. The binding of 
stem cell factor (SCF) or mutational activation leads to phosphorylation of tyrosine residues which 
serve as binding sites for various cell signaling proteins; such as the PI3-K/AKT, RAS/RAF/MAPK 
and the JAK/STAT pathways. The activated KIT/PDGFRA stimulates intracellular signaling 
pathways controlling glucose metabolism, apoptosis and cell proliferation.  
 
 
The role of mutation analysis in monitoring patients with GIST is still debated. 
Guidelines from the National Comprehensive Cancer Network (NCCN) 
recommend KIT immunostaining for all suspected GISTs, and if negative, mutation 
analysis (Demetri, 2010; Von Mehren, 2012). They do not recommend routine 
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genotyping of KIT positive GISTs, but specifies that mutation analysis may to 
some extent predict treatment response to TKI. 
 
2.1.5. Clinical presentation 
There is a large variation in the clinical presentation of GISTs. Small GISTs (< 2 
cm) are usually asymptomatic and an incidental finding on CT and endoscopy. 
GISTs are usually associated with non-specific symptoms i.e. bloating, early 
satiety etc. unless they ulcerate, bleed or grow large enough to give pain or 
obstruction (DeMatteo, 2000). Nilsson et al found in their population-based study 
in western Sweden that the median tumor size of GISTs was 8.9, 2.7 and 3.4 cm 
when detected based on symptoms, incidental findings, or at autopsy, respectively 
(Nilsson, 2005). The clinical presentation depends on its localization and size. 
GIST metastasize to liver and peritoneum and only rarely to lymph nodes or extra-
abdominal sites (Miettinen, 2006). 
 
2.1.6. Treatment of GIST 
Surgery is the standard treatment for patients with primary resectable GIST 
(Joensuu, 2012b). All GISTs  2 cm should be resected (Demetri, 2010; Casali, 
2010). For smaller GISTs, the malignant potential is unknown and there is a lack of 
consensus of the optimal management of these small tumors. 
 
The majority of localized GISTs allow complete resection (R0), but unfortunately 
up to half of the patients will relapse within five years despite R0 resection 
(DeMatteo, 2000; Samiian, 2004). A complete gross resection of the tumor with an 
intact pseudocapsule is the surgical goal. Routine lymphadenoectomi is not 
indicated because metastases to lymph nodes are uncommon. GISTs often grow 
extraluminally and displace rather than invade adjacent organs. During surgery, 
the abdominal cavity should be carefully explored with emphasis on liver and 
peritoneum to exclude metastatic spread. En bloc resection is essential as tumor 
rupture increases the risk for relapse (Joensuu, 2008; Rutkowski, 2011).  
 
Standard chemotherapy and radiotherapy are not effective in GIST (Dematteo 
2002). Until recently, treatment options for patients with advanced GIST were 
limited and the median survival was approximately 18 months (DeMatteo, 2002). 
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With an understanding of the key role of the KIT tyrosin kinase expression and the 
subsequent introduction of the TKI imatinib, a new era in the management of this 
tumor entity began (Joensuu, 2001). Imatinib was originally developed for the 
treatment of chronic myeloid leukemia (CML) because of its ability to inhibit BCR-
ABL (Druker, 1996). It was further observed that KIT and other TKs shared 
structural similarity with ABL (Heinrich, 2000).  
 
2.1.6.1. Treatment of patients with advanced GIST 
Imatinib is the standard first-line treatment for advanced GISTs (Fletcher, 2007). 
Most patients (50 – 70%) respond to imatinib and further 15 – 39% have disease 
stabilization (Demetri, 2002; Blanke, 2008a). Complete response to imatinib is 
rare, estimated to 3 – 5% (Chacon, 2005; Bauer, 2005; Blanke, 2008a). For 
patients with advanced disease median survival is 5 years and as many as 34% 
survive more than 9 years (Von Mehren, 11 A.D.) However, the majority of patients 
for whom imatinib is initially effective, will eventually develop resistance to the 
drug, usually through the mechanism of secondary mutations, but an amplification 
of the KIT gene is also suggested (Gramza, 2009). Secondary or late resistance 
develops after a median of almost 2 years of treatment (Demetri, 2002; Rutkowski, 
2007; Blanke, 2008b), and the emergence of drug-resistant tumor clones limits the 
long-term benefit of these drugs in most patients.  
 
Imatinib inhibits KIT by binding to the adenosin triphosphat (ATP)-binding site. 
Normally, the RTK is in equilibrium between the active and the inactive 
conformation, but imatinib stabilizes the receptor in the inactive state (Mol, 2004). 
Which factors that influence the extent of imatinib response are not fully 
understood (Rutkowski, 2007). In vitro studies demonstrate that imatinib inhibits 
KIT activity, leading to a down-regulation of AKT followed by a decreased glucose 
transport into the GIST cells (Tarn, 2006). 
 
Although TKI has become the standard treatment for metastatic GIST, surgery 
also plays a role in the management of these patients as a resection of 
residual/metastatic disease may delay or avoid development of resistant clones 
(DeMatteo, 2007). Retrospective studies suggest longer disease control after 
surgical resection in patients with limited metastatic disease (Rutkowski, 2006; 
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Gronchi, 2007). However, no randomized studies have been performed and it is 
unknown whether overall survival increases. Several studies conclude that surgery 
is advantageous only for patients who respond to TKI or show isolated progression 
(Raut, 2006; DeMatteo, 2007). Continued TKI treatment is required also after 
complete resection as progression free survival (PFS) is decreased in patients 
who discontinue TKI treatment (Rutkowski, 2006; DeMatteo, 2007; Gronchi, 2007). 
 
2.1.6.2. Adjuvant treatment of GIST  
The use of imatinib postoperatively in non-metastatic patients has demonstrated a 
marked decrease in recurrence after complete resection (DeMatteo, 2009). It is 
therefore important to identify patients who need closer monitoring or adjuvant 
treatment. In June 2009 imatinib was approved as adjuvant treatment for adult 
patients with significant recurrence risk after resection of a CD117 positive GIST. 
Norway participated in a study led by the Scandinavian and German sarcoma 
groups where the effect of one and three years treatment with 400 mg imatinib 
were compared (SSG XVIII). The results were recently published and showed 
significantly better results with three years of treatment (66% without relapse and 
92% alive after five years compared to 48% and 82% with one year treatment, 
respectively) (Joensuu, 2012a). Based on these findings the European Medicines 
Agency (EMA) in February 2012 approved three years of treatment for the high-
risk group. Only imatinib has been evaluated as adjuvant treatment in GIST. 
Treatment beyond three years has not been studied, and the optimal selection of 
patients for adjuvant treatment is still not settled.  
 
2.1.6.3. Neoadjuvant treatment 
If a GIST is borderline resectable or if surgery is anticipated to be mutilating, 
neoadjuvant treatment with imatinib may be preferable (Sjolund, 2010; 
Machlenkin, 2011). There are no accepted guidelines for neoadjuvant imatinib 
treatment, and no randomized trials have been published. However, retrospective 
data support that such a strategy could render initially non-resectable tumors 
resectable (Sjolund, 2010; Machlenkin, 2011). Optimal neoadjuvant treatment 
period must at present be evaluated individually and with frequent imaging during 
the treatment. FDG PET has been shown to be particularly useful in this setting 
(Demetri, 2010; Casali, 2010; Van den Abbeele, 2012).  
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2.1.6.4. Side-effects of imatinib  
About five percent of GIST patients receiving imatinib develop unacceptable 
adverse effects (Samiian, 2004; Demetri, 2006). In our single institution study 
(including 37 patients with metastatic GIST receiving imatinib) periorbital edema 
and nausea were the most frequent side-effects, maintained for more than one 
year in 20% of the patients (submitted). In general, adverse effects were reduced 
with treatment time. One patient discontinued imatinib because of generalized 
exantem, and two patients due to side-effects (edema and nausea, respectively) 
and disease progression. Two patients needed dose reduction for a period 
because of skin rash. Tumor bleeding occurred in four patients, one with fatal 
outcome, and one underwent stabilizing surgery (Figure 2) (submitted). 
 
 
Figure 2: Side effects registered the first year of imatinib treatment in 37 GIST patients. 
 
 
2.1.7. Development of resistance  
The most commonly observed resistance mechanism is the occurrence of point 
mutations in the BCR-ABL kinase domain that affect the ability of imatinib to bind 
effectively in the ATP pocket. Although new generation TKIs initially may be 
effective, consecutive new mutations will develop and again lead to resistance. It is 
unclear if new mutations develop or if primary therapy selects for pre-existing 
resistant clones. Mutations have been observed early in the disease process when 
patients still show treatment response. It therefore seems likely that some of these 
mutations are pre-existing and selected by therapy. Clinical resistance may be 
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manifested in several ways; growth of a nodule within a pre-existing dormant 
lesion, development of new lesions or expansion of multiple lesions in the liver or 
in the abdominal cavity. Different resistant mutations may be present at the same 
time in the same patient both at different sites or in the same metastasis (Heinrich, 
2006; Liegl, 2008). This heterogeneity is of course a challenge for the efficacy of 
further TKI therapy. 
 
Secondary mutations occur nearly always in the same gene and allele as the 
primary mutation (Antonescu, 2005) and are most common in GISTs harboring a 
primary KIT exon 11 mutation and have not been observed in wild-type GISTs 
(Heinrich, 2006).  
 
Primary mutations that activate KIT are mainly localized to the juxtamembrane 
regions encoded by exons 11 and 9. Secondary mutations are localized in two 
others regions of the KIT kinase, the same that is targeted by imatinib; the ATP-
binding pocket (encoded by exons 13 and 14) which directly hinder drug binding 
and the activating loop (encoded by exons 17 and 18) which stabilize KIT in the 
active form so that the TKI cannot interact (Figure 3). KIT exon 17 point mutations 
are the most frequent mutation considered to confer imatinib resistance, e.g. 
D816H. KIT exons 17 and 18 mutation can also be primary mutations, but are very 
rare. Secondary resistance in PDGFRA mutations has also been observed 
(Heinrich, 2006). 
 
2.1.8. Approaches to combat imatinib resistance 
In patients progressing under imatinib treatment, an increase of the imatinib dose 
is recommended. Some patients respond to a dose escalation, but usually only 
temporarily. Some patients will nevertheless have prolonged disease control 
lasting one year or more (Blanke, 2008b). Possible explanations for this 
observation include inadequate drug concentration and/or that a proportion of the 
GIST cells have maintained their primary imatinib sensitive mutation.    
 
If the disease progresses after a dose escalation with imatinib, the 
recommendation is to switch to another TKI. During the past years other TKIs such 
as sunitinib, nilotinib, sorafenib, dasatinib and pazopanib have been developed 
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Figure 3: Primary and secondary mutations in GIST and their drug sensitivities. 
 
 
(Samiian, 2004; Deremer, 2008; Novak, 2010; Reichardt, 2011). Of these new 
TKIs, only sunitinib has reached recommended clinical practice as second-line 
treatment (Samiian, 2004; Demetri, 2009; Demetri, 2012). KIT ATP-binding pocket 
mutations are sensitive to sunitinib, but the activation loop mutations are cross-
resistant to sunitinib. Many of the next generation TKIs also target vascular 
endothelial growth factors 1 and 2 (VEGFR1 and VEGFR 2) (Samiian, 2004; 
Deremer, 2008; Sawaki, 2011), and thereby inhibit angiogenesis. Unfortunately, 
none of the new inhibitors have the same striking effect given as second line 
treatment after imatinib failure as imatinib has in previously untreated patients. 
 
2.1.9. Treatment response evaluation 
Response to anticancer therapy has traditionally been evaluated on the basis of 
morphologic changes with reduction in tumor size being the gold standard. Size-
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based criteria originally designed to assess response to cytotoxic drugs have 
limitated value in response assessment to new molecular targeted therapies that 
have a cytostatic rather than a direct cytotoxic effect on cancer cells. The 
evaluation of therapeutic efficacy of TKI can therefore be difficult because they do 
not necessarily induce lesion shrinkage, or at least not before weeks or months 
(Benjamin, 2007; Deremer, 2008). Some responsive tumors even initially increase 
in size, reflecting tumor necrosis, myxoid degeneration or intratumoral hemorrhage 
(Choi, 2004). Furthermore, anatomic imaging has limited ability to differentiate 
treatment induced fibrosis from residual vital tumor tissue. CT has been the 
method of choice for monitoring patients with GIST and is the recommended 
modality (Demetri, 2010; Casali, 2010). International guidelines for objective 
response evaluation are established, such as the World Health Organization 
(WHO) criteria, the Southwest Oncology Group (SWOG) criteria and the Response 
Evaluation Criteria in Solid Tumors (RECIST), all of them solely based upon 
changes in tumor size assessed by morphological imaging. The most commonly 
used response criteria is RECIST (Eisenhauer, 2009). Briefly, the four response 
categories in RECIST are complete response (CR) defined as the disappearance 
of all target lesions, partial response (PR) defined as a decrease in the sum of the 
diameters of all target lesions by  30%, progressive disease (PD) defined as an 
increase of  20% or appearance of new lesions, and stable disease (SD) defined 
as changes in the sum of the diameters that are not sufficient to qualify for neither 
PR nor PD. Consequently, RECIST may underestimate the overall clinical benefit 
of TKI treatment (Benjamin, 2007; Revheim, 2011). In recent studies decreased 
tumor size and/or density on CT have been used to document GIST response to 
imatinib treatment (Benjamin, 2007). Response to treatment on CT, often referred 
to as the Choi criteria, is then defined as more than 15% decrease in CT density 
value or more than 10% decrease in tumour size (Benjamin, 2007; Choi, 2008).  
 
FDG PET has become an increasingly important tool for response evaluation in 
patients with cancer (Weber, 2005; Weber, 2007). In 1999 the European 
Organization for Research and Treatment of Cancer (EORTC) proposed PET 
response criteria (Young, 1999). At that time very limited data regarding treatment 
response were available and the criteria were based on reproducibility studies in 
PET. Briefly, progressive metabolic disease (PMD) is defined as > 25% increase 
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of maximum standardized uptake value (SUVmax) of the target lesions, or 
appearance of new lesions. Stable metabolic disease (SMD) includes change in 
SUVmax less than 25% and partial metabolic response (PMR) is defined as > 25% 
decrease of SUVmax in target lesions. Finally, complete metabolic response 
(CMR) is the disappearance of lesions on the PET image. Based upon the 
extensive numbers of articles supporting the use of FDG PET for the assessment 
of treatment response published after 1999, Wahl et al in 2009 made a draft of a 
new updated set of PET criteria named the Positron Emission tomography 
Response Criteria in Solid Tumors (PERCIST) (Wahl, 2009). In PERCIST, CMR is 
defined as the disappearance of all active lesions, PMR is defined as > 30% 
reduction in the lesion with highest uptake (this lesion does not need to be the 
same lesion as measured prior to treatment) and PMD is defined as an increase of 
> 30% or appearance of new lesions. PERCIST also includes performance of PET 
scans consistent with the National Cancer Institute recommendations and the 
Netherlands multicenter trial group (Shankar, 2006). Usually GISTs show high 
uptake of FDG when imaged by PET, and treatment response can be observed 
early (Joensuu, 2001; Shinto, 2008) (papers II, IV and V). Stroobants et al were 
the first group to use FDG PET for early treatment response evaluation to imatinib 
in 21 patients with soft-tissue sarcomas, 17 with GIST (Stroobants, 2003). FDG 
PET and CT were performed prior to treatment and 8 days after starting treatment. 
PET response was observed in 13 patients. Furthermore, one year PFS was 92% 
and 12% for the PET responders and non-responders, respectively.  
 
During the past decades, the use of DW MRI has increasingly being applied to 
extracranial cancers (Padhani, 2009). The signal intensity in DW MRI reflects the 
ability of protons to move within tissue. As tumor cells usually are more densely 
accumulated that the normal tissue from which they originate, tumors will appear 
with elevated signal intensity at DW MRI. There are only one case report (Matsui, 
2009) and a study consisting of five patients where DW MRI has been used in the 
diagnosis of GIST (Wong, 2012). Following our case report where DW MRI was 
used for both initial diagnosis and for assessment of treatment response in a rectal 
GIST patient receiving imatinib (paper IV), a Chinese group investigated DW MRI 
as an early response indicator in 32 GIST patients (Tang, 2011). Decreased 
cellular density during TKI treatment is anticipated to be accompanied by 
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decreased diffusion signal (Charles-Edwards, 2006). DW MRI response criteria 
and the best time-point for assessment are not yet established.  
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2.2. Imaging of GIST 
 
As mentioned previously, CT is the gold standard for diagnostics and follow-up in 
GIST patients. On CT, GIST appears as a solid, smoothly contoured, and 
hypervascular tumor (enhances brightly with i.v contrast). Large tumors may show 
signs of necrosis, hemorrhage and/or degenerating components. Hematogenous 
metastases most commonly occur in the liver, peritoneal cavity and omentum. 
Residual tumors often appear like cystic remnants of a larger mass. 
 
Endoscopy allows further characterization of a gastric tumor. GIST may appear as 
a submucosal mass with smooth margins, a normal overlying mucosa, some with 
a central ulceration, and bulging into the lumen. 
 
Functional imaging represents a promising approach for GIST and such methods 
may give improved characterization of the tumor, their aggressiveness and allow 
repeated assessment of treatment response. Hence, therapy can be adapted to 
each individual patient’s disease. Functional imaging of metabolism in GISTs with 
the glucose analog FDG PET has been reported to be particularly useful when the 
CT findings are inconclusive or inconsistent with the clinical findings (Demetri, 
2010; Von Mehren, 2012) and can detect both unknown primary site and unknown 
metastases. PET is also useful in patients with borderline resectable GIST where  
moving to alternative therapy is considered (Van den Abbeele, 2012; Von Mehren, 
2012). Response to targeted therapies assessed with FDG PET is characterized 
by a striking decrease in the glycolytic metabolism of GISTs seen within 24 hours 
of the first dose TKI (Shinto, 2008) (paper II) and has shown to predict long-term 
response (Van den Abbeele, 2008; Van den Abbeele, 2012). Little is known about 
the application of DW MRI for GIST patients, but for other cancers DW MRI has 
recently been used for tumor grading and monitoring of treatment response 
(Brindle, 2008; Nilsen, 2010; Roe, 2011). 
 
2.2.1. CT 
CT provides high spatial resolution images and allows whole body images to be 
obtained within seconds. Multi slice CT scanners were introduced in the early 
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2000s and are able to acquire up to 640 images per rotation. Standard 
reconstruction matrixes are 512 x 512, but it is possible to reconstruct in 768 x 768 
and 1024 x 1024 matrixes yielding reduced voxel sizes. The introduction of dual-
energy CT scanners enhances image quality further and improves differentiation of 
soft tissue and segmentation of tissue and iodine-based contrast agents. 
 
2.2.1.1 Principle of CT 
X-ray absorption depends on the electron densities of the tissue. The high electron 
density (high attenuation coefficient) of bone translates into a brighter signal on CT 
images compared to tissues with lower attenuation properties. Electrical signals 
are generated from x-rays that passes through the object and are captured in the 
detector system. The attenuation values of different tissue are assigned an 
attenuation value in Hounsfield Units (HU) (a value relative to the attenuation of 
water). 
 
2.2.2. PET 
PET is a nuclear medicine imaging technique that provides three-dimensional 
images of functional processes based on the chosen tracer.  
 
2.2.2.1. The tracer principle  
A fundamental principle in nuclear medicine is the radiotracer principle invented by 
George de Hevesy in 1912. He discovered that radioactive compounds had 
identical chemical properties as the non-radioactive form and thus could be used 
to track physiological processes in the body. In order to provide information of the 
unaltered system characteristics the amount of exogenously administered 
substance (the tracer) must be so small that it does not perturb the system. PET is 
a very sensitive method. It only takes a picogram of radioactively tagged 
compound for the PET scanner to perform a precise quantification and compute 
images of the process. In this way the radioactive compound given does not affect 
the normal biochemical equilibrium studied. 
 
2.2.2.2. Detection and quantification in PET 
PET is based on the simultaneous detection of two annihilation photons that are 
emitted when a positron-emitting radioisotope decays by releasing a positron (ȕ+) 
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that annihilates with an electron (Figure 4). The photons are emitted in opposite 
directions with energy equal to the sum of the rest energy of the positron and the 
electron (511keV). The traveling distance before annihilation depends on the 
positron’s initial energy and the density of the surrounding tissue (Table 2). The 
positron and the electron are not accurately at rest at the time of annihilation and 
thus, they are not emitted exactly at 180° (typically 180° ± 0.25°).This non-
colinearity will give raise to a blurry effect. The positron traveling distance in tissue 
together with non-colinearity is factors that limit the spatial resolution in PET 
images. The most commonly used radionuclide in both clinical and preclinical PET 
studies is 18-fluorine (18F).  18F has a ȕ+ max energy of 0.63 MeV and a mean 
range in water of 0.6 mm. Properties of the main positron emitting nuclides are 
listed in Table 2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: The principle of PET imaging. PET imaging is based on a process called annihilation; 
an interaction between an electron and a positron arise from the decay of a positron-emitting 
radioisotope. Two 511keV photons emitted at approximately 180° are simultaneously detected 
(coincidence detection) in the PET detectors.  
 
 
 
ϯϮ

Table 2: The main positron emitters and their properties. 
Nuclide  
11C 13N 15O 18F 
Half life (min) 20.4 9.9 2.1 109.8 
Emax (MeV) 0.959 1.197 1.738 0.633 
Mean range in water (mm) 1.1 1.5 2.5 0.6 
 
 
The energy from the annihilation photons is transformed to light when they hit the 
PET detector. Modern PET systems have detectors arranged in several rings and 
each ring is formed by blocks of scintillation crystals. A typical block contains 13 x 
13 crystals. The scintillator block is then coupled to four photomultiplier tubes 
(PMTs), and these tubes transform light into electric signals.   
 
Only the pairs of annihilation photons that hit the PET detector within a predefined 
time and energy window will be accepted. The line between two opposite hits is 
called a line of response (LOR). PET images are reconstructed from millions of 
LOR registrations providing a picture of the radiotracer’s distribution. The exact 
location of the annihilation event is based on mathematical processing of millions 
of LOR. Photons travel at the speed of light (3 x 108 m/s) and the detection time of 
a pair of photons is 2 – 3 ns. The coincidence timing window is typically around 5 
ns. The last generation PET scanners are able to detect annihilation photons 
within an extremely short time window. They can even calculate the time 
difference between the hits of a pair of annihilation photons in the coincidence 
window (Karp, 2008). 
 
PET has about 10-fold better sensitivity than conventional gamma cameras. The 
increased sensitivity is due to multiple full ring detectors and 3D acquisition without 
collimation. The higher spatial resolution of PET mainly results from the small 
sized detector elements and the coincidence detection technique. In theory, 
feasibility studies exploring small crystals have shown resolutions of about 0.4 mm 
(Stickel, 2005). The spatial resolution is nevertheless inferior to both CT and MRI. 
Almost all PET systems today are combined PET/CT scanners allowing high-
resolution CT images. The integrated CT is used for attenuation correction of the 
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PET images. For PET scanners without integrated CT, attenuation and scatter 
correction may be obtained by a transmission scan using external point sources of 
radiation. The most common point source is the long-lived 68Ge (T ½ = 270 d).  
 
2.2.2.3. Standardized uptake value (SUV) 
The SUV typically obtained one hour post-injection is traditionally used for clinical 
quantitative assessment of uptake in lesions. The use of SUV has been reviewed 
and discussed by several authors (Shankar, 2006; Wahl, 2009; Boellaard, 2009; 
Boellaard, 2010; Boellaard, 2011). The SUV is defined as the tissue activity 
concentration C (MBq/g) measured over a certain interval after FDG injection in a 
chosen region (ROI) or volume of interest (VOI) and normalized to the dose FDG 
injected corrected for physical decay (MBq) and parameters with effect on body 
distribution (Kim, 1996) such as body weight, lean body mass (body mass minus 
fat) and body surface (1.73 m2). The SUV normalized to lean body mass (lbm) is 
given by: 
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2.2.2.4. Dynamic PET 
Dynamic PET depicts the change of radiotracer distribution as a function of time 
after injection by acquisition of sequential scans. Mathematical pharmacokinetic 
modeling of the tracer distribution allows the conversion of altered radioactivity 
distribution into biologically meaningful variables. The kinetics can be described 
using a maximum of three compartments for most radiotracers; an arterial blood 
compartment with free or plasma protein bound tracer, a free compartment 
(extracellular or intracellular fluid) and a compartment with tracer bound either to 
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an enzyme, a receptor or metabolically trapped. An example of a compartmental 
model for the FDG uptake in a tumor is shown in Figure 5.  
 
Abnormal vasculature and elevated glucose metabolism in lesions are indicators of 
malignancy. With dynamic FDG PET, information about both the early distribution 
phase and the later metabolic phase are obtained (Roe, 2010). Kinetic modeling of 
the tracer uptake can thus provide information about blood flow, capillary 
permeability and tumor metabolism, information that may predict tumor 
aggressiveness and treatment outcome. 
 
 
 
 
Figure 5: Kinetic compartment model used to describe FDG kinetics. The compartment model 
used in extraction of kinetic information from dynamic 18F FDG PET. CP is the concentration of 
FDG in plasma and CT is the FDG concentration in tumor. CT is further separated into not 
metabolized or free FDG, CF, and metabolized or bound FDG, CB. The kinetic parameters k1 (min-1) 
and k2 (min-1) describes the forward and backward FDG diffusion, respectively. The k3 (min-1) and 
k4 (min-1) parameters signify the rates of FDG phosphorylation and dephosphorylations, 
respectively, i.e. reflecting the receptor binding or glucose metabolism. 
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2.2.2.5. Small animal PET 
PET scanners designed specifically for imaging small primates are used in pre-
clinical studies. These scanners are also referred to as MicroPET scanners and 
have higher spatial resolution than clinical systems due to smaller detector 
elements. However, there is a tradeoff between the obtainable spatial resolution 
and the sensitivity for a given detector size and field of view (FOV) (Table 3). The 
sensitivity has been maintained by increasing the number of crystal elements in 
the axial FOV and by a tighter packing to avoid space between adjacent crystals.  
 
 
Table 3: General scanner properties for human and small animal PET scanners.  
 Human PET Small animal PET 
Sensitivity 1 – 3 % ca 2 – 4 % 
Spatial resolution ca 5 mm 1 – 2 mm 
FOV ca 50 cm ca 7 cm 
 
  
2.2.2.6. FDG PET imaging in oncology 
Malignant tumors use, in contrast to most normal tissues, practically only glucose 
as their energy source. The glucose and energy consumption is also increased in 
malignant tumors due to increased proliferation compared to normal cells. FDG 
PET is established as a powerful tool for staging and restaging of a wide range of 
cancers, for detection of cancer recurrence, for discrimination between 
residual/recurrent disease and scar, and for detection of occult cancer in patients 
with metastases from an unknown primary tumor (Rohren, 2004; Weber, 2007; 
Weber, 2009). 
 
2.2.2.7. Aerobe glycolysis in cancer cells (Warburg effect) 
It is proposed that the phenotype of elevated glucose consumption in cancers is 
selected through somatic evolution. Increased glycolysis leads to increased acid 
production and the hypothesis is that production of acid is the key mechanism for 
cancer spread beyond the site of origin (Rofstad, 2006; Gillies, 2008). Aerobe 
glycolysis is a mystery in an evolutionary context. Glycolytic metabolism is very 
inefficient and produces only 2 mol ATP pr mol glucose while the citric acid cycle 
ϯϲ

produces 36 mol ATP pr mol glucose. Thus, it does not appear to be an adaptive 
advantage of aerobe glycolysis. Still, the majority of metastatic tumors rely on 
glycolysis when oxygen is present and thus promotes tumor development. 
 
2.2.2.8. Molecular mechanisms regulating glucose 
The function of glucose is to provide energy to the cancer cells, as ATP, as an 
alternative to mitochondrial respiration. The presence of oxygen is an important 
regulator of glucose consumption (the Pasteur effect) (Krebs, 1972), and the 
glucose consumption is higher in hypoxic tissue (Racker, 1958). Cancers consume 
glucose at high levels even with adequate oxygen tension (Gillies, 2008). This 
effect was first described by Warburg (the Warburg effect) (Warburg, 1956). 
 
There seems not to be a single cause for the increased glucose metabolic activity 
of cancer cells. Data suggest that increased uptake is not only due to cellular 
proliferation and intratumoral hypoxia, but also is a result of genetic alterations in 
different oncogenic signaling pathways resulting in resistance to apoptosis, 
activation of glycolysis and mitochondrial dysfunction (e.g shutdown of oxidative 
phosphorylation). The uptake is influenced by proliferation and by the tumor 
environment. Activation of oncogenes and loss of tumor suppressor genes can 
also affect FDG uptake (Gillies, 2008). 
 
 
2.2.2.9. Glucose transporters (GLUTs), hexokinase (HK) activity and Hypoxia-
inducible factor 1 alpha (HIF-1Į) 
Increased uptake of FDG in cancers is associated with the expression of GLUTs 
and HK activity (Zhao, 2005; Macheda, 2005; Van den Abbeele, 2012). Several 
cell specific isoforms of GLUTs are described (GLUTs 1 – 13). Their properties are 
specifically matched to the various cell types, and they are involved in different 
cancers. The majority of cancers over-express the GLUTs present in the tissue of 
origin, but they may also express GLUTs not expressed under normal conditions 
perhaps due to the increased need of energy for the uncontrolled proliferation 
(Macheda, 2005). 
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GISTs express different GLUTs (Prenen, 2005; Tarn, 2006; Kaida, 2010; Van den 
Abbeele, 2012) (Figure 6). Prenen et al found that the main GLUT in the imatinib 
sensitive GIST882 cell line was GLUT 2. This was also the main transporter in the 
imatinib resistant GIST-GDG1 cell line, but these cells also expressed GLUT 3 and 
GLUT 4 (Prenen, 2005).  
 
The enzyme HK phosphorylates glucose and decreases the activity of glucose-6-
phosphatase. An increased HK activity would result in the accumulation of 
phosphorylated FDG (which cannot pass the cell membrane) (Torizuka, 1995). 
However, GLUT expression is thought to be the most important feature of 
increased FDG accumulation in cancer cells (Chung, 1999; Brown, 2002). 
 
HIF-1 Į is over-expressed in many human cancers as a result of intratumoral 
hypoxia and genetic alterations (Figure 6). A consequence of HIF activation is 
increased transcription of glycolytic genes (Talks, 2000) and secondarily increased 
glycolysis. HIF-1 Į is also involved in angiogensis, cell survival and invasion. Over-
expression has been shown to be associated with treatment failure and increased 
mortality in several cancers (Talks, 2000; Bos, 2003). It has been postulated that 
HIF alone is responsible for the Warburg and the Pasteur effects (Seagroves, 
2001; Robey, 2005). 
 
 
Figure 6:  Immunohistochemistry. Paraffin-embedded sections staining (Dako EnVisionTM + 
System, Peroxidase (DAB) (K4011, Dako, Glostrup, Denmark) and a Dako Autostainer) in the 
human GIST xenograft AHAX; GLUT1-4 (A-D), Caspase 3 (E), Ki-67 (F) and HIF1-Į (G). Images 
provided by Ruth Holm, Department of Pathology, Oslo University Hospital, and printed with 
permission.  
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2.2.3. MRI 

2.2.3.1. Principle of MRI 
Clinical MRI exploits the magnetic properties of the hydrogen nucleus. Hydrogen 
nuclei (i.e. protons) placed in a strong static magnetic field can absorb energy and 
be excited to higher energy levels when exposed to radiofrequency (RF) pulses. 
When RF pulses are terminated, the protons will return to their equilibrium energy 
state by exchanging energy with the surrounding tissue (T1-relaxation) and by loss 
of phase coherence (T2-relaxation). These MR signals are the basis for all MR 
applications. Mapping of the distribution of protons and their relaxation properties 
creates high-resolution images of anatomic structures, where the contrast between 
different tissues originates from their differences in proton density and T1- and T2-
relaxation times.  
 
2.2.3.2. DW MRI 
DW MRI can provide functional information about underlying molecular and tumor-
physiological mechanisms in tissue.  In DW MRI the signal originates from random 
(Brownian) motion of water protons in tissue (Le, 1988; Koh, 2006) in the presence 
of magnetic field gradients. With the existence of microscopic cellular structures 
such as membranes, macromolecules, fibers, vessels and cell organelles, the 
proton diffusion is restricted (Figure 7). Densely accumulated cells like tumor 
tissue will therefore give increased signal intensity on DW MRI. The diffusion 
sensitization is regulated by the b value, an acquisition parameter determined by 
the strength, duration, and time interval between the bipolar gradients. The signal 
is inversely related to the degree of water diffusion i.e. restricted diffusion leads to 
increased signal. The apparent diffusion coefficient (ADC) quantifies the water 
diffusivity, and requires at least two DW images with different diffusion-weightings 
(b values) (Charles-Edwards, 2006).  
 
Change in ADC early in the course of treatment has been found to correlate to 
treatment outcome for some cancer diseases (Seierstad, 2007; Nilsen, 2010). 
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Figure 7: Diffusion of water molecules. 
Water molecules (blue circles with arrows) 
within extracellular space, intracellular 
space, and intravascular space, all of which 
contribute to the measured MR signal. 
Upper panel: Free diffusion, low cellularity 
and defective cell membranes. In less 
cellular environment, relative increase in 
extracellular space allows freer water 
diffusion than a more cellular environment 
would. Defective cell membranes also 
allow movement of water molecules 
between extracellular and intracellular 
spaces.  
Lower panel: Restricted diffusion, 
cellularity and intact cell membranes. In 
highly cellular environment, water diffusion 
is restricted because of reduced 
extracellular space and by cell membranes, 
which act as barriers to water movement.  
 
 
 
In GIST, DW MRI may represent a promising non-invasive instrument for the 
assessment of early and repeated therapy evaluation in individual patients (Tang, 
2011). Compared to the other established imaging modalities (PET and CT), DW 
MRI does not rely on the use of ionizing radiation, there is no need for 
administration of contrast agent or radioactivity, and the examination can be 
carried out in a few minutes.  
 
2.2.4. Combination of PET and CT (or MRI) 
PET/CT may be superior to CT or PET alone in the detection of early treatment 
response in GIST patients (Antoch, 2004; Goerres, 2005). CT complements PET 
by providing high-resolution anatomic information (Beyer, 2002). Low-resolution 
CT scans are routinely used for PET attenuation correction and anatomic 
localization. The combination of advanced CT scanner, with a PET scanner might 
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be beneficial for diagnostic work up (Goerres, 2005). An integrated whole body 
and simultaneous acquisition PET/MRI system has been developed and recently 
approved by the United States Food and Drug Administration (U.S. FDA). 
Research studies are at the moment actively conducted to identify benefits of the 
new PET/MRI diagnostic method. 
 
2.2.5. Xenograft models 
Immunodeficient mice are commonly used as hosts to enable human cancers to 
grow as xenografts (Garber, 2006). The human tumor tissue will be rejected in 
animals with normal and intact immune system and the animals used as hosts 
must have an immune defect. Athymic mice are nude mice and they are not 
capable to process T-lymphocytes responsible for the killing of foreign cells and 
the stimulation of other immune cells to produce antibodies. Implantation of human 
tumor tissue can be done subcutaneously (papers I, II and III) or at the site of the 
origin (orthotopic). 
 
.   
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3. AIMS OF THE THESIS 
 
The aim of this thesis was to expand tumor biological knowledge about GIST and 
to explore the optimal imaging in this patient group with emphasis on FDG PET for 
response evaluation to TKI in this cancer. Three specific aims were addressed: 
 
1. To establish and characterize a human GIST xenograft from a clinically 
imatinib-resistant tumor (the AHAX xenograft) (paper I). 
 
 
2. To explore treatment response mechanisms to TKIs in the GIST xenograft 
by assessing tumor volume, FDG uptake, mitotic rate and expression of 
HIF-1Į, caspase-3 and GLUTs (papers II and III). 
 
 
3. To explore the use of FDG PET, CT and DW MRI as predictors of treatment 
response in GIST patients receiving imatinib treatment (papers IV and V). 
 
 
 
 
 


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4. MATERIALS AND METHODS 
 
An overview of the experiments included in this doctorial thesis is presented in 
Figure 8. In this chapter, the model and the methods are briefly described. More 
details can be found in papers I – V.  
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Figure 8: Overview of the experiments. Abbreviations: PET; positron emission tomography, TKI; 
tyrosine kinase inhibitor, T/L ratio; tumor-to-liver ratio, SUV; standardized uptake value, DW MRI; 
diffusion weighted magnetic resonance imaging, ADC; apparent diffusion coefficient, H&E staining; 
hematoxylin & eosin staining, IHC; immunohistochemistry. 
 
 
Paper I describes the establishment of the human GIST xenograft AHAX. The 
AHAX xenograft was also used in papers II and III for evaluating treatment 
response to different TKI regimes. Paper IV is a case report using PET and DW 
MRI for the evaluation of neoadjuvant treatment with TKI. Finally, paper V 
describes the results from the first ten GIST patients included in our clinical trial 
Treatment response evaluation in patients with GIST using PET/CT and DW MRI. 
ϰϯ

 4.1. Animal studies 

4.1.1. The AHAX xenograft 
The human GIST AHAX xenograft was generated from a human GIST metastasis. 
Several GIST cell lines are available, but GIST xenografts have been difficult to 
establish, and there are a limited number of xenograft models available. AHAX 
harbors a primary mutation in exon 11 (c.1673_1687del, p.Lys558_Glu562del) and 
a secondary mutation in KIT exon 17, D816H (c.2446G>C, p.Asp816His). 
 
4.1.2. Animals 
Female athymic mice were bred at the animal department of our institution and 
kept under specific pathogen-free conditions at constant temperature (22 – 24 °C) 
and humidity (55 – 60 %). The mice were 5 – 7 weeks of age and their weight was 
25 – 30 g (papers I, II and III) when the implantation took place. They were given 
sterilized food and tap water ad libitum. All mice were ear-tagged and followed 
individually throughout the studies. The studies were approved by the Institutional 
and National Committees on Research and Animal Care, and the experiments 
were performed according to Interdisciplinary Principles and Guidelines for the 
Use of Animals in Research, Marketing and Education (New York Academy of 
Science, New York, NY). 
 
4.1.3. Implantation 
The AHAX xenograft was generated by the implantation of GIST tissue fragments 
of approximately 2 x 2 x 2 mm3 subcutaneously into both flanks of athymic mice. 
Tumor diameters were measured with a caliper, allowing estimation of tumor 
volumes. From implantation and throughout the experiments the tumor volumes 
were measured twice weekly (papers II and III). 
 
4.1.4. Anesthetics 
The mice were anesthetized with 0.025 ml/10 g body weight s.c. injections of 
tiletamine 2.4 mg/ml and zolazepam 2.4 mg/ml (Zoletil vet®, Virbac Laboratories, 
Carros, France), xylazine 3.8 mg/ml (Narcoxyl vet, Roche, Basel, Switzerland) and 
butorphanol 0.1 mg/ml (Torbugesic, Fort Dodge Laboratories, Fort Dodge, IA) prior 
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to inoculation of tumor tissue and prior to PET examinations. At the end of the 
experiment the mice were sacrificed by neck dislocation.  
 
4.1.5. TKI treatment 
Imatinib (Glivec®, Novartis Pharma GmbH, Basel, Switzerland) and sunitinib 
(Sutent®, Pfizer Inc., New York, NY, USA) were pulverized and dissolved in 
distilled water or dissolved in 50 mM citrate buffer (pH = 3.5), respectively. The 
mice were treated with either 100 mg/kg imatinib or 40 mg/kg sunitinib by oral 
gavage once daily (paper II) or 100 mg/kg imatinib continuously or intermittently (7 
days Imatinib, 7 days water) (paper III), whereas the control group received citrate 
buffer (paper II) or water (paper III). 
 
4.1.6. PET examination 
PET examinations were performed either in a human PET/CT scanner (Biograph 
16, Siemens, Erlangen, Germany) or in a dedicated small animal PET scanner 
(microPET Focus 120, Siemens Medical Solutions, Erlangen, Germany). All mice 
were fasting before i.p (paper II) or i.v injection of 7 – 10 MBq FDG. 
 
4.1.6.1. Small animal PET 
Static PET acquisition: One hour after injection of FDG the mice were scanned for 
10 minutes.  
 
Dynamic PET acquisition: A catheter flushed with heparinized saline was inserted 
in the tail vein. Acquisition of PET data in list-mode was started prior to 
administration of i.v bolus injections of FDG and lasted for 50 minutes post-
injection.  
 
Groups of 3 mice were placed on the examination table, centered within the 
scanner gantry (Figure 9). Attenuation and scatter correction was obtained for 
both static and dynamic PET by acquiring a 10 min transmission scan with a 68Ge 
point source. 3D dynamic emission data were reconstructed using OSEM-MAP (2 
OSEM iterations, 18 MAP iterations, ȕ  = 0.5, matrix size = 128×128×95) (Qi & 
Leahy, 2000), producing images frames with voxel size 0.87×0.87×0.80 mm3.  
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For the dynamic PET, the reconstructed time frames were 10 seconds during the 
initial 1.5 minutes followed by reduced temporal resolution for the remaining 
frames. In paper III, a 3D image volume of the accumulated FDG uptake during 
the entire acquisition period was generated from the dynamic FDG PET images. 
Axial images were reconstructed from the 3D volume. A VOI containing all tumor 
voxels was obtained by manually delineating tumor tissue in the axial slices, and 
subsequently the mean time activity curves (TACs) for each tumor were 
calculated. The TACs were normalized to individual arterial input functions (AIFs) 
to account for the differences in the injected FDG activity between the animals. 
Individual AIFs were determined by fitting the TAC from the left ventricle to a bi-
exponential function (using the Levenberg-Marquardt least squares minimization 
procedure).  
 
The compartmental model described in Figure 5 was used for kinetic modeling. 
The exchange of FDG between the two tissue compartments is described by the 
rate constants k1, k2, k3, and k4 [min-1], where k1 includes perfusion, vascular 
permeability and the binding of FDG to the GLUT receptors, k2 the clearance of 
FDG back into the blood, k3 the cellular internalization, and k4 the cellular 
externalization. The kinetic parameters were estimated by fitting the TAC to this 
model and non-linear least squares minimization. k4 was assumed to be low, and 
was set to zero in the calculations. The metabolic rate of FDG (MRFDG) was 
defined as (k1Âk3)/(k2+k3). The fit between the measured TACs and the curves 
obtained from modeling were evaluated by calculations of correction coefficients 
(r2) for each tumor voxel. 
 
4.1.6.2. Animal imaging in a Human PET scanner 
The mice were positioned in groups side by side on a heating cushion (Figure 9).  
A CT scan was obtained with a slice thickness of 1 mm and a pixel size of 0.49 × 
0.49 mm2. Subsequently, a 10 minute one bed position PET acquisition was 
obtained. Images were reconstructed by an OSEM iterative technique, using a 2 
mm Gaussian post-reconstruction smoothing filter. The image format was 256 × 
256, the pixel size was 2.67 × 2.67 mm2 and the slice thickness was 2 mm. 
Attenuation and scatter correction were applied before the images were 
transferred to a remote workstation for further image analysis.   
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Figure 9: Positioning of animals in the PET gantry. Anesthesized mice were placed in groups 
up to 10 mice side by side in the human PET scanner (A and B) or in groups of 3 in the center of 
the animal PET scanner gantry (C and D). 
  
 
The co-registered CT images (paper II) were used for guiding the delineations of 
individual regions of interest (ROIs) around tumor and liver. 
 
4.1.7. Tumor to liver ratio 
Tumor-to-liver uptake ratios for individual tumors were obtained by dividing mean 
tumor FDG uptake by the mean liver FDG uptake. All ratios were normalized to 
individual pre-treatment values. Tumor-to-liver uptake ratios obtained from the 
human PET/CT scanner, the small animal PET scanner and from ex vivo counting 
were compared.  
 
4.1.8. Gamma counter 
Immediately following imaging in the human PET/CT the three mice that 
underwent small animal PET examination 24 hours earlier, were sacrificed and 
tumor and liver were harvested (paper II). Tissue samples were separately 
weighted and counted for 1 minute in a gamma counter (Cobra II auto-gamma 
A                                          B 
C                                          D 
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detector, Packard Instrument Company, Meriden, CT, USA). The samples were 
normalized to sample weight. 
 
4.1.9. Histology and immunohistochemistry 
Paraffin-embedded tissue sections were stained with haematoxylin and eosin 
(HE). The mitotic index was counted in 10 (papers I and II) and 20 (paper III) high 
power fields (HPF) (objective x 40, area of a single HPF was 0.3066 mm2). 
 
Formalin-fixed, paraffin-embedded sections were stained using the Dako 
EnVisionTM + System, Peroxidase (DAB) (K4007 and K4011, Dako, Glostrup, 
Denmark) and Dako Autostainer. Semiquantitative classes were used to describe 
the extent (percent of positive tumor cells: absent, 0; < 10%, 1; 10 – 50%, 2; > 
50%, 3) and intensity of staining (absent, 0; weak, 1; moderate, 2; strong, 3). The 
scores (range, 0 to 9) were individually produced by multiplying the value for the 
extent by the intensity of the signal. 
 
4.1.10. Polymerase chain reaction (PCR) and sequencing 
DNA was extracted from the patients’ GIST metastasis (paper I) and from the 
xenografts (papers I, II and III). PCR was performed using 50 ng genomic DNA, 
Hotmaster Taq DNA polymerase (5 PRIME, Hamburg, Germany) and PCR 
primers (Invitrogen, Paisley UK). Cycling conditions were as follows: denaturation 
for 2 min at 94 °C; amplification for 40 cycles, with denaturation for 20 sec at 94 
°C, annealing for 10 sec at 60 °C and extension for 20 sec at 65 °C. After the last 
cycle, a final extension at 65°C for 4 min was performed. Sequencing reactions 
were performed using the BigDye Terminator v3.03 cycle sequencing kit (Applied 
Biosystems Inc, Foster City, CA, USA). The cycle sequencer products were run on 
an automatic capillary sequencer ABI PRISM 3100 Genetic Analyzer (Applied 
Biosystems). 
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4.2. Human studies 
 
Paper IV describes a patient with rectal GIST given neoadjuvant imatinib treatment 
where DW MRI, CT, PET and dynamic contrast enhanced (DCE) MRI were used 
to assess response to neoadjuvant imatinib treatment. Paper V represents 
preliminary results from the first 10 included patients included in the ongoing 
clinical trial entitled Treatment response evaluation in patients with GIST using 
PET/CT and DW MRI. The study protocol (ClinicalTrials identifier NCT01276483) 
was approved by the regional ethics committee of Southeast Norway (REK 
2010/2089) and by Oslo University Hospital (OUS 2010/22785). 
 
4.2.1. Patients 
Preliminary results from the first 10 patients with advanced GIST treated with 
imatinib are included in this thesis (paper V). This includes GIST patients with 
advanced disease; non-operable GIST, borderline resectable GIST (neoadjuvant 
treatment), recurrent and metastatic disease. The study population consisted of 
two women and eight men with an age span from 41 to 91 years (mean; 68 years). 
All patients had KIT mutations, nine with mutation in exon 11 and one with 
mutation in exon 9. The patients were included at different stages of the disease; 
three patients had primary GIST, one had recurrent GIST with metastases and six 
had metastatic GIST. Furthermore, the location of the primary tumor was located 
at different sites; in the stomach (n=6), in the small intestine (n=3) and in the 
duodenum (n=1). The patient from paper IV had a rectal GIST with a KIT mutation 
in exon 11. Written informed consent was obtained from all patients before 
inclusion.   
 
4.2.2. TKI treatment 
All patients received imatinib 400 mg except for one patient with KIT mutation in 
exon 9 who received 800 mg daily. 
 
4.2.3. Imaging 
Imaging was performed before treatment (Tp0) and early after onset of imatinib 
treatment (range; 8–18 days, Tp1). All examinations from the three modalities 
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PET, CT and MRI were performed the same day. Late treatment response was 
obtained from a CT examination performed after three months of treatment (Tp2, 
mean; 84 days). 
 
4.2.3.1. PET examination 
All human PET examinations were performed using a Siemens Biograph 64 
PET/CT scanner. The patients fasted 6 h before the examination. Blood samples 
were obtained before the tracer injection to document normal blood glucose levels. 
PET imaging was started approximately one hour after the administration of 5 
MBq/kg FDG. PET from Tp0 and Tp1 was assessed qualitatively and semi-
quantitatively (SUVmax) using the EORTC recommendations (Young, 1999) and 
PERCIST (Wahl 2009). Both PET examinations were analyzed using the same 
display techniques to provide a consistent intensity of background soft tissue 
activity, and SUVmax was determined. 
 
4.2.3.2. CT examination  
CT with intravenous contrast administration was performed using the Siemens 
Biograph 64 PET/CT scanner, in accordance with clinical protocols. Prior to 
contrast injection the kidney function was evaluated by estimating glomerular 
filtration rate (GFR) from a blood sample. The patients were scanned with the 
contrast in the portovenous phase, using a bolus tracking. The scan was 
automatically started when the contrast attenuation (measured in Hounsfield Units 
(HU)) in the aorta reached a predetermined level, corresponding to the 
portovenous phase. Treatment response evaluation was done according to the 
RECIST and the Choi criteria. 
 
4.2.3.3. MRI examination  
Patients underwent MRI examination using a 1.5 T Discovery 450 MR scanner 
(General Electric Medical systems, Milwaukee, USA) and a cardiac 32-channel 
phased-array coil. The MRI protocol included single-shot sagittal and axial fast 
spin echo T2-weighted images in addition to a free breathing, fat-saturated single-
shot spin-echo echo-planar imaging sequence and 13 b values (ranging from 0–
2000 s/mm2) in three orthogonal directions. Treatment response was quantified as 
change in tumor volume and ADC.  
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5. SUMMARY OF PAPERS 

Paper I: Establishment and Characterization of a Human Gastrointestinal 
Stromal Tumour (GIST) Xenograft in Athymic Nude Mice  
Tumor tissue from surgically removed GISTs from four patients was implanted into 
athymic nude mice, but only tissue from one patient engrafted. Tumor growth was 
monitored and reached one cm in diameter after three months. This xenograft 
(AHAX) revealed similar morphology, showed positive staining for CD117 and the 
mutations were identical to those found in the biopsy from the patient metastasis 
obtained after ten months with imatinib treatment. The mutation status of the 
xenograft thus reflectes the most common clinical scenario in advanced GIST; a 
primary mutation followed by a treatment induced secondary mutation.The mitotic 
count in the xenograft was higher than in the human metastasis. Cytogenetic 
analysis of xenograft tissue confirmed that it was of human origin.  
 
Conclusion: A human GIST xenograft (AHAX) with KIT mutations in exon 11 and 
17 (D816H) was established.  
 
 
Paper II: Monitoring the effect of targeted therapies in a gastrointestinal 
stromal tumor xenograft using a clinical PET/CT 
The human GIST xenograft AHAX was used to assess treatment response to the 
two TKIs imatinib and sunitinib. The mice received imatinib, sunitinib or placebo 
daily for seven consecutive days. FDG-PET/CT was performed in a human 
PET/CT scanner at baseline (day 0), and at follow-up after one and seven days of 
treatment. Treatment response was assessed by measuring tumor volumes and 
by calculation of tumor-to-liver F-FDG uptake ratios. Tumor-to-liver uptake ratio in 
a clinical and a dedicated animal PET scanner were compared to tumor-to-liver 
ratio obtained from ex vivo gamma counter measurement. 
 
Minor reductions in tumor volume were observed in both treatment groups. For the 
two treatment groups significantly decreased tumor-to-liver uptake ratios were 
observed at day 1 and 8, when compared to baseline. In the control tumors, 
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neither tumor volumes nor tumor-to-liver uptake ratios were altered during the 8 
day experimental period. Despite that the AHAX originated from a patient with a 
clinically imatinib-resistant tumor, significant anti-tumor effects of imatinib and 
sunitinib were demonstrated. This may be explained by tumor heterogeneity with 
clones sensitive to imatinib coexisting with resistant clones. Tumor-to-liver ratio 
from ex vivo counting and from in vivo imaging revealed an excellent correlation 
for both the human PET/CT scanner and for the dedicated small animal PET 
scanner. 
 
Conclusion: Despite originating from a clinically imatinib-resistant tumor, anti-tumor 
effects of imatinib and sunitinib were demonstrated in the AHAX xenograft. A 
human PET/CT scanner can be used in the assessment of treatment response to 
novel targeted therapies in small animal models.  
 
 
Paper III: Intermittent and continuous imatinib in a human GIST xenograft 
model carrying KIT exon 17 resistance mutation D816H 
In this study we explored if treatment with intermittent imatinib could prolong 
overall time of imatinib benefit due to less selection pressure compared to the 
routine use of continuous administration. Treatment response was assessed in 
AHAX xenografts by measuring tumor volumes in addition to dynamic PET 
imaging, mutation rate and immunohistochemistry for expression of HIF-1Į, 
caspase-3 and GLUTs.  
 
Both intermittent and continuous imatinib significantly delayed tumor growth 
compared to placebo. The tumour doubling time was significantly shorter in the 
intermittent imatinib group compared to the continuous group. The kinetic rate 
parameter k1, was higher in the intermittent group compared to the continuous 
group, whereas k3 and MRFDG were lower. Tumor GLUT 3 expression was higher 
following intermittent imatinib administration compared to continuous 
administration. Furthermore, the expression of plasmatic GLUT 1 and 2 was higher 
in both treatment groups compared to placebo. This may be explained by 
treatment induced translocation of the receptors.  
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Conclusion: Imatinib reduced AHAX GIST xenograft growth rate despite presence 
of D816H, suggesting that some patients with a secondary resistance mutation 
may still benefit from imatinib. The schedule of imatinib administration may 
influence tumor glucose uptake rate and tumor metabolic rate. Tumor growth was 
slower with continuous administration. 
 
 
Paper IV: DW MRI for evaluation of treatment response to imatinib in a rectal 
gastrointestinal stromal tumor 
A patient with rectal GIST received imatinib for cytoreduction prior to surgery. FDG 
PET/CT after two weeks of imatinib treatment showed decreased metabolic 
activity (76 %). Two months after onset of imatinib treatment CT showed a 
decrease in attenuation to 35 HU (46 %). MRI performed prior to surgery, following 
6 months of imatinib treatment, showed reduced tumour volume (63%). Signal 
intensity at DW MRI was dramatically reduced. ADC was approximately 2.0 x 10-3 
mm2/s, a typical value for non-cystic necrotic tissue. A repeated CT at the same 
time showed unchanged attenuation.  
 
Conclusion: This case report illustrated the potential of DW MRI as a tool for 
monitoring of treatment response in GISTs following TKI.  
 
 
Paper V: Multimodal functional imaging for early response assessment in 
GIST patients treated with imatinib  
Tumor biological properties precede tumor size regression and FDG PET has 
been suggested as a biomarker for early treatment response to imatinib in GISTs. 
In this study we explored the feasibility of DW MRI, FDG PET/CT and CT for early 
response assessment in GIST patients receiving imatinib. 
 
Eight out of 10 patients were responders according to RECIST following three 
months of treatment. For nine patients the ADC change after 12 days of treatment 
correctly predicted treatment outcome. When volumetry was added, all patients 
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were correctly classified with MRI. Seven patients had initial FDG-avid lesions. 
The SUVmax of these had a marked decreased at after 12 days. Increased ADC, 
indicative of treatment response, was found in the three non-FDG avid lesions.  
 
Conclusion: DW MRI correctly predicted treatment response in all patients at an 
early stage. Standardization and the establishment of optimal time-point for 
imaging and treatment response criteria are warranted. 
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6. DISCUSSION 
 
6.1. Animal studies 

6.1.1. Xenografts 
Subcutaneous AHAX xenografts were obtained by implanting tumor tissue 
fragments into the rear flanks of nude mice. At this location the tumors are easily 
accessible, and the contribution from background FDG activity (from surrounding 
organs with physiologic uptake) is minimized. Furthermore, artifacts due to 
respiratory movement and intestinal peristalsis during image acquisition are 
avoided. The subcutaneous xenografts are however, growing in an artificial site 
that is different from where most human GISTdevelop.  
 
Orthotopic models tend to be more clinically relevant since the tumors grow in the 
primary tissue of origin or as a secondary metastasis, and thus orthotopic models 
more realistically reflect tumor growth and recapitulate the human pathways of 
metastasis. To my knowledge, there are no established orthotopic murine GIST 
xenografts available.  
 
Neither subcutaneous nor orthotopic xenografts are ideal models for human 
cancer, and care must be taken when preclinical results are translated into the 
clinical setting. The human tumor does not develop naturally in the mouse, 
containing murine stroma and thus lacks the cellular interactions with the host 
environment, and its vasculature is provided by the host animal. In humans the 
immune system plays an important role in cancers. When using xenograft models 
the immune system has to be suppressed to avoid rejection of the human tumor 
cells. This suppression influences both tumor growth characteristics and response 
to treatment. 
 
Genetically engineered mice spontaneously develop orthotopic GIST. Transgenic 
mice with an activating mutation in KIT were first described by Sommer et al in 
2003 (Sommer, 2003), and this model was later used in a study combining 
targeted molecular therapy and immune therapy (Balachandran, 2011). Two years 
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later another group developed a similar transgenic mouse model (Rubin, 2005) 
followed by another group in 2007 (Nakai, 2008). All models represent KIT 
mutations associated with familiar GIST syndromes. In transgenic models both the 
tumor and the stromal cells are of the same species.  
 
Regardless of the mouse model chosen, there are several hurdles to interpreting 
the relevance to a cancer in human beings. Tumor growth in mice is faster than in 
humans. Hence, cancer agents targeting faster dividing cells may give a positive 
outcome for mice but not necessarily in humans. Slower growth may allow 
establishment of a more “human-like” microenvironment. The fact that the 
metabolism is approximately five to seven times faster in mice than in humans 
must be taken into account when results are interpreted. Another limitation for all 
these preclinical models is that every human tumor is built on a unique genetic 
background, and mouse models with different genetic backgrounds need to be 
tested. Despite these limitations, xenografts in cancer research are widely used 
(Krupke, 2008), and growth characteristics and treatment effects often correspond 
well with results obtained in human cancers (Sausville, 2006). 
 
6.1.2. Animal handling 
Animal handling may influence the biodistribution of FDG, and three to four-fold 
changes in FDG uptake have been reported (Fueger, 2006). Fasting condition, 
body temperature and anesthesia have the highest impact.   
  
In humans, the dietary state has a profound impact on FDG biodistribution. 
Elevated blood glucose level inhibits FDG uptake because FDG competes with 
glucose for transport and phosphorylation, whereas insulin stimulates FDG uptake 
in myocardium and skeletal muscles. Fasting is also necessary because FDG 
uptake in brown adipose tissue increases during feeding. In the literature, the 
duration of fasting varies from 3 – 20 hours. A fasting period of four hours, as used 
in paper II, may have been too short with respect to the anesthetic drugs used 
(discussed below). Since the mice underwent three PET examinations in a period 
of seven days, possible weight loss and animal welfare had to be taken into 
consideration. In paper III FDG PET was performed after overnight fasting. 
  
ϱϲ

FDG uptake in brown fat due to ambient temperature is a well known problem, 
particularly pronounced during seasonal change in humans. This effect is even 
more pronounced in mice (Fueger, 2006). Mice have a zone of thermoneutrality 
between 30 and 34°C, and in lower temperatures mice generate heat by activation 
of brown fat and muscle. In all our studies the mice were positioned on a heated 
cushion to maintain their body temperature and to minimize FDG uptake in brown 
fat.   
 
Subcutaneous injection of Zoletil- Narcoxyl- Torbugesic mixture was given prior to 
all procedures requiring anesthesia (papers I, II and III). This mixture is widely 
used in our institution. The combination of ketamine and xylazine has been the 
most used anesthetic agents given to rodents for imaging studies (Lei, 2001). 
Zoletil consists of tiletamine and zolazepam. Tiletamin is a dissociative anesthetic 
and classified as a NMDA receptor antagonist, and is related to ketamine. 
Zolezepam is a benzodiazepine. Narcoxyl is the brand name for xylazine, an 
agonist of the Į2 class of adrenergic receptor and butorphanol is a morphin type 
synthetic opioid analgestic. Ketamine and xylazine anesthesia have demonstrated 
increased blood FDG activity and reduced plasma insulin levels (Lee, 2005; 
Fueger, 2006). Prolonged fasting reduces xylazine induced hyperglycemia (Lee, 
2005), but may be impractical due to weight loss and when the mice are 
repeatedly imaged within a short time. Xylazine is also known to have diuretic 
effects, and together with increased blood activity of FDG this may be a problem 
when the ROI is placed near the kidney or the bladder (Lee, 2005). Gas 
anesthesia, e.g. isoflurane, provides a safe and effective method for immobilizing 
animals for imaging, but requires both safe supply and exhaust of anesthesia gas. 
Gas anesthesia with isoflurane is considered being the best anesthesia in 
research animal imaging with FDG PET, because of its favorable effect on FDG 
biodistribution. However, the anesthetic method depends on the clinical problem. 
For myocardial studies, isoflurane can mask pathological uptake (Fueger, 2006) 
due to induced increased activity concentration in myocardium.  
Gas anesthesia was not available at the time of these experiments. All 
experiments used identical (per weight) injections of the anesthetic mixture to 
minimize potential influence on the parameters studied.  
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Tracer uptake is slower after i.p injection as compared to i.v injection, but normal 
physiological uptake in organs as well as uptake in tumors has been shown to be 
similar 60 minutes after injection (Fueger, 2006). We had previously performed a 
pilot study and experienced partial paravenous injection in some animals. This 
could bias our comparisons, and we therefore decided to use i.p injection of FDG 
(paper II). For dynamic PET acquisitions i.v injections were required (paper III).  
 
6.1.3. PET imaging of mice  
The availability of dedicated small animal PET scanners is limited, and thus 
researchers have applied adapted clinical imaging systems in animal experiments. 
Aide et al demonstrated that a state-of-the art clinical PET/CT could provide high 
quality images and accurate quantification of the FDG uptake with spatial 
resolution comparable to dedicated small animal scanners (Aide, 2010). This study 
was performed using a modern PET scanner with the latest technology. The FDG 
PET response to TKI in GIST comes early if effective, and is of great magnitude. A 
threshold of 65% reduction in FDG uptake has been proposed as an optimum 
response (Stroobants, 2003; Choi, 2008). We therefore anticipated that a human 
scanner would be able to detect this response in xenografts within tumor volumes 
of approximately 500 mm3. The resolution of the human PET/CT scanner is clearly 
inferior to that of the small animal PET-scanner. With the selected gaussian filter, 
the full-width at half maximum (FWHM) of the point spread function of the human 
PET scanner is 4.8 mm in the centre of the field. If there are tissues adjacent to or 
overlapping with the xenograft or liver, one would get a systematic error when 
calculating the tumor-to-liver ratios. With subcutaneous xenografts in the flanks, 
this background contribution was small. Despite the inferior quality of our human 
scanner, the ex vivo tumor-to-liver ratios were comparable to the ratios obtained 
from imaging. This supports the validity of our conclusions (paper II).   
 
The human PET/CT-scanner has the advantage of being able to handle a large 
number of small animals simultaneously, thereby allowing high throughput 
imaging. Identical hardware, software and acquisition protocols for easier 
examination of animals and humans ensure consistency of the data recorded. This 
provides easier translation of developments from mouse to man in a clinical 
setting.  
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For the small animal PET studies anatomic co-registered CT images were not 
available. Tumor heterogeneity will give variation in uptake intensity in different 
parts of the xenograft and this could influence tumor delineation. If tumor areas 
with low activity are not included in the ROI, the overall tumor uptake will be 
overestimated. In order to minimize this influence, 3D techniques were used.  
 
The FDG dose was not corrected for residual activity in the syringe or 
administration system. Consequently the exact injected FDG dose was not 
measured and SUV could not be calculated. In retrospect, calculation of SUV 
should have been included as this would have allowed an easier comparison with 
patient imaging. 
 
6.1.4. Dynamic small animal PET 
High-quality compartment
 
modeling requires repeated invasive arterial blood 
sampling for the accurate determination of the AIF. This can be difficult to obtain 
from mice without affecting the physiological function. Reference tissue models 
have been developed where the arterial input curve (AIC) is substituted with the 
TAC assuming that non-specific binding and free tracer in reference tissue and in 
all tissues is identical. These models do not allow a full kinetic analysis, but have 
been shown useable (Hjornevik, 2010). In our study, FDG uptake in the heart and 
in the tumor was obtained in the same acquisition, and three-dimensional 
individual AIFs were obtained. AIFs were not compared to arterial blood sampling, 
and this is a limitation in our study. A validation of the AIFs is therefore required. 
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6.2. Human studies 
 
A patient with a rectal GIST receiving neoadjuvant imatinib treatment is presented 
in paper IV. This patient underwent PET, CT and MRI (including DW MRI) before 
the initiation of imatinib treatment. As the different imaging modalities in paper IV 
were applied at different time points, the value of response parameters obtained 
from different modalities could not be directly compared. A reliable comparison 
requires standardized acquisition parameters and post-procession procedure as 
well as experienced readers blinded to the results from the other imaging 
modalities – a design being used in the ongoing clinical study where our first 
experiences are presented (paper V).  
 
6.2.1. Patients 
There was a variation in site of origin and stage of disease between the included 
patients, factors known to carry prognostic information. However, all patients 
harbored a KIT mutation. It could be anticipated that the influence of these 
prognostic factors is more important for tissue characterization than for 
assessment of treatment response which is the focus of our clinical study (paper 
V). The patient population is limited and the heterogeneity might influence our 
initial conclusions. More patients must be included in order to add power to our 
findings. However, the patient population is representative for the clinical spectrum 
in GIST. 
 
6.2.2.1. PET examination 
The PET examinations were analyzed using the same standardized PET protocol 
and display techniques to provide a consistent intensity of background soft tissue 
activity. As the SUVmean of liver between consecutive PET examinations was less 
than 0.8 units, the measured changes in SUV can reliably be attributed to 
treatment induced changes in tumor metabolism.   
 
6.2.2.2. CT examination 
Each patient was scanned with the contrast in the portovenous phase, obtained 90 
seconds after i.v administration. This fixed approach does not account for patient-
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dependent factors such as reduced cardiac output. Time to tissue and tumor 
enhancement will increase when cardiac output decreases. A bolus tracking 
program would have eliminated most patient dependent factors and given 
reproducible contrast load in the tumor. In paper V we compared differences 
between individual examinations performed within a limited time interval, and 
therefore large variations in patient dependent factors were not expected.   
 
6.2.2.3. MRI examination 
DW MRI was performed and analyzed using the same standardized protocol with 
13 b values. Several interpreter-dependent factors as well as b value selection and 
post-processing algorithm will influence the ADC. The differential diagnostic 
accuracy might be improved by the inclusion of high b values (> 1000 s/mm2) in 
the ADC calculation (Ochi, 2011). On the other hand, such high b values can 
impact on the available signal to noise ratio and the ADC might be 
underestimated. The absolute ADC of GISTs is important for tissue differentiation 
and characterization. For treatment response monitoring in individual patients 
reproducibility is essential. Acquisition of two repeated MRI examinations within a 
short time interval would have allowed access to such reproducibility data. In our 
clinical protocol it is challenging to incorporate a second MRI examination in 
addition to the already scheduled PET/CT, CT and MRI.  
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6.3. Representative tissue samples  

Cancer treatment outcome is often confounded by tumor heterogeneity and GIST 
is no exception (Corless, 2011). A common approach to analysis of altered protein 
expression in cancers is to include immunohistochemistry on biopsy samples. All 
immunohistostaining and scorings in the papers I – V were obtained from a single 
tumor section. Failure to evaluate the entire tumor may lead to sampling errors 
related to tumor heterogeneity, errors similar to those connected with many 
invasive methods in the clinic.   
 
 
6.4. Prediction of treatment response  

Visual reading is the main method for image interpretation in clinical practice. 
Usually this is an adequate method, but treatment response evaluation may be 
challenging. The method should be accurate and ideally observer-independent. 
Response to treatment can be assessed using qualitative and/or quantitative 
parameters, and a response scale can be binary or continuous. The focus of the 
subsequent discussion will be the use of FDG PET for evaluation of therapy.  
   
6.4.1. Prediction of treatment response with PET 
In qualitative analysis the tumor uptake is compared with uptake in normal 
structures such as brain, liver and blood pool. This is the recommended method 
when evaluating lymphoma, and the most frequently used criteria also dichotomize 
the PET results into positive and negative findings compared to the blood pool, 
liver or nearby normal structure uptake (Juweid, 2007; Cheson, 2007). This 
approach has been shown to be reliable (Kasamon, 2007), but can be challenged 
when it comes to “borderline” patterns of FDG uptake often termed as minimal 
residual uptake. PET scoring using a five-point visual scale has also been used 
(Kasamon, 2009). 
 
Several studies have explored the reproducibility of FDG PET (Weber, 1999; Krak, 
2005; Nahmias, 2008). Mainly, the reproducibility depends on lesion size, image 
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acquisition method, reconstruction parameters and analysis. Variability in 
quantitative measurements has been reported to be up to 50% or even more 
(Boellaard, 2004; Weber, 2005; Krak, 2005). Quantitative measures may range 
from semi-quantitative methods such as SUV to full kinetic measurement such as 
Patlak (Gjedde, 1981; Patlak, 1983). Lammertsma et al discussed the relationship 
between simplified methods and full kinetic analysis. All such studies have 
concluded that caution should be taken when using simplified methods for 
evaluation of treatment (Hoekstra, 2000; Lammertsma, 2006). In papers VI and V 
SUV measurements were used for the evaluation of treatment response. A full 
kinetic analysis is anticipated to have provided more information, but with today’s 
PET technology acquisition of dynamic PET data is limited to a single FOV 
(ranging from 13 and up to 22 cm).  
 
The EORTC first provided guidelines for the assessment of tumor response with 
FDG PET (Young, 1999), but did not take into account the limitations and accuracy 
of the different analytical methods for response evaluation. The PERCIST has tried 
to standardize the qualitative and quantitative approach to tumor treatment 
assessment with FDG PET (Wahl, 2009). The proposed guidelines were used in 
papers IV and V to increase the reliability of our findings. 
 
Some GISTs do not show sufficient FDG uptake or may be to small to be detected 
by PET (Choi, 2004; Goerres, 2005). Choi reported that 36 out of 173 (21%) 
lesions did not have detectable FDG uptake on pretreatment PET and 17 of these 
were > 2 cm in size (Choi, 2004; Choi, 2008). Goerres et al detected 46% more 
lesions on pretreatment contrast enhanced CT, but CT provided insufficient 
prognostic power concerning treatment response. They also reported absent FDG 
uptake in seven out of 34 patients (Goerres, 2005). Of the 10 GIST patients 
included in paper V, three did not have sufficient FDG uptake for further response 
evaluation, which emphasizes the need for a multimodal approach. All the FDG-
avid lesions had a pronounced decrease in SUVmax after 12 days on treatment, 
(mean reduction of 78%), but only five out of these seven patients were classified 
as responders according to RECIST after three months of treatment. The other 
two patients with decreased SUVmax were both classified as having stable 
disease. Thus, response assessed with PET could be correctly predicted in only 
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five out of 10 patients. Previous studies show that both imatinib responders and 
patients attaining disease stabilization achieve similar survival outcome (Demetri, 
2002; Blanke, 2008a; Blanke, 2008b). The importance of distinguish between 
response and stable disease may therefore be artificial.  
 
6.4.2. Prediction of treatment response with CT 
Our clinical study (paper V) demostrated that evaluation of early response to TKI in 
GIST was not reliable when only change in tumor size was used as response 
parameter. This finding is in accordance with several other studies (Stroobants, 
2003; Antoch, 2004; Goerres, 2005; Van den Abbeele, 2008; Van den Abbeele, 
2012). The antitumor activity will for the majority of GISTs eventually translate into 
tumor shrinkage, but changes in tumor density may occur much earlier. This 
should be scored as response, even in situations with increased tumor size. In our 
study only two out of the 10 GIST patients were were classified as responders 
according to RECIST. Five more patients showed a decreased attenuation above 
the Choi criteria response cut-off (15%) 12 days after onset of imatinib treatment. 
Dudeck et al questioned the clinical value of the Choi criteria as no predictive 
value of discriminating between partial response from stable disease after 3 
months was found in a study of 52 GIST patients receiving sunitinib treatment 
(Dudeck, 2011). The Choi criteria were based on GISTs naïve to TKI medication, 
and the use of these criteria in patients previously treated with TKIs is 
controversial (Dudeck, 2011). In our study (paper V), with not all patients being 
naïve to TKI medication, the performance of CT and the Choi criteria was superior 
to FDG PET. A larger study population is needed to confirm our findings.  
 
GISTs can develop intratumoral (within the tumor) nodules where and when 
secondary resistance first occurs (Shankar, 2005; DeMatteo, 2007). An 
intratumoral nodule will appear as a change in density and structure at CT. 
However, it may be difficult to distinguish a “nodule in a mass” due to the 
development of secondary resistance from other causes e.g tumor bleeding.  
 
6.4.3. Prediction of treatment response with DW MRI 
Treatment leading to necrosis or lysis will give increased tissue water diffusivity, 
decreased signal intensity at high b values, and increased ADC. However, 
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increases in ADC as a result of tumor cell death may not be prolonged and will 
with time fall due to phagocytosis of dead cells, remodeling of tissues, vascular 
normalization and development of fibrosis (Padhani, 2011). If the tumors develop 
resistance followed by repopulation, the ADC will also decrease. Thus it can be 
difficult to distinguish between remodeling of tissue and growth of malignant cells.  
Furthermore, biological heterogeneity of GISTs and their variable response to 
imatinib treatment challenge the interpretation of images from these patients. 
Thus, in-depth knowledge of the physical principles underlying image information 
and treatment mechanisms are essential for interpretation of treatment response. 
When tumor tissue is intermixed with normal tissue and the tumor consists of 
several tissue components, image values obtained for the entire lesion may be of 
limited clinical value since the response to treatment may be different for different 
components. Isolated use of mean ADC may therefore be misleading, and 
histogram analysis or functional mapping may increase the predictive outcome of 
ADC measurements. In order to fulfill these requirements, an experienced MR 
radiologist in oncology interpreted both the DW MRI and ADC maps in the clinical 
study (paper V). 
 
The use of increased ADC as an early marker of treatment response has been 
reported in several preclinical and clinical studies for different cancers (Hamstra, 
2005; Seierstad, 2007; Cui, 2008; Dudeck, 2008; Lee, 2010). Tang et al have 
explored the predictive use of ADC at different time points after onset of imatinib 
treatment in GIST. They found that the largest difference in ADC change between 
responders and non-responders was observed after one week of imatinib 
treatment, with a median ADC increase of 44.8% and 1.5% for the responders and 
non-responders, respectively (Tang, 2011). Although the time interval between our 
registrations was a few days more than one week, the median increase in ADC for 
responders was of similar magnitude in our study (paper V) (mean 64%). The 
extent of change in ADC needed to anticipate a true treatment effect has not been 
established. Reported reproducibility results range from 10 – 30% (Koh, 2009; 
Miquel, 2012; Kim, 2012) and the ADC increase for responders in Tang et al and 
our own findings in paper V support a cut-off of 30%. Larger prospective studies 
with special emphasis on the establishment of optimal time-point for imaging and 
treatment response criteria are needed.  
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In paper V, the change in ADC after 12 days of treatment correctly predicted 
treatment outcome in nine out of 10 patients after three months. When MRI 
volumetry was added all patients were correctly classified. Thus, in our limited 
study population DW MRI was superior to FDG PET and CT for early assessment 
of treatment response. 
 
Tissue movement and water motion (cardiac pulsations, peristalsis and 
respiration) affect image quality. Schemes that detect the direction and magnitude 
can partly correct for these motions. Furthermore, heart- and respiration gating or 
images in breath-hold, will reduce motion artifacts. In paper V, respiratory-
triggering was used when lesions were located in the upper abdomen. Peristalsis 
can be suppressed by administration of spasmolytic agents, such as butyl 
scopolamine and/or administration of glucagon. In paper V only one patient had a 
GIST in the intestine (duodenum), and anti-peristaltic medication was anticipated 
to have limited value and was therefore not given. The patient with rectal GIST in 
paper IV received premedication with both butyl scopolamine and glucagon prior to 
the MRI examinations.  
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6.5. FDG PET quantification 

A systematic overview of factors affecting FDG PET quantification is given in 
Supplement to JNM May 2009 (Boellaard, 2009) and some of them are discussed 
below.  
 
6.5.1. SUV measurements 
The SUV is limited by its dependency on patient preparation, scanning procedure, 
image reconstruction and image analysis (Weber, 2005; Boellaard, 2009). 
Standardized procedures to avoid these limitations are therefore warranted 
(Weber, 2005; Shankar, 2006; Boellaard, 2009). 
 
Full kinetic analysis by the use of AIF and TAC in combination with the FDG kinetic 
model and plasma glucose levels (referred to as Patlak) (Patlak, 1983) provides a 
more true measurement of the metabolic rate of glucose. However, good 
correlation of the percentage change between SUV and Patlak is reported 
(Freedman, 2003). 
 
SUV calculations have, however, proven to be reproducible on the same PET 
scanner and in the same patient (Weber, 1999; Nahmias, 2008). Sequential follow-
up with SUV for cancer patients is therefore valuable. Standardization is, however, 
mandatory, being specified in the EORTC criteria and the PERCIST. 
Methodological factors found to be highly variable between imaging centers were 
the uptake period, handling of patients with diabetes and/or high plasma glucose 
levels, FDG dose, imaging time per bed, imaging reconstruction, processing, and 
data analysis (Beyer, 2011; Graham, 2011). Figures 10, 11 and 12 illustrate 
effects due to image reconstructions and respiration. By standardization of the 
clinical protocol the variability of SUV and image artifacts were minimized in 
papers VI and V. 
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Figure 10: Reconstruction with Gaussian post-reconstruction filters with FWHM equal 5.0 
(upper panel) and 2.0 mm (lower panel) in a patient with a metastasis on the right side of the neck 
with a size of 7 mm. SUVmax was 4 and 11, respectively.  
 
Previous studies have shown that malignant lesions often continue to accumulate 
FDG from an early phase to a delayed phase (Chan, 2011a; Miyake, 2012). 
Consequently, time between FDG injection and PET will influence SUV. As the 
time difference between consecutive FDG PET/CT examinations included in paper 
V was less than 16 minutes (median; 9, range; 3 –16) this influence was minimal in 
our study.  
 
SUV can be normalized to body weight (bw), lean body mass (lbm) or body 
surface area (bsa), the two last being less dependent on body habitus. SUV 
normalized to lean body mass (SUVlbm) and body weight (SUVbw) are usually 
relatively similar. FDG does not accumulate in white fat in a fasting state and 
patients with high body weight will therefore have high SUVbw in normal organs 
and overestimated SUV (Sugawara, 1999; Shankar, 2006) as illustrated in Figure 
11. SUVlbm is therefore more consistent between patients. Furthermore, changes 
in body weight may occur during the course of treatment and thus, lbm may be 
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preferable for response assessment studies. Normalization to lbm is also 
recommended in the PERCIST (Wahl, 2009) and the EORTC criteria from 1999 
(Young, 1999). In papers IV and V SUVmax prior to and after onset of treatment 
were normalized to lean body mass to account for possible alteration in body 
composition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: SUV normalized to body weight (bw, left column) and lean body mass (lbm, right 
column) for a patient with an adenocarcinoma in the right lung. SUVmax normalized to bw and lbm 
was 5.8 and 2.3, respectively. 
 
6.5.1.1. SUVmax, SUVmean and SUVpeak 
SUVmax is obtained from the most metabolically active part of the tumor and thus, 
probably reflects the most clinically interesting part. SUVmax is usually measured 
with high interobserver reproducibility (Wahl, 2009; Lodge, 2012). The use of 
SUVmax is less affected by partial-volume effects in small tumors (Soret, 2007). 
Furthermore, SUVmax has the practical advantage that it can be determined 
without precise tumor delineation. However, a single pixel measurement can be a 
vulnerable parameter regarding image noise (Boellaard, 2004; Lodge, 2012). This 
may be one of the reasons for the reduced reproducibility observed for SUVmax 
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compared to SUVmean in a larger ROI observed in replicate studies (Nahmias, 
2008). By using single-pixel SUVmax as a marker for treatment response caution 
must therefore be applied (Boellaard, 2004; Lodge, 2012). A recent study of Lodge 
et al (Lodge, 2012) concluded that for images with noise properties, such as in 
human whole-body PET, SUVpeak is a more robust parameter. SUVpeak is 
defined as the mean SUV within a small, fixed-size ROI centered around a high 
uptake region of the tumor (Wahl, 2009). SUVpeak represents measurements in a 
larger volume and is therefore less affected by noise and may reduce uncertainties 
in the quantification of treatment response. Calculation of SUVpeak was not 
available at the time when studies IV and V were performed, and we therefore 
decided to use SUVmax for the assessment of treatment response.  
 
6.5.2. Partial volume effect or intensity diffusion  
The true FDG uptake corresponds to the intensity uptake in a tumor with a size of 
more than three times the FWHM of the reconstructed image resolution with 
homogeneously distributed FDG uptake (Soret, 2007). If a tumor is small, has an 
irregular shape or a heterogeneous activity concentration, the uptake will be 
underestimated due to intensity diffusion. This phenomenon originates from the 
physical characteristics of the PET detector, the reconstruction properties and 
post-reconstruction smoothing filters giving an image where the signal from a point 
source appears to be spread over a wider area. (Soret, 2007; Skretting, 2009; 
Skretting, 2010).This distribution will, if the point source is reconstructed with small 
enough voxels be Gaussian distributed. FWHM of the Gaussian function is 
approximately 5 – 8 mm and as low as 3 – 4 mm in the latest generation of PET 
scanners. This phenomenon will give underestimation of the FDG uptake in both 
the visual impression and in SUV measurements in small structures. For structures 
less than 15 mm this effect is highly significant (Soret, 2007; Skretting, 2009; 
Skretting, 2010). Thus, a small tumor will appear larger and less aggressive than it 
truly is. The partial volume effect, perhaps better described with the term intensity 
diffusion (Skretting, 2009), may also occur in the opposite direction with diffusion 
into a lesion from the surroundings with higher activity. Correction factors have 
been proposed (Soret, 2007; Srinivas, 2009) but the use of such recovery factors 
has not reached clinical practice and is also seldom used in preclinical studies.     
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In our xenograft studies, some of the xenografts were smaller than 15 mm in 
diameter. The FDG uptake in these tumors was probably underestimated due to 
intensity diffusion. There were no significant differences in the average size of the 
tumors from the different groups. Hence, the impact of intensity diffusion should be 
the same in all three groups. In our clinical studies none of the detected GIST 
lesions were smaller than 20 mm with an average size of 39 mm.  
 
6.5.3. Blood glucose level 
The blood glucose level affects the FDG uptake and in non-fasting patients and 
hyperglycemic patients the high blood glucose will cause competitive replacement 
of FDG (Wahl, 1992). It has been suggested that SUV should be corrected for 
elevated blood glucose levels (Shankar, 2006) and the EANM procedure 
guidelines for tumor PET imaging: version 1.0, (Boellaard, 2010), recommend SUV 
calculations with and without plasma glucose correction in all response monitoring 
assessment studies, but this has not yet reached clinical practice. Weber et al 
(Weber, 1999) concluded that the reproducibility of SUV was less dependent on 
glucose correction factors, and that the ROI and the size of the lesion were the 
most important factors in the test-retest setting. The PERCIST criteria do not 
recommend glucose correction.  
 
In case of high glucose values (> 11 mmol) the guidelines state that the PET study 
should be postponed (Shankar, 2006; Boellaard, 2009). This cut-off value is 
almost two-fold higher than normal blood glucose levels and such a high value 
may result in lower SUV.  
 
In our clinical studies (papers IV and V) all patients fasted for at least 6 hours and 
glucose level was measured prior to FDG administration. None of the patients had 
a glucose level > 7 mmol/L and the mean blood glucose level was 5.5 mmol/L. In 
the xenograft studies (papers II and III) the blood glucose level was not measured. 
This topic is discussed under Animal handling and Anesthesia.  
 
6.5.4. Selection of ROI  
Use of a ROI located within the metabolically most active part of the tumor, or a 
ROI including the total tumor volume, will inevitably provide different activity 
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measurement. Studies on stem cell biology suggest that the most aggressive parts 
of the tumors are of outmost importance (Matsui, 2008). This is controversial, but 
has proven to be sufficient for different cancers. The total tumor volume and its 
metabolic activity, i.e. the total glycolytic volume, may be useful for studying the 
whole tumor behavior.  
 
Different ROI selection metrics have been used: manually defined ROIs, irregular 
isocontour ROIs based on fixed percentage threshold of the pixel with maximum 
uptake, fixed SUV threshold, background-level threshold, and small fixed-
dimension ROIs placed over the part of tumor with highest uptake (e.g. SUVpeak 
as recommended in PERCIST). The most common approach in the clinical setting 
is the SUV obtained from a pixel or a voxel with the highest uptake (SUVmax) 
being a sort of single-pixel/voxel ROI, but there is a growing use of SUVpeak 
(Wahl, 2009).  
 
Furthermore, the size of ROI may influence the reproducibility of SUV since SUVs 
from large, fixed ROIs are more accurate than single-pixel SUVs (Krak, 2005; 
Nahmias, 2008). In papers IV and V, SUVmax calculation was obtained from a 
spherical VOI placed over the tumor region with visually highest uptake. By using a 
VOI (three dimensional volume) in papers IV and V, errors due to placement of 
ROIs (two dimensional area)  were reduced.  
 
6.5.5. EORTC and PERCIST criteria – application to GIST 
Based on reproducibility studies a more than 20% decrease in SUV could be 
defined as a response (Weber, 1999). However, when the baseline SUV is low, 
even a minor change in SUV can reach a threshold of more than 20 – 30%. 
Whereas EORTC criteria do not take this into account, PERCIST has defined a 
minimal measurable level of tumor uptake (liver SUVmean x 1.5 + 2 SDs and an 
absolute change in SUV of 0.8 units). 
 
A 15%/25% (after one cycle- /two or more cycles of chemotherapy), and 30% 
decrease in SUV as proposed as thresholds for response in the EORTC criteria 
and PERCIST, respectively, do not appear to correlate with good outcomes in 
GIST patients treated with imatinib. Stroobants et al showed that a modest 
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decrease in SUV of 30% after therapy was not associated with improved outcome, 
suggesting that a larger threshold was needed (Stroobants, 2003). Choi identified 
a threshold for “good response” on FDG PET as a decrease in SUV > 70% from 
baseline or a drop in absolute SUVmax > 2.5 (Benjamin, 2007; Choi, 2008), and 
found this to be an excellent prognostication in terms of PFS (Benjamin, 2007). A 
recently published study reported a mean decrease in SUV > 85% in patients with 
exon 11 mutations receiving neoadjuvant imatinib (Van den Abbeele, 2012). 
However, Prior et al found that in early FDG PET prediction (after 4 weeks) of 
response to sunitinib after imatinib failure, the use of the EORTC criteria with a 
decrease of FDG > 25% was predictive of PFS (Prior, 2009). In paper V, all seven 
patients with FDG avid lesions at baseline were responders after 12 days of 
treatment according to the EORTC criteria and the PERCIST. In two of these 
patients the marked decrease in SUVmax was not followed by a reduction in tumor 
diameter after three months and both were classified as having stable disease. As 
discussed earlier, the importance of distinguishing between response and stable 
disease is debatable. In papers IV and V all patients received imatinib, and the 
mean decrease in FDG avid lesions was 76% and 78% (range 48 – 96%) 
supporting previous reports suggesting that a higher threshold than proposed in 
EORTC and PERCIST may be appropriate (Stroobants, 2003; Choi, 2008; Van 
den Abbeele, 2012). 
 
Complete metabolic response as assessed with FDG PET has frequently been 
reported in GIST patients receiving TKI; however, cure is rare in a metastatic 
setting (Chacon, 2005; Blanke, 2008a). A negative PET during TKI treatment may 
suggest good treatment response, but does not ensure the nonexistence of cancer 
cells (Agaram, 2007; Corless, 2011). One out of the 10 patients included in paper 
V provides a good illustration of this phenomenon: The patient underwent liver 
resection of a solitaire metastasis after 11 weeks of imatinib treatment. Compared 
to the primary tumor, the resected metastasis showed less cellularity with more 
collagenous fibres, but only very small areas with necrosis. The histological 
response was graded as low, > 10 and  50% supportive of stable disease. 
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6.5.6. Motion correction and precise co-registration between PET and CT 
Static PET/CT imaging of tumors in areas with physiologic movements, such as 
the heart, intestine, lungs and upper abdomen may be affected in two ways that 
appear simultaneously: First, a mismatch between the CT used for attenuation 
correction and the PET acquisition may lead to significant over- or underestimation 
of the tumor uptake. Second, the smearing of the image of a tumor leads to 
quantification errors, positional uncertainties or errors and overestimation of tumor 
size, especially for small tumors (Liu, 2011).  
 
Tumors within or close to the liver may be misregistrated into the liver or into the 
lung because of respiratory movements. Such misregistrations may be difficult to 
discover. However, respiratory gating may provide the correct localization of such 
tumors (Figure 12).  
 
 
 
Figure 12: Misregistration between PET and CT performed during normal breathing in a patient 
with a metastasis (red arrows) in the dome of the liver (upper row). By performing repeated breath-
hold respiratory gating the focal FDG uptake is correctly located in the liver and with higher uptake 
intensity (lower row). Since attenuation correction was performed on the basis of lung tissue 
instead of liver tissue the attenuation correction was markedly insufficient, and SUVmax increased 
from 8.7 to 18 following repeated breath-hold respiratory gating.  
 
No PET/CT motion corrections were performed in the included papers. By 
implanting the xenografts subcutaneously in both flanks, artifacts due to 
respiratory- and intestinal peristaltic movements during acquisition were 
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minimized. In the clinical studies (papers IV and V) tissue movements and 
mismatch between PET and CT images might have affected the SUVmax 
measurements. Several of the included patients in paper V had GIST lesions in the 
upper abdomen, and respiratory movements might have affected the co-
registration, the attenuation correction and the estimation of tumor uptake. This is 
a clear limitation in this study. 
 
6.5.7. FDG 
FDG is not a cancer specific imaging tracer. Positive findings are observed in 
active inflammation and infection, too. High FDG uptake indicates enhanced 
cellular glucose metabolism independent of the normal physiological uptake of the 
cells. Both activated macrophages and metabolically active cancer cells will 
accumulate FDG. Sarcoidosis and sarcoid reactions can occur in cancer patients 
(”sarcoid reactions”) referring to the development of noncaseating epithelioid cell 
granulomas in patients who do not fulfill the criteria for systemic sarcoidosis 
(Cohen, 2007). This phenomenon predominantly occurs in patients with Hodgkin 
lymphoma (Haran, 2002), but can also occur in patients with solid tumors (Okada, 
2005; Martella, 2012). It has been suggested that anticancer therapy may result in 
the release of an antigen that is able to trigger the onset of a sarcoid reaction 
(Brincker, 1995) (Figure 13). Due to limited specificity of FDG PET, FDG positive 
lesions may require histological verification to establish correct diagnosis.  
 
6.5.8. Correlation between FDG and GLUT expression in GIST  
Studies suggest that changes in expression of GLUTs and glucose metabolism 
may be the cause of the anticancer mechanism of imatinib (Prenen, 2005; Tarn, 
2006). GIST cells are anticipated to express different GLUTs (Prenen, 2005) with 
translocation to the plasma membrane from an intracellular storage described for 
GLUT 1 and GLUT 4 (Prenen, 2005; Tarn, 2006). We also found a higher 
cytoplasmic GLUT 1 and GLUT 2 expression in both treatment groups compared 
to the control group in paper III, which may be explained by an imatinib induced 
GLUT translocation via endocytosis from the plasma membrane to cytosol. In vitro 
experiments performed by Tarn et al have confirmed that decreased glucose 
transport into GIST cells after imatinib is due to inhibition of the AKT activity. 
Observed cell growth arrest and apoptosis were, however, found independently of 
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Figure 13: Patient with rectal GIST prior to (left) and after 2 weeks of imatinib treatment (right) who 
developed metabolically active lymphadenopathy in the mediastinum (sarcoid reaction). The 
patient did not have any symptoms of lung infection or elevated infection parameters (patient from 
paper IV).  
 
 
AKT activity, suggesting that the glucose uptake was not the only mechanism 
behind imatinib induced growth arrest and cell death (Tarn, 2006). 
 
FDG is transported across the cell membrane by GLUTs. Intracellular FDG is 
phosphorylated in the same way as glucose. In contrast to glucose-6-phosphate, 
phosphorylated FDG is metabolically trapped. In vitro studies have shown that 
changes in glucose metabolism can be identified on FDG PET (Prenen, 2006; 
Tarn, 2006). However, in contrast to FDG PET observations during cytotoxic 
therapy showing a slow and gradual reduction in glucose metabolism, the change 
in glucose metabolism during imatinib treatment is rapid with an almost complete 
shutdown (Shinto, 2008) (paper II). This observation may be due to a direct 
treatment effect on the glucose metabolism rather than a direct antitumor effect. 
This hypothesis is consistent with the observation of a tremendous decrease in 
FDG uptake after initialization of treatment, although areas with high cellularity are 
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still demonstrated microscopically (paper IV). Recently, two clinical studies 
investigated GLUT expression in GIST patient. A case report found GLUT 4 to be 
the main glucose transporter in an esophageal GIST with high FDG uptake at PET 
(Kaida, 2010). GLUT 4 expression was also examined in 22 patients before 
receiving neoadjuvant imatinib (biopsy). A decrease in GLUT 4 expression was 
seen in posttreatment specimens (resection) from 19 patients while GLUT 4 was 
unchanged in three patients (Van den Abbeele, 2012).  
 
In paper III, a significant difference in the expression of GLUT 3 between 
continuous and intermittent treatment with imatinib was found. GLUT 3 is known 
for its expression in neurons and has originally been designated as the neuronal 
GLUT. GISTs are thought to arise from the progenitor cells of Cajal and show both 
muscle and neuronal differentiation. Increased GLUT 3 expression can lead to the 
observed increased FDG uptake, and may thus partly explain the increased 
exchange rate k1 at dynamic PET in the intermittent treatment group.  
 
ϳϳ

6.6. Mutation type 
 
The mutation status can to some extent predict treatment response to TKI 
(Heinrich, 2003a; Corless, 2005; Heinrich, 2008). GIST with KIT exon 11 mutations 
have better response to imatinib and longer time to progression (receiving 400 mg 
imatinib daily) compared to KIT exon 9 mutations or wild-type (Heinrich, 2008). KIT 
exon 9 mutations have longer recurrence free survival treated with 800 mg vs 400 
mg imatinib daily, and respond better to sunitinib than GIST with KIT exon 11 
mutations (Heinrich, 2008; Demetri, 2012). A point mutation in the PDGFRA exon 
18, D842V is resistant to imatinib (Demetri, 2002; Corless, 2005). Furthermore, an 
association between development of resistance/secondary mutations and TKI 
response is seen (Corless, 2011). Patients with secondary KIT exon 13 and 14 
mutations receiving sunitinib have increased overall survival compared to KIT exon 
17 (e.g. D816H) and 18 mutations (Heinrich, 2008; Demetri, 2012). 
 
The AHAX xenograft used in papers I, II and III, harbors a primary KIT exon 11 
deletion mutation involving codon 558 (c.1673_1687del, p.Lys558_Glu562del) 
associated with poor survival and a secondary mutation in KIT exon 17, D816H 
(c.2446G>C, p.Asp816His) associated with resistance to imatinib and sunitinib.  
From a clinical point of view this is an interesting model since the KIT exon 11 
deletion mutation is the most common mutation in GIST, and exon 17 point 
mutations are the most frequent mutations considered to confer imatinib 
resistance. This model thus reflects the most common clinical scenario in imatinib-
resistant GIST.  
 
It has been postulated that the mutation status correlates with the degree of FDG 
uptake intensity reduction; the most common KIT mutation having highest 
metabolic response and the wild-type showing a somewhat lower metabolic 
response (Van den Abbeele, 2012). However, in our preliminary results (paper V) 
three out of 10 patients did not have sufficient FDG uptake at baseline to be 
monitored by PET. These patients all had common mutations in KIT (two in exon 
11 and one in exon 9). 
 
ϳϴ

7. CONCLUSION  
 
The work presented in this thesis describes the establishment of the human GIST 
xenograft AHAX harboring KIT exon 11 and KIT exon 17 mutations, i.e. it reflects 
the most common clinical scenario in imatinib-resistant GIST. KIT exon 11 is the 
most common site of mutation in primary GIST and KIT exon 17, such as D816H, 
is the most frequent site of a secondary resistance mutation. 
 
Despite originating from a patient who was clinically regarded to have an imatinib- 
and sunitinib resistant tumor, significant anti-tumor effects of both these TKIs were 
demonstrated in the AHAX xenograft studies. The original primary mutation is 
virtually always present in GISTs that contain a secondary resistance mutation and 
this KIT exon 11 mutation, unlike the mutation in KIT exon 17, continues to be 
sensitive to imatinib or sunitinib, which may results in a less active KIT kinase as 
compared to a kinase where both mutations are uninhibited. The findings in this 
thesis may have relevance to many GIST patients with an imatinib/sunitinib-
sensitive primary mutation and an imatinib/sunitinib-insensitive secondary 
mutation. Our findings thus lend support to a rechallenge with imatinib or sunitinib, 
even in cases where multiple secondary resistance mutations are present, 
provided that the primary mutation is sensitive.  
 
The schedule of imatinib administration may influence tumor growth, tumor 
glucose uptake rate and the tumor metabolic rate. Continuous imatinib 
administration as well as intermittent administration (one week on - one week off) 
slowed down tumor progression in the AHAX xenograft. Continuous administration 
gave significantly slower tumor growth compared to intermittent administration. We 
found differences in FDG uptake kinetics and tumor FDG metabolic rate between 
the continuous and the intermittent imatinib administration groups, but the clinical 
significance of this observation remains unknown. 
 
In vivo studies using the AHAX xenografts demonstrated the feasibility of using a 
human PET scanner for small animal studies.  
 
ϳϵ
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Early treatment induced changes in GIST patients examined with FDG PET and 
DW MRI parameters were shown to improve the prediction of treatment outcome 
as compared to changes in tumor size observed with CT. 
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8. FUTURE PERSPECTIVES 
 
Imaging plays a pivotal role in the follow up of GIST patients and in the decisions 
whether to continue, discontinue or change the treatment regime. Morphological 
imaging has limitations, particularly in the assessment of newer targeted therapies 
that more often stabilize disease rather than shrink the tumors. The challenge in 
the future will be to validate imaging modalities and protocols that can be used 
both for the diagnosis and in the follow-up of these patients. We believe that 
multifunctional imaging approaches are needed to determine treatment effects of 
novel multi-targeted therapies. 
 
Most studies report single parameters from ROIs or VOIs, presented as means, 
medians or ranges. This approach does not take into account that tumor 
heterogeneity usually is more pronounced when response to treatment occurs. 
Functional response maps have been designed where quantification of the area or 
the proportion of tumor that shows significant changes are registered.  
 
Standardization of examinations is probably the main challenge for the 
implementation into clinical practice. The suggested PERCIST criteria have been a 
valuable contribution for FDG PET studies regarding standardization, but similar 
guidelines for DW MRI have yet to be developed.  
 
8.1. Tailored PET protocols  
Conventional radiological imaging protocols have increasingly been tailored for 
specific indications, and this is also necessary for PET protocols. A PET 
examination usually follows a standard procedure with a whole-body protocol with 
an acquisition time of 3 minutes per bed. For PET studies of the liver, imaging with 
a prolonged acquisition time and repeated breath-hold respiratory gating gives 
measurable improvement in image quality, and better detection and quantification 
of FDG-uptake in liver metastases compared to a standard whole body protocol 
(Revheim ME, 2012). In our current clinical GIST PET protocol, prolonged 
acquisition time with 8 minutes per bed over the liver is included. Our experience 
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so far is that such simple and little time-consuming modifications of PET protocols 
give improved detection and quantification of lesions and better image quality. 
 
Previous studies have shown that malignant lesions often continue to accumulate 
FDG from an early phase to a delayed phase, whereas FDG uptake tends to 
decrease in benign lesions. The background activity will also decrease with time, 
and the tumor-to-background ratio therefore increases with time in malignant 
tumors. A dual-time-point PET might thus improve the detection of malignant 
lesions and facilitate the differentiation between malignant and benign lesions 
(Caprio, 2010; Chan, 2011b; Miyake, 2012). 
 
Although FDG PET has been successfully included in the diagnostic workup of 
GIST, some weaknesses of the method have been revealed. Some GISTs are not 
FDG avid (Choi, 2004; Goerres, 2005) (paper V), and in monitoring treatment 
response normal physiological FDG uptake does not exclude viable residual tumor 
tissue (Agaram, 2007; Corless, 2011). Dynamic FDG PET in patients with GISTs 
has only been explored in a single study (Apostolopoulos, 2011), demonstrating 
higher sensitivity for detecting progression in liver metastases compared to a 
standard static one hour FDG PET (70.6% versus 50.0%) (Apostolopoulos, 2011). 
Clinically relevant information, such as blood flow, exchange rates and 
phosphorylation and dephosphorylation rates can be extracted from dynamic 
acquisition. Dynamic PET is an under-investigated application that deserves 
further attention. 
 
8.2. New radiopharmaceuticals and new applications 
Although FDG is the mainstay radiopharmaceutical for PET, it is not suited for all 
applications. Other radiopharmaceuticals are available and new ones are 
consecutively being developed. More specific tracers will probably be developed 
for the monitoring of specialized therapies. 
 
The thymidine analog 3-18F-3-deoxythymidine (FLT) is the most common PET 
marker for DNA synthesis and is used to visualize cellular proliferation (Weber, 
2010). FLT is a substrate for the enzyme thymidine kinase that is active during cell 
division. FLT is phosphorylated and trapped intracellularily. FLT PET has been 
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shown to improve differentiation between malignancy and inflammation compared 
to FDG PET. The FLT uptake is usually lower than that observed with FDG, but 
the tumor delineation by FLT PET is easier due to higher tumor-to-background 
ratios. However, FLT uptake in bone marrow is usually high and osseous 
metastases can be masked. FDG may be better for evaluation of the skeleton 
(Dittmann, 2003). Another thymidine analog is 18F-1-(2-deoxy-2-fluoro-ȕ-D-
arabinofuranosyl (FMAU) (Dunphy, 2009). FMAU has lower uptake in normal bone 
marrow and may thus suitable for the detection of bone metastases. Bone 
metastases are rare in GIST patients (Burkill, 2003; Jati, 2012). Jati et al 
concluded that all bone metastases detected were lytic, well defined and often 
multiple, the axial skeleton most commonly involved. Lytic lesions usually have 
high FDG uptake and in this study all metastases showed intense FDG uptake, 
which decreased following TKI treatment (Jati, 2012). 
 
Hypoxia in malignant tumors is a common feature of aggressive behavior (Brown, 
1999). Evaluation of hypoxia might be useful both in the development of new drugs 
and in our understanding of tumor biology. There is also evidence that modification 
of tumor hypoxia can significantly improve loco-regional tumor control and overall 
survival (Tatum, 2006). Low oxygenation in the tumor environment is sufficient to 
activate HIF-1-dependent gene expression stimulating processes like glycolysis, 
angiogenesis and apoptosis (Talks, 2000; Bos, 2003). HIF-1Į has been studied in 
many cancers, including GIST, showing a correlation between expression of HIF-
1Į and tumor aggressiveness, rate of recurrence and distant metastases (Chen, 
2005). Hypoxic tissues increase their anaerobic glucose metabolism and can 
theoretically be detected with FDG PET. However, the usability of FDG as a 
marker for hypoxia is questionable because of variation in baseline (aerob) 
glucose metabolism (Busk, 2008). 60/62/64Cu-diacetyl-bis-(N4-
metylthiosemicarbazone (Cu-ATSM) and 18F-fluoromisonidazole (FMISO) are the 
two most used PET tracers for hypoxia imaging (Dunphy, 2009). Cu-ATSM binds 
to certain intracellular macromolecules in viable cells with low oxygen tensions 
(Padhani, 2007). 64Cu’s half-life (12.7 h) makes it practical to work with, and its 
production and delivery is widespread (Lewis, 2008). 15O-H2O has been used as a 
PET agent for the assessment of tumor perfusion (Laking, 2010), but due to the 
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very short half-life of 15O (122 s) few institutions perform 15O-H2O-PET studies in 
routine clinical practice. 
 
Angiogenesis is the formation of new blood vessels and is one of the hallmarks of 
cancer. Several of the next generation TKIs target vascular endothelial growth 
factor 1 and 2 (VEGFR1 and VEGFR 2) (Samiian, 2004; Deremer, 2008; Sawaki, 
2011) and thereby inhibit angiogenesis. Because FDG has a high level of 
extraction in tissues, changes in perfusion, which is likely to follow antiangiogenic 
therapy, can be measured with dynamic FDG PET imaging. The first pass uptake 
of FDG correlates with 15O-H2O measured blood flow (Mullani, 2008). Different 
specific angiogenetic factors in the angiogenetic cascade can, however, be 
targeted by PET agents (Vallabhajosula, 2011). PET imaging of angiogenesis for 
the assessment of antiangiogenic therapy in GIST patients may be used in the 
future.  
 
Different steps in the apoptotic cascade (e.g the caspase activity) can be targeted 
and visualized with PET (Reshef, 2010). TKIs suppress the TK signal transduction 
pathway resulting in reduced cell proliferation and the induction of apoptosis 
(Tuveson, 2001). PET imaging of apoptosis may therefore be useful in treatment 
assessment in GIST patients. Malignant cells also have increased uptake of amino 
acids and high protein synthesis. Numerous new PET probes targeting amino acid 
metabolism and protein synthesis have been developed (Dunphy, 2009). 11C 
methyl-L-methionine (MET) is currently the leading amino acid PET agent 
(Dunphy, 2009), mainly used for the detection, characterization and treatment 
assessment of brain tumors (Terakawa, 2008). The brain cortex and basal ganglia 
have high FDG uptake, and brain metastases can be masked with standard PDG 
PET. Amino acid agents have very low brain uptake but high uptake in malignant 
lesions. However, brain metastases in GIST patients are extremely rare (Naoe, 
2011), and only 9 case reports were found when reviewing the literature. 
 
Bombesin receptors are overexpressed in different cancers including prostate 
cancer (Markwalder, 1999) and in breast cancer (Gugger, 1999) and GIST (Reubi, 
2004).  Reubi et al reported that primary GISTs (imatinib sensitive and imatinib 
insensitive tumors) and GIST metastases expressed bombesin subtype 2 
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receptors, known as gastrin releasing peptide receptors (GRPr) (Reubi, 2004). By 
using a 68Ga-bombesin agonist Dimitrakopoulous-Strauss et al performed PET 
studies with 68Ga-BZH3 and FDG in 17 GIST patients. Their aims were to 
investigate the impact on diagnosis compared to FDG PET and the potential for 
radionuclide treatment. The FDG PET showed increased uptake in 14 out of 17 
patients and BZH3 PET in seven out of 17 patients. A recurrent GIST was only 
detected by BZH3 (mitrakopoulou-Strauss, 2007). Unfavorable pharmacokinetics in 
normal receptor-positive organs and mitogenic effects were later revealed. More 
recently an in vitro and in vivo (murine model) study of prostate cancer found 
better tracer properties by using a bombesin antagonist (Abiraj, 2011) with the 
chelator DOTA and the positron emitter 64Cu. Bombesin shows specific and high 
tumor uptake, and fast washout from the normal organs. These are favorable 
properties, and several approaches toward clinical translation for targeted imaging 
and radionuclide therapy are under investigation. This may be an exciting 
approach to explore in future GIST clinical trials. 
 
8.3. Improved technology 
The latest PET technology has improved spatial resolution due to additional 
detector rings, time-of-flight detection (TOF) and new reconstruction algorithms. 
Introduction of PET/MRI allowing simultaneous acquisition of PET and MR images 
will improve motion correction. The new generation PET scanners often use TOF 
technology or image reconstruction based on the point spread function (PSF) to 
achieve high spatial resolution and good contrast. Fast scintillators, electronics 
with high counting-rate performance and increased FOV can reduce scanning 
time.  
 
Aggressive tumors with poor differentiation are thought to be more vascular and 
may therefore be distinguished from more well differentiated lesions by perfusion 
imaging. Only one study has been performed using perfusion CT for treatment 
assessment in GISTs (Schlemmer, 2011). They reported a characteristic perfusion 
pattern of metastatic GIST lesions distinguishing good from poor responders to 
imatinib or sunitinib in 24 patients (Schlemmer, 2011). The duration of therapy was 
however varying, but all patients had at least received medication for 3.5 weeks, 
and most patients had completed several months of therapy. How rapid the 
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vascular changes occur were not taken into account, and their findings were not 
compared to other functional modalities such as FDG PET or DW MRI. Studies 
suggest that the early uptake patterns in tumors observed by dynamic FDG PET 
and perfusion CT are similar, and one may consider only using dynamic PET. A 
high resolution CT may of course still be needed for diagnostic purposes (Malinen, 
2011). 
 
The heterogeneity of GIST is usually more pronounced when response to 
treatment occurs. It is, however, most common to report single values in DW MRI, 
mainly the mean ADC. If tumor consists of necrosis or cystic components at 
baseline, these areas might be excluded for ADC measurements at all time points. 
Typically, tumors may initially have an enhancing rim equivalent to increased 
perfusion, but after treatment the central part of tumor can show a greater 
antivascular response than the periphery. Functional response maps have been 
designed where quantification of an area or the proportion of tumor that shows 
significant changes in response are registered. This mapping is particularly 
challenging in areas with physiologic movements. Functional diffusion maps have 
been used in clinical trials of bone (Lee, 2007) and brain malignancies (Hamstra, 
2008) with promising results. Implementation of functional mapping in GIST will 
probably give an improved understanding of tumor biology and a more correct 
assessment of treatment response in DW MRI.   
 
Whole-body MRI from vertex to the thigh, analogous to a typical PET/CT scan, can 
be performed in 25 minutes with the latest MRI systems (Lenz, 2011). Whole-body 
DW MRI has been compared to FDG PET/CT for the diagnosis and response 
assessment in oncology showing similar sensitivity and specificity for the detection 
of malignancy and the assessment of treatment response (Heusner, 2010; Wu, 
2011). For bone metastases whole-body DW MRI showed superior sensitivity to 
FDG PET/CT (Kruger, 2009). GIST is associated with other malignancy (Salar, 
2005; Kalender, 2007; Basu, 2008; Basu, 2010), and by the increased use of 
whole-body imaging the identification of such other primary tumors will further 
increase. Full integration of PET and MRI at the same time point will reduce 
misregistrations. There are high expectations to this combined system’s efficacy. 
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8.4. Novel targeted therapies 
Other agents that inhibit targets downstream of KIT and PDGFRA, such as the 
phosphoinositide 3-kinase (PI3K) and AKT/mammalian target of rapamycin 
(mTOR) signaling pathway are under evaluation. PI3K inhibitors have shown a 40 
– 75% inhibition of cellular proliferation and a threefold increase in caspase activity 
in GIST cell lines (Bauer, 2007). mTOR inhibitors did not show the same marked 
effect. This indicates that the most important signaling is located downstream of 
PI3K but upstream of mTOR (Bauer, 2007). Heat shock protein 90 (HSP90) 
inhibitors have shown antitumor effects in xenografts, and the antitumor response 
was enhanced when given in combination with TKIs (Floris, 2011a; Floris, 2011b).  
 
8.5. Response to TKI therapy  
Existing data suggest that even long-term TKI treatment fails to eliminate all GIST 
cells, and that the disease persists, but in an inactive form. Le Cesne et al 
randomized 434 patients with non-progressive disease after 3 years with imatinib 
treatment to either continue or discontinue treatment. They found that the 2-year-
PFS was 80% in the group with continuous treatment and 16% in the interruption 
group (Le, 2010). Another study examined histological GIST lesions with clinical 
response to imatinib (1 to 31 months) from 28 patients (43 lesions) and found a 10 
– 90% reduction in tumor cellularity. Residual tumor cells in 75% of the lesions 
were quiescent, with a proliferation index (Ki67) of 0% and no mitoses. Some 
tumor cells showed transdifferentiation towards a smooth mucle phenotype, 
suggesting that GIST cells under imatinib suppression may circumvent apoptosis 
by bypassing the cell cycle and expressing other genes (Agaram, 2007). Bardsley 
et al recently reported that native ICC stem cells in murine GISTs are resistant to 
KIT inhibition, and this resistance was retained after acquisition of an oncogenic 
KIT mutation (Bardsley, 2010). This has raised the hypothesis of the existence of a 
GIST tumor stem cell that is independent of KIT, and therefore not controlled or 
eradicated by TKI alone (Bardsley, 2010). 
 
8.6. Imaging guided personalized medicine  
Functional and molecular imaging is in a front position in the trend of personalized 
cancer treatment. The goals are to individualize the diagnostic work-up and 
treatments, in order to optimize treatment outcome and minimize toxicity. 
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Monitoring factors that influence treatment, resistance, metabolism, proliferation 
and hypoxia prior to, during and after treatment may be important for such 
individualized treatment regimes.  
 
For many GIST patients the standard imatinib dose is well tolerated, but patients 
with large tumor burden and poor performance status may benefit from a more 
tailored dosage. Around 5% of the patients develop unacceptable adverse effects 
(Demetri, 2006), and may benefit from dose reduction monitored by PET or DW 
MRI. A low-dose imatinib regime with 200 mg daily (100mg x 2) may be effective in 
disease suppression in cases with side effects evaluated with FDG PET (Basu, 
2010).  
 
Resistance to treatment is considered to be one of the major challenges to 
targeted therapy (Gramza, 2009). Knowledge of resistance mechanisms based on 
markers of response and resistance could spare patients from an insufficient 
therapy and allow earlier decisions for change in treatment strategies that may be 
more effective and, furthermore to enable identification of new targets for drugs. 
Up to 19% of GISTs show initial primary resistance to imatinib (Demetri, 2002), 
and functional imaging (FDG PET and DW MRI) performed early after onset of TKI 
treatment can probably identify these patients. As already mentioned, most 
patients with advanced GIST respond to imatinib, but the majority eventually 
progress with the median time to imatinib resistance being approximately two 
years (Blanke, 2008a). The development of secondary resistance in GIST can 
manifest itself as a nodule in an otherwise responding lesion or as new 
metastases. FDG PET is able to detect such secondary drug resistance early, also 
known as the “metabolic switch-on”. The term nodule within a mass is already 
accepted and used in CT interpretations. However, it might be difficult to 
distinguish active progressive tissue from another etiology on a CT scan. A 
decrease in ADC during treatment will be taken as an indicator of residual active 
disease. 
 
Novel therapeutic drugs are launched, particularly for the treatment of imatinib-
resistant GISTs (Demetri, 2011; Giuliani, 2012). Preclinical studies have showed 
that response to novel agents can be monitored with FDG PET and probably with 
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other tracers as well (Pantaleo, 2009). The role of DW MRI in this context is not 
yet explored.  
 
 
 
 
Figure 14: The clinical impact of the implementation of functional imaging in GIST patients. 
 
 
8.7. Main message 
GIST is the most common sarcoma in the GI tract. The TKI imatinib has 
revolutionized the management of GIST. The therapeutic approach to GIST today 
is focused on the kinase mutations, but future identifications of other drivers of 
GIST biology is likely to be identified and targeted. I believe the combination of 
molecular biology, genetics, tumor markers and functional imaging followed by 
targeted personalized and flexible therapy will improve survival and reduce side 
effects for GIST patients in the future.  
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ĨƌĞƋƵĞŶƚůǇƐŚŽǁĐͲ</dŵƵƚĂƚŝŽŶƐ͘ŵ:^ƵƌŐWĂƚŚŽůϯϭ;ϭͿ͗ϭϭϯͲϭϮϬ
ŐĂƌĂŵEW͕ĞƐŵĞƌW͕tŽŶŐ'͕'ƵŽd͕^ŽĐĐŝE͕DĂŬŝZ'͕Ğ^ĂŶƚŝƐ͕ƌĞŶŶĂŶD&͕^ŝŶŐĞƌ^͕
ĞDĂƚƚĞŽZW͕ŶƚŽŶĞƐĐƵZ;ϮϬϬϳͿWĂƚŚŽůŽŐŝĐĂŶĚŵŽůĞĐƵůĂƌŚĞƚĞƌŽŐĞŶĞŝƚǇŝŶŝŵĂƚŝŶŝďͲƐƚĂďůĞŽƌ
ŝŵĂƚŝŶŝďͲƌĞƐƉŽŶƐŝǀĞŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘ůŝŶĂŶĐĞƌZĞƐϭϯ;ϭͿ͗ϭϳϬͲϭϴϭ
ŐĂƌĂŵEW͕>ĂƋƵĂŐůŝĂDW͕hƐƚƵŶ͕'ƵŽd͕tŽŶŐ'͕^ŽĐĐŝE͕DĂŬŝZ'͕ĞDĂƚƚĞŽZW͕ĞƐŵĞƌW͕
ŶƚŽŶĞƐĐƵZ;ϮϬϬϴͿDŽůĞĐƵůĂƌĐŚĂƌĂĐƚĞƌŝǌĂƚŝŽŶŽĨƉĞĚŝĂƚƌŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘ůŝŶ
ĂŶĐĞƌZĞƐϭϰ;ϭϬͿ͗ϯϮϬϰͲϯϮϭϱ
ŝĚĞE͕ĞƐŵŽŶƚƐ͕ƌŝĂŶĚD͕DĞƌǇĞƚͲ&ŝŐƵŝĞƌĞD͕WŽƵůĂŝŶ>;ϮϬϭϬͿ,ŝŐŚͲƚŚƌŽƵŐŚƉƵƚƐŵĂůůĂŶŝŵĂů
WdŝŵĂŐŝŶŐŝŶĐĂŶĐĞƌƌĞƐĞĂƌĐŚ͗ĞǀĂůƵĂƚŝŽŶŽĨƚŚĞĐĂƉĂďŝůŝƚǇŽĨƚŚĞ/ŶǀĞŽŶƐĐĂŶŶĞƌƚŽŝŵĂŐĞĨŽƵƌ
ŵŝĐĞƐŝŵƵůƚĂŶĞŽƵƐůǇ͘EƵĐůDĞĚŽŵŵƵŶϯϭ;ϭϬͿ͗ϴϱϭͲϴϱϴ
ŶĚĞƌƐƐŽŶ:͕ƵŵŵŝŶŐW͕DĞŝƐͲ<ŝŶĚďůŽŵ:D͕^ŝŚƚŽ,͕EƵƉƉŽŶĞŶE͕:ŽĞŶƐƵƵ,͕KĚĞŶ͕
'ƵƐƚĂǀƐƐŽŶ͕<ŝŶĚďůŽŵ>'͕EŝůƐƐŽŶ;ϮϬϬϲͿ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐǁŝƚŚ</dĞǆŽŶϭϭ
ĚĞůĞƚŝŽŶƐĂƌĞĂƐƐŽĐŝĂƚĞĚǁŝƚŚƉŽŽƌƉƌŽŐŶŽƐŝƐ͘'ĂƐƚƌŽĞŶƚĞƌŽůŽŐǇϭϯϬ;ϲͿ͗ϭϱϳϯͲϭϱϴϭ
ŶĚĞƌƐƐŽŶ:͕^ŝŚƚŽ,͕DĞŝƐͲ<ŝŶĚďůŽŵ:D͕:ŽĞŶƐƵƵ,͕EƵƉƉŽŶĞŶE͕<ŝŶĚďůŽŵ>';ϮϬϬϱͿE&ϭͲ
ĂƐƐŽĐŝĂƚĞĚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐŚĂǀĞƵŶŝƋƵĞĐůŝŶŝĐĂů͕ƉŚĞŶŽƚǇƉŝĐ͕ĂŶĚŐĞŶŽƚǇƉŝĐ
ĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐ͘ŵ:^ƵƌŐWĂƚŚŽůϮϵ;ϵͿ͗ϭϭϳϬͲϭϭϳϲ
ŶƚŽĐŚ'͕<ĂŶũĂ:͕ĂƵĞƌ^͕<ƵĞŚů,͕ZĞŶǌŝŶŐͲ<ŽĞŚůĞƌ<͕^ĐŚƵĞƚƚĞ:͕ŽĐŬŝƐĐŚ͕ĞďĂƚŝŶ:&͕
&ƌĞƵĚĞŶďĞƌŐ>^;ϮϬϬϰͿŽŵƉĂƌŝƐŽŶŽĨWd͕d͕ĂŶĚĚƵĂůͲŵŽĚĂůŝƚǇWdͬdŝŵĂŐŝŶŐĨŽƌŵŽŶŝƚŽƌŝŶŐ
ŽĨŝŵĂƚŝŶŝď;^d/ϱϳϭͿƚŚĞƌĂƉǇŝŶƉĂƚŝĞŶƚƐǁŝƚŚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘:EƵĐůDĞĚϰϱ;ϯͿ͗
ϯϱϳͲϯϲϱ
ŶƚŽŶĞƐĐƵZ͕ĞƐŵĞƌW͕'ƵŽd͕ƌŬƵŶ<͕,Žŵ'͕<ŽƌǇŽƚŽǁƐŬŝ͕>ĞǀĞƌƐŚĂD͕:ĞĨĨƌĞǇW͕
Ğ^ĂŶƚŝƐ͕^ŝŶŐĞƌ^͕ƌĞŶŶĂŶD&͕DĂŬŝZ'͕ĞDĂƚƚĞŽZW;ϮϬϬϱͿĐƋƵŝƌĞĚƌĞƐŝƐƚĂŶĐĞƚŽŝŵĂƚŝŶŝď
ŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌŽĐĐƵƌƐƚŚƌŽƵŐŚƐĞĐŽŶĚĂƌǇŐĞŶĞŵƵƚĂƚŝŽŶ͘ůŝŶĂŶĐĞƌZĞƐϭϭ
;ϭϭͿ͗ϰϭϴϮͲϰϭϵϬ
ŶƚŽŶĞƐĐƵZ͕^ŽŵŵĞƌ'͕^ĂƌƌĂŶ>͕dƐĐŚĞƌŶǇĂǀƐŬǇ^:͕ZŝĞĚĞů͕tŽŽĚƌƵĨĨ:D͕ZŽďƐŽŶD͕DĂŬŝZ͕
ƌĞŶŶĂŶD&͕>ĂĚĂŶǇŝD͕ĞDĂƚƚĞŽZW͕ĞƐŵĞƌW;ϮϬϬϯͿƐƐŽĐŝĂƚŝŽŶŽĨ</dĞǆŽŶϵŵƵƚĂƚŝŽŶƐǁŝƚŚ
ŶŽŶŐĂƐƚƌŝĐƉƌŝŵĂƌǇƐŝƚĞĂŶĚĂŐŐƌĞƐƐŝǀĞďĞŚĂǀŝŽƌ͗</dŵƵƚĂƚŝŽŶĂŶĂůǇƐŝƐĂŶĚĐůŝŶŝĐĂůĐŽƌƌĞůĂƚĞƐŽĨ
ϭϮϬŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘ůŝŶĂŶĐĞƌZĞƐϵ;ϵͿ͗ϯϯϮϵͲϯϯϯϳ
ƉŽƐƚŽůŽƉŽƵůŽƐ:͕ŵŝƚƌĂŬŽƉŽƵůŽƵͲ^ƚƌĂƵƐƐ͕,ŽŚĞŶďĞƌŐĞƌW͕ZŽƵŵŝĂ^͕^ƚƌĂƵƐƐ>';ϮϬϭϭͿ
WĂƌĂŵĞƚƌŝĐŝŵĂŐĞƐǀŝĂĚǇŶĂŵŝĐϭϴ&ͲĨůƵŽƌŽĚĞŽǆǇŐůƵĐŽƐĞƉŽƐŝƚƌŽŶĞŵŝƐƐŝŽŶƚŽŵŽŐƌĂƉŚŝĐĚĂƚĂ
ĂĐƋƵŝƐŝƚŝŽŶŝŶƉƌĞĚŝĐƚŝŶŐŵŝĚƚĞƌŵŽƵƚĐŽŵĞŽĨůŝǀĞƌŵĞƚĂƐƚĂƐĞƐƐĞĐŽŶĚĂƌǇƚŽŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂů
ƐƚƌŽŵĂůƚƵŵŽƵƌƐ͘Ƶƌ:EƵĐůDĞĚDŽů/ŵĂŐŝŶŐϯϴ;ϳͿ͗ϭϮϭϮͲϭϮϮϯ
ϵϬ

ĂůĂĐŚĂŶĚƌĂŶsW͕ĂǀŶĂƌD:͕ĞŶŐ^͕ĂŵďŽĂƚD͕KĐƵŝŶ>D͕KďĂŝĚ,͕^ŽƌĞŶƐŽŶ͕WŽƉŽǁZ͕
ƌŝǇĂŶ͕ZŽƐƐŝ&͕ĞƐŵĞƌW͕'ƵŽd͕ŶƚŽŶĞƐĐƵZ͕dĂŐƵĐŚŝd͕zƵĂŶ:͕tŽůĐŚŽŬ:͕ůůŝƐŽŶ:W͕
ĞDĂƚƚĞŽZW;ϮϬϭϭͿ/ŵĂƚŝŶŝďƉŽƚĞŶƚŝĂƚĞƐĂŶƚŝƚƵŵŽƌdĐĞůůƌĞƐƉŽŶƐĞƐŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂů
ƚƵŵŽƌƚŚƌŽƵŐŚƚŚĞŝŶŚŝďŝƚŝŽŶŽĨ/ĚŽ͘EĂƚDĞĚϭϳ;ϵͿ͗ϭϬϵϰͲϭϭϬϬ
ĂƌĚƐůĞǇDZ͕,ŽƌǀĂƚŚs:͕ƐƵǌƵd͕>ŽƌŝŶĐǌ͕ZĞĚĞůŵĂŶ͕,ĂǇĂƐŚŝz͕WŽƉŬŽ>E͕zŽƵŶŐ>͕
>ŽŵďĞƌŬ'͕hƌƌƵƚŝĂZ͕&ĂƌƌƵŐŝĂ'͕ZƵďŝŶW͕KƌĚŽŐd;ϮϬϭϬͿ<ŝƚůŽǁƐƚĞŵĐĞůůƐĐĂƵƐĞƌĞƐŝƐƚĂŶĐĞ
ƚŽ<ŝƚͬƉůĂƚĞůĞƚͲĚĞƌŝǀĞĚŐƌŽǁƚŚĨĂĐƚŽƌĂůƉŚĂŝŶŚŝďŝƚŽƌƐŝŶŵƵƌŝŶĞŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘
'ĂƐƚƌŽĞŶƚĞƌŽůŽŐǇϭϯϵ;ϯͿ͗ϵϰϮͲϵϱϮ
ĂƐƵ^;ϮϬϭϬͿWdĂŶĚWdͬdŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƵƌƐ͗ƚŚĞƵŶĂŶƐǁĞƌĞĚƋƵĞƐƚŝŽŶƐĂŶĚ
ƚŚĞƉŽƚĞŶƚŝĂůŶĞǁĞƌĂƉƉůŝĐĂƚŝŽŶƐ͘Ƶƌ:EƵĐůDĞĚDŽů/ŵĂŐŝŶŐϯϳ;ϳͿ͗ϭϮϱϱͲϭϮϱϴ
ĂƐƵ^͕DŽŚĂŶĚĂƐ<D͕WĞƐŚǁĞ,͕ƐŽƉĂZ͕sǇĂǁĂŚĂƌĞD;ϮϬϬϴͿ&'ͲWdĂŶĚWdͬdŝŶƚŚĞ
ĐůŝŶŝĐĂůŵĂŶĂŐĞŵĞŶƚŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ͘EƵĐůDĞĚŽŵŵƵŶϮϵ;ϭϮͿ͗ϭϬϮϲͲϭϬϯϵ
ĂƵĞƌ^͕ƵĞŶƐŝŶŐ͕ĞŵĞƚƌŝ'͕&ůĞƚĐŚĞƌ:;ϮϬϬϳͿ</dŽŶĐŽŐĞŶŝĐƐŝŐŶĂůŝŶŐŵĞĐŚĂŶŝƐŵƐŝŶ
ŝŵĂƚŝŶŝďͲƌĞƐŝƐƚĂŶƚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ͗W/ϯͲŬŝŶĂƐĞͬ<dŝƐĂĐƌƵĐŝĂůƐƵƌǀŝǀĂůƉĂƚŚǁĂǇ͘
KŶĐŽŐĞŶĞϮϲ;ϱϰͿ͗ϳϱϲϬͲϳϱϲϴ
ĂƵĞƌ^͕>ĂŶŐ,͕^ĐŚƵƚƚĞ:͕,ĂƌƚŵĂŶŶ:d;ϮϬϬϱͿŽŵƉůĞƚĞƌĞŵŝƐƐŝŽŶǁŝƚŚŝŵĂƚŝŶŝďŝŶŵĞƚĂƐƚĂƐƚŝĐ
ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘:ůŝŶKŶĐŽůϮϯ;ϮϳͿ͗ϲϴϬϬͲϲϴϬϭ
ĞŶũĂŵŝŶZ^͕ŚŽŝ,͕DĂĐĂƉŝŶůĂĐ,͕ƵƌŐĞƐƐD͕WĂƚĞů^Z͕ŚĞŶ>>͕WŽĚŽůŽĨĨ͕ŚĂƌŶƐĂŶŐĂǀĞũ
;ϮϬϬϳͿtĞƐŚŽƵůĚĚĞƐŝƐƚƵƐŝŶŐZ/^d͕ĂƚůĞĂƐƚŝŶ'/^d͘:ůŝŶKŶĐŽůϮϱ;ϭϯͿ͗ϭϳϲϬͲϭϳϲϰ
ĞǇĞƌd͕ǌĞƌŶŝŶ:͕&ƌĞƵĚĞŶďĞƌŐ>^;ϮϬϭϭͿsĂƌŝĂƚŝŽŶƐŝŶĐůŝŶŝĐĂůWdͬdŽƉĞƌĂƚŝŽŶƐ͗ƌĞƐƵůƚƐŽĨĂŶ
ŝŶƚĞƌŶĂƚŝŽŶĂůƐƵƌǀĞǇŽĨĂĐƚŝǀĞWdͬdƵƐĞƌƐ͘:EƵĐůDĞĚϱϮ;ϮͿ͗ϯϬϯͲϯϭϬ
ĞǇĞƌd͕dŽǁŶƐĞŶĚt͕ůŽĚŐĞƚƚdD;ϮϬϬϮͿƵĂůͲŵŽĚĂůŝƚǇWdͬdƚŽŵŽŐƌĂƉŚǇĨŽƌĐůŝŶŝĐĂů
ŽŶĐŽůŽŐǇ͘Y:EƵĐůDĞĚϰϲ;ϭͿ͗ϮϰͲϯϰ
ůĂŶŬĞ͕ĞŵĞƚƌŝ'͕ǀŽŶDD͕,ĞŝŶƌŝĐŚD͕ŝƐĞŶďĞƌŐ͕&ůĞƚĐŚĞƌ:͕ŽƌůĞƐƐ>͕&ůĞƚĐŚĞƌ͕
ZŽďĞƌƚƐW:͕,ĞŝŶǌ͕tĞŚƌĞ͕EŝŬŽůŽǀĂ͕:ŽĞŶƐƵƵ,;ϮϬϬϴĂͿ>ŽŶŐͲƚĞƌŵƌĞƐƵůƚƐĨƌŽŵĂƌĂŶĚŽŵŝǌĞĚ
ƉŚĂƐĞ//ƚƌŝĂůŽĨƐƚĂŶĚĂƌĚͲǀĞƌƐƵƐŚŝŐŚĞƌͲĚŽƐĞŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞĨŽƌƉĂƚŝĞŶƚƐǁŝƚŚƵŶƌĞƐĞĐƚĂďůĞŽƌ
ŵĞƚĂƐƚĂƚŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐĞǆƉƌĞƐƐŝŶŐ</d͘:ůŝŶKŶĐŽůϮϲ;ϰͿ͗ϲϮϬͲϲϮϱ
ůĂŶŬĞ͕ZĂŶŬŝŶ͕ĞŵĞƚƌŝ'͕ZǇĂŶt͕ǀŽŶDD͕ĞŶũĂŵŝŶZ^͕ZĂǇŵŽŶĚ<͕ƌĂŵǁĞůůs,͕
ĂŬĞƌ>,͕DĂŬŝZ'͕dĂŶĂŬĂD͕,ĞĐŚƚ:Z͕,ĞŝŶƌŝĐŚD͕&ůĞƚĐŚĞƌ͕ƌŽǁůĞǇ::͕ŽƌĚĞŶ;ϮϬϬϴďͿ
WŚĂƐĞ///ƌĂŶĚŽŵŝǌĞĚ͕ŝŶƚĞƌŐƌŽƵƉƚƌŝĂůĂƐƐĞƐƐŝŶŐŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞĂƚƚǁŽĚŽƐĞůĞǀĞůƐŝŶƉĂƚŝĞŶƚƐ
ǁŝƚŚƵŶƌĞƐĞĐƚĂďůĞŽƌŵĞƚĂƐƚĂƚŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐĞǆƉƌĞƐƐŝŶŐƚŚĞŬŝƚƌĞĐĞƉƚŽƌ
ƚǇƌŽƐŝŶĞŬŝŶĂƐĞ͗^ϬϬϯϯ͘:ůŝŶKŶĐŽůϮϲ;ϰͿ͗ϲϮϲͲϲϯϮ
ŽĞůůĂĂƌĚZ;ϮϬϬϵͿ^ƚĂŶĚĂƌĚƐĨŽƌWdŝŵĂŐĞĂĐƋƵŝƐŝƚŝŽŶĂŶĚƋƵĂŶƚŝƚĂƚŝǀĞĚĂƚĂĂŶĂůǇƐŝƐ͘:EƵĐůDĞĚ
ϱϬ^ƵƉƉůϭϭϭ^ͲϮϬ^
ŽĞůůĂĂƌĚZ;ϮϬϭϭͿEĞĞĚĨŽƌƐƚĂŶĚĂƌĚŝǌĂƚŝŽŶŽĨϭϴ&Ͳ&'WdͬdĨŽƌƚƌĞĂƚŵĞŶƚƌĞƐƉŽŶƐĞ
ĂƐƐĞƐƐŵĞŶƚƐ͘:EƵĐůDĞĚϱϮ^ƵƉƉůϮϵϯ^ͲϭϬϬ^
ŽĞůůĂĂƌĚZ͕<ƌĂŬE͕,ŽĞŬƐƚƌĂK^͕>ĂŵŵĞƌƚƐŵĂ;ϮϬϬϰͿĨĨĞĐƚƐŽĨŶŽŝƐĞ͕ŝŵĂŐĞƌĞƐŽůƵƚŝŽŶ͕ĂŶĚ
ZK/ĚĞĨŝŶŝƚŝŽŶŽŶƚŚĞĂĐĐƵƌĂĐǇŽĨƐƚĂŶĚĂƌĚƵƉƚĂŬĞǀĂůƵĞƐ͗ĂƐŝŵƵůĂƚŝŽŶƐƚƵĚǇ͘:EƵĐůDĞĚϰϱ;ϵͿ͗
ϭϱϭϵͲϭϱϮϳ
ϵϭ

ŽĞůůĂĂƌĚZ͕KΖŽŚĞƌƚǇD:͕tĞďĞƌt͕DŽƚƚĂŐŚǇ&D͕>ŽŶƐĚĂůĞDE͕^ƚƌŽŽďĂŶƚƐ^'͕KǇĞŶt:͕
<ŽƚǌĞƌŬĞ:͕,ŽĞŬƐƚƌĂK^͕WƌƵŝŵ:͕DĂƌƐĚĞŶW<͕dĂƚƐĐŚ<͕,ŽĞŬƐƚƌĂ:͕sŝƐƐĞƌW͕ƌĞŶĚƐ͕
sĞƌǌŝũůďĞƌŐĞŶ&:͕ŝũůƐƚƌĂ:D͕ŽŵĂŶƐ&͕>ĂŵŵĞƌƚƐŵĂ͕WĂĂŶƐD͕tŝůůĞŵƐĞŶd͕ĞǇĞƌd͕
ŽĐŬŝƐĐŚ͕^ĐŚĂĞĨĞƌͲWƌŽŬŽƉ͕ĞůďĞŬĞ͕ĂƵŵZW͕Śŝƚŝ͕<ƌĂƵƐĞ:;ϮϬϭϬͿ&'WdĂŶĚ
Wdͬd͗EDƉƌŽĐĞĚƵƌĞŐƵŝĚĞůŝŶĞƐĨŽƌƚƵŵŽƵƌWdŝŵĂŐŝŶŐ͗ǀĞƌƐŝŽŶϭ͘Ϭ͘Ƶƌ:EƵĐůDĞĚDŽů
/ŵĂŐŝŶŐϯϳ;ϭͿ͗ϭϴϭͲϮϬϬ
ŽƐZ͕ǀĂŶĚĞƌ'W͕'ƌĞŝũĞƌ͕^ŚǀĂƌƚƐ͕DĞŝũĞƌ^͕WŝŶĞĚŽ,D͕^ĞŵĞŶǌĂ'>͕ǀĂŶŝĞƐƚW:͕ǀĂŶĚĞƌ
t;ϮϬϬϯͿ>ĞǀĞůƐŽĨŚǇƉŽǆŝĂͲŝŶĚƵĐŝďůĞĨĂĐƚŽƌͲϭĂůƉŚĂŝŶĚĞƉĞŶĚĞŶƚůǇƉƌĞĚŝĐƚƉƌŽŐŶŽƐŝƐŝŶƉĂƚŝĞŶƚƐ
ǁŝƚŚůǇŵƉŚŶŽĚĞŶĞŐĂƚŝǀĞďƌĞĂƐƚĐĂƌĐŝŶŽŵĂ͘ĂŶĐĞƌϵϳ;ϲͿ͗ϭϱϳϯͲϭϱϴϭ
ƌŝŶĐŬĞƌ,;ϭϵϵϱͿ^ĂƌĐŽŝĚŽƐŝƐĂŶĚŵĂůŝŐŶĂŶĐǇ͘ŚĞƐƚϭϬϴ;ϱͿ͗ϭϰϳϮͲϭϰϳϰ
ƌŝŶĚůĞ<;ϮϬϬϴͿEĞǁĂƉƉƌŽĂĐŚĞƐĨŽƌŝŵĂŐŝŶŐƚƵŵŽƵƌƌĞƐƉŽŶƐĞƐƚŽƚƌĞĂƚŵĞŶƚ͘EĂƚZĞǀĂŶĐĞƌϴ
;ϮͿ͗ϵϰͲϭϬϳ
ƌŽǁŶ:D;ϭϵϵϵͿdŚĞŚǇƉŽǆŝĐĐĞůů͗ĂƚĂƌŐĞƚĨŽƌƐĞůĞĐƚŝǀĞĐĂŶĐĞƌƚŚĞƌĂƉǇͲͲĞŝŐŚƚĞĞŶƚŚƌƵĐĞ&͘ĂŝŶ
DĞŵŽƌŝĂůǁĂƌĚůĞĐƚƵƌĞ͘ĂŶĐĞƌZĞƐϱϵ;ϮϯͿ͗ϱϴϲϯͲϱϴϳϬ
ƌŽǁŶZ^͕'ŽŽĚŵĂŶdD͕ĂƐĂĚŶǇ<Z͕'ƌĞĞŶƐŽŶ:<͕tĂŚůZ>;ϮϬϬϮͿǆƉƌĞƐƐŝŽŶŽĨŚĞǆŽŬŝŶĂƐĞ//
ĂŶĚ'ůƵƚͲϭŝŶƵŶƚƌĞĂƚĞĚŚƵŵĂŶďƌĞĂƐƚĐĂŶĐĞƌ͘EƵĐůDĞĚŝŽůϮϵ;ϰͿ͗ϰϰϯͲϰϱϯ
ƵƌŬŝůů':͕ĂĚƌĂŶD͕ůͲDƵĚĞƌŝƐK͕DĞŝƌŝŽŶd:͕:ƵĚƐŽŶ/Z͕&ŝƐŚĞƌ͕DŽƐŬŽǀŝĐ;ϮϬϬϯͿDĂůŝŐŶĂŶƚ
ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ͗ĚŝƐƚƌŝďƵƚŝŽŶ͕ŝŵĂŐŝŶŐĨĞĂƚƵƌĞƐ͕ĂŶĚƉĂƚƚĞƌŶŽĨŵĞƚĂƐƚĂƚŝĐƐƉƌĞĂĚ͘
ZĂĚŝŽůŽŐǇϮϮϲ;ϮͿ͗ϱϮϳͲϱϯϮ
ƵƐŬD͕,ŽƌƐŵĂŶDZ͕<ƌŝƐƚũĂŶƐĞŶW͕ǀĂŶĚĞƌ<ŽŐĞů:͕ƵƐƐŝŶŬ:͕KǀĞƌŐĂĂƌĚ:;ϮϬϬϴͿĞƌŽďŝĐ
ŐůǇĐŽůǇƐŝƐŝŶĐĂŶĐĞƌƐ͗ŝŵƉůŝĐĂƚŝŽŶƐĨŽƌƚŚĞƵƐĂďŝůŝƚǇŽĨŽǆǇŐĞŶͲƌĞƐƉŽŶƐŝǀĞŐĞŶĞƐĂŶĚ
ĨůƵŽƌŽĚĞŽǆǇŐůƵĐŽƐĞͲWdĂƐŵĂƌŬĞƌƐŽĨƚŝƐƐƵĞŚǇƉŽǆŝĂ͘/Ŷƚ:ĂŶĐĞƌϭϮϮ;ϭϮͿ͗ϮϳϮϲͲϮϳϯϰ
ĂƉƌŝŽD'͕ĂŶŐŝĂŶŽ͕/ŵďƌŝĂĐŽD͕^ŽƐĐŝĂ&͕ŝD'͕&ĂƌŝŶĂ͕ǀŝƚĂďŝůĞ'͕WĂĐĞ>͕&ŽƌĞƐƚŝĞƌŝW͕
^ĂůǀĂƚŽƌĞD;ϮϬϭϬͿƵĂůͲƚŝŵĞͲƉŽŝŶƚ΀ϭϴ&΁Ͳ&'WdͬdŝŶƚŚĞĚŝĂŐŶŽƐƚŝĐĞǀĂůƵĂƚŝŽŶŽĨƐƵƐƉŝĐŝŽƵƐ
ďƌĞĂƐƚůĞƐŝŽŶƐ͘ZĂĚŝŽůDĞĚϭϭϱ;ϮͿ͗ϮϭϱͲϮϮϰ
ĂƌŶĞǇ:;ϭϵϵϵͿ'ĂƐƚƌŝĐƐƚƌŽŵĂůƐĂƌĐŽŵĂ͕ƉƵůŵŽŶĂƌǇĐŚŽŶĚƌŽŵĂ͕ĂŶĚĞǆƚƌĂͲĂĚƌĞŶĂů
ƉĂƌĂŐĂŶŐůŝŽŵĂ;ĂƌŶĞǇdƌŝĂĚͿ͗ŶĂƚƵƌĂůŚŝƐƚŽƌǇ͕ĂĚƌĞŶŽĐŽƌƚŝĐĂůĐŽŵƉŽŶĞŶƚ͕ĂŶĚƉŽƐƐŝďůĞĨĂŵŝůŝĂů
ŽĐĐƵƌƌĞŶĐĞ͘DĂǇŽůŝŶWƌŽĐϳϰ;ϲͿ͗ϱϰϯͲϱϱϮ
ĂƐĂůŝW'͕ůĂǇ:z;ϮϬϭϬͿ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƵƌƐ͗^DKůŝŶŝĐĂůWƌĂĐƚŝĐĞ'ƵŝĚĞůŝŶĞƐĨŽƌ
ĚŝĂŐŶŽƐŝƐ͕ƚƌĞĂƚŵĞŶƚĂŶĚĨŽůůŽǁͲƵƉ͘ŶŶKŶĐŽůϮϭ^ƵƉƉůϱǀϵϴͲϭϬϮ
ŚĂĐŽŶD͕ZŽĐĂ͕,ƵĞƌƚĂƐ͕>ŽƌŝĂ&^͕ŽŵĞŶĞĐŚŝŶŝ;ϮϬϬϱͿ^ϯ͘WĂƚŚŽůŽŐŝĐĐŽŵƉůĞƚĞ
ƌĞŵŝƐƐŝŽŶŽĨŵĞƚĂƐƚĂƚŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌĂĨƚĞƌŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞ͘:ůŝŶKŶĐŽůϮϯ;ϳͿ͗
ϭϱϴϬͲϭϱϴϮ
ŚĂŶt>͕ZĂŵƐĂǇ^͕^ǌĞƚŽZ͕&ƌĞƵŶĚ:͕WŽŚůĞŶ:D͕dĂƌůŝŶƚŽŶ>͕zŽƵŶŐ͕,ŝĐŬĞǇ͕ƵƌĂZ
;ϮϬϭϭďͿƵĂůͲƚŝŵĞͲƉŽŝŶƚ;ϭϴͿ&Ͳ&'ͲWdͬdŝŵĂŐŝŶŐŝŶƚŚĞĂƐƐĞƐƐŵĞŶƚŽĨƐƵƐƉĞĐƚĞĚŵĂůŝŐŶĂŶĐǇ͘:
DĞĚ/ŵĂŐŝŶŐZĂĚŝĂƚKŶĐŽůϱϱ;ϰͿ͗ϯϳϵͲϯϵϬ
ŚĂŶt>͕ZĂŵƐĂǇ^͕^ǌĞƚŽZ͕&ƌĞƵŶĚ:͕WŽŚůĞŶ:D͕dĂƌůŝŶƚŽŶ>͕zŽƵŶŐ͕,ŝĐŬĞǇ͕ƵƌĂZ
;ϮϬϭϭĂͿƵĂůͲƚŝŵĞͲƉŽŝŶƚ;ϭϴͿ&Ͳ&'ͲWdͬdŝŵĂŐŝŶŐŝŶƚŚĞĂƐƐĞƐƐŵĞŶƚŽĨƐƵƐƉĞĐƚĞĚŵĂůŝŐŶĂŶĐǇ͘:
DĞĚ/ŵĂŐŝŶŐZĂĚŝĂƚKŶĐŽůϱϱ;ϰͿ͗ϯϳϵͲϯϵϬ
ϵϮ

ŚĂƌůĞƐͲĚǁĂƌĚƐD͕ĚĞ^ŽƵǌĂED;ϮϬϬϲͿŝĨĨƵƐŝŽŶͲǁĞŝŐŚƚĞĚŵĂŐŶĞƚŝĐƌĞƐŽŶĂŶĐĞŝŵĂŐŝŶŐĂŶĚŝƚƐ
ĂƉƉůŝĐĂƚŝŽŶƚŽĐĂŶĐĞƌ͘ĂŶĐĞƌ/ŵĂŐŝŶŐϲϭϯϱͲϭϰϯ
ŚĞŶ>>͕^ĂďƌŝƉŽƵƌD͕ŶĚƚďĂĐŬĂZ,͕WĂƚĞů^Z͕&ĞŝŐt͕DĂĐĂƉŝŶůĂĐ,͕ŚŽŝ,͕tƵ&͕&ƌĂǌŝĞƌ
D>͕ĞŶũĂŵŝŶZ^;ϮϬϬϱͿ/ŵĂƚŝŶŝďƌĞƐŝƐƚĂŶĐĞŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘ƵƌƌKŶĐŽůZĞƉϳ
;ϰͿ͗ϮϵϯͲϮϵϵ
ŚĞƐŽŶ͕WĨŝƐƚŶĞƌ͕:ƵǁĞŝĚD͕'ĂƐĐŽǇŶĞZ͕^ƉĞĐŚƚ>͕,ŽƌŶŝŶŐ^:͕ŽŝĨĨŝĞƌ͕&ŝƐŚĞƌZ/͕
,ĂŐĞŶďĞĞŬ͕ƵĐĐĂ͕ZŽƐĞŶ^d͕^ƚƌŽŽďĂŶƚƐ^͕>ŝƐƚĞƌd͕,ŽƉƉĞZd͕ƌĞǇůŝŶŐD͕dŽďŝŶĂŝ<͕sŽƐĞ
:D͕ŽŶŶŽƌƐ:D͕&ĞĚĞƌŝĐŽD͕ŝĞŚůs;ϮϬϬϳͿZĞǀŝƐĞĚƌĞƐƉŽŶƐĞĐƌŝƚĞƌŝĂĨŽƌŵĂůŝŐŶĂŶƚůǇŵƉŚŽŵĂ͘:
ůŝŶKŶĐŽůϮϱ;ϱͿ͗ϱϳϵͲϱϴϲ
ŚŽŝ,;ϮϬϬϴͿZĞƐƉŽŶƐĞĞǀĂůƵĂƚŝŽŶŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘KŶĐŽůŽŐŝƐƚϭϯ^ƵƉƉůϮϰͲϳ
ŚŽŝ,͕ŚĂƌŶƐĂŶŐĂǀĞũ͕ĚĞĂƐƚƌŽ&^͕dĂŵŵW͕ĞŶũĂŵŝŶZ^͕:ŽŚŶƐŽŶDD͕DĂĐĂƉŝŶůĂĐ,͕
WŽĚŽůŽĨĨ;ϮϬϬϰͿdĞǀĂůƵĂƚŝŽŶŽĨƚŚĞƌĞƐƉŽŶƐĞŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐĂĨƚĞƌŝŵĂƚŝŶŝď
ŵĞƐǇůĂƚĞƚƌĞĂƚŵĞŶƚ͗ĂƋƵĂŶƚŝƚĂƚŝǀĞĂŶĂůǇƐŝƐĐŽƌƌĞůĂƚĞĚǁŝƚŚ&'WdĨŝŶĚŝŶŐƐ͘:Zŵ:
ZŽĞŶƚŐĞŶŽůϭϴϯ;ϲͿ͗ϭϲϭϵͲϭϲϮϴ
ŚƵŶŐ:<͕>ĞĞz:͕<ŝŵ͕ŚŽŝ^Z͕<ŝŵD͕>ĞĞ<͕:ĞŽŶŐ:D͕>ĞĞ^͕:ĂŶŐ::͕>ĞĞD;ϭϵϵϵͿ
DĞĐŚĂŶŝƐŵƐƌĞůĂƚĞĚƚŽ΀ϭϴ&΁ĨůƵŽƌŽĚĞŽǆǇŐůƵĐŽƐĞƵƉƚĂŬĞŽĨŚƵŵĂŶĐŽůŽŶĐĂŶĐĞƌƐƚƌĂŶƐƉůĂŶƚĞĚŝŶ
ŶƵĚĞŵŝĐĞ͘:EƵĐůDĞĚϰϬ;ϮͿ͗ϯϯϵͲϯϰϲ
ŽŚĞŶWZ͕<ƵƌǌƌŽĐŬZ;ϮϬϬϳͿ^ĂƌĐŽŝĚŽƐŝƐĂŶĚŵĂůŝŐŶĂŶĐǇ͘ůŝŶĞƌŵĂƚŽůϮϱ;ϯͿ͗ϯϮϲͲϯϯϯ
ŽƌůĞƐƐ>͕ĂƌŶĞƚƚD͕,ĞŝŶƌŝĐŚD;ϮϬϭϭͿ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƵƌƐ͗ŽƌŝŐŝŶĂŶĚ
ŵŽůĞĐƵůĂƌŽŶĐŽůŽŐǇ͘EĂƚZĞǀĂŶĐĞƌϭϭ;ϭϮͿ͗ϴϲϱͲϴϳϴ
ŽƌůĞƐƐ>͕&ůĞƚĐŚĞƌ:͕,ĞŝŶƌŝĐŚD;ϮϬϬϰͿŝŽůŽŐǇŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘:ůŝŶKŶĐŽů
ϮϮ;ϭϴͿ͗ϯϴϭϯͲϯϴϮϱ
ŽƌůĞƐƐ>͕^ĐŚƌŽĞĚĞƌ͕'ƌŝĨĨŝƚŚ͕dŽǁŶ͕DĐ'ƌĞĞǀĞǇ>͕,ĂƌƌĞůůW͕^ŚŝƌĂŐĂ^͕ĂŝŶďƌŝĚŐĞd͕
DŽƌŝĐŚ:͕,ĞŝŶƌŝĐŚD;ϮϬϬϱͿW'&ZŵƵƚĂƚŝŽŶƐŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͗ĨƌĞƋƵĞŶĐǇ͕
ƐƉĞĐƚƌƵŵĂŶĚŝŶǀŝƚƌŽƐĞŶƐŝƚŝǀŝƚǇƚŽŝŵĂƚŝŶŝď͘:ůŝŶKŶĐŽůϮϯ;ϮϯͿ͗ϱϯϱϳͲϱϯϲϰ
Ƶŝz͕ŚĂŶŐyW͕^ƵŶz^͕dĂŶŐ>͕^ŚĞŶ>;ϮϬϬϴͿƉƉĂƌĞŶƚĚŝĨĨƵƐŝŽŶĐŽĞĨĨŝĐŝĞŶƚ͗ƉŽƚĞŶƚŝĂůŝŵĂŐŝŶŐ
ďŝŽŵĂƌŬĞƌĨŽƌƉƌĞĚŝĐƚŝŽŶĂŶĚĞĂƌůǇĚĞƚĞĐƚŝŽŶŽĨƌĞƐƉŽŶƐĞƚŽĐŚĞŵŽƚŚĞƌĂƉǇŝŶŚĞƉĂƚŝĐŵĞƚĂƐƚĂƐĞƐ͘
ZĂĚŝŽůŽŐǇϮϰϴ;ϯͿ͗ϴϵϰͲϵϬϬ
ĞDĂƚƚĞŽZW͕ĂůůŵĂŶ<s͕ŶƚŽŶĞƐĐƵZ͕DĂŬŝZ'͕WŝƐƚĞƌƐWt͕ĞŵĞƚƌŝ'͕ůĂĐŬƐƚĞŝŶD͕ůĂŶŬĞ
͕ǀŽŶDD͕ƌĞŶŶĂŶD&͕WĂƚĞů^͕DĐĂƌƚĞƌD͕WŽůŝŬŽĨĨ:͕dĂŶZ͕KǁǌĂƌ<;ϮϬϬϵͿĚũƵǀĂŶƚ
ŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞĂĨƚĞƌƌĞƐĞĐƚŝŽŶŽĨůŽĐĂůŝƐĞĚ͕ƉƌŝŵĂƌǇŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƵƌ͗Ă
ƌĂŶĚŽŵŝƐĞĚ͕ĚŽƵďůĞͲďůŝŶĚ͕ƉůĂĐĞďŽͲĐŽŶƚƌŽůůĞĚƚƌŝĂů͘>ĂŶĐĞƚϯϳϯ;ϵϲϲϵͿ͗ϭϬϵϳͲϭϭϬϰ
ĞDĂƚƚĞŽZW͕,ĞŝŶƌŝĐŚD͕ůͲZŝĨĂŝtD͕ĞŵĞƚƌŝ';ϮϬϬϮͿůŝŶŝĐĂůŵĂŶĂŐĞŵĞŶƚŽĨ
ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͗ďĞĨŽƌĞĂŶĚĂĨƚĞƌ^d/Ͳϱϳϭ͘,ƵŵWĂƚŚŽůϯϯ;ϱͿ͗ϰϲϲͲϰϳϳ
ĞDĂƚƚĞŽZW͕>ĞǁŝƐ::͕>ĞƵŶŐ͕DƵĚĂŶ^^͕tŽŽĚƌƵĨĨ:D͕ƌĞŶŶĂŶD&;ϮϬϬϬͿdǁŽŚƵŶĚƌĞĚ
ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͗ƌĞĐƵƌƌĞŶĐĞƉĂƚƚĞƌŶƐĂŶĚƉƌŽŐŶŽƐƚŝĐĨĂĐƚŽƌƐĨŽƌƐƵƌǀŝǀĂů͘ŶŶ^ƵƌŐ
Ϯϯϭ;ϭͿ͗ϱϭͲϱϴ
ϵϯ

ĞDĂƚƚĞŽZW͕DĂŬŝZ'͕^ŝŶŐĞƌ^͕'ŽŶĞŶD͕ƌĞŶŶĂŶD&͕ŶƚŽŶĞƐĐƵZ;ϮϬϬϳͿZĞƐƵůƚƐŽĨƚǇƌŽƐŝŶĞ
ŬŝŶĂƐĞŝŶŚŝďŝƚŽƌƚŚĞƌĂƉǇĨŽůůŽǁĞĚďǇƐƵƌŐŝĐĂůƌĞƐĞĐƚŝŽŶĨŽƌŵĞƚĂƐƚĂƚŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂů
ƚƵŵŽƌ͘ŶŶ^ƵƌŐϮϰϱ;ϯͿ͗ϯϰϳͲϯϱϮ
ĞŵĞƚƌŝ';ϮϬϭϭͿŝĨĨĞƌĞŶƚŝĂůƉƌŽƉĞƌƚŝĞƐŽĨĐƵƌƌĞŶƚƚǇƌŽƐŝŶĞŬŝŶĂƐĞŝŶŚŝďŝƚŽƌƐŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂů
ƐƚƌŽŵĂůƚƵŵŽƌƐ͘^ĞŵŝŶKŶĐŽůϯϴ^ƵƉƉůϭ^ϭϬͲ^ϭϵ
ĞŵĞƚƌŝ'͕'ĂƌƌĞƚƚZ͕^ĐŚŽĨĨƐŬŝW͕^ŚĂŚD,͕sĞƌǁĞŝũ:͕>ĞǇǀƌĂǌ^͕,Ƶƌǁŝƚǌ,/͕WŽƵƐĂ>͕>Ğ͕
'ŽůĚƐƚĞŝŶ͕WĂǌͲƌĞƐ>͕ůĂǇ:z͕DĐƌƚŚƵƌ'͕yƵY͕,ƵĂŶŐy͕,ĂƌŵŽŶ^͕dĂƐƐĞůůs͕ŽŚĞŶW͕
ĂƐĂůŝW';ϮϬϭϮͿŽŵƉůĞƚĞ>ŽŶŐŝƚƵĚŝŶĂůŶĂůǇƐĞƐŽĨƚŚĞZĂŶĚŽŵŝǌĞĚ͕WůĂĐĞďŽͲŽŶƚƌŽůůĞĚ͕WŚĂƐĞ///
dƌŝĂůŽĨ^ƵŶŝƚŝŶŝďŝŶWĂƚŝĞŶƚƐǁŝƚŚ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂů^ƚƌŽŵĂůdƵŵŽƌĨŽůůŽǁŝŶŐ/ŵĂƚŝŶŝď&ĂŝůƵƌĞ͘ůŝŶ
ĂŶĐĞƌZĞƐϭϴ;ϭϭͿ͗ϯϭϳϬͲϯϭϳϵ
ĞŵĞƚƌŝ'͕,ĞŝŶƌŝĐŚD͕&ůĞƚĐŚĞƌ:͕&ůĞƚĐŚĞƌ͕sĂŶĚĞŶďďĞĞůĞ͕ŽƌůĞƐƐ>͕ŶƚŽŶĞƐĐƵ
Z͕'ĞŽƌŐĞ^͕DŽƌŐĂŶ:͕ŚĞŶD,͕ĞůůŽ>͕,ƵĂŶŐy͕ŽŚĞŶW͕ĂƵŵD͕DĂŬŝZ';ϮϬϬϵͿ
DŽůĞĐƵůĂƌƚĂƌŐĞƚŵŽĚƵůĂƚŝŽŶ͕ŝŵĂŐŝŶŐ͕ĂŶĚĐůŝŶŝĐĂůĞǀĂůƵĂƚŝŽŶŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ
ƉĂƚŝĞŶƚƐƚƌĞĂƚĞĚǁŝƚŚƐƵŶŝƚŝŶŝďŵĂůĂƚĞĂĨƚĞƌŝŵĂƚŝŶŝďĨĂŝůƵƌĞ͘ůŝŶĂŶĐĞƌZĞƐϭϱ;ϭϴͿ͗ϱϵϬϮͲϱϵϬϵ
ĞŵĞƚƌŝ'͕ǀĂŶKŽƐƚĞƌŽŵd͕'ĂƌƌĞƚƚZ͕ůĂĐŬƐƚĞŝŶD͕^ŚĂŚD,͕sĞƌǁĞŝũ:͕DĐƌƚŚƵƌ'͕
:ƵĚƐŽŶ/Z͕,ĞŝŶƌŝĐŚD͕DŽƌŐĂŶ:͕ĞƐĂŝ:͕&ůĞƚĐŚĞƌ͕'ĞŽƌŐĞ^͕ĞůůŽ>͕,ƵĂŶŐy͕ĂƵŵD͕
ĂƐĂůŝW';ϮϬϬϲͿĨĨŝĐĂĐǇĂŶĚƐĂĨĞƚǇŽĨƐƵŶŝƚŝŶŝďŝŶƉĂƚŝĞŶƚƐǁŝƚŚĂĚǀĂŶĐĞĚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂů
ƚƵŵŽƵƌĂĨƚĞƌĨĂŝůƵƌĞŽĨŝŵĂƚŝŶŝď͗ĂƌĂŶĚŽŵŝƐĞĚĐŽŶƚƌŽůůĞĚƚƌŝĂů͘>ĂŶĐĞƚϯϲϴ;ϵϱϰϰͿ͗ϭϯϮϵͲϭϯϯϴ
ĞŵĞƚƌŝ'͕ǀŽŶDD͕ŶƚŽŶĞƐĐƵZ͕ĞDĂƚƚĞŽZW͕'ĂŶũŽŽ<E͕DĂŬŝZ'͕WŝƐƚĞƌƐWt͕ZĂƵƚW͕
ZŝĞĚĞůZ&͕^ĐŚƵĞƚǌĞ^͕^ƵŶĚĂƌ,D͕dƌĞŶƚ:͕tĂǇŶĞ:;ϮϬϭϬͿEEdĂƐŬ&ŽƌĐĞƌĞƉŽƌƚ͗ƵƉĚĂƚĞŽŶ
ƚŚĞŵĂŶĂŐĞŵĞŶƚŽĨƉĂƚŝĞŶƚƐǁŝƚŚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘:EĂƚůŽŵƉƌĂŶĐEĞƚǁϴ
^ƵƉƉůϮ^ϭͲϰϭ
ĞŵĞƚƌŝ'͕ǀŽŶDD͕ůĂŶŬĞ͕sĂŶĚĞŶďďĞĞůĞ͕ŝƐĞŶďĞƌŐ͕ZŽďĞƌƚƐW:͕,ĞŝŶƌŝĐŚD͕
dƵǀĞƐŽŶ͕^ŝŶŐĞƌ^͕:ĂŶŝĐĞŬD͕&ůĞƚĐŚĞƌ:͕^ŝůǀĞƌŵĂŶ^'͕^ŝůďĞƌŵĂŶ^>͕ĂƉĚĞǀŝůůĞZ͕<ŝĞƐĞ͕
WĞŶŐ͕ŝŵŝƚƌŝũĞǀŝĐ^͕ƌƵŬĞƌ:͕ŽƌůĞƐƐ͕&ůĞƚĐŚĞƌ͕:ŽĞŶƐƵƵ,;ϮϬϬϮͿĨĨŝĐĂĐǇĂŶĚƐĂĨĞƚǇŽĨ
ŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞŝŶĂĚǀĂŶĐĞĚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘EŶŐů:DĞĚϯϰϳ;ϳͿ͗ϰϳϮͲϰϴϬ
ĞƌĞŵĞƌ>͕hƐƚƵŶ͕EĂƚĂƌĂũĂŶ<;ϮϬϬϴͿEŝůŽƚŝŶŝď͗ĂƐĞĐŽŶĚͲŐĞŶĞƌĂƚŝŽŶƚǇƌŽƐŝŶĞŬŝŶĂƐĞŝŶŚŝďŝƚŽƌ
ĨŽƌƚŚĞƚƌĞĂƚŵĞŶƚŽĨĐŚƌŽŶŝĐŵǇĞůŽŐĞŶŽƵƐůĞƵŬĞŵŝĂ͘ůŝŶdŚĞƌϯϬ;ϭϭͿ͗ϭϵϱϲͲϭϵϳϱ
ŝƚƚŵĂŶŶ,͕ŽŚŵĞŶD͕WĂƵůƐĞŶ&͕ŝĐŚŚŽƌŶ<͕ƐĐŚŵĂŶŶ^D͕,ŽƌŐĞƌD͕tĞŚƌŵĂŶŶD͕
DĂĐŚƵůůĂ,:͕ĂƌĞƐZ;ϮϬϬϯͿ΀ϭϴ&΁&>dWdĨŽƌĚŝĂŐŶŽƐŝƐĂŶĚƐƚĂŐŝŶŐŽĨƚŚŽƌĂĐŝĐƚƵŵŽƵƌƐ͘Ƶƌ:EƵĐů
DĞĚDŽů/ŵĂŐŝŶŐϯϬ;ϭϬͿ͗ϭϰϬϳͲϭϰϭϮ
ƌƵŬĞƌ:͕dĂŵƵƌĂ^͕ƵĐŚĚƵŶŐĞƌ͕KŚŶŽ^͕^ĞŐĂů'D͕&ĂŶŶŝŶŐ^͕ŝŵŵĞƌŵĂŶŶ:͕>ǇĚŽŶE
;ϭϵϵϲͿĨĨĞĐƚƐŽĨĂƐĞůĞĐƚŝǀĞŝŶŚŝďŝƚŽƌŽĨƚŚĞďůƚǇƌŽƐŝŶĞŬŝŶĂƐĞŽŶƚŚĞŐƌŽǁƚŚŽĨĐƌͲďůƉŽƐŝƚŝǀĞ
ĐĞůůƐ͘EĂƚDĞĚϮ;ϱͿ͗ϱϲϭͲϱϲϲ
ƵĚĞĐŬK͕ĞŝůĞD͕WŝŶŬ͕WĞĐŚD͕dƵŶŶWh͕ZĞŝĐŚĂƌĚƚW͕>ƵĚǁŝŐt͕,Ăŵŵ;ϮϬϬϴͿŝĨĨƵƐŝŽŶͲ
ǁĞŝŐŚƚĞĚŵĂŐŶĞƚŝĐƌĞƐŽŶĂŶĐĞŝŵĂŐŝŶŐĂůůŽǁƐŵŽŶŝƚŽƌŝŶŐŽĨĂŶƚŝĐĂŶĐĞƌƚƌĞĂƚŵĞŶƚĞĨĨĞĐƚƐŝŶ
ƉĂƚŝĞŶƚƐǁŝƚŚƐŽĨƚͲƚŝƐƐƵĞƐĂƌĐŽŵĂƐ͘:DĂŐŶZĞƐŽŶ/ŵĂŐŝŶŐϮϳ;ϱͿ͗ϭϭϬϵͲϭϭϭϯ
ƵĚĞĐŬK͕ĞŝůĞD͕ZĞŝĐŚĂƌĚƚW͕WŝŶŬ;ϮϬϭϭͿŽŵƉĂƌŝƐŽŶŽĨZ/^dĂŶĚŚŽŝĐƌŝƚĞƌŝĂĨŽƌ
ĐŽŵƉƵƚĞĚƚŽŵŽŐƌĂƉŚŝĐƌĞƐƉŽŶƐĞĞǀĂůƵĂƚŝŽŶŝŶƉĂƚŝĞŶƚƐǁŝƚŚĂĚǀĂŶĐĞĚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂů
ƚƵŵŽƌƚƌĞĂƚĞĚǁŝƚŚƐƵŶŝƚŝŶŝď͘ŶŶKŶĐŽůϮϮ;ϴͿ͗ϭϴϮϴͲϭϴϯϯ
ϵϰ

ƵŶƉŚǇDW͕>ĞǁŝƐ:^;ϮϬϬϵͿZĂĚŝŽƉŚĂƌŵĂĐĞƵƚŝĐĂůƐŝŶƉƌĞĐůŝŶŝĐĂůĂŶĚĐůŝŶŝĐĂůĚĞǀĞůŽƉŵĞŶƚĨŽƌ
ŵŽŶŝƚŽƌŝŶŐŽĨƚŚĞƌĂƉǇǁŝƚŚWd͘:EƵĐůDĞĚϱϬ^ƵƉƉůϭϭϬϲ^ͲϭϮϭ^
ŝƐĞŶŚĂƵĞƌ͕dŚĞƌĂƐƐĞW͕ŽŐĂĞƌƚƐ:͕^ĐŚǁĂƌƚǌ>,͕^ĂƌŐĞŶƚ͕&ŽƌĚZ͕ĂŶĐĞǇ:͕ƌďƵĐŬ^͕
'ǁǇƚŚĞƌ^͕DŽŽŶĞǇD͕ZƵďŝŶƐƚĞŝŶ>͕^ŚĂŶŬĂƌ>͕ŽĚĚ>͕<ĂƉůĂŶZ͕>ĂĐŽŵďĞ͕sĞƌǁĞŝũ:;ϮϬϬϵͿ
EĞǁƌĞƐƉŽŶƐĞĞǀĂůƵĂƚŝŽŶĐƌŝƚĞƌŝĂŝŶƐŽůŝĚƚƵŵŽƵƌƐ͗ƌĞǀŝƐĞĚZ/^dŐƵŝĚĞůŝŶĞ;ǀĞƌƐŝŽŶϭ͘ϭͿ͘Ƶƌ:
ĂŶĐĞƌϰϱ;ϮͿ͗ϮϮϴͲϮϰϳ
&ůĞƚĐŚĞƌ;ϮϬϬϮĂͿůŝŶŝĐŽƉĂƚŚŽůŽŐŝĐĐŽƌƌĞůĂƚŝŽŶƐŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘,ƵŵWĂƚŚŽů
ϯϯ;ϱͿ͗ϰϱϱ
&ůĞƚĐŚĞƌ͕ĞƌŵĂŶ::͕ŽƌůĞƐƐ͕'ŽƌƐƚĞŝŶ&͕>ĂƐŽƚĂ:͕>ŽŶŐůĞǇ:͕DŝĞƚƚŝŶĞŶD͕KΖ>ĞĂƌǇd:͕
ZĞŵŽƚƚŝ,͕ZƵďŝŶW͕^ŚŵŽŽŬůĞƌ͕^ŽďŝŶ>,͕tĞŝƐƐ^t;ϮϬϬϮďͿŝĂŐŶŽƐŝƐŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂů
ƐƚƌŽŵĂůƚƵŵŽƌƐ͗ĂĐŽŶƐĞŶƐƵƐĂƉƉƌŽĂĐŚ͘/Ŷƚ:^ƵƌŐWĂƚŚŽůϭϬ;ϮͿ͗ϴϭͲϴϵ
&ůĞƚĐŚĞƌ:͕ZƵďŝŶW;ϮϬϬϳͿ</dŵƵƚĂƚŝŽŶƐŝŶ'/^d͘ƵƌƌKƉŝŶ'ĞŶĞƚĞǀϭϳ;ϭͿ͗ϯͲϳ
&ůŽƌŝƐ'͕ďŝĞĐͲZǇĐŚƚĞƌD͕tŽǌŶŝĂŬ͕^ƚĞĨĂŶ͕EŽƌŵĂŶƚ͕&ĂĂ'͕DĂĐŚŝĞůƐ<͕sĂŶůĞĞƵǁh͕^ĐŝŽƚZ͕
^ĐŚŽĨĨƐŬŝW;ϮϬϭϭĂͿdŚĞŚĞĂƚƐŚŽĐŬƉƌŽƚĞŝŶϵϬŝŶŚŝďŝƚŽƌ/W/ͲϱϬϰŝŶĚƵĐĞƐ</dĚĞŐƌĂĚĂƚŝŽŶ͕ƚƵŵŽƌ
ƐŚƌŝŶŬĂŐĞ͕ĂŶĚĐĞůůƉƌŽůŝĨĞƌĂƚŝŽŶĂƌƌĞƐƚŝŶǆĞŶŽŐƌĂĨƚŵŽĚĞůƐŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘
DŽůĂŶĐĞƌdŚĞƌϭϬ;ϭϬͿ͗ϭϴϵϳͲϭϵϬϴ
&ůŽƌŝƐ'͕^ĐŝŽƚZ͕tŽǌŶŝĂŬ͕sĂŶ>d͕tĞůůĞŶƐ:͕&ĂĂ'͕EŽƌŵĂŶƚ͕ďŝĞĐͲZǇĐŚƚĞƌD͕^ĐŚŽĨĨƐŬŝW
;ϮϬϭϭďͿdŚĞEŽǀĞů,^WϵϬŝŶŚŝďŝƚŽƌ͕/W/Ͳϰϵϯ͕ŝƐŚŝŐŚůǇĞĨĨĞĐƚŝǀĞŝŶŚƵŵĂŶŐĂƐƚƌŽƐƚƌŽŝŶƚĞƐƚŝŶĂů
ƐƚƌŽŵĂůƚƵŵŽƌǆĞŶŽŐƌĂĨƚƐĐĂƌƌǇŝŶŐŚĞƚĞƌŽŐĞŶĞŽƵƐ</dŵƵƚĂƚŝŽŶƐ͘ůŝŶĂŶĐĞƌZĞƐϭϳ;ϭϳͿ͗ϱϲϬϰͲ
ϱϲϭϰ
&ƌĞĞĚŵĂŶED͕^ƵŶĚĂƌĂŵ^<͕<ƵƌĚǌŝĞů<͕ĂƌƌĂƐƋƵŝůůŽ:͕tŚĂƚůĞǇD͕ĂƌƐŽŶ:D͕^ĞůůĞƌƐ͕>ŝďƵƚƚŝ
^<͕zĂŶŐ:͕ĂĐŚĂƌĂĐŚ^>;ϮϬϬϯͿŽŵƉĂƌŝƐŽŶŽĨ^hsĂŶĚWĂƚůĂŬƐůŽƉĞĨŽƌŵŽŶŝƚŽƌŝŶŐŽĨĐĂŶĐĞƌ
ƚŚĞƌĂƉǇƵƐŝŶŐƐĞƌŝĂůWdƐĐĂŶƐ͘Ƶƌ:EƵĐůDĞĚDŽů/ŵĂŐŝŶŐϯϬ;ϭͿ͗ϰϲͲϱϯ
&ƵĞŐĞƌ:͕ǌĞƌŶŝŶ:͕,ŝůĚĞďƌĂŶĚƚ/͕dƌĂŶ͕,ĂůƉĞƌŶ^͕^ƚŽƵƚ͕WŚĞůƉƐD͕tĞďĞƌt;ϮϬϬϲͿ
/ŵƉĂĐƚŽĨĂŶŝŵĂůŚĂŶĚůŝŶŐŽŶƚŚĞƌĞƐƵůƚƐŽĨϭϴ&Ͳ&'WdƐƚƵĚŝĞƐŝŶŵŝĐĞ͘:EƵĐůDĞĚϰϳ;ϲͿ͗ϵϵϵͲ
ϭϬϬϲ
'ĂƌďĞƌ<;ϮϬϬϲͿZĞĂůŝƐƚŝĐƌŽĚĞŶƚƐ͍ĞďĂƚĞŐƌŽǁƐŽǀĞƌŶĞǁŵŽƵƐĞŵŽĚĞůƐŽĨĐĂŶĐĞƌ͘:EĂƚůĂŶĐĞƌ
/ŶƐƚϵϴ;ϭϳͿ͗ϭϭϳϲͲϭϭϳϴ
'ŝůůŝĞƐZ:͕ZŽďĞǇ/͕'ĂƚĞŶďǇZ;ϮϬϬϴͿĂƵƐĞƐĂŶĚĐŽŶƐĞƋƵĞŶĐĞƐŽĨŝŶĐƌĞĂƐĞĚŐůƵĐŽƐĞŵĞƚĂďŽůŝƐŵ
ŽĨĐĂŶĐĞƌƐ͘:EƵĐůDĞĚϰϵ^ƵƉƉůϮϮϰ^ͲϰϮ^
'ŝƵůŝĂŶŝ&͕ŽůƵĐĐŝ';ϮϬϭϮͿ/ƐƚŚĞƌĞƐŽŵĞƚŚŝŶŐŽƚŚĞƌƚŚĂŶŝŵĂƚŝŶŝďŵĞƐŝůĂƚĞŝŶƚŚĞƌĂƉĞƵƚŝĐŽƉƚŝŽŶƐ
ĨŽƌ'/^d͍ǆƉĞƌƚKƉŝŶdŚĞƌdĂƌŐĞƚƐϭϲ^ƵƉƉůϮ^ϯϱͲ^ϰϯ
'ũĞĚĚĞ;ϭϵϴϭͿ,ŝŐŚͲĂŶĚůŽǁͲĂĨĨŝŶŝƚǇƚƌĂŶƐƉŽƌƚŽĨͲŐůƵĐŽƐĞĨƌŽŵďůŽŽĚƚŽďƌĂŝŶ͘:EĞƵƌŽĐŚĞŵ
ϯϲ;ϰͿ͗ϭϰϲϯͲϭϰϳϭ
'ŽĞƌƌĞƐ't͕^ƚƵƉƉZ͕ĂƌŐŚŽƵƚŚ'͕,ĂŶǇd&͕WĞƐƚĂůŽǌǌŝ͕ŝǌĞŶĚŽƌĨ͕^ĐŚŶǇĚĞƌW͕>ƵƚŚŝ&͕ǀŽŶ
^ĐŚƵůƚŚĞƐƐ'<͕>ĞǇǀƌĂǌ^;ϮϬϬϱͿdŚĞǀĂůƵĞŽĨWd͕dĂŶĚŝŶͲůŝŶĞWdͬdŝŶƉĂƚŝĞŶƚƐǁŝƚŚ
ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƵƌƐ͗ůŽŶŐͲƚĞƌŵŽƵƚĐŽŵĞŽĨƚƌĞĂƚŵĞŶƚǁŝƚŚŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞ͘Ƶƌ:
EƵĐůDĞĚDŽů/ŵĂŐŝŶŐϯϮ;ϮͿ͗ϭϱϯͲϭϲϮ
ϵϱ

'ƌĂŚĂŵDD͕ĂĚĂǁŝZ͕tĂŚůZ>;ϮϬϭϭͿsĂƌŝĂƚŝŽŶƐŝŶWdͬdŵĞƚŚŽĚŽůŽŐǇĨŽƌŽŶĐŽůŽŐŝĐŝŵĂŐŝŶŐ
Ăƚh͘^͘ĂĐĂĚĞŵŝĐŵĞĚŝĐĂůĐĞŶƚĞƌƐ͗ĂŶŝŵĂŐŝŶŐƌĞƐƉŽŶƐĞĂƐƐĞƐƐŵĞŶƚƚĞĂŵƐƵƌǀĞǇ͘:EƵĐůDĞĚϱϮ
;ϮͿ͗ϯϭϭͲϯϭϳ
'ƌĂŵǌĂt͕ŽƌůĞƐƐ>͕,ĞŝŶƌŝĐŚD;ϮϬϬϵͿZĞƐŝƐƚĂŶĐĞƚŽdǇƌŽƐŝŶĞ<ŝŶĂƐĞ/ŶŚŝďŝƚŽƌƐŝŶ
'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂů^ƚƌŽŵĂůdƵŵŽƌƐ͘ůŝŶĂŶĐĞƌZĞƐϭϱ;ϮϰͿ͗ϳϱϭϬͲϳϱϭϴ
'ƌŽŶĐŚŝ͕&ŝŽƌĞD͕DŝƐĞůůŝ&͕>ĂŐŽŶŝŐƌŽD^͕ŽĐŽW͕DĞƐƐŝŶĂ͕WŝůŽƚƚŝ^͕ĂƐĂůŝW';ϮϬϬϳͿ^ƵƌŐĞƌǇ
ŽĨƌĞƐŝĚƵĂůĚŝƐĞĂƐĞĨŽůůŽǁŝŶŐŵŽůĞĐƵůĂƌͲƚĂƌŐĞƚĞĚƚŚĞƌĂƉǇǁŝƚŚŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞŝŶ
ĂĚǀĂŶĐĞĚͬŵĞƚĂƐƚĂƚŝĐ'/^d͘ŶŶ^ƵƌŐϮϰϱ;ϯͿ͗ϯϰϭͲϯϰϲ
'ƵŐŐĞƌD͕ZĞƵďŝ:;ϭϵϵϵͿ'ĂƐƚƌŝŶͲƌĞůĞĂƐŝŶŐƉĞƉƚŝĚĞƌĞĐĞƉƚŽƌƐŝŶŶŽŶͲŶĞŽƉůĂƐƚŝĐĂŶĚŶĞŽƉůĂƐƚŝĐ
ŚƵŵĂŶďƌĞĂƐƚ͘ŵ:WĂƚŚŽůϭϱϱ;ϲͿ͗ϮϬϲϳͲϮϬϳϲ
,ĂŵƐƚƌĂ͕ŚĞŶĞǀĞƌƚd>͕DŽĨĨĂƚ͕:ŽŚŶƐŽŶd͕DĞǇĞƌZ͕DƵŬŚĞƌũŝ^<͕YƵŝŶƚ:͕'ĞďĂƌƐŬŝ^^͕
&ĂŶy͕dƐŝĞŶ/͕>ĂǁƌĞŶĐĞd^͕:ƵŶĐŬ>͕ZĞŚĞŵƚƵůůĂ͕ZŽƐƐ;ϮϬϬϱͿǀĂůƵĂƚŝŽŶŽĨƚŚĞĨƵŶĐƚŝŽŶĂů
ĚŝĨĨƵƐŝŽŶŵĂƉĂƐĂŶĞĂƌůǇďŝŽŵĂƌŬĞƌŽĨƚŝŵĞͲƚŽͲƉƌŽŐƌĞƐƐŝŽŶĂŶĚŽǀĞƌĂůůƐƵƌǀŝǀĂůŝŶŚŝŐŚͲŐƌĂĚĞ
ŐůŝŽŵĂ͘WƌŽĐEĂƚůĐĂĚ^Đŝh^ϭϬϮ;ϰϲͿ͗ϭϲϳϱϵͲϭϲϳϲϰ
,ĂŵƐƚƌĂ͕'ĂůďĂŶ:͕DĞǇĞƌZ͕:ŽŚŶƐŽŶd͕^ƵŶĚŐƌĞŶW͕dƐŝĞŶ͕>ĂǁƌĞŶĐĞd^͕:ƵŶĐŬ>͕ZŽƐƐ
:͕ZĞŚĞŵƚƵůůĂ͕ZŽƐƐ͕ŚĞŶĞǀĞƌƚd>;ϮϬϬϴͿ&ƵŶĐƚŝŽŶĂůĚŝĨĨƵƐŝŽŶŵĂƉĂƐĂŶĞĂƌůǇŝŵĂŐŝŶŐ
ďŝŽŵĂƌŬĞƌĨŽƌŚŝŐŚͲŐƌĂĚĞŐůŝŽŵĂ͗ĐŽƌƌĞůĂƚŝŽŶǁŝƚŚĐŽŶǀĞŶƚŝŽŶĂůƌĂĚŝŽůŽŐŝĐƌĞƐƉŽŶƐĞĂŶĚŽǀĞƌĂůů
ƐƵƌǀŝǀĂů͘:ůŝŶKŶĐŽůϮϲ;ϮϬͿ͗ϯϯϴϳͲϯϯϵϰ
,ĂƌĂŶD͕&ĞůĚďĞƌŐ͕ĞƌƌĞďŝ;ϮϬϬϮͿ>ǇŵƉŚŽŵĂŵĂƐŬŝŶŐƐĂƌĐŽŝĚŽƐŝƐ͘>ĞƵŬ>ǇŵƉŚŽŵĂϰϯ;ϴͿ͗
ϭϳϬϵͲϭϳϭϬ
,ĞŝŶƌŝĐŚD͕ŽƌůĞƐƐ>͕ůĂŶŬĞ͕ĞŵĞƚƌŝ'͕:ŽĞŶƐƵƵ,͕ZŽďĞƌƚƐW:͕ŝƐĞŶďĞƌŐ>͕ǀŽŶDD͕
&ůĞƚĐŚĞƌ͕^ĂŶĚĂƵ<͕DĐŽƵŐĂůů<͕KƵt͕ŚĞŶ:͕&ůĞƚĐŚĞƌ:;ϮϬϬϲͿDŽůĞĐƵůĂƌĐŽƌƌĞůĂƚĞƐŽĨ
ŝŵĂƚŝŶŝďƌĞƐŝƐƚĂŶĐĞŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘:ůŝŶKŶĐŽůϮϰ;ϮϵͿ͗ϰϳϲϰͲϰϳϳϰ
,ĞŝŶƌŝĐŚD͕ŽƌůĞƐƐ>͕ĞŵĞƚƌŝ'͕ůĂŶŬĞ͕ǀŽŶDD͕:ŽĞŶƐƵƵ,͕DĐ'ƌĞĞǀĞǇ>^͕ŚĞŶ:͕sĂŶ
ĚĞŶďďĞĞůĞ͕ƌƵŬĞƌ:͕<ŝĞƐĞ͕ŝƐĞŶďĞƌŐ͕ZŽďĞƌƚƐW:͕^ŝŶŐĞƌ^͕&ůĞƚĐŚĞƌ͕^ŝůďĞƌŵĂŶ^͕
ŝŵŝƚƌŝũĞǀŝĐ^͕&ůĞƚĐŚĞƌ:;ϮϬϬϯĂͿ<ŝŶĂƐĞŵƵƚĂƚŝŽŶƐĂŶĚŝŵĂƚŝŶŝďƌĞƐƉŽŶƐĞŝŶƉĂƚŝĞŶƚƐǁŝƚŚ
ŵĞƚĂƐƚĂƚŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ͘:ůŝŶKŶĐŽůϮϭ;ϮϯͿ͗ϰϯϰϮͲϰϯϰϵ
,ĞŝŶƌŝĐŚD͕ŽƌůĞƐƐ>͕ƵĞŶƐŝŶŐ͕DĐ'ƌĞĞǀĞǇ>͕ŚĞŶ:͕:ŽƐĞƉŚE͕^ŝŶŐĞƌ^͕'ƌŝĨĨŝƚŚ:͕,ĂůĞǇ
͕dŽǁŶ͕ĞŵĞƚƌŝ'͕&ůĞƚĐŚĞƌ͕&ůĞƚĐŚĞƌ:;ϮϬϬϯďͿW'&ZĂĐƚŝǀĂƚŝŶŐŵƵƚĂƚŝŽŶƐŝŶ
ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘^ĐŝĞŶĐĞϮϵϵ;ϱϲϬϳͿ͗ϳϬϴͲϳϭϬ
,ĞŝŶƌŝĐŚD͕'ƌŝĨĨŝƚŚ:͕ƌƵŬĞƌ:͕tĂŝƚ>͕Kƚƚ<͕ŝŐůĞƌ:;ϮϬϬϬͿ/ŶŚŝďŝƚŝŽŶŽĨĐͲŬŝƚƌĞĐĞƉƚŽƌ
ƚǇƌŽƐŝŶĞŬŝŶĂƐĞĂĐƚŝǀŝƚǇďǇ^d/ϱϳϭ͕ĂƐĞůĞĐƚŝǀĞƚǇƌŽƐŝŶĞŬŝŶĂƐĞŝŶŚŝďŝƚŽƌ͘ůŽŽĚϵϲ;ϯͿ͗ϵϮϱͲϵϯϮ
,ĞŝŶƌŝĐŚD͕DĂŬŝZ'͕ŽƌůĞƐƐ>͕ŶƚŽŶĞƐĐƵZ͕,ĂƌůŽǁ͕'ƌŝĨĨŝƚŚ͕dŽǁŶ͕DĐ<ŝŶůĞǇ͕KƵ
t͕&ůĞƚĐŚĞƌ:͕&ůĞƚĐŚĞƌ͕,ƵĂŶŐy͕ŽŚĞŶW͕ĂƵŵD͕ĞŵĞƚƌŝ';ϮϬϬϴͿWƌŝŵĂƌǇĂŶĚ
ƐĞĐŽŶĚĂƌǇŬŝŶĂƐĞŐĞŶŽƚǇƉĞƐĐŽƌƌĞůĂƚĞǁŝƚŚƚŚĞďŝŽůŽŐŝĐĂůĂŶĚĐůŝŶŝĐĂůĂĐƚŝǀŝƚǇŽĨƐƵŶŝƚŝŶŝďŝŶ
ŝŵĂƚŝŶŝďͲƌĞƐŝƐƚĂŶƚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ͘:ůŝŶKŶĐŽůϮϲ;ϯϯͿ͗ϱϯϱϮͲϱϯϱϵ
,ĞƵƐŶĞƌd͕<ƵĞŵŵĞů^͕<ŽĞŶŝŶŐĞƌ͕,ĂŵĂŵŝD͕,ĂŚŶ^͕YƵŝŶƐƚĞŶ͕ŽĐŬŝƐĐŚ͕&ŽƌƐƚŝŶŐD͕
>ĂƵĞŶƐƚĞŝŶd͕ŶƚŽĐŚ'͕^ƚĂŚů;ϮϬϭϬͿŝĂŐŶŽƐƚŝĐǀĂůƵĞŽĨĚŝĨĨƵƐŝŽŶͲǁĞŝŐŚƚĞĚŵĂŐŶĞƚŝĐƌĞƐŽŶĂŶĐĞ
ŝŵĂŐŝŶŐ;t/ͿĐŽŵƉĂƌĞĚƚŽ&'WdͬdĨŽƌǁŚŽůĞͲďŽĚǇďƌĞĂƐƚĐĂŶĐĞƌƐƚĂŐŝŶŐ͘Ƶƌ:EƵĐůDĞĚDŽů
/ŵĂŐŝŶŐϯϳ;ϲͿ͗ϭϬϳϳͲϭϬϴϲ
ϵϲ

,ŝƌŽƚĂ^͕/ƐŽǌĂŬŝ<͕DŽƌŝǇĂŵĂz͕,ĂƐŚŝŵŽƚŽ<͕EŝƐŚŝĚĂd͕/ƐŚŝŐƵƌŽ^͕<ĂǁĂŶŽ<͕,ĂŶĂĚĂD͕<ƵƌĂƚĂ
͕dĂŬĞĚĂD͕DƵŚĂŵŵĂĚd'͕DĂƚƐƵǌĂǁĂz͕<ĂŶĂŬƵƌĂz͕^ŚŝŶŽŵƵƌĂz͕<ŝƚĂŵƵƌĂz;ϭϵϵϴͿ'ĂŝŶͲŽĨͲ
ĨƵŶĐƚŝŽŶŵƵƚĂƚŝŽŶƐŽĨĐͲŬŝƚŝŶŚƵŵĂŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘^ĐŝĞŶĐĞϮϳϵ;ϱϯϱϬͿ͗ϱϳϳͲϱϴϬ
,ŝƌŽƚĂ^͕KŚĂƐŚŝ͕EŝƐŚŝĚĂd͕/ƐŽǌĂŬŝ<͕<ŝŶŽƐŚŝƚĂ<͕^ŚŝŶŽŵƵƌĂz͕<ŝƚĂŵƵƌĂz;ϮϬϬϯͿ'ĂŝŶͲŽĨͲ
ĨƵŶĐƚŝŽŶŵƵƚĂƚŝŽŶƐŽĨƉůĂƚĞůĞƚͲĚĞƌŝǀĞĚŐƌŽǁƚŚĨĂĐƚŽƌƌĞĐĞƉƚŽƌĂůƉŚĂŐĞŶĞŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂů
ƐƚƌŽŵĂůƚƵŵŽƌƐ͘'ĂƐƚƌŽĞŶƚĞƌŽůŽŐǇϭϮϱ;ϯͿ͗ϲϲϬͲϲϲϳ
,ũŽƌŶĞǀŝŬd͕^ĐŚŽƵůƚǌt͕DĂƌƚŽŶ:͕'ũĞƌƐƚĂĚ:͕ƌǌĞǌŐĂ͕,ĞŶƌŝŬƐĞŶ'͕tŝůůŽĐŚ&;ϮϬϭϬͿ^ƉŝŶĂů
ůŽŶŐͲƚĞƌŵƉŽƚĞŶƚŝĂƚŝŽŶŝƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚƌĞĚƵĐĞĚŽƉŝŽŝĚŶĞƵƌŽƚƌĂŶƐŵŝƐƐŝŽŶŝŶƚŚĞƌĂƚďƌĂŝŶ͘ůŝŶ
WŚǇƐŝŽů&ƵŶĐƚ/ŵĂŐŝŶŐϯϬ;ϰͿ͗ϮϴϱͲϮϵϯ
,ŽĞŬƐƚƌĂ:͕WĂŐůŝĂŶŝƚŝ/͕,ŽĞŬƐƚƌĂK^͕^ŵŝƚ&͕WŽƐƚŵƵƐW͕dĞƵůĞ':͕>ĂŵŵĞƌƚƐŵĂ;ϮϬϬϬͿ
DŽŶŝƚŽƌŝŶŐƌĞƐƉŽŶƐĞƚŽƚŚĞƌĂƉǇŝŶĐĂŶĐĞƌƵƐŝŶŐ΀ϭϴ&΁ͲϮͲĨůƵŽƌŽͲϮͲĚĞŽǆǇͲͲŐůƵĐŽƐĞĂŶĚƉŽƐŝƚƌŽŶ
ĞŵŝƐƐŝŽŶƚŽŵŽŐƌĂƉŚǇ͗ĂŶŽǀĞƌǀŝĞǁŽĨĚŝĨĨĞƌĞŶƚĂŶĂůǇƚŝĐĂůŵĞƚŚŽĚƐ͘Ƶƌ:EƵĐůDĞĚϮϳ;ϲͿ͗ϳϯϭͲϳϰϯ
,ŽƐƚĞŝŶ/͕&ĂƵƌE͕WƌŝŵŽŝƐ͕ŽƵƌǇ&͕ĞŶĂƌĚ:͕ŵŝůĞ:&͕ƌŝŶŐƵŝĞƌWW͕^ĐŽĂǌĞĐ:z͕ŽŝŶĚƌĞ:D
;ϮϬϭϬͿZ&ŵƵƚĂƚŝŽŶƐƚĂƚƵƐŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘ŵ:ůŝŶWĂƚŚŽůϭϯϯ;ϭͿ͗ϭϰϭͲϭϰϴ
:ĂŶĞǁĂǇ<͕>ŝĞŐů͕,ĂƌůŽǁ͕>Ğ͕WĞƌĞǌͲƚĂǇĚĞ͕<ŽǌĂŬĞǁŝĐŚ,͕ŽƌůĞƐƐ>͕,ĞŝŶƌŝĐŚD͕
&ůĞƚĐŚĞƌ:;ϮϬϬϳͿWĞĚŝĂƚƌŝĐ</dǁŝůĚͲƚǇƉĞĂŶĚƉůĂƚĞůĞƚͲĚĞƌŝǀĞĚŐƌŽǁƚŚĨĂĐƚŽƌƌĞĐĞƉƚŽƌĂůƉŚĂͲǁŝůĚͲ
ƚǇƉĞŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐƐŚĂƌĞ</dĂĐƚŝǀĂƚŝŽŶďƵƚŶŽƚŵĞĐŚĂŶŝƐŵƐŽĨŐĞŶĞƚŝĐ
ƉƌŽŐƌĞƐƐŝŽŶǁŝƚŚĂĚƵůƚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘ĂŶĐĞƌZĞƐϲϳ;ϭϵͿ͗ϵϬϴϰͲϵϬϴϴ
:Ăƚŝ͕dĂƚůŝ^͕DŽƌŐĂŶ:͕'ůŝĐŬŵĂŶ:E͕ĞŵĞƚƌŝ'͕sĂŶĚĞŶ͕^ŝůǀĞƌŵĂŶ^';ϮϬϭϮͿ/ŵĂŐŝŶŐ
ĨĞĂƚƵƌĞƐŽĨďŽŶĞŵĞƚĂƐƚĂƐĞƐŝŶƉĂƚŝĞŶƚƐǁŝƚŚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘ŝĂŐŶ/ŶƚĞƌǀZĂĚŝŽů
ϭϴ;ϰͿ͗ϯϵϭͲϯϵϲ
:ŽĞŶƐƵƵ,;ϮϬϬϴͿZŝƐŬƐƚƌĂƚŝĨŝĐĂƚŝŽŶŽĨƉĂƚŝĞŶƚƐĚŝĂŐŶŽƐĞĚǁŝƚŚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ͘
,ƵŵWĂƚŚŽůϯϵ;ϭϬͿ͗ϭϰϭϭͲϭϰϭϵ
:ŽĞŶƐƵƵ,;ϮϬϭϮĂͿĚũƵǀĂŶƚƚƌĞĂƚŵĞŶƚŽĨ'/^d͗ƉĂƚŝĞŶƚƐĞůĞĐƚŝŽŶĂŶĚƚƌĞĂƚŵĞŶƚƐƚƌĂƚĞŐŝĞƐ͘EĂƚ
ZĞǀůŝŶKŶĐŽůϵ;ϲͿ͗ϯϱϭͲϯϱϴ
:ŽĞŶƐƵƵ,͕ĞDĂƚƚĞŽZW;ϮϬϭϮďͿdŚĞŵĂŶĂŐĞŵĞŶƚŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͗ĂŵŽĚĞů
ĨŽƌƚĂƌŐĞƚĞĚĂŶĚŵƵůƚŝĚŝƐĐŝƉůŝŶĂƌǇƚŚĞƌĂƉǇŽĨŵĂůŝŐŶĂŶĐǇ͘ŶŶƵZĞǀDĞĚϲϯϮϰϳͲϮϱϴ
:ŽĞŶƐƵƵ,͕ZŽďĞƌƚƐW:͕^ĂƌůŽŵŽͲZŝŬĂůĂD͕ŶĚĞƌƐƐŽŶ>͕dĞƌǀĂŚĂƌƚŝĂůĂW͕dƵǀĞƐŽŶ͕^ŝůďĞƌŵĂŶ^͕
ĂƉĚĞǀŝůůĞZ͕ŝŵŝƚƌŝũĞǀŝĐ^͕ƌƵŬĞƌ͕ĞŵĞƚƌŝ';ϮϬϬϭͿĨĨĞĐƚŽĨƚŚĞƚǇƌŽƐŝŶĞŬŝŶĂƐĞŝŶŚŝďŝƚŽƌ
^d/ϱϳϭŝŶĂƉĂƚŝĞŶƚǁŝƚŚĂŵĞƚĂƐƚĂƚŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ͘EŶŐů:DĞĚϯϰϰ;ϭϰͿ͗ϭϬϱϮͲ
ϭϬϱϲ
:ŽĞŶƐƵƵ,͕sĞŚƚĂƌŝ͕ZŝŝŚŝŵĂŬŝ:͕EŝƐŚŝĚĂd͕^ƚĞŝŐĞŶ^͕ƌĂďĞĐW͕WůĂŶŬ>͕EŝůƐƐŽŶ͕ŝƌŝůůŝ͕
ƌĂĐŽŶŝ͕ŽƌĚŽŶŝ͕DĂŐŶƵƐƐŽŶD<͕>ŝŶŬĞ͕^ƵĨůŝĂƌƐŬǇ:͕&ĞĚĞƌŝĐŽD͕:ŽŶĂƐƐŽŶ:'͕ĞŝdŽƐW͕
ZƵƚŬŽǁƐŬŝW;ϮϬϭϭͿZŝƐŬŽĨƌĞĐƵƌƌĞŶĐĞŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƵƌĂĨƚĞƌƐƵƌŐĞƌǇ͗ĂŶĂŶĂůǇƐŝƐ
ŽĨƉŽŽůĞĚƉŽƉƵůĂƚŝŽŶͲďĂƐĞĚĐŽŚŽƌƚƐ͘>ĂŶĐĞƚKŶĐŽů
:ƵǁĞŝĚD͕^ƚƌŽŽďĂŶƚƐ^͕,ŽĞŬƐƚƌĂK^͕DŽƚƚĂŐŚǇ&D͕ŝĞƚůĞŝŶD͕'ƵĞƌŵĂǌŝ͕tŝƐĞŵĂŶ'͕
<ŽƐƚĂŬŽŐůƵ>͕^ĐŚĞŝĚŚĂƵĞƌ<͕ƵĐŬ͕EĂƵŵĂŶŶZ͕^ƉĂĞƉĞŶ<͕,ŝĐŬƐZ:͕tĞďĞƌt͕ZĞƐŬĞ^E͕
^ĐŚǁĂŝŐĞƌD͕^ĐŚǁĂƌƚǌ>,͕ŝũůƐƚƌĂ:D͕^ŝĞŐĞů͕ŚĞƐŽŶ;ϮϬϬϳͿhƐĞŽĨƉŽƐŝƚƌŽŶĞŵŝƐƐŝŽŶ
ƚŽŵŽŐƌĂƉŚǇĨŽƌƌĞƐƉŽŶƐĞĂƐƐĞƐƐŵĞŶƚŽĨůǇŵƉŚŽŵĂ͗ĐŽŶƐĞŶƐƵƐŽĨƚŚĞ/ŵĂŐŝŶŐ^ƵďĐŽŵŵŝƚƚĞĞŽĨ
/ŶƚĞƌŶĂƚŝŽŶĂů,ĂƌŵŽŶŝǌĂƚŝŽŶWƌŽũĞĐƚŝŶ>ǇŵƉŚŽŵĂ͘:ůŝŶKŶĐŽůϮϱ;ϱͿ͗ϱϳϭͲϱϳϴ
ϵϳ

<ĂŝĚĂ,͕/ƐŚŝďĂƐŚŝD͕zƵǌƵƌŝŚĂD͕<ƵƌĂƚĂ^͕ƌŝŬĂǁĂ^͕<ĂǁĂŚĂƌĂ͕hŽǌƵŵŝ:͕hĐŚŝĚĂD͕
<ŽďĂǇĂƐŚŝD͕,ŝƌŽƐĞz͕&ƵũŝƚĂ,͕<ĂŐĞD͕,ĂǇĂďƵĐŚŝE;ϮϬϭϬͿ'ůƵĐŽƐĞƚƌĂŶƐƉŽƌƚĞƌĞǆƉƌĞƐƐŝŽŶŽĨĂŶ
ĞƐŽƉŚĂŐĞĂůŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƚƵŵŽƌĚĞƚĞĐƚĞĚďǇ&Ͳϭϴ&'Wdͬd͘ůŝŶEƵĐůDĞĚϯϱ;ϳͿ͗ϱϬϱͲϱϬϵ
<ĂůĞŶĚĞƌD͕^ĞǀŝŶĐ͕<ƵĐƵŬĚƵƌŵĂǌ͕ĂůŝŬ͕^Ăƌŝ/͕ĂŵĐŝ;ϮϬϬϳͿ'ĂƐƚƌŝĐĂŶĚƉƌŽƐƚĂƚĞ
ĂĚĞŶŽĐĂƌĐŝŶŽŵĂŝŶĂƉĂƚŝĞŶƚǁŝƚŚŵĞƚĂƐƚĂƚŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ͘KŶŬŽůŽŐŝĞϯϬ;ϭϭͿ͗
ϱϲϴͲϱϳϬ
<ĂƌƉ:^͕^Ƶƌƚŝ^͕ƵďĞͲtŝƚŚĞƌƐƉŽŽŶD͕DƵĞŚůůĞŚŶĞƌ';ϮϬϬϴͿĞŶĞĨŝƚŽĨƚŝŵĞͲŽĨͲĨůŝŐŚƚŝŶWd͗
ĞǆƉĞƌŝŵĞŶƚĂůĂŶĚĐůŝŶŝĐĂůƌĞƐƵůƚƐ͘:EƵĐůDĞĚϰϵ;ϯͿ͗ϰϲϮͲϰϳϬ
<ĂƐĂŵŽŶz>͕:ŽŶĞƐZ:͕tĂŚůZ>;ϮϬϬϳͿ/ŶƚĞŐƌĂƚŝŶŐWdĂŶĚWdͬdŝŶƚŽƚŚĞƌŝƐŬͲĂĚĂƉƚĞĚƚŚĞƌĂƉǇŽĨ
ůǇŵƉŚŽŵĂ͘:EƵĐůDĞĚϰϴ^ƵƉƉůϭϭϵ^ͲϮϳ^
<ĂƐĂŵŽŶz>͕tĂŚůZ>͕ŝĞƐƐŵĂŶ,͕ůĂĐŬĨŽƌĚ>͕'ŽŽĚŵĂŶ^E͕&ŝĚǇŬ͕ZŽŐĞƌƐ<D͕ŽůĂŶŽƐͲ
DĞĂĚĞ:͕ŽƌŽǁŝƚǌD:͕ŵďŝŶĚĞƌZ&͕:ŽŶĞƐZ:͕^ǁŝŶŶĞŶ>:;ϮϬϬϵͿWŚĂƐĞ//ƐƚƵĚǇŽĨƌŝƐŬͲĂĚĂƉƚĞĚ
ƚŚĞƌĂƉǇŽĨŶĞǁůǇĚŝĂŐŶŽƐĞĚ͕ĂŐŐƌĞƐƐŝǀĞŶŽŶͲ,ŽĚŐŬŝŶůǇŵƉŚŽŵĂďĂƐĞĚŽŶŵŝĚƚƌĞĂƚŵĞŶƚ&'ͲWd
ƐĐĂŶŶŝŶŐ͘ŝŽůůŽŽĚDĂƌƌŽǁdƌĂŶƐƉůĂŶƚϭϱ;ϮͿ͗ϮϰϮͲϮϰϴ
<ĂǁĂŶŽǁĂ<͕^ĂŬƵŵĂz͕^ĂŬƵƌĂŝ^͕,ŝƐŚŝŵĂd͕/ǁĂƐĂŬŝz͕^ĂŝƚŽ<͕,ŽƐŽǇĂz͕EĂŬĂũŝŵĂd͕&ƵŶĂƚĂE
;ϮϬϬϲͿ,ŝŐŚŝŶĐŝĚĞŶĐĞŽĨŵŝĐƌŽƐĐŽƉŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐŝŶƚŚĞƐƚŽŵĂĐŚ͘,ƵŵWĂƚŚŽů
ϯϳ;ϭϮͿ͗ϭϱϮϳͲϭϱϯϱ
<ŝŵ<͕'ƵƉƚĂE;ϭϵϵϲͿĞƉĞŶĚĞŶĐǇŽĨƐƚĂŶĚĂƌĚŝǌĞĚƵƉƚĂŬĞǀĂůƵĞƐŽĨĨůƵŽƌŝŶĞͲϭϴ
ĨůƵŽƌŽĚĞŽǆǇŐůƵĐŽƐĞŽŶďŽĚǇƐŝǌĞ͗ĐŽŵƉĂƌŝƐŽŶŽĨďŽĚǇƐƵƌĨĂĐĞĂƌĞĂĐŽƌƌĞĐƚŝŽŶĂŶĚůĞĂŶďŽĚǇŵĂƐƐ
ĐŽƌƌĞĐƚŝŽŶ͘EƵĐůDĞĚŽŵŵƵŶϭϳ;ϭϬͿ͗ϴϵϬͲϴϵϰ
<ŝŵ^z͕^ŽŽ>^͕ƵŵǁŽŽW͕<ŝŵE͕<ŝŵ:<͕WĂƌŬ^,͕ǇƵŶ:,͕^ŽŶŐ<:͕<ŽŽ:,͕<ǇƵŶŐ͕>ĞĞD'
;ϮϬϭϮͿZĞƉƌŽĚƵĐŝďŝůŝƚǇŽĨŵĞĂƐƵƌĞŵĞŶƚŽĨĂƉƉĂƌĞŶƚĚŝĨĨƵƐŝŽŶĐŽĞĨĨŝĐŝĞŶƚƐŽĨŵĂůŝŐŶĂŶƚŚĞƉĂƚŝĐ
ƚƵŵŽƌƐ͗ĨĨĞĐƚŽĨt/ƚĞĐŚŶŝƋƵĞƐĂŶĚĐĂůĐƵůĂƚŝŽŶŵĞƚŚŽĚƐ͘:DĂŐŶZĞƐŽŶ/ŵĂŐŝŶŐ
<ŝŶĚďůŽŵ>'͕ZĞŵŽƚƚŝ,͕ůĚĞŶďŽƌŐ&͕DĞŝƐͲ<ŝŶĚďůŽŵ:D;ϭϵϵϴͿ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƉĂĐĞŵĂŬĞƌĐĞůů
ƚƵŵŽƌ;'/WdͿ͗ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐƐŚŽǁƉŚĞŶŽƚǇƉŝĐĐŚĂƌĂĐƚĞƌŝƐƚŝĐƐŽĨƚŚĞ
ŝŶƚĞƌƐƚŝƚŝĂůĐĞůůƐŽĨĂũĂů͘ŵ:WĂƚŚŽůϭϱϮ;ϱͿ͗ϭϮϱϵͲϭϮϲϵ
<ŽŚD͕ůĂĐŬůĞĚŐĞD͕ŽůůŝŶƐ:͕WĂĚŚĂŶŝZ͕tĂůůĂĐĞd͕tŝůƚŽŶ͕dĂǇůŽƌE:͕^ƚŝƌůŝŶŐ::͕^ŝŶŚĂZ͕
tĂůŝĐŬĞW͕>ĞĂĐŚDK͕:ƵĚƐŽŶ/͕EĂƚŚĂŶW;ϮϬϬϵͿZĞƉƌŽĚƵĐŝďŝůŝƚǇĂŶĚĐŚĂŶŐĞƐŝŶƚŚĞĂƉƉĂƌĞŶƚ
ĚŝĨĨƵƐŝŽŶĐŽĞĨĨŝĐŝĞŶƚƐŽĨƐŽůŝĚƚƵŵŽƵƌƐƚƌĞĂƚĞĚǁŝƚŚĐŽŵďƌĞƚĂƐƚĂƚŝŶϰƉŚŽƐƉŚĂƚĞĂŶĚ
ďĞǀĂĐŝǌƵŵĂďŝŶĂƚǁŽͲĐĞŶƚƌĞƉŚĂƐĞ/ĐůŝŶŝĐĂůƚƌŝĂů͘ƵƌZĂĚŝŽůϭϵ;ϭϭͿ͗ϮϳϮϴͲϮϳϯϴ
<ŽŚD͕WĂĚŚĂŶŝZ;ϮϬϬϲͿŝĨĨƵƐŝŽŶͲǁĞŝŐŚƚĞĚDZ/͗ĂŶĞǁĨƵŶĐƚŝŽŶĂůĐůŝŶŝĐĂůƚĞĐŚŶŝƋƵĞĨŽƌ
ƚƵŵŽƵƌŝŵĂŐŝŶŐ͘ƌ:ZĂĚŝŽůϳϵ;ϵϰϰͿ͗ϲϯϯͲϲϯϱ
<ƌĂŬE͕ŽĞůůĂĂƌĚZ͕,ŽĞŬƐƚƌĂK^͕dǁŝƐŬ:t͕,ŽĞŬƐƚƌĂ:͕>ĂŵŵĞƌƚƐŵĂ;ϮϬϬϱͿĨĨĞĐƚƐŽĨZK/
ĚĞĨŝŶŝƚŝŽŶĂŶĚƌĞĐŽŶƐƚƌƵĐƚŝŽŶŵĞƚŚŽĚŽŶƋƵĂŶƚŝƚĂƚŝǀĞŽƵƚĐŽŵĞĂŶĚĂƉƉůŝĐĂďŝůŝƚǇŝŶĂƌĞƐƉŽŶƐĞ
ŵŽŶŝƚŽƌŝŶŐƚƌŝĂů͘Ƶƌ:EƵĐůDĞĚDŽů/ŵĂŐŝŶŐϯϮ;ϯͿ͗ϮϵϰͲϯϬϭ
<ƌĞďƐ,;ϭϵϳϮͿdŚĞWĂƐƚĞƵƌĞĨĨĞĐƚĂŶĚƚŚĞƌĞůĂƚŝŽŶƐďĞƚǁĞĞŶƌĞƐƉŝƌĂƚŝŽŶĂŶĚĨĞƌŵĞŶƚĂƚŝŽŶ͘
ƐƐĂǇƐŝŽĐŚĞŵϴϭͲϯϰ
<ƌƵŐĞƌ^͕ƵĐŬ<͕DŽƚƚĂŐŚǇ&D͕,ĂƐĞŶŬĂŵƉ͕WĂƵůƐ^͕^ĐŚƵŵĂŶŶ͕tŝďŵĞƌd͕DĞƌŬd͕
,ŽŵďĂĐŚs͕ZĞƐŬĞ^E;ϮϬϬϵͿĞƚĞĐƚŝŽŶŽĨďŽŶĞŵĞƚĂƐƚĂƐĞƐŝŶƉĂƚŝĞŶƚƐǁŝƚŚůƵŶŐĐĂŶĐĞƌ͗ϵϵŵdĐͲ
ϵϴ

DWƉůĂŶĂƌďŽŶĞƐĐŝŶƚŝŐƌĂƉŚǇ͕ϭϴ&ͲĨůƵŽƌŝĚĞWdŽƌϭϴ&Ͳ&'Wdͬd͘Ƶƌ:EƵĐůDĞĚDŽů/ŵĂŐŝŶŐ
ϯϲ;ϭϭͿ͗ϭϴϬϳͲϭϴϭϮ
<ƌƵƉŬĞD͕ĞŐůĞǇ͕^ƵŶĚďĞƌŐ:W͕Ƶůƚ:͕ƉƉŝŐ:d;ϮϬϬϴͿdŚĞDŽƵƐĞdƵŵŽƌŝŽůŽŐǇĚĂƚĂďĂƐĞ͘
EĂƚZĞǀĂŶĐĞƌϴ;ϲͿ͗ϰϱϵͲϰϲϱ
>ĂŬŝŶŐ'͕WƌŝĐĞW;ϮϬϭϬͿZĂĚŝŽŶƵĐůŝĚĞŝŵĂŐŝŶŐŽĨƉĞƌĨƵƐŝŽŶĂŶĚŚǇƉŽǆŝĂ͘Ƶƌ:EƵĐůDĞĚDŽů
/ŵĂŐŝŶŐϯϳ^ƵƉƉůϭ^ϮϬͲ^Ϯϵ
>ĂŵŵĞƌƚƐŵĂ͕,ŽĞŬƐƚƌĂ:͕'ŝĂĐĐŽŶĞ'͕,ŽĞŬƐƚƌĂK^;ϮϬϬϲͿ,ŽǁƐŚŽƵůĚǁĞĂŶĂůǇƐĞ&'Wd
ƐƚƵĚŝĞƐĨŽƌŵŽŶŝƚŽƌŝŶŐƚƵŵŽƵƌƌĞƐƉŽŶƐĞ͍Ƶƌ:EƵĐůDĞĚDŽů/ŵĂŐŝŶŐϯϯ^ƵƉƉůϭϭϲͲϮϭ
>ĂƐŽƚĂ:͕DŝĞƚƚŝŶĞŶD;ϮϬϬϲͿ</dĂŶĚW'&ZŵƵƚĂƚŝŽŶƐŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ
;'/^dƐͿ͘^ĞŵŝŶŝĂŐŶWĂƚŚŽůϮϯ;ϮͿ͗ϵϭͲϭϬϮ
>Ğ͕ƌĞƚŽŶ͕>ĂůůĞŵĂŶĚ͕ƵďŝŶD>͕sŝŐŶĂƵĚ:͕>ĂǀĂůͲ:ĞĂŶƚĞƚD;ϭϵϴϴͿ^ĞƉĂƌĂƚŝŽŶŽĨĚŝĨĨƵƐŝŽŶ
ĂŶĚƉĞƌĨƵƐŝŽŶŝŶŝŶƚƌĂǀŽǆĞůŝŶĐŽŚĞƌĞŶƚŵŽƚŝŽŶDZŝŵĂŐŝŶŐ͘ZĂĚŝŽůŽŐǇϭϲϴ;ϮͿ͗ϰϵϳͲϱϬϱ
>Ğ͕ZĂǇͲŽƋƵĂƌĚ/͕ƵŝE͕ĚĞŶŝƐ͕ZŝŽƐD͕ĞƌƚƵĐĐŝ&͕ƵĨĨĂƵĚ&͕ŚĞǀƌĞĂƵ͕ƵƉŝƐƐŽů͕
ŝŽĨĨŝ͕ŵŝůĞ:&͕ŚĂďĂƵĚ^͕WĞƌŽů͕ůĂǇ:z;ϮϬϭϬͿŝƐĐŽŶƚŝŶƵĂƚŝŽŶŽĨŝŵĂƚŝŶŝďŝŶƉĂƚŝĞŶƚƐǁŝƚŚ
ĂĚǀĂŶĐĞĚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƵƌƐĂĨƚĞƌϯǇĞĂƌƐŽĨƚƌĞĂƚŵĞŶƚ͗ĂŶŽƉĞŶͲůĂďĞůŵƵůƚŝĐĞŶƚƌĞ
ƌĂŶĚŽŵŝƐĞĚƉŚĂƐĞϯƚƌŝĂů͘>ĂŶĐĞƚKŶĐŽůϭϭ;ϭϬͿ͗ϵϰϮͲϵϰϵ
>ĞĞ<͕ƌĂĚůĞǇ͕,ƵƐƐĂŝŶD͕DĞǇĞƌZ͕ŚĞŶĞǀĞƌƚd>͕:ĂĐŽďƐŽŶ:͕:ŽŚŶƐŽŶd͕'ĂůďĂŶ:͕
ZĞŚĞŵƚƵůůĂ͕WŝĞŶƚĂ<:͕ZŽƐƐ;ϮϬϬϳͿĨĞĂƐŝďŝůŝƚǇƐƚƵĚǇĞǀĂůƵĂƚŝŶŐƚŚĞĨƵŶĐƚŝŽŶĂůĚŝĨĨƵƐŝŽŶŵĂƉ
ĂƐĂƉƌĞĚŝĐƚŝǀĞŝŵĂŐŝŶŐďŝŽŵĂƌŬĞƌĨŽƌĚĞƚĞĐƚŝŽŶŽĨƚƌĞĂƚŵĞŶƚƌĞƐƉŽŶƐĞŝŶĂƉĂƚŝĞŶƚǁŝƚŚ
ŵĞƚĂƐƚĂƚŝĐƉƌŽƐƚĂƚĞĐĂŶĐĞƌƚŽƚŚĞďŽŶĞ͘EĞŽƉůĂƐŝĂϵ;ϭϮͿ͗ϭϬϬϯͲϭϬϭϭ
>ĞĞ<,͕<Ž,͕WĂŝŬ:z͕:ƵŶŐ<,͕ŚŽĞz^͕ŚŽŝz͕<ŝŵd;ϮϬϬϱͿĨĨĞĐƚƐŽĨĂŶĞƐƚŚĞƚŝĐĂŐĞŶƚƐĂŶĚ
ĨĂƐƚŝŶŐĚƵƌĂƚŝŽŶŽŶϭϴ&Ͳ&'ďŝŽĚŝƐƚƌŝďƵƚŝŽŶĂŶĚŝŶƐƵůŝŶůĞǀĞůƐŝŶƚƵŵŽƌͲďĞĂƌŝŶŐŵŝĐĞ͘:EƵĐůDĞĚ
ϰϲ;ϵͿ͗ϭϱϯϭͲϭϱϯϲ
>ĞĞ^͕WŽƉƚĂŶŝ,͕WŝĐŬƵƉ^͕:ĞŶŬŝŶƐtd͕<ŝŵ^͕<ŽĐŚ:͕ĞůŝŬĂƚŶǇ:͕'ůŝĐŬƐŽŶ:;ϮϬϭϬͿĂƌůǇ
ĚĞƚĞĐƚŝŽŶŽĨƌĂĚŝĂƚŝŽŶƚŚĞƌĂƉǇƌĞƐƉŽŶƐĞŝŶŶŽŶͲ,ŽĚŐŬŝŶΖƐůǇŵƉŚŽŵĂǆĞŶŽŐƌĂĨƚƐďǇŝŶǀŝǀŽϭ,
ŵĂŐŶĞƚŝĐƌĞƐŽŶĂŶĐĞƐƉĞĐƚƌŽƐĐŽƉǇĂŶĚŝŵĂŐŝŶŐ͘EDZŝŽŵĞĚϮϯ;ϲͿ͗ϲϮϰͲϲϯϮ
>Ğŝ,͕'ƌŝŶďĞƌŐK͕EǁĂŝŐǁĞ/͕,ŽƵ,'͕tŝůůŝĂŵƐ,͕^ǁĂƌƚǌ,D͕ƵŶŶ:&;ϮϬϬϭͿdŚĞĞĨĨĞĐƚƐŽĨ
ŬĞƚĂŵŝŶĞͲǆǇůĂǌŝŶĞĂŶĞƐƚŚĞƐŝĂŽŶĐĞƌĞďƌĂůďůŽŽĚĨůŽǁĂŶĚŽǆǇŐĞŶĂƚŝŽŶŽďƐĞƌǀĞĚƵƐŝŶŐŶƵĐůĞĂƌ
ŵĂŐŶĞƚŝĐƌĞƐŽŶĂŶĐĞƉĞƌĨƵƐŝŽŶŝŵĂŐŝŶŐĂŶĚĞůĞĐƚƌŽŶƉĂƌĂŵĂŐŶĞƚŝĐƌĞƐŽŶĂŶĐĞŽǆŝŵĞƚƌǇ͘ƌĂŝŶZĞƐ
ϵϭϯ;ϮͿ͗ϭϳϰͲϭϳϵ
>ĞŶǌ͕<ůĂƌŚŽĨĞƌD͕^ĐŚĞĨĨůĞƌ<͕tŝŶƚĞƌ>͕^ŽŵŵĞƌ';ϮϬϭϭͿƐƐĞƐƐŝŶŐĞǆƚƌĂĐƌĂŶŝĂůƚƵŵŽƌƐƵƐŝŶŐ
ĚŝĨĨƵƐŝŽŶͲǁĞŝŐŚƚĞĚǁŚŽůĞͲďŽĚǇDZ/͘DĞĚWŚǇƐϮϭ;ϮͿ͗ϳϵͲϵϬ
>ĞǁŝƐ:^͕>ĂĨŽƌĞƐƚZ͕ĞŚĚĂƐŚƚŝ&͕'ƌŝŐƐďǇWt͕tĞůĐŚD:͕^ŝĞŐĞů;ϮϬϬϴͿŶŝŵĂŐŝŶŐĐŽŵƉĂƌŝƐŽŶ
ŽĨϲϰƵͲd^DĂŶĚϲϬƵͲd^DŝŶĐĂŶĐĞƌŽĨƚŚĞƵƚĞƌŝŶĞĐĞƌǀŝǆ͘:EƵĐůDĞĚϰϵ;ϳͿ͗ϭϭϳϳͲϭϭϴϮ
>ŝĞŐů͕<ĞƉƚĞŶ/͕>Ğ͕ŚƵD͕ĞŵĞƚƌŝ'͕,ĞŝŶƌŝĐŚD͕&ůĞƚĐŚĞƌ͕ŽƌůĞƐƐ>͕&ůĞƚĐŚĞƌ:
;ϮϬϬϴͿ,ĞƚĞƌŽŐĞŶĞŝƚǇŽĨŬŝŶĂƐĞŝŶŚŝďŝƚŽƌƌĞƐŝƐƚĂŶĐĞŵĞĐŚĂŶŝƐŵƐŝŶ'/^d͘:WĂƚŚŽůϮϭϲ;ϭͿ͗ϲϰͲϳϰ
>ŝƵ͕ůĞƐƐŝŽD͕<ŝŶĂŚĂŶW;ϮϬϭϭͿZĞƐƉŝƌĂƚŽƌǇŵŽƚŝŽŶĐŽƌƌĞĐƚŝŽŶĨŽƌƋƵĂŶƚŝƚĂƚŝǀĞWdͬdƵƐŝŶŐ
ĂůůĚĞƚĞĐƚĞĚĞǀĞŶƚƐǁŝƚŚŝŶƚĞƌŶĂůͲĞǆƚĞƌŶĂůŵŽƚŝŽŶĐŽƌƌĞůĂƚŝŽŶ͘DĞĚWŚǇƐϯϴ;ϱͿ͗ϮϳϭϱͲϮϳϮϯ
ϵϵ

>ŽĚŐĞD͕ŚĂƵĚŚƌǇD͕tĂŚůZ>;ϮϬϭϮͿEŽŝƐĞĐŽŶƐŝĚĞƌĂƚŝŽŶƐĨŽƌWdƋƵĂŶƚŝĨŝĐĂƚŝŽŶƵƐŝŶŐ
ŵĂǆŝŵƵŵĂŶĚƉĞĂŬƐƚĂŶĚĂƌĚŝǌĞĚƵƉƚĂŬĞǀĂůƵĞ͘:EƵĐůDĞĚϱϯ;ϳͿ͗ϭϬϰϭͲϭϬϰϳ
DĂĐŚĞĚĂD>͕ZŽŐĞƌƐ^͕ĞƐƚ:;ϮϬϬϱͿDŽůĞĐƵůĂƌĂŶĚĐĞůůƵůĂƌƌĞŐƵůĂƚŝŽŶŽĨŐůƵĐŽƐĞƚƌĂŶƐƉŽƌƚĞƌ
;'>hdͿƉƌŽƚĞŝŶƐŝŶĐĂŶĐĞƌ͘:ĞůůWŚǇƐŝŽůϮϬϮ;ϯͿ͗ϲϱϰͲϲϲϮ
DĂĐŚůĞŶŬŝŶ^͕WŝŶƐŬ/͕dƵůĐŚŝŶƐŬǇ,͕ŝǀz͕^ĂǇĨĂŶ:͕ƵĞŬ͕ZĂďĂƵD͕tĂůĨŝƐĐŚ^;ϮϬϭϭͿdŚĞĞĨĨĞĐƚ
ŽĨŶĞŽĂĚũƵǀĂŶƚ/ŵĂƚŝŶŝďƚŚĞƌĂƉǇŽŶŽƵƚĐŽŵĞĂŶĚƐƵƌǀŝǀĂůĂĨƚĞƌƌĞĐƚĂůŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂů
ƚƵŵŽƵƌ͘ŽůŽƌĞĐƚĂůŝƐϭϯ;ϭϬͿ͗ϭϭϭϬͲϭϭϭϱ
DĂůŝŶĞŶ͕ZŽĚĂů:͕<ŶƵĚƚƐĞŶ/^͕^ŽǀŝŬ͕^ŬŽŐŵŽ,<;ϮϬϭϭͿ^ƉĂƚŝŽƚĞŵƉŽƌĂůĂŶĂůǇƐŝƐŽĨƚƵŵŽƌ
ƵƉƚĂŬĞƉĂƚƚĞƌŶƐŝŶĚǇŶĂŵŝĐ;ϭϴͿ&'ͲWdĂŶĚĚǇŶĂŵŝĐĐŽŶƚƌĂƐƚĞŶŚĂŶĐĞĚd͘ĐƚĂKŶĐŽůϱϬ;ϲͿ͗
ϴϳϯͲϴϴϮ
DĂƌŬǁĂůĚĞƌZ͕ZĞƵďŝ:;ϭϵϵϵͿ'ĂƐƚƌŝŶͲƌĞůĞĂƐŝŶŐƉĞƉƚŝĚĞƌĞĐĞƉƚŽƌƐŝŶƚŚĞŚƵŵĂŶƉƌŽƐƚĂƚĞ͗
ƌĞůĂƚŝŽŶƚŽŶĞŽƉůĂƐƚŝĐƚƌĂŶƐĨŽƌŵĂƚŝŽŶ͘ĂŶĐĞƌZĞƐϱϵ;ϱͿ͗ϭϭϱϮͲϭϭϱϵ
DĂƌƚĞůůĂ^͕>ŽŚƐŝƌŝǁĂƚs͕ĂƌďĂůŚŽD͕ĞůůĂsW͕ŽƚƚŝŐůŝĞƌŝ>͕ƌĂŵďƵůůŽd͕'ŽƚƚĂƌĚŝ͕ZŝĞƚũĞŶƐD͕
WĞƚŝƚ:z;ϮϬϭϮͿ^ĂƌĐŽŝĚͲůŝŬĞƌĞĂĐƚŝŽŶŝŶďƌĞĂƐƚĐĂŶĐĞƌ͗ĂůŽŶŐͲƚĞƌŵĨŽůůŽǁͲƵƉƐĞƌŝĞƐŽĨĞŝŐŚƚ
ƉĂƚŝĞŶƚƐ͘^ƵƌŐdŽĚĂǇϰϮ;ϯͿ͗ϮϱϵͲϮϲϯ
DĂƌƚŝŶ:͕WŽǀĞĚĂ͕>ůŽŵďĂƌƚͲŽƐĐŚ͕ZĂŵŽƐZ͕>ŽƉĞǌͲ'ƵĞƌƌĞƌŽ:͕'ĂƌĐŝĂĚĞůD:͕DĂƵƌĞů:͕
ĂůĂďƵŝŐ^͕'ƵƚŝĞƌƌĞǌ͕'ŽŶǌĂůĞǌĚĞ^ĂŶĚĞ:>͕DĂƌƚŝŶĞǌ:͕Ğ:͕>ĂŝŶĞǌE͕>ŽƐĂ&͕ůŝũĂs͕ƐĐƵĚĞƌŽ
W͕ĂƐĂĚŽ͕'ĂƌĐŝĂW͕ůĂŶĐŽZ͕ƵĞƐĂ:D;ϮϬϬϱͿĞůĞƚŝŽŶƐĂĨĨĞĐƚŝŶŐĐŽĚŽŶƐϱϱϳͲϱϱϴŽĨƚŚĞĐͲ</d
ŐĞŶĞŝŶĚŝĐĂƚĞĂƉŽŽƌƉƌŽŐŶŽƐŝƐŝŶƉĂƚŝĞŶƚƐǁŝƚŚĐŽŵƉůĞƚĞůǇƌĞƐĞĐƚĞĚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂů
ƚƵŵŽƌƐ͗ĂƐƚƵĚǇďǇƚŚĞ^ƉĂŶŝƐŚ'ƌŽƵƉĨŽƌ^ĂƌĐŽŵĂZĞƐĞĂƌĐŚ;'/^Ϳ͘:ůŝŶKŶĐŽůϮϯ;ϮϱͿ͗ϲϭϵϬͲ
ϲϭϵϴ
DĂƌƚŝŶͲƌŽƚŽ:͕'ƵƚŝĞƌƌĞǌ͕'ĂƌĐŝĂͲĚĞůͲDƵƌŽy͕>ŽƉĞǌͲ'ƵĞƌƌĞƌŽ:͕DĂƌƚŝŶĞǌͲdƌƵĨĞƌŽ:͕ĚĞ^ĂŶĚĞ
>D͕>ĂŝŶĞǌE͕DĂƵƌĞů:͕Ğ:͕>ŽƐĂ&͕ŶĚƌĞƐZ͕ĂƐĂĚŽ͕dĞũŝĚŽW'͕ůĂŶĐŽZ͕ĂƌůĞƐ:͕ĞůůŵƵŶƚ:͕
'ŽŵĞǌͲƐƉĂŶĂ͕ZĂŵŽƐZ͕DĂƌƚŝŶĞǌͲ^ĞƌƌĂ:͕>ůŽŵďĂƌƚͲŽƐĐŚ͕WŽǀĞĚĂ;ϮϬϭϬͿWƌŽŐŶŽƐƚŝĐƚŝŵĞ
ĚĞƉĞŶĚĞŶĐĞŽĨĚĞůĞƚŝŽŶƐĂĨĨĞĐƚŝŶŐĐŽĚŽŶƐϱϱϳĂŶĚͬŽƌϱϱϴŽĨ</dŐĞŶĞĨŽƌƌĞůĂƉƐĞͲĨƌĞĞƐƵƌǀŝǀĂů
;Z&^ͿŝŶůŽĐĂůŝǌĞĚ'/^d͗Ă^ƉĂŶŝƐŚ'ƌŽƵƉĨŽƌ^ĂƌĐŽŵĂZĞƐĞĂƌĐŚ;'/^Ϳ^ƚƵĚǇ͘ŶŶKŶĐŽůϮϭ;ϳͿ͗
ϭϱϱϮͲϭϱϱϳ
DĂƚƐƵŝd͕DŝƚƐƵŝ,͕^ĞŬŝŐĂǁĂ<͕<ŽďĂǇĂƐŚŝ<͕KŬƵďŽD͕^Ž͕EĂŬĂĐŚŝ<͕,ĂƐŚŝŵŽƚŽE͕zĂŵĂŐƵĐŚŝ
,͕/ƐŚŝŬĂǁĂD͕KŬƵĚĂ:͕^ĂƚŽ<͕dĞƌĂƐŚŝŵĂ,͕<ŝƐŚŝĚĂz͕dĂŵƵƌĂ<͕^ƵǌƵŬŝd;ϮϬϬϵͿĐĂƐĞŽĨĂ
ĚƵŽĚĞŶĂůŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌĚŝĂŐŶŽƐĞĚǁŝƚŚƚŚĞĂŝĚŽĨĚŝĨĨƵƐŝŽŶͲǁĞŝŐŚƚĞĚŵĂŐŶĞƚŝĐ
ƌĞƐŽŶĂŶĐĞŝŵĂŐŝŶŐ͘ůŝŶŝĐĂů:ŽƵƌŶĂůŽĨ'ĂƐƚƌŽĞŶƚĞƌŽůŽŐǇϮ;ϲͿ͗ϯϴϰͲϯϴϳ͕ĚŽŝ͗ϭϬ͘ϭϬϬϳͬƐϭϮϯϮϴͲϬϬϵͲ
ϬϭϭϬͲǌ
DĂƚƐƵŝt͕tĂŶŐY͕ĂƌďĞƌ:W͕ƌĞŶŶĂŶ^͕^ŵŝƚŚ͕ŽƌƌĞůůŽ/͕DĐEŝĞĐĞ/͕>ŝŶ>͕ŵďŝŶĚĞƌZ&͕
WĞĂĐŽĐŬ͕tĂƚŬŝŶƐE͕,ƵĨĨ͕:ŽŶĞƐZ:;ϮϬϬϴͿůŽŶŽŐĞŶŝĐŵƵůƚŝƉůĞŵǇĞůŽŵĂƉƌŽŐĞŶŝƚŽƌƐ͕ƐƚĞŵ
ĐĞůůƉƌŽƉĞƌƚŝĞƐ͕ĂŶĚĚƌƵŐƌĞƐŝƐƚĂŶĐĞ͘ĂŶĐĞƌZĞƐϲϴ;ϭͿ͗ϭϵϬͲϭϵϳ
DŝĞƚƚŝŶĞŶD͕>ĂƐŽƚĂ:;ϮϬϬϲͿ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͗ƉĂƚŚŽůŽŐǇĂŶĚƉƌŽŐŶŽƐŝƐĂƚ
ĚŝĨĨĞƌĞŶƚƐŝƚĞƐ͘^ĞŵŝŶŝĂŐŶWĂƚŚŽůϮϯ;ϮͿ͗ϳϬͲϴϯ
DŝƋƵĞůD͕^ĐŽƚƚ͕DĂĐĚŽƵŐĂůůE͕ŽƵďĞƌƚĂŬŚZ͕ŚĂƌǁĂŶŝE͕ZŽĐŬĂůů';ϮϬϭϮͿ/ŶǀŝƚƌŽĂŶĚŝŶ
ǀŝǀŽƌĞƉĞĂƚĂďŝůŝƚǇŽĨĂďĚŽŵŝŶĂůĚŝĨĨƵƐŝŽŶͲǁĞŝŐŚƚĞĚDZ/͘ƌ:ZĂĚŝŽů
ϭϬϬ

ŵŝƚƌĂŬŽƉŽƵůŽƵͲ^ƚƌĂƵƐƐ͕,ŽŚĞŶďĞƌŐĞƌW͕,ĂďĞƌŬŽƌŶh͕DĂĐŬĞ,Z͕ŝƐĞŶŚƵƚD͕^ƚƌĂƵƐƐ>';ϮϬϬϳͿ
ϲϴ'ĂͲůĂďĞůĞĚďŽŵďĞƐŝŶƐƚƵĚŝĞƐŝŶƉĂƚŝĞŶƚƐǁŝƚŚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͗ĐŽŵƉĂƌŝƐŽŶǁŝƚŚ
ϭϴ&Ͳ&'͘:EƵĐůDĞĚϰϴ;ϴͿ͗ϭϮϰϱͲϭϮϱϬ
DŝǇĂŬĞ<<͕EĂŬĂŵŽƚŽz͕dŽŐĂƐŚŝ<;ϮϬϭϮͿƵĂůͲƚŝŵĞͲƉŽŝŶƚ;ϭϴͿ&Ͳ&'WdͬdŝŶƉĂƚŝĞŶƚƐǁŝƚŚ
ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ͗ĐůŝŶŝĐĂůǀĂůƵĞŽĨĞĂƌůǇĚĞůĂǇĞĚƐĐĂŶŶŝŶŐ͘ŶŶEƵĐůDĞĚ
DŽů͕ŽƵŐĂŶZ͕^ĐŚŶĞŝĚĞƌdZ͕^ŬĞŶĞZ:͕<ƌĂƵƐD>͕^ĐŚĞŝďĞE͕^ŶĞůů'W͕ŽƵ,͕^ĂŶŐ͕
tŝůƐŽŶ<W;ϮϬϬϰͿ^ƚƌƵĐƚƵƌĂůďĂƐŝƐĨŽƌƚŚĞĂƵƚŽŝŶŚŝďŝƚŝŽŶĂŶĚ^d/ͲϱϳϭŝŶŚŝďŝƚŝŽŶŽĨĐͲ<ŝƚƚǇƌŽƐŝŶĞ
ŬŝŶĂƐĞ͘:ŝŽůŚĞŵϮϳϵ;ϯϬͿ͗ϯϭϲϱϱͲϯϭϲϲϯ
DƵůůĂŶŝE͕,ĞƌďƐƚZ^͕KΖEĞŝůZ'͕'ŽƵůĚ<>͕ĂƌƌŽŶ:͕ďďƌƵǌǌĞƐĞ:>;ϮϬϬϴͿdƵŵŽƌďůŽŽĚĨůŽǁ
ŵĞĂƐƵƌĞĚďǇWdĚǇŶĂŵŝĐŝŵĂŐŝŶŐŽĨĨŝƌƐƚͲƉĂƐƐϭϴ&Ͳ&'ƵƉƚĂŬĞ͗ĂĐŽŵƉĂƌŝƐŽŶǁŝƚŚϭϱKͲůĂďĞůĞĚ
ǁĂƚĞƌͲŵĞĂƐƵƌĞĚďůŽŽĚĨůŽǁ͘:EƵĐůDĞĚϰϵ;ϰͿ͗ϱϭϳͲϱϮϯ
DƵƐƐŝ͕^ĐŚŝůĚŚĂƵƐ,h͕'ƌŽŶĐŚŝ͕tĂƌĚĞůŵĂŶŶ͕,ŽŚĞŶďĞƌŐĞƌW;ϮϬϬϴͿdŚĞƌĂƉĞƵƚŝĐ
ĐŽŶƐĞƋƵĞŶĐĞƐĨƌŽŵŵŽůĞĐƵůĂƌďŝŽůŽŐǇĨŽƌŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƉĂƚŝĞŶƚƐĂĨĨĞĐƚĞĚďǇ
ŶĞƵƌŽĨŝďƌŽŵĂƚŽƐŝƐƚǇƉĞϭ͘ůŝŶĂŶĐĞƌZĞƐϭϰ;ϭϰͿ͗ϰϱϱϬͲϰϱϱϱ
EĂŚŵŝĂƐ͕tĂŚů>D;ϮϬϬϴͿZĞƉƌŽĚƵĐŝďŝůŝƚǇŽĨƐƚĂŶĚĂƌĚŝǌĞĚƵƉƚĂŬĞǀĂůƵĞŵĞĂƐƵƌĞŵĞŶƚƐ
ĚĞƚĞƌŵŝŶĞĚďǇϭϴ&Ͳ&'WdŝŶŵĂůŝŐŶĂŶƚƚƵŵŽƌƐ͘:EƵĐůDĞĚϰϵ;ϭϭͿ͗ϭϴϬϰͲϭϴϬϴ
EĂŬĂŝE͕/ƐŚŝŬĂǁĂd͕EŝƐŚŝƚĂŶŝ͕>ŝƵEE͕^ŚŝŶĐŚŽD͕,ĂŽ,͕/ƐŽǌĂŬŝ<͕<ĂŶĚĂd͕EŝƐŚŝĚĂd͕&ƵũŝŵŽƚŽ
:͕,ŝƌŽƚĂ^;ϮϬϬϴͿŵŽƵƐĞŵŽĚĞůŽĨĂŚƵŵĂŶŵƵůƚŝƉůĞ'/^dĨĂŵŝůǇǁŝƚŚ</dͲƐƉϴϮϬdǇƌŵƵƚĂƚŝŽŶ
ŐĞŶĞƌĂƚĞĚďǇĂŬŶŽĐŬͲŝŶƐƚƌĂƚĞŐǇ͘:WĂƚŚŽůϮϭϰ;ϯͿ͗ϯϬϮͲϯϭϭ
EĂŽĞ,͕<ĂŬƵ͕/ĚŽz͕'ƵƐŚŝŵĂZ͕DĂŬŝz͕^ĂŝƚŽ,͕zŽŬŽƚĞ^͕'ƵƐŚŝŵĂZ͕EŽŶĂŬĂ<͕,ŽƐŚŝĚĂz͕
DƵƌĂŽd͕KǌĂŬŝd͕zŽŬŽŵŝŶĞ<͕dĂŶĂŬĂ,͕EĂŐĂŚĂŵĂ,͕^ĂŬƵƌĂŝ<͕dĂŶĂŬĂD͕/ǇĂŵĂ<͕ĂďĂ,͕
^ĂƐĂŬŝz;ϮϬϭϭͿƌĂŝŶŵĞƚĂƐƚĂƐŝƐĨƌŽŵŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ͗ĂĐĂƐĞƌĞƉŽƌƚĂŶĚƌĞǀŝĞǁŽĨ
ƚŚĞůŝƚĞƌĂƚƵƌĞ͘ĂƐĞZĞƉ'ĂƐƚƌŽĞŶƚĞƌŽůϱ;ϯͿ͗ϱϴϯͲϱϴϵ
EŝůƐĞŶ>͕&ĂŶŐďĞƌŐĞƚ͕'ĞŝĞƌK͕KůƐĞŶZ͕^ĞŝĞƌƐƚĂĚd;ϮϬϭϬͿŝĨĨƵƐŝŽŶͲǁĞŝŐŚƚĞĚŵĂŐŶĞƚŝĐ
ƌĞƐŽŶĂŶĐĞŝŵĂŐŝŶŐĨŽƌƉƌĞƚƌĞĂƚŵĞŶƚƉƌĞĚŝĐƚŝŽŶĂŶĚŵŽŶŝƚŽƌŝŶŐŽĨƚƌĞĂƚŵĞŶƚƌĞƐƉŽŶƐĞŽĨƉĂƚŝĞŶƚƐ
ǁŝƚŚůŽĐĂůůǇĂĚǀĂŶĐĞĚďƌĞĂƐƚĐĂŶĐĞƌƵŶĚĞƌŐŽŝŶŐŶĞŽĂĚũƵǀĂŶƚĐŚĞŵŽƚŚĞƌĂƉǇ͘ĐƚĂKŶĐŽůϰϵ;ϯͿ͗
ϯϱϰͲϯϲϬ
EŝůƐƐŽŶ͕ƵŵŵŝŶŐW͕DĞŝƐͲ<ŝŶĚďůŽŵ:D͕KĚĞŶ͕ŽƌƚŽŬ͕'ƵƐƚĂǀƐƐŽŶ͕^ĂďůŝŶƐŬĂ<͕<ŝŶĚďůŽŵ
>';ϮϬϬϱͿ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͗ƚŚĞŝŶĐŝĚĞŶĐĞ͕ƉƌĞǀĂůĞŶĐĞ͕ĐůŝŶŝĐĂůĐŽƵƌƐĞ͕ĂŶĚ
ƉƌŽŐŶŽƐƚŝĐĂƚŝŽŶŝŶƚŚĞƉƌĞŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞĞƌĂͲͲĂƉŽƉƵůĂƚŝŽŶͲďĂƐĞĚƐƚƵĚǇŝŶǁĞƐƚĞƌŶ^ǁĞĚĞŶ͘
ĂŶĐĞƌϭϬϯ;ϰͿ͗ϴϮϭͲϴϮϵ
EŽǀĂŬ͕dƌĞǀŝŶŽ:';ϮϬϭϬͿ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͗ĂƉĂƌĂĚŝŐŵĨŽƌƚŚĞƌĂƉĞƵƚŝĐŽƉƚŝŽŶƐŝŶ
ƐŽůŝĚŽƌŐĂŶƚƵŵŽƌƐ͘DŝŶŝZĞǀDĞĚŚĞŵϭϬ;ϳͿ͗ϲϮϰͲϲϯϰ
EŽǁĂŝŶ͕ŚĂŬƚĂ,͕WĂŝƐ^͕<ĂŶĞů'͕sĞƌŵĂ^;ϮϬϬϱͿ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͗ĐůŝŶŝĐĂů
ƉƌŽĨŝůĞ͕ƉĂƚŚŽŐĞŶĞƐŝƐ͕ƚƌĞĂƚŵĞŶƚƐƚƌĂƚĞŐŝĞƐĂŶĚƉƌŽŐŶŽƐŝƐ͘:'ĂƐƚƌŽĞŶƚĞƌŽů,ĞƉĂƚŽůϮϬ;ϲͿ͗ϴϭϴͲϴϮϰ
KĐŚŝD͕<ƵƌŽŝǁĂd͕^ƵŶĂŵŝ^͕DƵƌĂŬĂŵŝ:͕DŝǇĂŚĂƌĂ^͕EĂŐĂŝĞd͕KǇĂD͕zĂďƵƵĐŚŝ,͕,ĂƚĂŬĞŶĂŬĂ
D;ϮϬϭϭͿŝĨĨƵƐŝŽŶͲǁĞŝŐŚƚĞĚŝŵĂŐŝŶŐ;ďǀĂůƵĞсϭϱϬϬƐͬŵŵ;ϮͿͿŝƐƵƐĞĨƵůƚŽĚĞĐƌĞĂƐĞĨĂůƐĞͲƉŽƐŝƚŝǀĞ
ďƌĞĂƐƚĐĂŶĐĞƌĐĂƐĞƐĚƵĞƚŽĨŝďƌŽĐǇƐƚŝĐĐŚĂŶŐĞƐ͘ƌĞĂƐƚĂŶĐĞƌ
KŬĂĚĂ<͕^ĂƐĂŬŝD͕EĂŶũŽ,͕/ƚŽD͕dĂŬĂŚĂƐŚŝ^͕/ƚŽŝ;ϮϬϬϱͿĞŶŝŐŶůĞƐŝŽŶƐŝŶĐĂŶĐĞƌƉĂƚŝĞŶƚƐ͗
ĂƐĞϮ͘hŶƵƐƵĂůĂƐƐŽĐŝĂƚŝŽŶŽĨŽƐƚĞŽƐĂƌĐŽŵĂĂŶĚƐĂƌĐŽŝĚŽƐŝƐ͘:ůŝŶKŶĐŽůϮϯ;ϯͿ͗ϲϰϭͲϲϰϯ
ϭϬϭ

KƚŽŵŝz͕KƚƐƵŬĂ,͕DŽƌŝƚĂE͕dĞƌĂǌĂǁĂ<͕&ƵƌƵƚĂŶŝ<͕,ĂƌĂĚĂD͕EŝƐŚŝƚĂŶŝ,;ϮϬϭϬͿZĞůĂƚŝŽŶƐŚŝƉ
ďĞƚǁĞĞŶ&'ƵƉƚĂŬĞĂŶĚƚŚĞƉĂƚŚŽůŽŐŝĐĂůƌŝƐŬĐĂƚĞŐŽƌǇŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘:DĞĚ
/ŶǀĞƐƚϱϳ;ϯͲϰͿ͗ϮϳϬͲϮϳϰ
WĂĚŚĂŶŝZ͕<ŽŚD;ϮϬϭϭͿŝĨĨƵƐŝŽŶDZŝŵĂŐŝŶŐĨŽƌŵŽŶŝƚŽƌŝŶŐŽĨƚƌĞĂƚŵĞŶƚƌĞƐƉŽŶƐĞ͘DĂŐŶ
ZĞƐŽŶ/ŵĂŐŝŶŐůŝŶEŵϭϵ;ϭͿ͗ϭϴϭͲϮϬϵ
WĂĚŚĂŶŝZ͕<ƌŽŚŶ<͕>ĞǁŝƐ:^͕ůďĞƌD;ϮϬϬϳͿ/ŵĂŐŝŶŐŽǆǇŐĞŶĂƚŝŽŶŽĨŚƵŵĂŶƚƵŵŽƵƌƐ͘Ƶƌ
ZĂĚŝŽůϭϳ;ϰͿ͗ϴϲϭͲϴϳϮ
WĂĚŚĂŶŝZ͕>ŝƵ'͕<ŽŚD͕ŚĞŶĞǀĞƌƚd>͕dŚŽĞŶǇ,͕dĂŬĂŚĂƌĂd͕ǌŝŬͲ:ƵƌĂƐǌ͕ZŽƐƐ͕sĂŶD͕
ŽůůŝŶƐ͕,ĂŵŵŽƵĚ͕ZƵƐƚŝŶ':͕dĂŽƵůŝ͕ŚŽǇŬĞW>;ϮϬϬϵͿŝĨĨƵƐŝŽŶͲǁĞŝŐŚƚĞĚŵĂŐŶĞƚŝĐ
ƌĞƐŽŶĂŶĐĞŝŵĂŐŝŶŐĂƐĂĐĂŶĐĞƌďŝŽŵĂƌŬĞƌ͗ĐŽŶƐĞŶƐƵƐĂŶĚƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐ͘EĞŽƉůĂƐŝĂϭϭ;ϮͿ͗
ϭϬϮͲϭϮϱ
WĂŶƚĂůĞŽD͕ƐƚŽůĨŝ͕/ŶĚŝŽs͕DŽŽƌĞZ͕dŚŝĞƐƐĞŶE͕,ĞŝŶƌŝĐŚD͕'ŶŽĐĐŚŝ͕^ĂŶƚŝŶŝ͕ĂƚĞŶĂ&͕
&ŽƌŵŝĐĂ^͕DĂƌƚĞůůŝW>͕ĂƐĂĚŝŽZ͕WĞƐƐŝŽŶ͕ŝĂƐĐŽ';ϮϬϭϭͿ^,ůŽƐƐͲŽĨͲĨƵŶĐƚŝŽŶŵƵƚĂƚŝŽŶƐŝŶ
</dͲW'&ZǁŝůĚͲƚǇƉĞŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐŝĚĞŶƚŝĨŝĞĚďǇŵĂƐƐŝǀĞůǇƉĂƌĂůůĞůƐĞƋƵĞŶĐŝŶŐ͘
:EĂƚůĂŶĐĞƌ/ŶƐƚϭϬϯ;ϭϮͿ͗ϵϴϯͲϵϴϳ
WĂŶƚĂůĞŽD͕>ĂŶĚƵǌǌŝ>͕EŝĐŽůĞƚƚŝ'͕EĂŶŶŝ͕ŽƐĐŚŝ^͕WŝĂǌǌŝ'͕^ĂŶƚŝŶŝ͕ŝD͕ĂƐƚĞůůƵĐĐŝW͕
>ŽĚŝ&͕&ĂŶƚŝ^͕>ŽůůŝŶŝW>͕ŝĂƐĐŽ';ϮϬϬϵͿĚǀĂŶĐĞƐŝŶƉƌĞĐůŝŶŝĐĂůƚŚĞƌĂƉĞƵƚŝĐƐĚĞǀĞůŽƉŵĞŶƚƵƐŝŶŐ
ƐŵĂůůĂŶŝŵĂůŝŵĂŐŝŶŐĂŶĚŵŽůĞĐƵůĂƌĂŶĂůǇƐĞƐ͗ƚŚĞŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐŵŽĚĞů͘ůŝŶǆƉ
DĞĚϵ;ϯͿ͗ϭϵϵͲϮϬϱ
WĂƉƉŽ^͕:ĂŶĞǁĂǇ<;ϮϬϬϵͿWĞĚŝĂƚƌŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘,ĞŵĂƚŽůKŶĐŽůůŝŶEŽƌƚŚ
ŵϮϯ;ϭͿ͗ϭϱͲϯϰ͕ǀŝŝ
WĂƚůĂŬ^͕ůĂƐďĞƌŐZ'͕&ĞŶƐƚĞƌŵĂĐŚĞƌ:;ϭϵϴϯͿ'ƌĂƉŚŝĐĂůĞǀĂůƵĂƚŝŽŶŽĨďůŽŽĚͲƚŽͲďƌĂŝŶƚƌĂŶƐĨĞƌ
ĐŽŶƐƚĂŶƚƐĨƌŽŵŵƵůƚŝƉůĞͲƚŝŵĞƵƉƚĂŬĞĚĂƚĂ͘:ĞƌĞďůŽŽĚ&ůŽǁDĞƚĂďϯ;ϭͿ͗ϭͲϳ
WƌĞŶĞŶ,͕ĞƌŽŽƐĞ͕sĞƌŵĂĞůĞŶW͕^ĐŝŽƚZ͕ďŝĞĐͲZǇĐŚƚĞƌD͕^ƚƌŽŽďĂŶƚƐ^͕DŽƌƚĞůŵĂŶƐ>͕^ĐŚŽĨĨƐŬŝ
W͕ǀĂŶK;ϮϬϬϲͿƐƚĂďůŝƐŚŵĞŶƚŽĨĂŵŽƵƐĞŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƵƌŵŽĚĞůĂŶĚĞǀĂůƵĂƚŝŽŶ
ŽĨƌĞƐƉŽŶƐĞƚŽŝŵĂƚŝŶŝďďǇƐŵĂůůĂŶŝŵĂůƉŽƐŝƚƌŽŶĞŵŝƐƐŝŽŶƚŽŵŽŐƌĂƉŚǇ͘ŶƚŝĐĂŶĐĞƌZĞƐϮϲ;ϮͿ͗
ϭϮϰϳͲϭϮϱϮ
WƌĞŶĞŶ,͕^ƚĞĨĂŶ͕>ĂŶĚƵǇƚ͕sĞƌŵĂĞůĞŶW͕ĞďŝĞĐͲZǇĐŚƚĞƌD͕ŽůůĞŶD͕^ƚƌŽŽďĂŶƚƐ^͕ĚĞƌƵŝũŶ
͕DŽƌƚĞůŵĂŶƐ>͕^ĐŝŽƚZ͕^ĐŚŽĨĨƐŬŝW͕ǀĂŶKŽƐƚĞƌŽŵd;ϮϬϬϱͿ/ŵĂƚŝŶŝďŵĞƐǇůĂƚĞŝŶŚŝďŝƚƐŐůƵĐŽƐĞ
ƵƉƚĂŬĞŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌĐĞůůƐďǇĚŽǁŶƌĞŐƵůĂƚŝŽŶŽĨƚŚĞŐůƵĐŽƐĞƚƌĂŶƐƉŽƌƚĞƌƐ
ƌĞĐƌƵŝƚŵĞŶƚƚŽƚŚĞƉůĂƐŵĂŵĞŵďƌĂŶĞ͘ŵ:ŝŽĐŚĞŵŝŽƚĞĐŚŶŽů;ϭͿ͗ϵϱͲϭϬϮ
WƌŝŽƌ:K͕DŽŶƚĞŵƵƌƌŽD͕KƌĐƵƌƚŽDs͕DŝĐŚŝĞůŝŶK͕>ƵƚŚŝ&͕ĞŶŚĂƚƚĂƌ:͕'ƵŝůůŽƵ>͕ůƐŝŐs͕^ƚƵƉƉZ͕
ĞůĂůŽǇĞ͕>ĞǇǀƌĂǌ^;ϮϬϬϵͿĂƌůǇƉƌĞĚŝĐƚŝŽŶŽĨƌĞƐƉŽŶƐĞƚŽƐƵŶŝƚŝŶŝďĂĨƚĞƌŝŵĂƚŝŶŝďĨĂŝůƵƌĞďǇ
ϭϴ&ͲĨůƵŽƌŽĚĞŽǆǇŐůƵĐŽƐĞƉŽƐŝƚƌŽŶĞŵŝƐƐŝŽŶƚŽŵŽŐƌĂƉŚǇŝŶƉĂƚŝĞŶƚƐǁŝƚŚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂů
ƚƵŵŽƌ͘:ůŝŶKŶĐŽůϮϳ;ϯͿ͗ϰϯϵͲϰϰϱ
ZĂĐŬĞƌ͕^ĐŚƌŽĞĚĞƌ;ϭϵϱϴͿdŚĞƌĞĚƵĐƚŝǀĞƉĞŶƚŽƐĞƉŚŽƐƉŚĂƚĞĐǇĐůĞ͘//͘^ƉĞĐŝĨŝĐͲϭ
ƉŚŽƐƉŚĂƚĂƐĞƐĨŽƌĨƌƵĐƚŽƐĞϭ͕ϲͲĚŝƉŚŽƐƉŚĂƚĞĂŶĚƐĞĚŽŚĞƉƚƵůŽƐĞϭ͕ϳͲĚŝƉŚŽƐƉŚĂƚĞ͘ƌĐŚŝŽĐŚĞŵ
ŝŽƉŚǇƐϳϰ;ϮͿ͗ϯϮϲͲϯϰϰ
ZĂƵƚW͕WŽƐŶĞƌD͕ĞƐĂŝ:͕DŽƌŐĂŶ:͕'ĞŽƌŐĞ^͕ĂŚƌŝĞŚ͕&ůĞƚĐŚĞƌ͕ĞŵĞƚƌŝ'͕ĞƌƚĂŐŶŽůůŝ
DD;ϮϬϬϲͿ^ƵƌŐŝĐĂůŵĂŶĂŐĞŵĞŶƚŽĨĂĚǀĂŶĐĞĚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐĂĨƚĞƌƚƌĞĂƚŵĞŶƚ
ǁŝƚŚƚĂƌŐĞƚĞĚƐǇƐƚĞŵŝĐƚŚĞƌĂƉǇƵƐŝŶŐŬŝŶĂƐĞŝŶŚŝďŝƚŽƌƐ͘:ůŝŶKŶĐŽůϮϰ;ϭϱͿ͗ϮϯϮϱͲϮϯϯϭ
ϭϬϮ

ZĞŝĐŚĂƌĚƚW͕DŽŶƚĞŵƵƌƌŽD;ϮϬϭϭͿůŝŶŝĐĂůĞǆƉĞƌŝĞŶĐĞƚŽĚĂƚĞǁŝƚŚŶŝůŽƚŝŶŝďŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂů
ƐƚƌŽŵĂůƚƵŵŽƌƐ͘^ĞŵŝŶKŶĐŽůϯϴ^ƵƉƉůϭ^ϮϬͲ^Ϯϳ
ZĞƐŚĞĨ͕^ŚŝƌǀĂŶ͕ŬƐĞůƌŽĚͲĂůůŝŶ͕tĂůů͕ŝǀ/;ϮϬϭϬͿ^ŵĂůůͲŵŽůĞĐƵůĞďŝŽŵĂƌŬĞƌƐĨŽƌĐůŝŶŝĐĂů
WdŝŵĂŐŝŶŐŽĨĂƉŽƉƚŽƐŝƐ͘:EƵĐůDĞĚϱϭ;ϲͿ͗ϴϯϳͲϴϰϬ
ZĞƵďŝ:͕<ŽƌŶĞƌD͕tĂƐĞƌ͕DĂǌǌƵĐĐŚĞůůŝ>͕'ƵŝůůŽƵ>;ϮϬϬϰͿ,ŝŐŚĞǆƉƌĞƐƐŝŽŶŽĨƉĞƉƚŝĚĞ
ƌĞĐĞƉƚŽƌƐĂƐĂŶŽǀĞůƚĂƌŐĞƚŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƵƌƐ͘Ƶƌ:EƵĐůDĞĚDŽů/ŵĂŐŝŶŐϯϭ
;ϲͿ͗ϴϬϯͲϴϭϬ
ZĞǀŚĞŝŵD͕,ĂƵŐǀŝŬ^W:ŽŚŶƐƌƵĚ<DĂƚŚŝƐĞŶT'ŝůƚǀĞĚƚ,^ƉŝƚĞŶ^ŬƌĞƚƚŝŶŐ͘dĂŝůŽƌĞĚ&'Ͳ
WdƉƌŽƚŽĐŽůǁŝƚŚƉƌŽůŽŶŐĞĚĂĐƋƵŝƐŝƚŝŽŶĂŶĚƌĞƐƉŝƌĂƚŽƌǇŐĂƚŝŶŐŝŵƉƌŽǀĞƐĚĞƚĞĐƚŝŽŶŽĨŵĞƚĂƐƚĂƚŝĐ
ůĞƐŝŽŶƐŝŶƚŚĞůŝǀĞƌ͘:EƵĐůDĞĚ͘ϱϯ΀^ƵƉƉůĞŵĞŶƚϭ΁͘ϵͲϲͲϮϬϭϮ͘
ZĞĨdǇƉĞ͗ďƐƚƌĂĐƚ
ZĞǀŚĞŝŵD͕tŝŶŐĞͲDĂŝŶ<͕,ĂŐĞŶ'͕&ũĞůĚ:'͕&ŽƐƐĂ^͕>ŝůůĞďǇt;ϮϬϭϭͿŽŵďŝŶĞĚƉŽƐŝƚƌŽŶ
ĞŵŝƐƐŝŽŶƚŽŵŽŐƌĂƉŚǇͬĐŽŵƉƵƚĞĚƚŽŵŽŐƌĂƉŚǇŝŶƐƵŶŝƚŝŶŝďƚŚĞƌĂƉǇĂƐƐĞƐƐŵĞŶƚŽĨƉĂƚŝĞŶƚƐǁŝƚŚ
ŵĞƚĂƐƚĂƚŝĐƌĞŶĂůĐĞůůĐĂƌĐŝŶŽŵĂ͘ůŝŶKŶĐŽů;ZŽůůZĂĚŝŽůͿϮϯ;ϱͿ͗ϯϯϵͲϯϰϯ
ZŽďĞǇ/&͕>ŝĞŶ͕tĞůƐŚ^:͕ĂŐŐĞƚƚ<͕'ŝůůŝĞƐZ:;ϮϬϬϱͿ,ǇƉŽǆŝĂͲŝŶĚƵĐŝďůĞĨĂĐƚŽƌͲϭĂůƉŚĂĂŶĚƚŚĞ
ŐůǇĐŽůǇƚŝĐƉŚĞŶŽƚǇƉĞŝŶƚƵŵŽƌƐ͘EĞŽƉůĂƐŝĂϳ;ϰͿ͗ϯϮϰͲϯϯϬ
ZŽĞ<͕ůĞŬƐĂŶĚĞƌƐĞŶd͕<ƌŝƐƚŝĂŶ͕EŝůƐĞŶ>͕^ĞŝĞƌƐƚĂĚd͕YƵ,͕ZĞĞ,͕KůƐĞŶZ͕DĂůŝŶĞŶ
;ϮϬϭϬͿWƌĞĐůŝŶŝĐĂůĚǇŶĂŵŝĐϭϴ&Ͳ&'͘ĐƚĂKŶĐŽůϰϵ;ϳͿ͗ϵϭϰͲϵϮϭ
ZŽĞ<͕<ĂŬĂƌD͕^ĞŝĞƌƐƚĂĚd͕ZĞĞ,͕KůƐĞŶZ;ϮϬϭϭͿĂƌůǇƉƌĞĚŝĐƚŝŽŶŽĨƌĞƐƉŽŶƐĞƚŽƌĂĚŝŽƚŚĞƌĂƉǇ
ĂŶĚĂŶĚƌŽŐĞŶͲĚĞƉƌŝǀĂƚŝŽŶƚŚĞƌĂƉǇŝŶƉƌŽƐƚĂƚĞĐĂŶĐĞƌďǇƌĞƉĞĂƚĞĚĨƵŶĐƚŝŽŶĂůDZ/͗ĂƉƌĞĐůŝŶŝĐĂů
ƐƚƵĚǇ͘ZĂĚŝĂƚKŶĐŽůϲϲϱ
ZŽĨƐƚĂĚ<͕DĂƚŚŝĞƐĞŶ͕<ŝŶĚĞŵ<͕'ĂůĂƉƉĂƚŚŝ<;ϮϬϬϲͿĐŝĚŝĐĞǆƚƌĂĐĞůůƵůĂƌƉ,ƉƌŽŵŽƚĞƐ
ĞǆƉĞƌŝŵĞŶƚĂůŵĞƚĂƐƚĂƐŝƐŽĨŚƵŵĂŶŵĞůĂŶŽŵĂĐĞůůƐŝŶĂƚŚǇŵŝĐŶƵĚĞŵŝĐĞ͘ĂŶĐĞƌZĞƐϲϲ;ϭϯͿ͗
ϲϲϵϵͲϲϳϬϳ
ZŽŚƌĞŶD͕dƵƌŬŝŶŐƚŽŶd'͕ŽůĞŵĂŶZ;ϮϬϬϰͿůŝŶŝĐĂůĂƉƉůŝĐĂƚŝŽŶƐŽĨWdŝŶŽŶĐŽůŽŐǇ͘ZĂĚŝŽůŽŐǇ
Ϯϯϭ;ϮͿ͗ϯϬϱͲϯϯϮ
ZŽƐƐŝ&͕ŚůĞƌƐ/͕ŐŽƐƚŝs͕^ŽĐĐŝE͕sŝĂůĞ͕^ŽŵŵĞƌ'͕zŽǌŐĂƚz͕DĂŶŽǀĂ<͕ŶƚŽŶĞƐĐƵZ͕
ĞƐŵĞƌW;ϮϬϬϲͿKŶĐŽŐĞŶŝĐ<ŝƚƐŝŐŶĂůŝŶŐĂŶĚƚŚĞƌĂƉĞƵƚŝĐŝŶƚĞƌǀĞŶƚŝŽŶŝŶĂŵŽƵƐĞŵŽĚĞůŽĨ
ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ͘WƌŽĐEĂƚůĐĂĚ^Đŝh^ϭϬϯ;ϯϰͿ͗ϭϮϴϰϯͲϭϮϴϰϴ
ZƵďŝŶW͕ŶƚŽŶĞƐĐƵZ͕^ĐŽƚƚͲƌŽǁŶĞ:W͕ŽŵƐƚŽĐŬD>͕'Ƶz͕dĂŶĂƐDZ͕tĂƌĞ͕tŽŽĚĞůů:
;ϮϬϬϱͿŬŶŽĐŬͲŝŶŵŽƵƐĞŵŽĚĞůŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌŚĂƌďŽƌŝŶŐŬŝƚ<ϲϰϭ͘ĂŶĐĞƌZĞƐ
ϲϱ;ϭϱͿ͗ϲϲϯϭͲϲϲϯϵ
ZƵďŝŶW͕&ůĞƚĐŚĞƌ:͕&ůĞƚĐŚĞƌ;ϮϬϬϬͿDŽůĞĐƵůĂƌ/ŶƐŝŐŚƚƐŝŶƚŽƚŚĞ,ŝƐƚŽŐĞŶĞƐŝƐĂŶĚ
WĂƚŚŽŐĞŶĞƐŝƐŽĨ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂů^ƚƌŽŵĂůdƵŵŽƌƐ͘/Ŷƚ:^ƵƌŐWĂƚŚŽůϴ;ϭͿ͗ϱͲϭϬ
ZƵďŝŶW͕^ŝŶŐĞƌ^͕dƐĂŽ͕ƵĞŶƐŝŶŐ͕>ƵǆD>͕ZƵŝǌZ͕,ŝďďĂƌĚD<͕ŚĞŶ:͕yŝĂŽ^͕dƵǀĞƐŽŶ͕
ĞŵĞƚƌŝ'͕&ůĞƚĐŚĞƌ͕&ůĞƚĐŚĞƌ:;ϮϬϬϭͿ</dĂĐƚŝǀĂƚŝŽŶŝƐĂƵďŝƋƵŝƚŽƵƐĨĞĂƚƵƌĞŽĨ
ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘ĂŶĐĞƌZĞƐϲϭ;ϮϮͿ͗ϴϭϭϴͲϴϭϮϭ
ZƵƚŬŽǁƐŬŝW͕ďŝĞĐͲZǇĐŚƚĞƌD͕EŽǁĞĐŬŝ/͕tŽǌŶŝĂŬ͕DŝĐŚĞũt͕>ŝŵŽŶ:͕^ŝĞĚůĞĐŬŝ:͕:ĞƌǌĂŬsĞů
͕'ƌǌĞƐŝĂŬŽǁƐŬĂh͕EĂƐŝĞƌŽǁƐŬĂͲ'ƵƚƚŵĞũĞƌ͕^ǇŐƵƚ:͕EǇĐŬŽǁƐŬŝW͕<ƌĂǁĐǌǇŬD͕ZƵŬĂt
ϭϬϯ

;ϮϬϬϳͿŝĨĨĞƌĞŶƚĨĂĐƚŽƌƐĂƌĞƌĞƐƉŽŶƐŝďůĞĨŽƌƉƌĞĚŝĐƚŝŶŐƌĞůĂƉƐĞƐĂĨƚĞƌƉƌŝŵĂƌǇƚƵŵŽƌƐƌĞƐĞĐƚŝŽŶĂŶĚ
ĨŽƌŝŵĂƚŝŶŝďƚƌĞĂƚŵĞŶƚŽƵƚĐŽŵĞƐŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘DĞĚ^ĐŝDŽŶŝƚϭϯ;ϭϭͿ͗
ZϱϭϱͲZϱϮϮ
ZƵƚŬŽǁƐŬŝW͕ǇůŝŶĂ͕tŽǌŶŝĂŬ͕EŽǁĞĐŬŝ/͕KƐƵĐŚ͕DĂƚůŽŬD͕^ǁŝƚĂũd͕DŝĐŚĞũt͕tƌŽŶƐŬŝD͕
'ůƵƐǌĞŬ^͕<ƌŽĐ:͕EĂƐŝĞƌŽǁƐŬĂͲ'ƵƚƚŵĞũĞƌ͕:ŽĞŶƐƵƵ,;ϮϬϭϭͿsĂůŝĚĂƚŝŽŶŽĨƚŚĞ:ŽĞŶƐƵƵƌŝƐŬ
ĐƌŝƚĞƌŝĂĨŽƌƉƌŝŵĂƌǇƌĞƐĞĐƚĂďůĞŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƵƌͲƚŚĞŝŵƉĂĐƚŽĨƚƵŵŽƵƌƌƵƉƚƵƌĞŽŶ
ƉĂƚŝĞŶƚŽƵƚĐŽŵĞƐ͘Ƶƌ:^ƵƌŐKŶĐŽůϯϳ;ϭϬͿ͗ϴϵϬͲϴϵϲ
ZƵƚŬŽǁƐŬŝW͕EŽǁĞĐŬŝ͕EǇĐŬŽǁƐŬŝW͕ǌŝĞǁŝƌƐŬŝt͕'ƌǌĞƐŝĂŬŽǁƐŬĂh͕EĂƐŝĞƌŽǁƐŬĂͲ'ƵƚƚŵĞũĞƌ͕
<ƌĂǁĐǌǇŬD͕ZƵŬĂt;ϮϬϬϲͿ^ƵƌŐŝĐĂůƚƌĞĂƚŵĞŶƚŽĨƉĂƚŝĞŶƚƐǁŝƚŚŝŶŝƚŝĂůůǇŝŶŽƉĞƌĂďůĞĂŶĚͬŽƌ
ŵĞƚĂƐƚĂƚŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ;'/^dͿĚƵƌŝŶŐƚŚĞƌĂƉǇǁŝƚŚŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞ͘:^ƵƌŐ
KŶĐŽůϵϯ;ϰͿ͗ϯϬϰͲϯϭϭ
^ĂůĂƌ͕ZĂŵŽŶ:D͕ĂƌƌĂŶĐŽ͕EŝĞƚŽD͕WƌĂƚƐD͕^ĞƌƌĂŶŽ^͕ĞƐƐĞƐ;ϮϬϬϱͿŽƵďůĞĚŝĂŐŶŽƐŝƐŝŶ
ĐĂŶĐĞƌƉĂƚŝĞŶƚƐĂŶĚĐƵƚĂŶĞŽƵƐƌĞĂĐƚŝŽŶƌĞůĂƚĞĚƚŽŐĞŵĐŝƚĂďŝŶĞ͗^ϭ͘^ǇŶĐŚƌŽŶŽƵƐŵƵĐŽƐĂͲ
ĂƐƐŽĐŝĂƚĞĚůǇŵƉŚŽŝĚƚŝƐƐƵĞůǇŵƉŚŽŵĂĂŶĚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐŽĨƚŚĞƐƚŽŵĂĐŚ͘:ůŝŶ
KŶĐŽůϮϯ;ϮϴͿ͗ϳϮϮϭͲϳϮϮϯ
^ĂŵŝŝĂŶ>͕tĞĂǀĞƌD͕sĞůĂŶŽǀŝĐŚs;ϮϬϬϰͿǀĂůƵĂƚŝŽŶŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐĨŽƌ
ƌĞĐƵƌƌĞŶĐĞƌĂƚĞƐĂŶĚƉĂƚƚĞƌŶƐŽĨůŽŶŐͲƚĞƌŵĨŽůůŽǁͲƵƉ͘ŵ^ƵƌŐϳϬ;ϯͿ͗ϭϴϳͲϭϵϭ
^ĂŶĚǀŝŬKD͕^ŽƌĞŝĚĞ<͕<ǀĂůŽǇ:d͕'ƵĚůĂƵŐƐƐŽŶ͕^ŽƌĞŝĚĞ:;ϮϬϭϭͿƉŝĚĞŵŝŽůŽŐǇŽĨ
ŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƵƌƐ͗ƐŝŶŐůĞͲŝŶƐƚŝƚƵƚŝŽŶĞǆƉĞƌŝĞŶĐĞĂŶĚĐůŝŶŝĐĂůƉƌĞƐĞŶƚĂƚŝŽŶŽǀĞƌ
ƚŚƌĞĞĚĞĐĂĚĞƐ͘ĂŶĐĞƌƉŝĚĞŵŝŽůϯϱ;ϲͿ͗ϱϭϱͲϱϮϬ
^ĂƵƐǀŝůůĞ͕ƵƌŐĞƌD;ϮϬϬϲͿŽŶƚƌŝďƵƚŝŽŶƐŽĨŚƵŵĂŶƚƵŵŽƌǆĞŶŽŐƌĂĨƚƐƚŽĂŶƚŝĐĂŶĐĞƌĚƌƵŐ
ĚĞǀĞůŽƉŵĞŶƚ͘ĂŶĐĞƌZĞƐϲϲ;ϳͿ͗ϯϯϱϭͲϰ͕ĚŝƐĐƵƐƐŝŽŶ
^ĂǁĂŬŝ͕EŝƐŚŝĚĂd͕Žŝd͕zĂŵĂĚĂz͕<ŽŵĂƚƐƵz͕<ĂŶĚĂd͕<ĂŬĞũŝz͕KŶŽǌĂǁĂz͕zĂŵĂƐĂŬŝD͕
KŚƚƐƵ;ϮϬϭϭͿWŚĂƐĞϮƐƚƵĚǇŽĨŶŝůŽƚŝŶŝďĂƐƚŚŝƌĚͲůŝŶĞƚŚĞƌĂƉǇĨŽƌƉĂƚŝĞŶƚƐǁŝƚŚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂů
ƐƚƌŽŵĂůƚƵŵŽƌ͘ĂŶĐĞƌ
^ĐŚůĞŵŵĞƌD͕^ŽƵƌďƌŽŶ^W͕^ĐŚŝŶǁĂůĚE͕EŝŬŽůĂŽƵ<͕ĞĐŬĞƌZ͕ZĞŝƐĞƌD&͕ĞƌŐĞƌ&;ϮϬϭϭͿ
WĞƌĨƵƐŝŽŶƉĂƚƚĞƌŶƐŽĨŵĞƚĂƐƚĂƚŝĐŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌůĞƐŝŽŶƐƵŶĚĞƌƐƉĞĐŝĨŝĐŵŽůĞĐƵůĂƌ
ƚŚĞƌĂƉǇ͘Ƶƌ:ZĂĚŝŽůϳϳ;ϮͿ͗ϯϭϮͲϯϭϴ
^ĞĂŐƌŽǀĞƐdE͕ZǇĂŶ,͕>Ƶ,͕tŽƵƚĞƌƐ'͕<ŶĂƉƉD͕dŚŝďĂƵůƚW͕>ĂĚĞƌŽƵƚĞ<͕:ŽŚŶƐŽŶZ^;ϮϬϬϭͿ
dƌĂŶƐĐƌŝƉƚŝŽŶĨĂĐƚŽƌ,/&ͲϭŝƐĂŶĞĐĞƐƐĂƌǇŵĞĚŝĂƚŽƌŽĨƚŚĞƉĂƐƚĞƵƌĞĨĨĞĐƚŝŶŵĂŵŵĂůŝĂŶĐĞůůƐ͘DŽů
ĞůůŝŽůϮϭ;ϭϬͿ͗ϯϰϯϲͲϯϰϰϰ
^ĞŝĞƌƐƚĂĚd͕&ŽůŬǀŽƌĚ^͕ZŽĞ<͕&ůĂƚŵĂƌŬ<͕^ŬƌĞƚƚŝŶŐ͕KůƐĞŶZ;ϮϬϬϳͿĂƌůǇĐŚĂŶŐĞƐŝŶĂƉƉĂƌĞŶƚ
ĚŝĨĨƵƐŝŽŶĐŽĞĨĨŝĐŝĞŶƚƉƌĞĚŝĐƚƚŚĞƋƵĂŶƚŝƚĂƚŝǀĞĂŶƚŝƚƵŵŽƌĂůĂĐƚŝǀŝƚǇŽĨĐĂƉĞĐŝƚĂďŝŶĞ͕ŽǆĂůŝƉůĂƚŝŶ͕ĂŶĚ
ŝƌƌĂĚŝĂƚŝŽŶŝŶ,dϮϵǆĞŶŽŐƌĂĨƚƐŝŶĂƚŚǇŵŝĐŶƵĚĞŵŝĐĞ͘EĞŽƉůĂƐŝĂϵ;ϱͿ͗ϯϵϮͲϰϬϬ
^ŚĂŶŬĂƌ><͕,ŽĨĨŵĂŶ:D͕ĂĐŚĂƌĂĐŚ^͕'ƌĂŚĂŵDD͕<ĂƌƉ:͕>ĂŵŵĞƌƚƐŵĂ͕>ĂƌƐŽŶ^͕DĂŶŬŽĨĨ
͕^ŝĞŐĞů͕sĂŶĞŶ͕zĂƉ:͕^ƵůůŝǀĂŶ;ϮϬϬϲͿŽŶƐĞŶƐƵƐƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐĨŽƌƚŚĞƵƐĞŽĨ
ϭϴ&Ͳ&'WdĂƐĂŶŝŶĚŝĐĂƚŽƌŽĨƚŚĞƌĂƉĞƵƚŝĐƌĞƐƉŽŶƐĞŝŶƉĂƚŝĞŶƚƐŝŶEĂƚŝŽŶĂůĂŶĐĞƌ/ŶƐƚŝƚƵƚĞdƌŝĂůƐ͘
:EƵĐůDĞĚϰϳ;ϲͿ͗ϭϬϱϵͲϭϬϲϲ
^ŚĂŶŬĂƌ^͕ǀĂŶ^ŽŶŶĞŶďĞƌŐ͕ĞƐĂŝ:͕ŝƉŝƌŽW:͕sĂŶĞŶ͕ĞŵĞƚƌŝ';ϮϬϬϱͿ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂů
ƐƚƌŽŵĂůƚƵŵŽƌ͗ŶĞǁŶŽĚƵůĞͲǁŝƚŚŝŶͲĂͲŵĂƐƐƉĂƚƚĞƌŶŽĨƌĞĐƵƌƌĞŶĐĞĂĨƚĞƌƉĂƌƚŝĂůƌĞƐƉŽŶƐĞƚŽŝŵĂƚŝŶŝď
ŵĞƐǇůĂƚĞ͘ZĂĚŝŽůŽŐǇϮϯϱ;ϯͿ͗ϴϵϮͲϴϵϴ
ϭϬϰ

^ŚŝŶƚŽ͕EĂŝƌE͕Ƶƚƚ͕ĂŐŚĞůE^;ϮϬϬϴͿĂƌůǇƌĞƐƉŽŶƐĞĂƐƐĞƐƐŵĞŶƚŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂů
ƚƵŵŽƌƐǁŝƚŚ&'WdƐĐĂŶϮϰŚŽƵƌƐĂĨƚĞƌĂƐŝŶŐůĞĚŽƐĞŽĨŝŵĂƚŝŶŝď͘ůŝŶEƵĐůDĞĚϯϯ;ϳͿ͗ϰϴϲͲϰϴϳ
^ŝŶŐĞƌ^͕ZƵďŝŶW͕>ƵǆD>͕ŚĞŶ:͕ĞŵĞƚƌŝ'͕&ůĞƚĐŚĞƌ͕&ůĞƚĐŚĞƌ:;ϮϬϬϮͿWƌŽŐŶŽƐƚŝĐǀĂůƵĞ
ŽĨ</dŵƵƚĂƚŝŽŶƚǇƉĞ͕ŵŝƚŽƚŝĐĂĐƚŝǀŝƚǇ͕ĂŶĚŚŝƐƚŽůŽŐŝĐƐƵďƚǇƉĞŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͘:
ůŝŶKŶĐŽůϮϬ;ϭϴͿ͗ϯϴϵϴͲϯϵϬϱ
^ũŽůƵŶĚ<͕ŶĚĞƌƐƐŽŶ͕EŝůƐƐŽŶ͕EŝůƐƐŽŶK͕ŚůŵĂŶ,͕EŝůƐƐŽŶ;ϮϬϭϬͿŽǁŶƐŝǌŝŶŐƚƌĞĂƚŵĞŶƚ
ǁŝƚŚƚǇƌŽƐŝŶĞŬŝŶĂƐĞŝŶŚŝďŝƚŽƌƐŝŶƉĂƚŝĞŶƚƐǁŝƚŚĂĚǀĂŶĐĞĚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ
ŝŵƉƌŽǀĞĚƌĞƐĞĐƚĂďŝůŝƚǇ͘tŽƌůĚ:^ƵƌŐϯϰ;ϵͿ͗ϮϬϵϬͲϮϬϵϳ
^ŬƌĞƚƚŝŶŐ;ϮϬϬϵͿΖ/ŶƚĞŶƐŝƚǇĚŝĨĨƵƐŝŽŶΖŝƐĂďĞƚƚĞƌĚĞƐĐƌŝƉƚŝŽŶƚŚĂŶΖƉĂƌƚŝĂůǀŽůƵŵĞĞĨĨĞĐƚΖ͘Ƶƌ:
EƵĐůDĞĚDŽů/ŵĂŐŝŶŐϯϲ;ϯͿ͗ϱϯϲͲϱϯϳ
^ŬƌĞƚƚŝŶŐ͕'ůŽŵƐĞƚK͕ŽŐƐƌƵĚds;ϮϬϭϬͿƉŚĂŶƚŽŵĨŽƌŝŶǀĞƐƚŝŐĂƚŝŽŶŽĨƚƵŵŽƵƌƐŝŐŶĂůĂŶĚŶŽŝƐĞ
ŝŶWdƌĞĐŽŶƐƚƌƵĐƚŝŽŶǁŝƚŚǀĂƌŝŽƵƐƐŵŽŽƚŚŝŶŐĨŝůƚĞƌƐ͗ĞǆƉĞƌŝŵĞŶƚƐĂŶĚĐŽŵƉĂƌŝƐŽŶƐǁŝƚŚ
ƐŝŵƵůĂƚĞĚŝŶƚĞŶƐŝƚǇĚŝĨĨƵƐŝŽŶ͘ZĂĚŝĂƚWƌŽƚŽƐŝŵĞƚƌǇϭϯϵ;ϭͲϯͿ͗ϭϵϭͲϭϵϰ
^ŽŵŵĞƌ'͕ŐŽƐƚŝs͕ŚůĞƌƐ/͕ZŽƐƐŝ&͕ŽƌďĂĐŝŽŐůƵ^͕&ĂƌŬĂƐ:͕DŽŽƌĞD͕DĂŶŽǀĂ<͕ŶƚŽŶĞƐĐƵZ͕
ĞƐŵĞƌW;ϮϬϬϯͿ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐŝŶĂŵŽƵƐĞŵŽĚĞůďǇƚĂƌŐĞƚĞĚŵƵƚĂƚŝŽŶŽĨƚŚĞ
<ŝƚƌĞĐĞƉƚŽƌƚǇƌŽƐŝŶĞŬŝŶĂƐĞ͘WƌŽĐEĂƚůĐĂĚ^Đŝh^ϭϬϬ;ϭϭͿ͗ϲϳϬϲͲϲϳϭϭ
^ŽƌĞƚD͕ĂĐŚĂƌĂĐŚ^>͕ƵǀĂƚ/;ϮϬϬϳͿWĂƌƚŝĂůͲǀŽůƵŵĞĞĨĨĞĐƚŝŶWdƚƵŵŽƌŝŵĂŐŝŶŐ͘:EƵĐůDĞĚϰϴ
;ϲͿ͗ϵϯϮͲϵϰϱ
^ƌŝŶŝǀĂƐ^D͕ŚƵƌĂŝƌĂũd͕ĂƐƵ^͕ƵƌĂů'͕^Ƶƌƚŝ^͕ůĂǀŝ;ϮϬϬϵͿƌĞĐŽǀĞƌǇĐŽĞĨĨŝĐŝĞŶƚŵĞƚŚŽĚĨŽƌ
ƉĂƌƚŝĂůǀŽůƵŵĞĐŽƌƌĞĐƚŝŽŶŽĨWdŝŵĂŐĞƐ͘ŶŶEƵĐůDĞĚϮϯ;ϰͿ͗ϯϰϭͲϯϰϴ
^ƚĞŝŐĞŶ^͕ŝĚĞd:;ϮϬϬϲͿdƌĞŶĚƐŝŶŝŶĐŝĚĞŶĐĞĂŶĚƐƵƌǀŝǀĂůŽĨŵĞƐĞŶĐŚǇŵĂůŶĞŽƉůĂƐŵŽĨƚŚĞ
ĚŝŐĞƐƚŝǀĞƚƌĂĐƚǁŝƚŚŝŶĂĚĞĨŝŶĞĚƉŽƉƵůĂƚŝŽŶŽĨŶŽƌƚŚĞƌŶEŽƌǁĂǇ͘WD/^ϭϭϰ;ϯͿ͗ϭϵϮͲϮϬϬ
^ƚŝĐŬĞů:Z͕ŚĞƌƌǇ^Z;ϮϬϬϱͿ,ŝŐŚͲƌĞƐŽůƵƚŝŽŶWdĚĞƚĞĐƚŽƌĚĞƐŝŐŶ͗ŵŽĚĞůůŝŶŐĐŽŵƉŽŶĞŶƚƐŽĨ
ŝŶƚƌŝŶƐŝĐƐƉĂƚŝĂůƌĞƐŽůƵƚŝŽŶ͘WŚǇƐDĞĚŝŽůϱϬ;ϮͿ͗ϭϳϵͲϭϵϱ
^ƚƌŽŽďĂŶƚƐ^͕'ŽĞŵŝŶŶĞ:͕^ĞĞŐĞƌƐD͕ŝŵŝƚƌŝũĞǀŝĐ^͕ƵƉŽŶƚW͕EƵǇƚƐ:͕DĂƌƚĞŶƐD͕ǀĂŶĚĞŶ͕
ŽůĞW͕^ĐŝŽƚZ͕ƵŵĞǌ,͕^ŝůďĞƌŵĂŶ^͕DŽƌƚĞůŵĂŶƐ>͕ǀĂŶK;ϮϬϬϯͿϭϴ&'ͲWŽƐŝƚƌŽŶĞŵŝƐƐŝŽŶ
ƚŽŵŽŐƌĂƉŚǇĨŽƌƚŚĞĞĂƌůǇƉƌĞĚŝĐƚŝŽŶŽĨƌĞƐƉŽŶƐĞŝŶĂĚǀĂŶĐĞĚƐŽĨƚƚŝƐƐƵĞƐĂƌĐŽŵĂƚƌĞĂƚĞĚǁŝƚŚ
ŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞ;'ůŝǀĞĐͿ͘Ƶƌ:ĂŶĐĞƌϯϵ;ϭϰͿ͗ϮϬϭϮͲϮϬϮϬ
^ƵŐĂǁĂƌĂz͕ĂƐĂĚŶǇ<Z͕EĞƵŚŽĨĨt͕tĂŚůZ>;ϭϵϵϵͿZĞĞǀĂůƵĂƚŝŽŶŽĨƚŚĞƐƚĂŶĚĂƌĚŝǌĞĚƵƉƚĂŬĞ
ǀĂůƵĞĨŽƌ&'͗ǀĂƌŝĂƚŝŽŶƐǁŝƚŚďŽĚǇǁĞŝŐŚƚĂŶĚŵĞƚŚŽĚƐĨŽƌĐŽƌƌĞĐƚŝŽŶ͘ZĂĚŝŽůŽŐǇϮϭϯ;ϮͿ͗ϱϮϭͲ
ϱϮϱ
dĂůŬƐ<>͕dƵƌůĞǇ,͕'ĂƚƚĞƌ<͕DĂǆǁĞůůW,͕WƵŐŚt͕ZĂƚĐůŝĨĨĞW:͕,ĂƌƌŝƐ>;ϮϬϬϬͿdŚĞĞǆƉƌĞƐƐŝŽŶ
ĂŶĚĚŝƐƚƌŝďƵƚŝŽŶŽĨƚŚĞŚǇƉŽǆŝĂͲŝŶĚƵĐŝďůĞĨĂĐƚŽƌƐ,/&ͲϭĂůƉŚĂĂŶĚ,/&ͲϮĂůƉŚĂŝŶŶŽƌŵĂůŚƵŵĂŶ
ƚŝƐƐƵĞƐ͕ĐĂŶĐĞƌƐ͕ĂŶĚƚƵŵŽƌͲĂƐƐŽĐŝĂƚĞĚŵĂĐƌŽƉŚĂŐĞƐ͘ŵ:WĂƚŚŽůϭϱϳ;ϮͿ͗ϰϭϭͲϰϮϭ
dĂŶŐ>͕ŚĂŶŐyW͕^ƵŶz^͕^ŚĞŶ>͕>ŝ:͕Yŝ>W͕Ƶŝz;ϮϬϭϭͿ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐƚƌĞĂƚĞĚ
ǁŝƚŚŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞ͗ĂƉƉĂƌĞŶƚĚŝĨĨƵƐŝŽŶĐŽĞĨĨŝĐŝĞŶƚŝŶƚŚĞĞǀĂůƵĂƚŝŽŶŽĨƚŚĞƌĂƉǇƌĞƐƉŽŶƐĞŝŶ
ƉĂƚŝĞŶƚƐ͘ZĂĚŝŽůŽŐǇϮϱϴ;ϯͿ͗ϳϮϵͲϳϯϴ
ϭϬϱ

dĂƌŶ͕^ŬŽƌŽďŽŐĂƚŬŽzs͕dĂŐƵĐŚŝd͕ŝƐĞŶďĞƌŐ͕ǀŽŶDD͕'ŽĚǁŝŶ<;ϮϬϬϲͿdŚĞƌĂƉĞƵƚŝĐĞĨĨĞĐƚ
ŽĨŝŵĂƚŝŶŝďŝŶŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌƐ͗<dƐŝŐŶĂůŝŶŐĚĞƉĞŶĚĞŶƚĂŶĚŝŶĚĞƉĞŶĚĞŶƚ
ŵĞĐŚĂŶŝƐŵƐ͘ĂŶĐĞƌZĞƐϲϲ;ϭϬͿ͗ϱϰϳϳͲϱϰϴϲ
dĂƚƵŵ:>͕<ĞůůŽĨĨ':͕'ŝůůŝĞƐZ:͕ƌďĞŝƚ:D͕ƌŽǁŶ:D͕ŚĂŽ<^͕ŚĂƉŵĂŶ:͕ĐŬĞůŵĂŶt͕&ǇůĞƐ
t͕'ŝĂĐĐŝĂ:͕,ŝůůZW͕<ŽĐŚ:͕<ƌŝƐŚŶĂD͕<ƌŽŚŶ<͕>ĞǁŝƐ:^͕DĂƐŽŶZW͕DĞůŝůůŽ'͕WĂĚŚĂŶŝZ͕
WŽǁŝƐ'͕ZĂũĞŶĚƌĂŶ:'͕ZĞďĂZ͕ZŽďŝŶƐŽŶ^W͕^ĞŵĞŶǌĂ'>͕^ǁĂƌƚǌ,D͕sĂƵƉĞůW͕zĂŶŐ͕ƌŽĨƚ͕
,ŽĨĨŵĂŶ:͕>ŝƵ'͕^ƚŽŶĞ,͕^ƵůůŝǀĂŶ;ϮϬϬϲͿ,ǇƉŽǆŝĂ͗ŝŵƉŽƌƚĂŶĐĞŝŶƚƵŵŽƌďŝŽůŽŐǇ͕ŶŽŶŝŶǀĂƐŝǀĞ
ŵĞĂƐƵƌĞŵĞŶƚďǇŝŵĂŐŝŶŐ͕ĂŶĚǀĂůƵĞŽĨŝƚƐŵĞĂƐƵƌĞŵĞŶƚŝŶƚŚĞŵĂŶĂŐĞŵĞŶƚŽĨĐĂŶĐĞƌƚŚĞƌĂƉǇ͘
/Ŷƚ:ZĂĚŝĂƚŝŽůϴϮ;ϭϬͿ͗ϲϵϵͲϳϱϳ
dĞƌĂŬĂǁĂz͕dƐƵǇƵŐƵĐŚŝE͕/ǁĂŝz͕zĂŵĂŶĂŬĂ<͕,ŝŐĂƐŚŝǇĂŵĂ^͕dĂŬĂŵŝd͕KŚĂƚĂ<;ϮϬϬϴͿ
ŝĂŐŶŽƐƚŝĐĂĐĐƵƌĂĐǇŽĨϭϭͲŵĞƚŚŝŽŶŝŶĞWdĨŽƌĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶŽĨƌĞĐƵƌƌĞŶƚďƌĂŝŶƚƵŵŽƌƐĨƌŽŵ
ƌĂĚŝĂƚŝŽŶŶĞĐƌŽƐŝƐĂĨƚĞƌƌĂĚŝŽƚŚĞƌĂƉǇ͘:EƵĐůDĞĚϰϵ;ϱͿ͗ϲϵϰͲϲϵϵ
dŽƌŝǌƵŬĂd͕dĂŵĂŬŝE͕/ŶŽŬƵŵĂd͕DĂŐĂƚĂz͕^ĂƐĂǇĂŵĂ^͕zŽŶĞŬƵƌĂz͕dĂŶĂŬĂ͕zĂŵĂŽŬĂz͕
zĂŵĂŵŽƚŽ<͕<ŽŶŝƐŚŝ:;ϭϵϵϱͿ/ŶǀŝǀŽĂƐƐĞƐƐŵĞŶƚŽĨŐůƵĐŽƐĞŵĞƚĂďŽůŝƐŵŝŶŚĞƉĂƚŽĐĞůůƵůĂƌ
ĐĂƌĐŝŶŽŵĂǁŝƚŚ&'ͲWd͘:EƵĐůDĞĚϯϲ;ϭϬͿ͗ϭϴϭϭͲϭϴϭϳ
dŽƌŶŝůůŽ>͕dĞƌƌĂĐĐŝĂŶŽ>D;ϮϬϬϲͿŶƵƉĚĂƚĞŽŶŵŽůĞĐƵůĂƌŐĞŶĞƚŝĐƐŽĨŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂů
ƚƵŵŽƵƌƐ͘:ůŝŶWĂƚŚŽůϱϵ;ϲͿ͗ϱϱϳͲϱϲϯ
dƌĂŶd͕ĂǀŝůĂ:͕ůͲ^ĞƌĂŐ,;ϮϬϬϱͿdŚĞĞƉŝĚĞŵŝŽůŽŐǇŽĨŵĂůŝŐŶĂŶƚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂů
ƚƵŵŽƌƐ͗ĂŶĂŶĂůǇƐŝƐŽĨϭ͕ϰϱϴĐĂƐĞƐĨƌŽŵϭϵϵϮƚŽϮϬϬϬ͘ŵ:'ĂƐƚƌŽĞŶƚĞƌŽůϭϬϬ;ϭͿ͗ϭϲϮͲϭϲϴ
dƵǀĞƐŽŶ͕tŝůůŝƐE͕:ĂĐŬƐd͕'ƌŝĨĨŝŶ:͕^ŝŶŐĞƌ^͕&ůĞƚĐŚĞƌ͕&ůĞƚĐŚĞƌ:͕ĞŵĞƚƌŝ';ϮϬϬϭͿ
^d/ϱϳϭŝŶĂĐƚŝǀĂƚŝŽŶŽĨƚŚĞŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌĐͲ</dŽŶĐŽƉƌŽƚĞŝŶ͗ďŝŽůŽŐŝĐĂůĂŶĚĐůŝŶŝĐĂů
ŝŵƉůŝĐĂƚŝŽŶƐ͘KŶĐŽŐĞŶĞϮϬ;ϯϲͿ͗ϱϬϱϰͲϱϬϱϴ
sĂůůĂďŚĂũŽƐƵůĂ^;ϮϬϭϭͿ'ƵĞƐƚĚŝƚŽƌŝĂů͗ŶĞǁWdƌĂĚŝŽƉŚĂƌŵĂĐĞƵƚŝĐĂůƐĂƐŵŽůĞĐƵůĂƌŝŵĂŐŝŶŐ
ƉƌŽďĞƐ͘^ĞŵŝŶEƵĐůDĞĚϰϭ;ϰͿ͗ϮϰϰͲϮϰϱ
sĂŶĚĞŶďďĞĞůĞ;ϮϬϬϴͿdŚĞůĞƐƐŽŶƐŽĨ'/^dͲͲWdĂŶĚWdͬd͗ĂŶĞǁƉĂƌĂĚŝŐŵĨŽƌŝŵĂŐŝŶŐ͘
KŶĐŽůŽŐŝƐƚϭϯ^ƵƉƉůϮϴͲϭϯ
sĂŶĚĞŶďďĞĞůĞ͕'ĂƚƐŽŶŝƐ͕ĚĞsƌŝĞƐ:͕DĞůĞŶĞǀƐŬǇz͕^ǌŽƚͲĂƌŶĞƐ͕zĂƉ:d͕'ŽĚǁŝŶ<͕
ZŝŶŬ>͕,ƵĂŶŐD͕ůĞǀŝŶƐD͕^ŝĐŬƐ:͕ŝƐĞŶďĞƌŐ͕^ŝĞŐĞů;ϮϬϭϮͿZ/EϲϲϲϱͬZdK'ϬϭϯϮƉŚĂƐĞ//
ƚƌŝĂůŽĨŶĞŽĂĚũƵǀĂŶƚŝŵĂƚŝŶŝďŵĞƐǇůĂƚĞĨŽƌŽƉĞƌĂďůĞŵĂůŝŐŶĂŶƚŐĂƐƚƌŽŝŶƚĞƐƚŝŶĂůƐƚƌŽŵĂůƚƵŵŽƌ͗
ŵŽŶŝƚŽƌŝŶŐǁŝƚŚϭϴ&Ͳ&'WdĂŶĚĐŽƌƌĞůĂƚŝŽŶǁŝƚŚŐĞŶŽƚǇƉĞĂŶĚ'>hdϰĞǆƉƌĞƐƐŝŽŶ͘:EƵĐůDĞĚϱϯ
;ϰͿ͗ϱϲϳͲϱϳϰ
sŽŶDĞŚƌĞŶD͕ĞŶũĂŵŝŶZ^͕ƵŝDD͕ĂƐƉĞƌ^͕ŽŶƌĂĚh͕///͕ĞůĂŶĞǇd&͕'ĂŶũŽŽ<E͕'ĞŽƌŐĞ
^͕'ŽŶǌĂůĞǌZ͕,ĞƐůŝŶD:͕<ĂŶĞ:D͕///͕DĂǇĞƌƐŽŶ:͕DĐ'ĂƌƌǇ^s͕DĞǇĞƌ͕KΖŽŶŶĞůůZ:͕WĂǌ͕
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Abstract
Purpose: The purpose of this study is to assess treatment responses induced by the two
tyrosine kinase inhibitors, Imatinib and Sunitinib, in a gastrointestinal stromal tumor (GIST)
xenograft using a clinical positron emission tomography/computed tomography (PET/CT)
scanner.
Methods: Nude mice bearing human GIST xenografts with mutations in exons 11 and 17 were
randomly allocated to treatment with Imatinib, Sunitinib, or placebo daily for seven consecutive
days. 2-deoxy-2-[18F]fluoro-D-glucose PET (18F-FDG-PET/CT) was performed in a clinical PET/CT
scanner at baseline (day 0) and 1 and 7 days after onset of treatment. Treatment response was
assessed by measuring tumor volumes and by calculation of tumor-to-liver 18F-FDG uptake ratios.
Results: Minor reductions in tumor volume were observed in both treatment groups. For the two
treatment groups, significantly decreased tumor-to-liver uptake ratios were observed both at
day 1 (Imatinib, −41%, p=.002; Sunitinib, −55%, pG .001) and at day 8 (Imatinib, −35%, pG .001;
Sunitinib, −50%, pG .001), when compared to individual baseline values. For the control tumors,
neither tumor volumes nor tumor-to-liver uptake ratios were altered during the 8 days the
experiment lasted.
Conclusions: Significant anti-tumor effects were demonstrated following treatment with both
Imatinib and Sunitinib. Decreased tumor-to-liver uptake ratios were more pronounced than
tumor volume reductions. Effects of novel targeted therapies can be evaluated in the GIST
xenograft model using a clinical PET/CT scanner.
Key words: GIST xenograft, AHAX, Imatinib, Sunitinib, Clinical PET/CT scanner
Introduction
Gastrointestinal stromal tumor (GIST) is the mostcommon mesenchymal cancer of the digestive system
and may occur in the entire length of the gastrointestinal
tract [1]. GISTs develop from interstitial cells of Cajal [2]
and typically express mutations in the c-KIT oncogene [3].
With an understanding of the key role of the KIT tyrosine
kinase expression [4] and the subsequent introduction of the
tyrosine kinase inhibitor (TKI) Imatinib, a new era in the
management of this tumor entity began [5]. Imatinib has
Correspondence to: Mona-Elisabeth Revheim; e-mail: mona.elisabeth.
revheim@ous-hf.no
shown an eminent effect in patients with metastatic GIST
[6], albeit often temporarily [7, 8]. Further understanding of
the molecular basis of GIST oncogenesis has led to the
development of a variety of novel agents for the treatment of
Imatinib refractory GIST [9, 10], such as the multitargeted
TKI, Sunitinib [11–13].
Computed tomography (CT) has conventionally been the
method of choice to monitor patients with GIST. However,
new targeted therapies for GIST have revealed insufficiency in
the current solid tumor size-based response assessment criteria
(RECIST), since initial treatment effect seldom is observed as
tumor volume reduction [14, 15]. Recent studies have used
decreased both in tumor size and in density values on CT for
the evaluation of GIST response to Imatinib treatment [16],
often referred to as the Choi criteria [17]. Treatment response is
defined as more than 15% decrease in CT density value or
more than 10% reduction in tumor size. Using the Choi criteria,
a sensitivity of 97% and a specificity of 100% in identifying
positron emission tomography (PET) responders have been
reported [17]. In contrast, the corresponding values based on
RECIST were 52% and 100%.
Most GISTs show high uptake of 2-deoxy-2-[18F]fluoro-
D-glucose (18F-FDG) when imaged by PET, and treatment
response can be observed early [6], even 24 h after onset of
treatment [18]. Albeit still a controversial issue, a certain
percentage of GISTs may probably be without any uptake of
18F-FDG and still be overtly malignant [16, 19].
As with Imatinib, KIT mutation status seems to be a
predictor of response to Sunitinib [20, 21]. Knowledge on
the relative responsiveness of different molecular subgroups
of Imatinib-resistant GIST may optimize the treatment and
thereby contribute to a better understanding of the mecha-
nisms of resistance and how to circumvent them. The
interest in other signal transduction inhibitors to overcome
this resistance is thus growing.
The development of novel targeted therapies necessitates
animal models, providing the same inherent molecular tumor
heterogeneity as observed in the clinical setting in order to
allow evaluation of treatment efficacy. To evaluate response
to targeted therapies, it is important to assess the inhibition
of tumor metabolism and not only tumor shrinkage. This
stresses the importance of integrating molecular imaging
technologies in treatment response evaluation.
The availability of dedicated small animal PET scanners
is limited, and thus researchers have tried using adapted
clinical systems [22–24]. Recently, Aide et al. demonstrated
that a state-of-the art clinical PET/CT could provide high
quality images and accurate quantification of the 18F-FDG
uptake with comparable spatial resolution as dedicated small
animal scanners [25]. Based on these findings, we conducted
a preclinical therapy study assessing therapeutic efficacy in
human GIST xenografts receiving Imatinib or Sunitinib
treatment in a clinical PET/CT. This approach may, if
rigorously validated, be used for high throughput evaluation
of new TKIs and other pharmaceuticals being developed to
circumvent treatment resistance.
The aims of this study were twofold: first, to
evaluate treatment response to Imatinib or Sunitinib in
the human GIST AHAX xenograft and second, to
evaluate if a clinical PET/CT scanner can be used for
this assessment.
Materials and Methods
Xenografts and Animals
The human GIST xenograft AHAX with mutations in exon 11
(c.1673_1687del, p.Lys558_Glu562del) and exon 17 (c.2446G9C,
p.Asp816His) was used [26]. Xenografts were established by
subcutaneous implantation of tumor tissue fragments (~2×2×
2 mm3) bilaterally into 36 female NCR athymic mice (5–7 weeks;
25–30 g). The mice were bred at the animal department of our
institution and kept under specific pathogen-free conditions at
constant temperature (22–24°C) and humidity (55–60%). They
were given sterilized food and tap water ad libitum. The animal
study was approved by the Institutional Committee on Research
Animal Care. All mice were ear-tagged and followed individually
throughout the study. After 3 months, tumor volumes were 515±
45 mm3. At this time point, the 33 mice were randomly allocated
into three groups, and baseline measurements were obtained. Three
separate mice, not included in the treatment study, were used for
comparing tumor-to-liver uptake ratio in a clinical and a dedicated
animal PET scanner.
Treatment
Imatinib (Glivec®, Novartis Pharma GmbH, Basel, Switzerland)
and Sunitinib (Sutent®, Pfizer Inc., New York, NY, USA) were
pulverized and dissolved in distilled water or dissolved in
50 mM citrate buffer (pH=3.5), respectively. Mice in the two
treatment groups were given either 100 mg/kg Imatinib (group
1) or 40 mg/kg Sunitinib (group 2) by oral gavage once daily,
whereas the control group received citrate buffer only (group
3). At the end of the experiment, the mice were sacrificed by
neck dislocation.
Tumor Measurements
Tumor volumes were estimated by caliper measurements from
implantation until the end of the experiment using themodified ellipsoid
formulae [27, 28]: V mm3ð Þ ¼ p=6ð Þ  a mmð Þ  b2 mm2ð Þ,
with a and b being the longest and the perpendicular tumor
diameters, respectively. Measurements were normalized to
individual pre-treatment (day 0) tumor volumes.
Histopathological Examination
Material from the primary tumor and subsequent surgical speci-
mens were reviewed by an experienced sarcoma pathologist.
Paraffin-embedded tissue was processed for staining with hema-
toxylin and eosin (HE) and microscopic examination. The mitotic
M.-E. Revheim et al.: Treatment Evaluation by PET in a GIST Xenograft 1235
index was counted in ten high power fields (HPF; objective ×40,
area of a single HPF; 0.3066 mm2).
18F-FDG PET/CT in a Clinical Scanner
PET examinations were performed before treatment (day 0), 24 h
(day 1), and 7 days after onset of treatment with Imatinib,
Sunitinib, or placebo. The mice were examined after 4 h of fasting
using a clinical PET/CT scanner (Biograph 16, Siemens, Erlangen,
Germany). The mice were anesthetized with 0.025 ml/10 g s.c.
injections of tiletamine 2.4 mg/ml and zolazepam 2.4 mg/ml
(Zoletil vet®, Virbac Laboratories, Carros, France), xylazine
3.8 mg/ml (Narcoxyl vet, Roche, Basel, Switzerland), and
butorphanol 0.1 mg/ml (Torbugesic, Fort Dodge Laboratories, Fort
Dodge, IA, USA) before examination. One hour after intra-
peritoneal injections of 7–10 MBq 18F-FDG (GE Healthcare AS,
Oslo, Norway), the mice were positioned in groups side by side on
a heating cushion. A CT scan was obtained with a slice thickness of
1 mm and a pixel size of 0.49×0.49 mm2. Subsequently, a 10-min
one-bed position PET acquisition was obtained. Images were
reconstructed by an OSEM iterative technique, using a 2-mm
Gaussian post-reconstruction smoothing filter. The image format
was 256×256, the pixel size was 2.67×2.67 mm2, and the slice
thickness was 2 mm. Attenuation and scatter correction were
applied before the images were transferred to a remote workstation
for further image analysis.
18F-FDG PET in a Dedicated Animal Scanner
To validate the use of a clinical scanner for assessment of
quantitative 18F-FDG uptake, three separate, untreated mice were
subjected to 18F-FDG-PET examination in a dedicated small animal
PET scanner (microPET Focus 120, Siemens Medical Solutions,
Erlangen, Germany). Following 4 h of fasting, the mice were
anesthetized, and 7–10 MBq 18F-FDG was injected intraperito-
neally [29]. After 1 h, the mice were scanned for 10 min.
Attenuation correction was obtained by a 10-min transmission scan
with a 68Ge point source after 18F-FDG-PET. Data collected in list
mode were reconstructed using 3-D OSEM-MAP [30–32] (2
OSEM iterations, 18 MAP iterations, β=0.5, 128×128×95 matrix
size, 0.87×0.87×0.80 mm3 voxel size). Images were transferred to
a remote workstation for further analysis.
Image Analysis
The PET/CT images were analyzed using IDL (Interactive Data
Language v6.2, Research Systems Inc., Boulder, CO, USA).
Initially, an image volume covering all animals was reconstructed.
All coronal planes were added to form a two-dimensional
representation of the three-dimensional volume elements. These
images were used to draw individual regions of interests (ROIs)
around tumor and liver. The co-registered CT images were used for
guiding the delineations. Tumor-to-liver uptake ratios for individual
tumors were obtained by dividing mean tumor 18F-FDG uptake by
the mean liver 18F-FDG uptake. All ratios were normalized to
individual pre-treatment values.
Ex Vivo Counting
Immediately following clinical PET/CT, the three mice that
underwent small animal PET examination 24 h earlier were
sacrificed, and tumor and liver were harvested. Tissue samples
were separately weighed and counted for 1 min in a gamma counter
(Cobra II auto-gamma detector, Packard Instrument Company,
Meriden, CT, USA). The samples were normalized to sample
weight. Tumor-to-liver uptake ratios obtained from the clinical
PET/CT scanner, the dedicated small animal PET scanner, and
from ex vivo counting were compared.
Statistical Analysis
Statistical analyses were performed using SPSS version 16.0 (SPSS
Science, Chicago, IL, USA). The Kolmogorov–Smirnov test was
applied to test for normality. Statistical differences between groups
were analyzed using one-way ANOVA, two-sided t test, and
Pearson correlation coefficient. Significance was assigned at p≤ .05.
Results
Tumor Growth
The 33 mice developed 49 tumors giving a tumor take of
74.2%. Prior to therapy, tumor volumes did not differ
significantly between the three groups (p=.54). Initial tumor
volumes were normally distributed (p=.19), and results are
presented as means and standard deviations. Normalized
tumor volumes for the two treatment groups and the control
group as function of time after treatment are shown in Fig. 1.
Tumor volume in the control group increased, although not
significantly, with 11.5% from days 0 to 8 (p=.27).
Compared to individual baseline values, the mean volume
of the tumors in the Imatinib group was reduced by 15.7% at
Fig. 1. Normalized tumor volumes for the human GIST
AHAX xenografts prior to therapy and after 1 and 7 days of
daily Sunitinib, Imatinib, or placebo treatment. Error bars
represent standard deviations.
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day 8 (pG .01). In the Sunitinib group, no statistically
significant tumor decrease was observed (−8.8%, p=.41).
The mitotic index in tissue samples obtained from all
three groups was Imatinib, 2/10 HPF; Sunitinib, 8/10 HPF;
and control, 21/10 HPF.
Treatment Response Assessed with PET/CT
Mean number of pixels within the ROI used for the
measurement of 18F-FDG uptake was 6.6 (range, 2–15)
and 12.4 (range, 6–22)pixels for tumor and liver, respec-
tively. Normalized tumor-to-liver ratio as function of time
after onset of treatment is shown in Fig. 2. Pre-treatment
metabolic activity was not significantly different between
control and the two treatment groups (p=.358). One-way
ANOVA revealed no changes in tumor-to-liver uptake ratios
for the control group during the 8 days the experiment lasted
(p=.536). One day after onset of therapy, normalized tumor-
to-liver uptake ratios in the Imatinib- and Sunitinib-treated
groups decreased by 40.8±8.8% (pG .01) and 54.9±8.1%
(pG .01), respectively. At day 8, normalized tumor-to-liver
uptake ratios were reduced by 35.2% (pG .001) and 50.1%
(pG .001) for the Imatinib and the Sunitinib groups,
respectively, relative to individual baseline values. It should,
however, be noted that tumor-to-liver uptake ratios at days 1
and 8 were not significantly different (Imatinib, p=.56;
Sunitinib, p=.64). An example of 18F-FDG uptake in a nude
mouse prior to therapy and 24 h after start of Sunitinib
treatment is shown in Fig. 3.
In Vivo Imaging Versus Ex Vivo Counting
Pearson correlation coefficient between tumor-to-liver
obtained from ex vivo counting and from in vivo imaging
was 0.99 for both the clinical PET/CT scanner and for the
dedicated small animal PET scanner. It should however be
noted that the absolute tumor-to-liver ratios were different;
the clinical scanner yielded about 18% higher values, and
the dedicated animal scanner yielded about 23% lower
values, when compared to the ex vivo counting.
Discussion
This preclinical study demonstrates that tumor-to-liver 18F-
FDG uptake ratio decreases following Imatinib and Sunitinib
treatment in the human GIST AHAX xenograft, originating
from a clinical Imatinib-resistant patients [26]. This study
also shows that a clinical PET/CT can be used to assess
treatment response in small animals.
For both treatment groups, significantly reduced 18F-FDG
uptake was observed in the treated GIST xenografts 24 h
after onset of treatment, and the level remained low during
the entire experiment. The immediate metabolic shut-down
has previously been reported for human GISTs [18]. This is
in accordance with current knowledge that TKIs like
Imatinib, directly targeting glucose uptake metabolism
[33], will cause a rapid reduction in 18F-FDG uptake (within
hours to days). The prevailing hypothesis is that the decrease
reflects changes in glucose uptake mechanisms. Such early
decrease in 18F-FDG uptake correlates to therapeutic out-
come [34, 35], supporting its use as an early prognostic
marker.
The AHAX xenograft originates from a patient with a
clinically Imatinib-resistant GIST. The pronounced treat-
ment effect of both Imatinib and Sunitinib is intriguing since
the patient harbored mutations in exon 11 and exon 17,
leading to treatment resistance. Loss of the genetic mutation
leading to resistance could explain the observed treatment
effect. Mutation analysis of the implanted xenograft tissue
was however performed and revealed that both mutations
(exon 11 and 17), as seen in the patient, were maintained in
the xenografts [26].
Fig. 2. Normalized tumor-to-liver uptake ratios for the GIST
AHAX xenografts prior to therapy and after 1 and 7 days of
daily Imatinib, Sunitinib, or placebo treatment. Error bars
represent standard deviations.
Fig. 3. Clinical PET/CT images acquired before and 24 h
after treatment with Sunitinib.
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Clinical experience has shown that tumors with mutations in
exon 11 are less sensitive to Sunitinib treatment, and that exon
17mutations (which encode the activation loop) are resistant to
Imatinib [20] and have weak or no sensitivity to Sunitinib [36].
The observed response to both treatments suggests that AHAX
xenograft contains both Imatinib- and Sunitinib-sensitive
clones. This fits well with knowledge of the heterogeneity of
GISTs, with numerous different mutations being harbored
within a single tumor [37]. The maintenance of such hetero-
geneity after eight generations, which was the source of our
implanted tumor material, may be due to a selection of the most
virulent clones (or the clones harboring the highest mitotic
rate). Imatinib resistancemay also be incomplete. Low doses of
either Imatinib or Sunitinib have been shown to have a partial
inhibitory effect on KIT phosphorylation in a GIST cell line
with mutations in exon 11 and exon 17, presumably due to
inhibition of a minor population of cells with exon 11
mutations [36]. The antiangiogenic effects of Sunitinib [38]
may also contribute to the observed treatment response.
In our study, the 18F-FDG uptake in the two treatment
groups remained reduced for the 8 days the experiment
lasted. For both groups, tumor-to-liver ratios increased
slightly, but not significantly. This could possibly be
attributed to the development of a selection pressure,
promoting the growth of resistant clones or a change in
glucose uptake mechanisms [39, 40].
The clinical PET/CT scanner has the advantage of being
able to handle a large number of small animals simulta-
neously, thereby allowing high throughput imaging. Fig. 4
shows the experimental set-up in our study with ten mice
within one bed position. Identical hardware, software, and
acquisition protocols for examination of animals and humans
ensure consistency of data and provide easy translation of
developments from mouse to human in a clinical setting.
Tumor-to-liver uptake ratios obtained from ex vivo counting
differed in a systematic way from the ratios obtained from the
clinical and the animal scanner. Because of intensity, diffusion
signal intensities in small and irregular-shaped organs can
Fig. 4. Representative CT (a), PET (b), and PET/CT (c) images of ten mice bearing AHAX xenografts obtained using a clinical
PET/CT scanner. The anesthetized mice were positioned side by side on a heating cushion during acquisition of data.
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never be accurately reproduced [41], and this effect is much
more pronounced on a clinical PET scanner. The spatial
resolution of the clinical PET/CT scanner is clearly inferior to
that of the dedicated small animal PET scanner.With the actual
Gaussian filter, the full-width at half maximum of the point
spread function on the clinical scanner is 4.8 mm in the center
of the field. The resulting point spread function smearing is
most pronounced for small high-intensity objects. Systematic
over- and underestimation of tumor-to-liver uptake ratios for
the PET systems seem to have resulted from the way the ROIs
were drawn at the different modalities. In order to obtain the
most accurate assessment of tumor signal intensity in the
clinical scanner images, a smaller ROI than the actual size of
the tumor was used. On the other hand, CT information was
used to draw the liver region, and the imaging process had also
led to loss of intensity across the region border. Since the ratios
were calculated on a per-average-pixel-value basis, this
methodology is the probable reason for overestimation of the
tumor-to-liver ratio from the measurements on the clinical
scanner. The lack of co-registered CT images from the animal
PET scanner may have led to the inclusion of signal intensities
from tissues adjacent to or overlapping with the liver, resulting
in a systematic increased average liver signal intensity and thus
an underestimation of the tumor-to-liver ratio.
Despite the fact that the absolute ratios were different, the
correlations between ratios obtained with different methods
were very strong. Thus, the ratios obtained in this study are
well suited for comparisons between groups, but less
suitable for absolute quantification purposes. However, the
present study demonstrated that the clinical PET/CT system
yielded sufficient spatial resolution to obtain clinically
relevant information from this animal model.
More accurate assessment of treatment response can be
achieved by measuring tumor uptake as function of injected
dose for individual mice. This approach, which we will use
in our future studies, allows each animal to be its own
control and will reduce the influence of intensity diffusion
by allowing larger tumor ROIs to be drawn.
Conclusion
Significant anti-tumor effects of Imatinib and Sunitinib were
demonstrated in a human GIST xenograft originating from a
patient with a clinically Imatinib-resistant tumor. The meas-
ured treatment response, combined with the results from
comparison between PET-assessed tumor-to-liver uptake ratio
and ex vivo counting, demonstrates that a clinical PET/CT
offers non-invasive and longitudinal assessment of treatment
response to novel targeted therapies in preclinical models.
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Abstract 
BACKGROUND: Acquired resistance to imatinib is frequently caused by secondary KIT mutations. We 
have investigated the effects of imatinib in mice with human gastrointestinal stromal tumour 
(GIST) xenograft that harbours a primary exon 11 deletion mutation and a secondary imatinib 
resistance mutation D816H in exon 17. Such mutations are commonly present in humans with 
imatinib-resistant GIST. METHODS: The mice were randomly allocated to receive imatinib either 
continuously or intermittently. Dynamic 18F-FDG PET was performed and blood volume fraction (vB), 
rate constants (k1, k2, k3) and metabolic rate of 
18F-FDG (MRFDG) were computed using a three-
compartment model. Tumours were evaluated for the mitotic rate and expression of HIF-1α , 
caspase-3 and glucose transporters (GLUTs).  
RESULTS: Both intermittent and continuous imatinib delayed tumour growth significantly compared 
to placebo, significantly in favor of the latter. k1 (representing perfusion, vascular permeability 
and binding of 18F-FDG to the GLUTs) was significantly higher in the intermittent group compared 
to the continuous group, as was tumour GLUT-3 expression. k3 (representing internalization of 
18F-
FDG to cells) and MRFDG were significant lower.  
CONCLUSION: Imatinib delays GIST xenograft growth despite presence of the D816H resistance 
mutation. The schedule of imatinib administration may influence tumour glucose uptake rate and 
metabolic rate. 
 
Keywords: GIST, imatinib, xenograft, intermittent administration, dynamic 18F-FDG PET, glucose 
transporters 
 
 
INTRODUCTION 
Gastrointestinal stromal tumour (GIST) is the 
most common sarcoma of the digestive tract 
(Miettinen and Lasota, 2003). Approximately 
95% of GISTs express KIT, the receptor for the 
stem cell factor (Hirota et al, 1998). KIT 
mutations frequently result in KIT 
phosphorylation and constitutive activation. 
In a few GISTs (5-10%) a mutation is found in 
the gene encoding the platelet derived 
growth factor receptor alpha (PDGFRA). Both 
KIT and PDGFRA receptors are tyrosine 
kinases and key players in GIST 
tumourigenesis (Rubin et al, 2001). By the 
introduction of the tyrosine kinase inhibitor 
(TKI) imatinib, a selective inhibitor of KIT, 
PDGFRA and a few other kinases, a new era in 
the management of GIST began (Joensuu et 
al, 2001;Cassier and Blay, 2010). Most 
patients with advanced GIST respond to 
imatinib, the standard first-line treatment 
but the majority eventually progress with the 
median time to imatinib resistance being 
approximately two years (Blanke et al, 2008). 
In acquired imatinib resistance secondary 
mutations in KIT exons 13 and 17 are common 
resulting in a kinase conformation that 
prohibits imatinib from binding to the kinase 
(Gramza et al, 2009).  
A metabolic response to imatinib in 
GIST may be observed early with 2-deoxy-2-
[18F]fluoro-D-glucose (18F-FDG) positron 
emission tomography (PET) (Joensuu et al, 
2001), sometimes even within a few hours 
after starting imatinib (Shinto et al, 
2008;Revheim et al, 2011). Dynamic 18F-FDG 
PET enables assessment of tissue uptake of 
  
  
the tracer in space and time following 
injection and may offer valuable information 
about tumour vascularization and its 
metabolic characteristics (Roe et al, 
2010;Malinen et al, 2011).  
Human tumour xenografts are useful 
for evaluating novel therapeutic agents, since 
tumour vascular and stromal components 
cannot be addressed in vitro. The GIST human 
xenograft model AHAX (Revheim et al, 2009) 
originates from a patient with a clinically 
imatinib-resistant GIST harboring a primary 
KIT exon 11 mutation (sensitive to imatinib) 
and a secondary KIT exon 17 mutation (likely 
treatment-induced mutation). Since KIT exon 
11 is the most common site of mutation in 
primary GIST and KIT exon 17 is the most 
frequent site of a secondary resistance 
mutation (Heinrich et al, 2006), this model 
reflects the most common clinical scenario in 
imatinib-resistant GIST.  
Imatinib, administered usually 
continuously at a dose of 400 mg/day, is 
generally well tolerated and despite prior 
tumour progression during first-line imatinib 
it is often considered as the last-line 
palliative systemic treatment for patients 
with advanced GIST (National Comprehensive 
Cancer Network, 2012). This practice is, 
however, controversial in the absence of 
other than anecdotal supportive clinical 
experiences. A randomized clinical trial is 
currently comparing imatinib plus the best 
supportive care to the latter alone as 
palliative treatment of advanced GIST 
(ClinicalTrials.gov identifier NCT1151852). 
Somewhat unexpectedly withdrawal of 
imatinib in responding patients and 
reinstitution of imatinib at the time of 
metastatic progression, did not affect survival 
in a large randomized clinical trial (Blay et 
al, 2007;Le et al, 2010).  
The aim of the present study was to 
evaluate the potential benefits of continuous 
and intermittent imatinib administration in 
an experimental human GIST xenograft model 
harboring imatinib resistance mutation. This 
was evaluated by tumour growth 
measurements and assessment of tumour 
metabolic activity (with dynamic 18F-FDG 
PET), mitotic rate, and expression of HIF-1α, 
caspase-3 and GLUTs.   
 
MATERIALS AND METHODS 
Animals and xenografts 
Human GIST AHAX xenografts with a mutation 
in KIT exon 11 (c.1673_1687del, 
p.Lys558_Glu562del) and KIT exon 17 
(c.2446G>C, p.Asp816His) (Revheim et al, 
2009) were established by subcutaneous 
implantation of tumour tissue fragments 
(a2x2x2 mm3) bilaterally into NCR athymic 
mice. The mice were kept under specific 
pathogen-free conditions at a constant 
temperature (22-24°C) and humidity (55-
60%), and were given sterilized food and tap 
water ad libitum.  
Six weeks after implantation 37 mice 
were randomly allocated into a control group 
(n=12) or to one of two imatinib treatment 
groups, where imatinib was administrated 
either continuously (n=13) or intermittently 
(n=12, one week on and one week off). The 
study was approved by the Institutional and 
National Committee on Research on Animal 
Care and was performed according to 
Interdisciplinary Principles and Guidelines for 
the Use of Animals in Research, Marketing and 
Education (New York Academy of Science, 
New York, NY). 
 
Tumour volume measurements 
Tumour size was measured by a caliper twice 
weekly from the date of implantation Tumour 
volume was calculated using the modified 
ellipsoid formula (Euhus et al, 1986), where 
the volume V(mm3)=(л/6)×a(mm)×b2(mm2), a 
and b being the longest and the 
perpendicular tumour diameters, 
respectively. The measurements were 
normalized to individual pre-treatment (day 
0) tumour volumes. Estimated tumour volume 
doubling time was calculated using linear 
regression on ln-transformed normalized 
tumour volumes.  
 
Imatinib administration 
Imatinib (Glivec®, Novartis Pharma GmbH, 
Basel, Switzerland) was dissolved in distilled 
water and given by oral gavage: either 100 
mg/kg once daily (the continuous treatment 
group) or in 2-week cycles, with imatinib 
given daily for 7 days followed by placebo 
(water) for 7 days (the intermittent 
treatment group). The control group received 
water only by oral gavage. The duration of 
the experiment was 91 days.  
 
Dynamic 18F-FDG PET imaging 
Four mice from each of the three groups 
underwent dynamic 18F-FDG PET one day prior 
to sacrifice, using a small animal PET scanner 
(microPET Focus 120, Siemens Medical 
Solutions, Erlangen, Germany). Following 
overnight fasting the mice were anesthetized 
and given an i.v. bolus injection of 7-10 MBq 
  
  
18F-FDG (GE Healthcare AS, Oslo, Norway) 
diluted in heparinized saline (Revheim et al, 
2011) . Acquisition of list-mode data started 
prior to 18F-FDG injection and lasted for 50 
minutes post-injection. The dynamic PET 
images were reconstructed using an OSEM-
MAP computer program (Qi et al, 1998;Qi and 
Leahy, 2000) producing images with a voxel 
size of 0.87x0.87x0.80 mm3. The 
reconstructed time frames were 10 seconds 
during the initial 1.5 minutes followed by 
reduced temporal resolution for the 
remaining frames. Kinetic modeling of the 
DICOM-images was performed using in-house 
written IDL-programs (Interactive Data 
Language, v6.2, Research Systems Inc., 
Boulder, CO). Briefly, the mean time activity 
curves (TACs) for each tumour were 
calculated and normalized to individual 
arterial input functions (AIFs) to account for 
differences in the injected 18F-FDG activity 
between the animals (Roe et al, 2010). 
 A three-compartment model 
consisting of a blood compartment and two 
sequential tissue compartments was used to 
evaluate the 18F-FDG kinetics. The 
concentration in tissue (CT) is assumed to be 
separated into a free (non-metabolized) and 
a bound (metabolized) compartment with 
tracer concentrations of CF and CB, 
respectively (Figure 1).  
 
Figure 1 The three-compartment model used for 
extracting pharmacokinetic information from dynamic 
18F-FDG PET. CP is the concentration of 18F-FDG in plasma 
and CT is the 18F-FDG concentration in tumour. CT is 
further separated into not metabolized or free 18F-FDG, 
CF, and metabolized or bound 18F-FDG, CB. The kinetic 
parameters k1 (min-1) and k2 (min-1) describe the forward 
and backward 18F-FDG diffusion, respectively. The k3 
(min-1) and k4 (min-1) parameters signify the rates of 18F-
FDG phosphorylation and dephosphorylation, 
respectively, i.e. reflecting protein binding or glucose 
metabolism. 
 
The exchange of 18F-FDG between the two 
tissue compartments is described by the rate 
constants k1, k2, k3, and k4 [min
-1], where k1 
includes perfusion, vascular permeability and 
the binding of 18F-FDG to the GLUT receptors, 
k2 the clearance of 
18F-FDG back into the 
blood, k3 the cellular internalization, and k4 
the cellular externalization. The kinetic 
parameters were estimated by fitting the TAC 
to this model and non-linear least squares 
minimization. k4 was assumed to be low, and 
was set to zero in the calculations. The blood 
volume fraction (vB) was estimated as 
described previously (Kamasak et al, 2005). 
The metabolic rate of 18F-FDG (MRFDG) was 
defined as (k1∙k3)/(k2+k3). The fit between 
the measured TACs and the curves obtained 
from modeling were evaluated by calculating 
correction coefficients (r2) for each tumour 
voxel. 
 
Histopathology and 
immunohistochemistry  
At the end of the experiment the mice were 
sacrificed by neck dislocation and tumour 
sites were matched with the in vivo imaging 
slices. The xenografts were excised and 
divided in two; one half was snap-frozen in 
liquid nitrogen and stored at -80°C, while the 
second half was formalin-fixed and paraffin-
embedded.  
The paraffin-embedded sections were 
stained using a standard method (Dako 
EnVisionTM + System, Peroxidase (DAB) 
(K4011, Dako, Glostrup, Denmark) and a Dako 
Autostainer). The primary antibodies, 
dilutions, pH retrieval solution and the 
positive controls are listed in Table 1. The 
proportion of positively staining tumour cells 
was assessed semiquantitatively as absent (0, 
no immunostaining), slight (1, <10% of tumour 
cells were stained), moderate (2, 10-50% of 
cells showed staining), or strong (3, >50% of 
cells were stained). The intensity of staining 
was recorded as absent (0), weak (1), 
moderate (2) or strong (3). A staining score 
was obtained by multiplying these two  
values. The mitotic index was counted per 20 
high power fields (HPFs) using a Leica DM2500 
microscope (Leica Microsystems CMS, 
Germany) with an objective x40 giving an 
area of 0.31 mm2 for a single HPF. 
 
KIT and PDGFRA mutation analysis  
Genomic DNA was extracted from 10 AHAX 
xenografts. Thirty nanograms of DNA was 
amplified using Phusion® Hot Start DNA 
polymerase and Phusion GC buffer 
(Finnzymes, Espoo, Finland). The thermal 
cycling conditions were DNA denaturation at 
98°C for 30 seconds, 5 cycles at 98°C for 10 
seconds, 65°C for 15 seconds and 72°C for 10 
seconds, followed by 35 similar cycles where 
Vascular space 
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Cellular space 
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Cellular space 
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Arterial flow Venous flow 
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the annealing temperature was reduced to 
60°C. Final extension was allowed at 72°C for 
1 minute. The forward and reverse PCR 
primer pairs used are provided in Table 2. The 
sequencing reactions were performed in two 
directions using the BigDye® Terminator v1.1 
Cycle Sequencing Kit (Life Techologies, 
Carlsbad, CA). The sequencing products were  
 
 
 
Table 1 The primary antibodies used for immunohistochemistry 
Antibody 
target Company 
Catalogue  
number Dilution 
Retrieval solution 
pH* Positive control 
GLUT-1 Abcam, Cambridge, UK Ab652 1:200 Low pH Kidney cancer 
GLUT-2 Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA, USA 
Sc-9117 1:100 Low pH Pancreas 
GLUT-3 Abcam, Cambridge, UK Ab53095 1:200 High pH Testis 
GLUT-4 AbD Serotec, Oxford, UK 4670-1704 1:1000 High pH Salivary gland 
HIF-1D Novus Biologicals, Cambridge, UK NB100-499 1:300 High pH Placenta 
Caspase-3 Cell Signaling Technology, 
Danvers, MA, USA 
9664 1:100 High pH Large cell 
lymphoma 
* Low pH: citrate buffer, pH 6.1 (K8005, Dako, Glostrup, Denmark). High pH: Tris/EDTA, pH 9 (K8004, Dako, Glostrup, 
Denmark) 
 
run on an automatic capillary sequencer 
(3130xl Genetic Analyzer, Life Techologies, 
Paisley, UK). 
 
Statistical analysis 
Statistical analyses were performed using 
Excel® (Microsoft Corporation, Redmond, 
Washington, USA) and SPSS version 18.0 (SPSS 
Science, Chicago, IL). Non-Gaussian 
distributions were compared using the non-
parametric Mann-Whitney U-test. Two-sided 
t-test was used to compare the first order 
least-square linear regression estimated 
tumour doubling times. Significance was set 
to 5%. 
 
RESULTS  
Tumour growth 
Tumour growth was observed in 70 (95%) out 
of the 74 implants in the 37 mice. One mouse 
was sacrificed prematurely because of 
oesophageal perforation and was excluded 
from the study. The tumour volumes did not 
differ significantly between the three groups 
prior to therapy, with a median pretreatment 
tumour volume of 120 mm3 (range; 22-340 
mm3, SE; ±73 mm3). The normalized tumour  
volume growth curves are shown in Figure 2. 
The tumour volume doubling time in the 
control group was 24.7 days (95% CI; 21.9-
28.4 days). The tumour doubling time was 
significantly shorter in the intermittent 
imatinib group (47.4 days; 95% CI, 40.6-56.9 
days) compared to the continuous group 
(130.9 days; 95% CI, 84.2-293.5 days; 
p<0.001). Both treatment groups showed 
significantly longer tumour volume doubling 
times compared to the untreated tumours (p 
< 0.001). 
Dynamic 18F-FDG PET  
18F-FDG PET of the treated animals was 
performed after 88 days of treatment, at a 
time point where both treatment groups were 
receiving imatinib. Figure 3A shows a series 
of 18F-FDG PET images demonstrating tracer 
uptake in a flank tumour in the continuous 
imatinib group. The TACs from the tumours 
treated with intermittent imatinib showed 
higher uptake and reached a plateau earlier 
after tracer injection as compared to the 
tumours treated with continuous imatinib (25 
minutes vs. 30 minutes, respectively). The 
median area under the normalized TAC curve 
was 20% higher for the intermittent group, 
albeit not significantly different (p=0.08) 
(data not shown). 
TACs of two voxels located at 
different sites within a continuous imatinib-
treated xenograft are shown in Figure 3B. 
Using kinetic modeling, the TAC of the voxels 
were separated into free (not metabolized) 
and bound (metabolized) components. The 
goodness of fit between the measured TACs 
and the uptake curves obtained from 
modeling ranged from 0.91 to 0.98 with no 
significant differences between the two 
treatment groups. Mean k1, k2, k3, MRFDG and 
vB for both treatment groups are summarized 
in Table 3. Significant differences were found 
for the kinetic parameters k1, k3 and MRFDG. 
The influx k1 parameter was 32% higher in the 
intermittent group (p=0.01), while k3 and 
MRFDG were 95% (p=0.01) and 50% (p=0.03) 
higher in the continuous treatment group, 
respectively. No significant correlations were 
found between the tumour volumes and the 
tumour pharmacokinetic parameters.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Normalized tumour volume growth of the human GIST AHAX xenograft in mice receiving either imatinib (100 
mg/kg/day) continuously, intermittently (one week on, one week off) or placebo (water). At the end of experiment, mice 
with particularly large tumours were scarified, causing a dip in tumour volume growth (the light grey symbols). The data are 
given as means and standard errors of the means. 
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Figure 3 An example of cumulative 
18F-FDG uptake with time in a human 
GIST AHAX xenograft model (A). The 
white arrows point at the tumour. 18F-
FDG uptake as a function of time for 
two selected voxels within the 
xenograft is shown in (B). The uptake 
curves for the free and bound 18F-FDG 
components obtained from kinetic 
modeling are provided
. 
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Tumour histology and 
immunohistochemistry 
Microscopic examination of the haematoxylin 
stained tumour sections revealed no 
differences in tumour morphology between 
the three groups. However, the mitotic index 
was significantly higher in the control group 
(median; 13 mitoses/20 HPFs) as compared to 
the continuous and the intermittent group 
(both medians 4/20 HPFs, p=0.02). The 
cytoplasmic GLUT-1 expression was 
significantly higher in the control group as 
compared to the intermittent group (median 
score 9 vs. 6; p=0.023) and the continuous 
group (median score 6; p=0.009). Both 
treatment groups had a significantly higher 
expression of cytoplasmic GLUT-2 (both 
median scores 9) than the control group 
(median score 3; p<0.001). The expression of 
both the cytoplasmic and the membranous 
form of GLUT-3 were significantly higher 
(p<0.001) in xenografts treated with 
intermittent imatinib (median score 3 and 3, 
respectively) as compared to xenografts 
treated with continuous imatinib (median 
score 0 and 0, respectively). There were no 
differences between the three groups with 
respect to HIF-1α or caspase-3 expression 
(data not shown).   
 
KIT and PDGFRA mutations  
Ten xenografts (continuous group, 4; 
intermittent group, 3; control group, 3) were 
analysed for KIT and PDGFRA mutations to 
investigate tumour mutation status at the end 
of the experiment. Sequencing confirmed 
that all xenografts had maintained the 
original mutation in KIT exon 11 
(c.1673_1687del, p.Lys558_Glu562del) and in 
KIT exon 17 (c.2446G>C, p.Asp816His). No 
further mutations were detected in KIT exons 
9, 14 or 17, or in PDGFRA exons 12, 14 or 18. 
 
DISCUSSION 
We explored the effects of imatinib 
administered either intermittently or 
continuously in a human GIST xenograft 
harboring the D816H mutation, which is a 
mutation considered to cause clinical 
imatinib resistance in GIST patients. The 
results show that the tumours do not regress 
either with intermittent or continuous 
imatinib, but, notably, they grow at a 
substantially slower rate than tumours 
treated with placebo. This finding suggests 
that GISTs with a KIT 11 deletion mutation 
coupled with a D816H substitution mutation 
are not entirely imatinib resistant. From a 
clinical point of view this is potentionally an 
important observation, since the KIT exon 11 
deletion mutation is the most common 
mutation in GIST, and exon 17 point 
mutations are the most frequent mutations 
considered to confer imatinib resistance. In 
clinical practice, imatinib administration is 
often discontinued when advanced GIST stops 
to respond to imatinib, and alternative 
treatments such as sunitinib or other TKIs are 
instituted. Anecdotal clinical experience 
suggests that reinstitution of imatinib after 
failure of the second-line or third-line TKI 
treatments may still slow down GIST 
progression compared to no systemic 
treatment. Although firm clinical evidence is 
lacking, reinstitution of imatinib may still be 
advantageous as the last-line palliative care 
(National Comprehensive Cancer Network, 
2012).  
The reason for imatinib benefit in the 
presence of D816H remains hypothetical. The 
KIT exon 11 deletion mutation, unlike the 
D816H mutation, continues to be sensitive to 
imatinib, which may results in a less active 
KIT kinase in the presence of imatinib as 
compared to a kinase where both mutations 
are uninhibited. If this hypothesis is correct, 
the present findings may have relevance to 
many GISTs with an imatinib-sensitive primary 
mutation and an imatinib-insensitive 
secondary mutation. The original primary 
mutation is virtually always present in GISTs 
that contain a secondary resistance mutation 
(Heinrich et al, 2006). Of note, more than 
one secondary mutation are commonly found 
in tumours that grow during imatinib 
treatment, sometimes even within the same 
metastasis (Liegl et al, 2008). Our findings 
may thus lend support to rechallenge with 
imatinib, even in cases when multiple 
secondary resistance mutations are present, 
provided that the primary mutation is 
imatinib-sensitive.  
The French Sarcoma Group 
investigated in the randomized BRF14 trial 
the effect of interrupting imatinib treatment 
at after either 1, 3 or 5 years of treatment in 
patients with advanced GIST who continued 
to respond to imatinib. Interruption of 
imatinib resulted in rapid GIST progression in 
the majority of patients, but almost all 
patients responded to imatinib reinstitution. 
No overall survival difference was seen 
  
  
between the interruption and the 
continuation groups, regardless of the timing 
of imatinib interruption (Blay et al, 2007;Le 
et al, 2010). Rapid cycling of imatinib 
administration (one week on, one week off) 
has not been tested in clinical trials, but the 
present result showed no benefits during the 
91-day observation period.   
The AHAX xenograft model of human 
GIST has proven useful for studying 18F-FDG 
uptake responses to TKIs (Revheim et al, 
2011). In the current study we found 
differences in the dynamic 18F-FDG uptake 
characteristics between the intermittent and 
the continuous treatment groups imaged 
while the mice were on imatinib. The TAC 
amplitude was higher in the intermittent 
group indicating either increased perfusion 
and/or increased metabolism compared to 
the continuous group. The tumour metabolic 
rate (MRFDG), in turn, was higher in the 
continuous group, whereas k1 was higher and 
k3  lower in the intermittent group as 
compared to the continuous group suggesting 
presence of more perfusion, vascular 
permeability or vascular damage (high flow, 
leaky vessels) in the intermittent group 
(Mullani et al, 2008). Taken together, these 
findings suggest that the schedule of imatinib 
administration influences tumour glucose 
uptake and metabolic rate. This observation 
should, however, be interpreted with some 
caution, since only four mice from each group 
underwent dynamic PET and the tumours 
showed heterogeneity in the PET parameters. 
The GLUTs play a central role in the 
accumulation of 18F-FDG within tumour cells. 
GLUT-1 is present in most cell types and is a 
key factor in glucose uptake, but different 
cancers express different GLUTs (Yamamoto 
et al, 1990;Godoy et al, 2006;Paudyal et al, 
2008). We found a difference in GLUT-3 
expression between the two treatment 
groups. GLUT-3 is expressed in neurons and 
was originally designated as the neuronal 
GLUT. GISTs may show both muscle and 
neuronal differentiation and GLUT-3 
expression may in part be related to rapid 
18F-FDG uptake in GISTs (Gogvadze et al, 
2008). Imatinib induces GLUT translocation 
from the plasma membrane to the cytosol via 
endocytosis (Prenen et al, 2005;Tarn et al, 
2006). In line with this, we found higher 
cytoplamic GLUT-1 and GLUT-2 expression in 
both imatinib groups compared to the 
placebo group.   
 In conclusion, the present study 
suggests that continuation of imatinib 
treatment may still benefit some GIST 
patients despite presence of an imatinib 
resistance mutation, such as D816H. In this 
setting, imatinib may slow down tumour 
progression, possibly by inhibiting the 
imatinib-sensitive primary mutation. Both 
continuous imatinib administration and the 
alternating one week on - one week off 
administration slowed down tumour 
progression, but the tumour growth was 
significantly more rapid with the alternating 
scheme. We found differences in 18F-FDG 
uptake kinetics and tumour 18F-FDG metabolic 
rate between the continuous and the 
intermittent imatinib administration groups, 
but their clinical significance remains 
unknown. 
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':05,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 DQG HDUO\ DIWHU RQVHW RI WUHDWPHQW 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)RUQLQHSDWLHQWVWKH$'&FKDQJHDW7SFRUUHFWO\SUHGLFWHGWUHDWPHQW
RXWFRPHDW7S:KHQYROXPHWU\ZDVDGGHGDOOSDWLHQWVZHUHFRUUHFWO\FODVVLILHGZLWK05,6HYHQ
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.H\ZRUGV *DVWURLQWHVWLQDO6WURPDO7XPRXUV
  'LIIXVLRQ0DJQHWLF5HVRQDQFH,PDJLQJ
  )OXRURGHR[\JOXFRVH)3RVLWURQ(PLVVLRQ7RPRJUDSK\DQG&RPSXWHG7RPRJUDSK\
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
,QWURGXFWLRQ
*DVWURLQWHVWLQDO VWURPDO WXPRXU *,67 LV WKH
PRVW FRPPRQ VRIWWLVVXH VDUFRPD >@ ZLWK
UHSRUWHG DQQXDO LQFLGHQFH RI ² FDVHV SHU
PLOOLRQ >@ $SSUR[LPDWHO\ KDOI RI WKH
SDWLHQWVZLOOUHODSVHZLWKLQILYH\HDUVGHVSLWH
FRPSOHWHVXUJLFDOUHVHFWLRQ>@DQGVWDQGDUG
FKHPRWKHUDS\ DQG UDGLRWKHUDS\ DUH QRW
HIIHFWLYH >@ +RZHYHU WKH PDMRULW\ RI
SDWLHQWVZLWK ORFDOO\ DGYDQFHG RUPHWDVWDWLF
*,67 UHVSRQG WR WKH W\URVLQHNLQDVH LQKLELWRU
7.,LPDWLQLE>@EXWDUHVHOGRPFXUHG>
@$SSUR[LPDWHO\RI*,67VDUHSULPDULO\
LPDWLQLEUHVLVWDQW DQG PRVW UHVSRQGHUV
GHYHORSVHFRQGDU\UHVLVWDQFHWRLPDWLQLE>@
$GYHUVH HIIHFWV RI LPDWLQLE DUH GRVHUHODWHG
>@DQGHVSHFLDOO\SDWLHQWVZLWKODUJHWXPRXU
EXUGHQ DQG SRRU JHQHUDO FRQGLWLRQ DUH
H[SRVHG >@ (DUO\ WUHDWPHQW DVVHVVPHQW
PD\ FRQWULEXWH WR D PRUH LQGLYLGXDOL]HG
WUHDWPHQW UHJLPH DYRLGLQJ LQHIIHFWLYH
WUHDWPHQWDQGXQQHFHVVDU\WR[LFLW\
7UDGLWLRQDOO\&RPSXWHG7RPRJUDSK\&7DQG
WKH 5HVSRQVH (YDOXDWLRQ &ULWHULD LQ 6ROLG
7XPRXUV5(&,67>@KDYHEHHQXVHGIRUWKH
 
DVVHVVPHQW RI WUHDWPHQW UHVSRQVH LQ *,67
SDWLHQWV %DVHG VROHO\ RQ PHDVXUHPHQWV RI
WXPRXU VL]H IXQFWLRQDO DQG PHWDEROLF
UHVSRQVHVDUHQRW LQFOXGHG:KHQ LPDJHGE\
)IOXRURGHR[\JOXFRVH SRVLWURQ HPLVVLRQ
WRPRJUDSK\ ))'* 3(7 PRVW *,67V VKRZ
KLJK PHWDEROLF DFWLYLW\ KLJK XSWDNH RI )
)'* DQG WUHDWPHQW UHVSRQVH FDQ EH
REVHUYHG DV UHGXFHG XSWDNH DV HDUO\ DV 
KRXUV DIWHU RQVHW RI 7., WUHDWPHQW > @
$ERXW  RI XQWUHDWHG *,67VPD\ KRZHYHU
EH ZLWKRXW YLVLEO\ LQFUHDVHG ))'* XSWDNH
DQG VWLOO EH RYHUWO\ PDOLJQDQW >@
)XUWKHUPRUH ))'* 3(7 LV D FRVWO\
H[DPLQDWLRQ ZLWK OLPLWHG DYDLODELOLW\
5HFHQWO\ GLIIXVLRQZHLJKWHG PDJQHWLF
UHVRQDQFHLPDJLQJ':05,KDVEHHQDSSOLHG
IRU PRQLWRULQJ WXPRXU UHVSRQVH IROORZLQJ
WKHUDSHXWLFLQWHUYHQWLRQV>@0DOLJQDQW
WXPRXUVXVXDOO\VKRZKLJKVLJQDO LQWHQVLW\RQ
':05,EHFDXVHRIWKHLUKLJKFHOOXODUGHQVLW\
DQG OLPLWHG PRWLRQ RI ZDWHU PROHFXOHV >
@'XULQJ7.,WUHDWPHQWWKHFHOOXODUGHQVLW\
LV DQWLFLSDWHG WR GHFUHDVH DQG WKHUHE\ DOVR
WKH GLIIXVLRQ VLJQDO >@ :H UHFHQWO\
SXEOLVKHGDFDVHZKHUH':05,ZDVXVHGIRU
ERWK LQLWLDO GLDJQRVLV DQG IRU DVVHVVPHQW RI
WUHDWPHQW UHVSRQVH LQ D UHFWDO *,67 SDWLHQW
UHFHLYLQJLPDWLQLE>@)ROORZLQJWKLVUHSRUW
7DQJ HW DO LQYHVWLJDWHG WKH XVH RI WKH
GLIIXVLRQ FRHIILFLHQW VHSDUDWHO\ DV DQ HDUO\
UHVSRQVH LQGLFDWRU LQ WKHVHSDWLHQWVZLWKRXW
FRPSDULVRQ WR RWKHU IXQFWLRQDO PRGDOLWLHV
>@
7KHDLPRI WKLV VWXG\ZDV WRH[SORUH
WKHDELOLW\RI':05,))'*3(7&7DQG&7
WR GHWHFW HDUO\ UHVSRQVH LQ *,67 SDWLHQWV
UHFHLYLQJLPDWLQLE
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3DWLHQWV
7HQ FRQVHFXWLYH SDWLHQWV PHDQ DJH 
\HDUV UDQJH ² \HDUV ZLWK DGYDQFHG
*,67 QRW VXUJLFDOO\ FXUDEOH UHIHUUHG WR RXU
LQVWLWXWLRQ IRU LPDWLQLE WUHDWPHQW ZHUH
LQFOXGHG EHWZHHQ )HEUXDU\  DQG $SULO
 7KH VWXG\ &OLQLFDO7ULDOVJRY ,GHQWLILHU
1&7 ZDV DSSURYHG E\ WKH UHJLRQDO
PHGLFDO HWKLFV FRPPLWWHH DQG ZULWWHQ
LQIRUPHG FRQVHQW ZDV REWDLQHG 3DWLHQW DQG
WXPRXU FKDUDFWHULVWLFV DUH VXPPDUL]HG LQ
7DEOH

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': 05, ))'* 3(7&7 DQG &7 ZHUH
SHUIRUPHG SULRU WR 7S DQG HDUO\ DIWHU
RQVHW RI LPDWLQLE WUHDWPHQW UDQJH ²
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7S ZHUH SHUIRUPHG RQ WKH VDPH GD\ /DWH
WUHDWPHQW UHVSRQVH ZDV REWDLQHG IURP D &7
H[DPLQDWLRQSHUIRUPHGDIWHUWKUHHPRQWKVRI
WUHDWPHQW7S
05LPDJLQJZDVSHUIRUPHGXVLQJD
7'LVFRYHU\05VFDQQHU*HQHUDO(OHFWULF
0HGLFDO V\VWHPV 0LOZDXNHH 86$ DQG D
FDUGLDFFKDQQHOSKDVHGDUUD\FRLO7KH05,
SURWRFRO LQFOXGHG VLQJOHVKRW VDJLWWDO DQG
D[LDO IDVW VSLQ HFKR 7ZHLJKWHG LPDJHV
UHSHWLWLRQ WLPH 75  PV HFKR WLPH
7( PV ILHOG RI YLHZ )29 PP [
 PP PDWUL[ VL]H  [  VOLFH
WKLFNQHVVPPVOLFHJDSPPQXPEHURI
H[FLWDWLRQV 1(;  7KH ': 05 LPDJHV
ZHUH DFTXLUHG XVLQJ D IUHH EUHDWKLQJ IDW
VDWXUDWHG VLQJOHVKRW VSLQHFKR HFKRSODQDU
LPDJLQJ VHTXHQFH DQG  E YDOXHV UDQJLQJ
IURP ² VPP LQ WKUHH RUWKRJRQDO
GLUHFWLRQV75PV7(PV)29
PP [  PP PDWUL[ VL]H  [  VOLFH
WKLFNQHVV  PP VOLFH JDS  PP 1(; 
5HVSLUDWRU\WULJJHULQJZDV XVHGZKHQ OHVLRQV
ZHUHORFDWHGLQWKHXSSHUDEGRPHQ
))'* 3(7&7 DQG &7 ZHUH
SHUIRUPHG RQ D K\EULG 3(7&7 V\VWHP
6LHPHQV %LRJUDSK  6LHPHQV 0HGLFDO
6\VWHPV (UODQJHQ *HUPDQ\ $OO SDWLHQWV
IDVWHGIRUDW OHDVWKRXUVDQGEORRGJOXFRVH
OHYHO ZDV PHDVXUHG SULRU WR LQWUDYHQRXV
DGPLQLVWUDWLRQ RI  0%TNJ ))'* *(
+HDOWKFDUH $6 2VOR 1RUZD\ )ROORZLQJ DQ
XSWDNH SKDVH RI DSSUR[LPDWHO\  KRXU WKH
SDWLHQW ZDV SODFHG LQ D VXSLQH DUPXS
 
SRVLWLRQDIWHUKDYLQJHYDFXDWHGWKHLUEODGGHU
)RU ))'* 3(7&7 WKH ORZGRVH &7 GDWD
ZHUH ILUVW DFTXLUHG WXEH YROWDJH  N9S
H[SRVXUH DXWRPDWLF H[SRVXUH FRQWURO $(&
ZLWKP$VDVUHIHUHQFHH[WHQGHG)29
PP WXEH URWDWLRQ WLPH  V VOLFH
WKLFNQHVV  PP SLWFK  7KH ))'*
3(7LPDJHVIURPWKHWKLJKVWRWKHVNXOOEDVH
ZHUHDFTXLUHGZLWKPLQXWHVSHUEHGZLWKDQ
RYHUODS RI  EHWZHHQ EHGV DQG
UHFRQVWUXFWHG XVLQJ WKH ' RUGHUHG VXEVHW
H[SHFWDWLRQ PD[LPL]DWLRQ 26(0 LWHUDWLYH
DOJRULWKP VXEVHWV  LWHUDWLRQV  LPDJH
IRUPDW[SL[HOVSL[HOVL]HPP
ILOWHU  PP IXOOZLGWK DW KDOI PD[LPXP
):+0*DXVVLDQVPRRWKLQJILOWHU&RQWUDVW
HQKDQFHG &7 LPDJHV ZHUH REWDLQHG 
VHFRQGV DIWHU LQWUDYHQRXV DGPLQLVWUDWLRQ RI
,RGL[DQRO  PJP/ 9LVLSDTXH *(
+HDOWKFDUH 2VOR 1RUZD\  P/NJ UDQJH
² P/NJ DW D UDWH RI  P/V 7KH
IROORZLQJ DFTXLVLWLRQ SDUDPHWHUV ZHUH XVHG
WXEHYROWDJHN9H[SRVXUH$(&ZLWK
P$V DV UHIHUHQFH )29  PP WXEH
URWDWLRQ WLPH  V VOLFH WKLFNQHVV  PP
SLWFK
7KH ))'* 3(7 &7 DQG 05,
H[DPLQDWLRQV ZHUH LQWHUSUHWHG E\
H[SHULHQFHGUHDGHUVKDYLQJDQG\HDU
RI H[SHULHQFH LQ 3(7 0(5 &7 /- DQG
05, .++ UHVSHFWLYHO\ 7KH UHDGHUV ZHUH
EOLQGHG WR HDFK RWKHU·V UHDGLQJ EXW ZHUH
DZDUH RI WKH XQGHUO\LQJ GLVHDVH DQG LWV
WUHDWPHQW
7KHVWDQGDUGL]HGXSWDNHYDOXH689
GHILQHGDVWKHDFWLYLW\FRQFHQWUDWLRQLQWLVVXH
QRUPDOL]HG WR WKH LQMHFWHG ))'*GRVHDQG
OHDQERG\PDVVZDVFDOFXODWHG3ULRUWR )
)'* 3(7&7 WKH JOXFRVH OHYHO ZDV EHORZ 
PPRO/ IRU DOO SDWLHQWV 7LPH EHWZHHQ )
)'*LQMHFWLRQ DQG LPDJH DFTXLVLWLRQ GLIIHUHG
E\ OHVV WKDQ PLQXWHV IRU FRQVHFXWLYH )
)'* 3(7&7 H[DPLQDWLRQV LQ LQGLYLGXDO
SDWLHQWV PHGLDQ  UDQJH ² 7KH
PD[LPXP 689 689PD[ ZDV REWDLQHG IURP
HDFK OHVLRQ E\ SODFLQJ D VSKHULFDO YROXPHRI
LQWHUHVW92,RYHUWKHDUHDZLWKKLJKHVW )
)'* XSWDNH 7KH UHOLDELOLW\ RI 689 DW
GLIIHUHQW WLPH SRLQWV ZDV DVVHVVHG E\
PHDVXULQJPHDQ))'*XSWDNH689PHDQLQD
 FP VSKHULF UHJLRQ RI LQWHUHVW 52, LQ WKH
ULJKW OLYHU OREH DQG YDOXHV RI OHVV WKDQ 
XQLWV EHWZHHQ LQGLYLGXDO H[DPLQDWLRQV ZHUH
UHTXLUHG >@ ,QFUHDVHG ))'* XSWDNH ZDV
GHILQHG LI WKH 689PD[ ZDV KLJKHU WKDQ OLYHU
 [ 689PHDQ RI OLYHU  WZR VWDQGDUG
GHYLDWLRQV 6'V >@ RU KLJKHU WKDQ WKH
VXUURXQGLQJWLVVXHXSWDNH
3RVWSURFHVVLQJ RI WKH ': 05, ZDV
SHUIRUPHG XVLQJ WKH Q,&( VRIWZDUH SDFNDJH
1RUGLF1HXUR/DE%HUJHQ1RUZD\$SSDUHQW
'LIIXVLRQ &RHIILFLHQW $'& PDSV ZHUH
REWDLQHGXVLQJWKHPRQRH[SRQHQWLDODSSURDFK
DQG DOO E YDOXHV (DFK WXPRXUZDVPDQXDOO\
GHOLQHDWHG LQ WKH$'&PDSZKHUH WKH OHVLRQ
KDGLWV ODUJHVWH[WHQW\LHOGLQJPHDQ$'&DQG
6'IRULQGLYLGXDO OHVLRQV7XPRXUYROXPHV9
ZHUH FDOFXODWHG IURP WKH WZR RUWKRJRQDO
VLQJOHVKRW 7 ZHLJKWHG VHULHV XVLQJ WKH
HOOLSVRLG IRUPXOD 9FDOF   ÃÃZLGWK D[LV
UDGLXVÃOHQJWK D[LV UDGLXVÃKHLJKW D[LV
UDGLXV 7KH DWWHQXDWLRQ FRHIILFLHQW LQ
+RXQVILHOG 8QLWV +8 IURP VHSDUDWH 52,V
ZLWKLQHDFK OHVLRQZDVREWDLQHGIURPWKH&7
LPDJHV$FFRUGLQJWRWKHSURWRFRODQGFOLQLFDO
SUDFWLFH FRQWUDVWHQKDQFHG &7 ZDV QRW
SHUIRUPHGLQWZRSDWLHQWVDWIROORZXSGXHWR
HOHYDWHG FUHDWLQH OHYHOV )RU WKHVH SDWLHQWV
SDWLHQWVDQGDWWHQXDWLRQZDVREWDLQHG
IURPWKHQRQHQKDQFHG&7LPDJHV
7RHQVXUHWKHLQGHSHQGHQFHRIYDULDEOHVRQO\
RQHWDUJHWOHVLRQWKHODUJHVWOHVLRQGHWHFWHG
DW05,DQG&7DQGWKHOHVLRQZLWKWKHKLJKHVW
))'* XSWDNH DW 3(7 ZDV XVHG IRU WKH
VWDWLVWLFDO FRPSDULVRQV 'DWD IURP DOO
LQGLYLGXDO OHVLRQV DUH KRZHYHU LQFOXGHG LQ
7DEOH

$VVHVVPHQWRIWUHDWPHQWUHVSRQVH
(DUO\ WUHDWPHQW UHVSRQVH ZDV GHILQHG DV
SHUFHQWDJH FKDQJH LQ LPDJLQJ SDUDPHWHUV
EHWZHHQ 7S DQG 7S &KDQJH LQ ORQJHVW
WXPRXUGLDPHWHUDW&7EHWZHHQ7SDQG7S
ZDVGHILQHGDVILQDOWUHDWPHQWRXWFRPH2QH
SDWLHQW XQGHUZHQW VXUJHU\ RQH ZHHN EHIRUH
7SSDWLHQW/RQJHVWWXPRXUGLDPHWHURI
WKH UHVHFWHG OLYHU OHVLRQ ZDV XVHG LQ WKH
DQDO\VLV IRU WKLV SDWLHQW7UHDWPHQW UHVSRQVH
DW 7S ZDV DOVR FDWHJRULVHG XVLQJ WKH
PRGLILHG 5(&,67 P5(&,67 >@ WKH &KRL
FULWHULD >@ WKH (XURSHDQ 2UJDQL]DWLRQ IRU
5HVHDUFK DQG 7UHDWPHQW RI &DQFHU (257&
FULWHULD >@ DQG WKH 3RVLWURQ (PLVVLRQ
WRPRJUDSK\ 5HVSRQVH &ULWHULD ,Q 6ROLG
7XPRXUV 3(5&,67  >@ %DVHG RQ
SUHYLRXV UHSURGXFLELOLW\ VWXGLHV >@
UHVSRQGHUV DW ': 05, ZDV GHILQHG DV WKRVH
KDYLQJDQ$'&LQFUHDVHRI!RUDUHGXFWLRQ
LQ05,DVVHVVHGYROXPHWU\RI!DW7S

6WDWLVWLFDODQDO\VLV
&KDQJHV LQ LPDJH SDUDPHWHUV EHWZHHQ 7S
DQG 7S ZHUH FRPSDUHG ZLWK FKDQJH LQ
ORQJHVWGLDPHWHUEHWZHHQ7SDQG7SXVLQJ
6SHDUPDQFRUUHODWLRQ6WDWLVWLFDODQDO\VLVZDV
SHUIRUPHG XVLQJ 3$6: 6WDWLVWLFV 9HUVLRQ
6366&KLFDJR,/86$



 
5HVXOWV
7HQ *,67 SDWLHQWV ZLWK D WRWDO RI  OHVLRQV
ZHUHLQFOXGHGLQWKLVVWXG\,PDJHILQGLQJVIRU
DOOSDWLHQWVDUHVXPPDUL]HGLQ7DEOH$W7S
PHGLDQ ORQJHVW WXPRXU GLDPHWHUZDV PP
UDQJH ² PP 0HDQ UHGXFWLRQ LQ
ORQJHVWWXPRXUGLDPHWHUDW7SDQG7SZDV
UDQJH²DQGUDQJH²
UHVSHFWLYHO\$W 7S RQO\ WZR SDWLHQWV ZHUH
FODVVLILHGDVUHVSRQGHUVDFFRUGLQJWRP5(&,67
>@ ZKHUHDV DW 7S DOO H[FHSW WZR SDWLHQW
ZLWK VWDEOH GLVHDVH ZHUH FODVVLILHG DV
UHVSRQGHUV
,Q WKUHHSDWLHQWVZLWKD WRWDORI IRXU
OHVLRQV SDWLHQWV   DQG  WKH ))'*
XSWDNH LQ WKH OHVLRQV ZDV ORZHU WKDQ WKH
VXUURXQGLQJ EDFNJURXQG DFWLYLW\ 7KHVH
SDWLHQWV ORQJHVWEDVHOLQHGLDPHWHUVRI²
PP ZHUH WKHUHIRUH H[FOXGHG IURP IXUWKHU
))'* 3(7 DQDO\VHV )RU WKH UHPDLQLQJ
VHYHQSDWLHQWVPHGLDQ689PD[DWEDVHOLQHZDV
UDQJH²$W7SPHDQ689PD[ZDV
UHGXFHG E\  UDQJH ² )LYH RXW RI
WKH VHYHQ SDWLHQWV VKRZLQJ PHWDEROLF
UHVSRQVHDW7SZHUHFODVVLILHGDVUHVSRQGHUV
DFFRUGLQJWRP5(&,67DW7S)RUWKHODVWWZR
SDWLHQWV SDWLHQWV  DQG  WKH GHFUHDVH RI
 DQG  LQ 689PD[ DW 7S ZDV QRW
IROORZHG E\ WXPRXU VKULQNDJH DW 7S 7KXV
UHVSRQVHFRXOGEHFRUUHFWO\SUHGLFWHGLQRQO\
ILYHRXWRISDWLHQWV

$W 7S PHGLDQ DWWHQXDWLRQ ZDV 
+8 UDQJH ² +8 $W 7S WKH PHDQ
DWWHQXDWLRQ FRHIILFLHQW ZDV UHGXFHG E\ 
UDQJH²2QO\ILYHSDWLHQWVVKRZHGD
GHFUHDVH DERYH WKH FXWRII ! IRU
UHVSRQVHDFFRUGLQJWRWKH&KRLFULHULD

0HGLDQ $'& DW 7S ZDV  [ 
PPV UDQJH²PPV$W7SPHDQ
$'&ZDVLQFUHDVHGE\UDQJH²
)RU WKUHH SDWLHQWV $'& DW 7S LQGLFDWHG QR
WUHDWPHQW UHVSRQVH $'& LQFUHDVH)RU
SDWLHQW  WKH  GHFUHDVH DW 7S ZDV
IROORZHG E\ D VOLJKW LQFUHDVH LQ ORQJHVW
WXPRXU GLDPHWHU DIWHU WKUHH PRQWKV 
3DWLHQWVKRZHGXQFKDQJHG$'&DW7SEXW
KDG D UHGXFWLRQ RI 05, WXPRXU YROXPH DQG
ORQJHVW WXPRXU GLDPHWHU RI  DQG  DW
7S UHVSHFWLYHO\ 3DWLHQW  VKRZHG QHLWKHU
VXIILFLHQW $'& LQFUHDVH  QRU VXIILFLHQW
UHGXFWLRQ LQ 05, YROXPH  WR TXDOLI\ IRU
UHVSRQVH ORQJHVW WXPRXU GLDPHWHU DQG
KLVWRORJLFDO DVVHVVPHQW DW 7S LQGLFDWHG
VWDEOH GLVHDVH 7KH WKUHH SDWLHQWV ZLWK IRXU
QRQ))'* DYLG OHVLRQV DOO VKRZHG $'&
LQFUHDVH !   DQG 
UHVSHFWLYHO\ DW 7S 7KXV ': 05, ZLWK
HYDOXDWLRQ RI $'& DQG WXPRXU YROXPWU\
FRUUHFWO\SUHGLFWHGWUHDWPHQW UHVSRQVH LQDOO
SDWLHQWV
$OOSDWLHQWVZLWK))'*DYLGOHVLRQV


7DEOH5HVSRQVHDVVHVVPHQWLQ*,67SDWLHQWVWUHDWHGZLWKLPDWLQLE
$'&DQGWXPRXUYROXPHIURP05,689PD[IURP))'*3(7&7DQGDWWHQXDWLRQDQGORQJHVWWXPRUGLDPHWHUIURP&7
IRU WKH LQFOXGHG*,67SDWLHQWVSULRU WR 7SDQGDIWHUGD\VRI LPDWLQLE WUHDWPHQW 7S  )LQDO WUHDWPHQW UHVSRQVH LV
FKDQJHLQORQJHVWWXPRXUGLDPHWHUDW&7DIWHUWKUHHPRQWKVRIWUHDWPHQW7S
$'&
>[PPV@
05,WXPRXU
YROXPH
>P/@
689PD[ $WWHQXDWLRQ
>+8@
/RQJHVWWXPRXU
GLDPHWHU>PP@
/RQJHVWWXPRXU
GLDPHWHU
UHGXFWLRQ>@D
3DWLHQW
7S 7S 7S 7S 7S  7S 7S 7S 7S 7S 
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 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 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$'&$SSDUHQW'LIIXVLRQ&RHIILFLHQW05,0DJQHWLF5HVRQDQFH,PDJLQJ689PD[0D[LPXP6WDQGDUGL]HG8SWDNH
9DOXH+RXQVILHOG8QLWV+8 
3DWLHQWVDUHOLVWHGDFFRUGLQJWRWUHDWPHQWHIIHFWDW7S$'&DQGDWWHQXDWLRQDUHJLYHQDVPHDQVDQGVWDQGDUG
GHYLDWLRQV
D%HWZHHQ7SDQG7S
E$WWHQXDWLRQYDOXHVZLWKRXWWKHXVHRILYFRQWUDVWGXHWRKLJKFUHDWLQHOHYHOV
F/RQJHVWWXPRXUGLDPHWHUPHDVXUHGIURPUHVHFWHGOLYHUVSHFLPHQZHHNSULRUWR7S


 
Q    DW 7S ZHUH UHVSRQGHUV DW 7S
DFFRUGLQJ WR (257& DQG 3(5&,67  8VLQJ
WKH&KRLFULWHULDDW7SWKUHHSDWLHQWVZHUH
QRQUHVSRQGHUV ZKHUHDV WKH RWKHUV PHW WKH
FULWHULD RI UHVSRQVH $SSOLFDWLRQ RI IRXU
FRPPRQO\ XVHG WUHDWPHQW UHVSRQVH FULWHULD
P5(&,67 &KRL (257& DQG 3(5&,67 WR WKH
LPDJLQJ SDUDPHWHUV DW 7S UHYHDOHG
FRQFRUGDQFH LQRQO\ WZR SDWLHQWV SDWLHQWV
DQG
,QRXUOLPLWHGVWXG\SRSXODWLRQWKHUHZHUHQR
FRUUHODWLRQV EHWZHHQ $'& DQG 689PD[
EHWZHHQ$'&DQG+8RUEHWZHHQ689PD[DQG
+8DW7SRUDW7S)XUWKHUPRUHWKHUHZDV
QR VLJQLILFDQW FRUUHODWLRQ EHWZHHQ ORQJHVW
WXPRXUGLDPHWHUUHGXFWLRQDW7SDQGFKDQJH
LQ689PD[$'&RU+8DW7S
,QRXU OLPLWHG VWXG\ SRSXODWLRQ WKHUH
ZHUH QR FRUUHODWLRQV EHWZHHQ $'& DQG
689PD[ EHWZHHQ $'& DQG +8 RU EHWZHHQ
689PD[ DQG +8 DW 7S RU DW 7S
)XUWKHUPRUH WKHUH ZDV QR VLJQLILFDQW
FRUUHODWLRQEHWZHHQORQJHVWWXPRXUGLDPHWHU
UHGXFWLRQDW7SDQGFKDQJHLQ689PD[$'&RU
+8DW7S


'LVFXVVLRQ
7KLV VWXG\ VKRZV WKDW ': 05, DW DQ HDUO\
VWDJHFDQUHOLDEO\SUHGLFWWUHDWPHQWRXWFRPH
LQ *,67 SDWLHQWV UHFHLYLQJ LPDWLQLE
(VWDEOLVKHG UHVSRQVH FULWHULD IRU &7 DQG )
)'* 3(7&7 GLG QRW SURYLGH WKH VDPH
FRUUHFWQHVV
 7KH XVHIXOQHVV RI VL]HEDVHG FULWHULD
DORQH IRU DVVHVVPHQW RI LQLWLDO UHVSRQVH LV
OLPLWHG DV HDUO\ FKDQJH LQ WXPRXU VL]H KDV
SURYHQ QRW SUHGLFWLYH RI XOWLPDWH UHVSRQVH
>@ $GGLWLRQDO &7 SDUDPHWHUV VXFK DV
DWWHQXDWLRQPHDVXUHPHQWVPD\SURYLGHXVHIXO
LQIRUPDWLRQDQGWKHFRPELQDWLRQRIGHFUHDVH
LQ WXPRXU VL]H DQG GHFUHDVH LQ GHQVLW\ KDV
EHHQIRXQGWREHYDOXDEOHSDUDPHWHUVIRUWKH
HYDOXDWLRQRI UHVSRQVH WR LPDWLQLE WUHDWPHQW
IRU *,67 SDWLHQWV &KRL FULWHULD > @ ,Q
WKHSUHVHQWVWXG\RQO\WZRRISDWLHQWVKDG
SDUWLDOUHVSRQVHDW7SDFFRUGLQJWRP5(&,67
EXW E\ LQFOXGLQJ WKH &KRL FULWHULD ILYH PRUH
SDWLHQWVZHUHFDWHJRULVHGDVUHVSRQGHUV
))'* 3(7&7 LV FODLPHG WR EH WKH
PRGDOLW\ RI FKRLFH IRU WKH HYDOXDWLRQ RI
WUHDWPHQWUHVSRQVHWRLPDWLQLE>@(YHQ
WKRXJK PRVW *,67V VKRZ LQFUHDVHG ))'*
XSWDNHVRPH*,67VGRQRWVKRZVXIILFLHQW)
)'*XSWDNHWREHGHWHFWHGE\3(7>@,Q
JHQHUDO 3(7·V DELOLW\ WR GHWHFW VPDOO OHVLRQV
PD\EH OLPLWHGE\ WKH VSDWLDO UHVROXWLRQ DQG
SK\VLRORJLF EDFNJURXQG DFWLYLW\ >@ &KRL HW
DO UHSRUWHG WKDW  RI   OHVLRQV GLG
QRW KDYH GHWHFWDEOH ))'* XSWDNH RQ SUH
WUHDWPHQW 3(7 DQG WKDW  RI WKHVH ZHUH
PRUH WKDQ  PP LQ GLDPHWHU > @
*RHUUHVHWDOUHSRUWHGDEVHQW))'*XSWDNH
LQ VHYHQ RI  SDWLHQWV  >@ ,Q WKH
SUHVHQW VWXG\ OHVLRQV LQ WKUHHRISDWLHQWV
ZHUH QRW GHWHFWHG E\ ))'* 3(7 7DEOH 
)LJSDWLHQW1RQHRIWKHVHOHVLRQVZHUH
OHVV WKDQ  PP PHGLDQ GLDPHWHU ZDV 
PP$G\QDPLFDFTXLVLWLRQPLJKWLPSURYHWKH
SHUIRUPDQFH RI ))'* 3(7 DV DQ HDUO\
ELRPDUNHU IRU UHVSRQVH &OLQLFDOO\ UHOHYDQW
LQIRUPDWLRQ VXFK DV EORRG IORZ H[FKDQJH
UDWHVSKRVSKRU\ODWLRQDQGGHSKRVSKRU\ODWLRQ
UDWHV FDQ EH H[WUDFWHG IURP D G\QDPLF
DFTXLVLWLRQ dŽ ŽƵƌ ŬŶŽǁůĞĚŐĞ ŽŶůǇ ŽŶĞ
ƐƚƵĚǇŚĂƐŝŶǀĞƐƚŝŐĂƚĞĚƚŚĞƉŽƚĞŶƚŝĂůƵƐĞŽĨ
ĚǇŶĂŵŝĐ ϭϴ&Ͳ&' Wd ŝŶ ƉĂƚŝĞŶƚƐ ǁŝƚŚ
'/^dƐ΀ϰϬ΁͘dŚŝƐƐƚƵĚǇĚĞŵŽŶƐƚƌĂƚĞĚŚŝŐŚĞƌ
ƐĞŶƐŝƚŝǀŝƚǇ ĨŽƌ ĚĞƚĞĐƚŝŶŐ ƉƌŽŐƌĞƐƐŝŽŶ ŝŶ
ůŝǀĞƌ ŵĞƚĂƐƚĂƐĞƐ ĐŽŵƉĂƌĞĚ ƚŽ Ă ƐƚĂŶĚĂƌĚ
ƐƚĂƚŝĐ ϭ ŚŽƵƌ ϭϴ&Ͳ&' Wd ;ϳϬ͘ϲй ǀĞƌƐƵƐ
ϱϬ͘ϬйͿ΀ϰϬ΁͘/ŶƚŚĞĐƵƌƌĞŶƚƐƚƵĚǇ͕ ƚŚĞĞĂƌůǇ
ĐŚĂŶŐĞƐ ŝŶ ^hsŵĂǆ ĨŽƌ ƚŚĞ ϭϴ&Ͳ&' ĂǀŝĚ
ůĞƐŝŽŶƐǁĞƌĞŽĨŐƌĞĂƚŵĂŐŶŝƚƵĚĞĂŶĚĞĂƐŝůǇ
ĚĞƚĞĐƚĞĚ͘ ,ŽǁĞǀĞƌ͕  ŝŶ ƚǁŽ ƉĂƚŝĞŶƚƐ
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хϭϬ ĂŶĚ чϱϬй ƌĞƐƉŽŶƐĞ >@ VXSSRUWLYH RI
VWDEOH GLVHDVH 7KH SURQRXQFHG UHGXFWLRQ LQ
))'* XSWDNH REVHUYHG LQ WKHVH WZR
SDWLHQWV FOHDUO\ TXDOLILHV DV UHVSRQGHUV DW
3(7 3UHYLRXV VWXGLHV KDYH VKRZQ WKDW ERWK
LPDWLQLE UHVSRQGHUV DQG SDWLHQWV DWWDLQLQJ
GLVHDVH VWDELOL]DWLRQ KDYH VLPLODU VXUYLYDO
RXWFRPH>@DQGWKXVWKHLPSRUWDQFH
RI GLVWLQJXLVKLQJ EHWZHHQ UHVSRQGHUV DQG
WKRVH ZLWK VWDEOH GLVHDVH PD\ WKHUHIRUH EH
DUWLILFLDO
 
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 7KH DWWHQXDWLRQZDV DOPRVW XQFKDQJHG DW &7 ))'*XSWDNHZDV
LQGLVWLQJXLVKDEOHIURPOLYHUSDUHQFK\PDDOUHDG\EHIRUHWUHDWPHQW$W05,WKHPHDQYDOXHDQGWKHUDQJHRI$'&VLQFUHDVHG
VXEVWDQWLDOO\ LQGLFDWLQJ JRRG UHVSRQVH0LFURVFRSLFH[DPLQDWLRQRI WKH UHVHFWHGPHWDVWDWLF OLYHU OHVLRQ VKRZHG VFDWWHUHG
WXPRXUFHOOVZLWKLQ ILEURXV WLVVXH7KHUHZHUHPLWRWLF ILJXUHVKLJKSRZHU ILHOGV7KH WXPRXUFHOOVZHUHSRVLWLYH IRU
&'DQG'2*7KHKLVWRORJLFDOUHVSRQVHZDV!DQG


&RPSOHWH PHWDEROLF UHVSRQVH DW )
)'*3(7KDVIUHTXHQWO\EHHQUHSRUWHGLQ*,67
SDWLHQWV KRZHYHU FXUDWLYH WUHDWPHQW ZLWK
LPDWLQLE LV UDUH >  @ $ QHJDWLYH )
)'*3(7DIWHUWUHDWPHQWRIWHQVXJJHVWVJRRG
WUHDWPHQW UHVSRQVH EXW GRHV QRW LQGLFDWH
DEVHQFH RI FDQFHU FHOOV >@ )LJ 
SDWLHQW$DQGGHFUHDVHLQ689DV
SURSRVHG DV WKUHVKROGV IRU UHVSRQVH LQ WKH
(257&DQG3(5&,67 UHVSHFWLYHO\GRQRW
QHFHVVDULO\ SUHGLFW IDYRUDEOH RXWFRPHV LQ
*,67 SDWLHQWV WUHDWHG ZLWK LPDWLQLE > 
@,QWKHSUHVHQWVWXG\DOOSDWLHQWVUHFHLYHG
LPDWLQLE DQG WKHPHDQGHFUHDVH LQ ))'*
DYLG OHVLRQV ZDV  VXSSRUWLQJ SUHYLRXV
UHSRUWV VXJJHVWLQJ WKDW D KLJKHU WKUHVKROG
WKDQSURSRVHGLQ(257&DQG3(5&,67PD\
EHDSSURSULDWH>@
)LJ3DWLHQW/LYHUPHWDVWDVLVZKLWHDUURZDW&7DG))'*3(7&7EHDQG$'&PDSFIEHIRUHDFDQGDIWHU
GD\V RI LPDWLQLE WUHDWPHQW GI ))'* 3(7&7 VKRZHG D GHFUHDVH LQ 689PD[ LQGLFDWLQJ JRRG UHVSRQVH ZKHUHDV $'&
LQFUHDVH LQGLFDWHGRQO\PLQRU UHVSRQVH0LFURVFRSLFH[DPLQDWLRQRI WKHUHVHFWHG OLYHU OHVLRQVKRZHGPRGHUDWHFHOOXODULW\
PLQLPDOQHFURVLVDQGODUJHDPRXQWVRIFROODJHQRXVILEUHVZLWKRXWYLVLEOHPLWRWLFILJXUHV7KHWXPRXUFHOOVZHUHSRVLWLYHIRU
&'DQG'2*7KHKLVWRORJLFDOUHVSRQVHZDVORZ!DQG
 
&RPSDUHGWR))'*3(7DQG&7':
05, GRHV QRW UHO\ RQ WKH XVH RI LRQL]LQJ
UDGLDWLRQWKHUHLVQRQHHGIRUDGPLQLVWUDWLRQ
RI FRQWUDVW DJHQW RU UDGLRDFWLYLW\ DQG WKH
H[DPLQDWLRQ FDQ EH FDUULHG RXW LQ IHZ
PLQXWHV)XUWKHUPRUH05,KDVWKHDGYDQWDJH
RI EHLQJ PRUH DYDLODEOH RIIHUV HDVLHU
H[DPLQDWLRQ ORJLVWLFV DQG ORZHU FRVW WKDQ
GRHV ))'* 3(7 %RWK SUHFOLQLFDO DQG
FOLQLFDOVWXGLHVKDYHVKRZQWKDW$'&LQFUHDVH
DV HDUO\ DV ² GD\V DIWHU LQLWLDWLQJ
WUHDWPHQW DUH FRUUHODWHG WR WUHDWPHQW
RXWFRPH >@ +RZHYHU LQFUHDVHV LQ $'&
DVDUHVXOWRIWXPRXUFHOOGHDWKPD\QRWEHD
SURORQJHGSKHQRPHQRQDQGZLOOZLWKWLPHIDOO
GXH WR YDVFXODU QRUPDOL]DWLRQ SKDJRF\WRVLV
RI GHDG FHOOV UHPRGHOLQJ RI WLVVXHV DQG
GHYHORSPHQW RI ILEURVLV >@ ,PDWLQLE KDV
VRPH DQWLDQJLRJHQHWLF HIIHFWV >@ DQG PD\
LQGXFHUHGXFWLRQLQEORRGDQGLQH[WUDFHOOXODU
VSDFHZKLFKSUHYHQWZDWHUPRYHPHQWLQWKH
H[WUDFHOOXODU VSDFH UHVXOWLQJ LQ D LQLWLDO
GHFUHDVHG $'& >@ 6XEVHTXHQW WXPRXU
QHFURVLV IROORZLQJ DQWLYDVFXODU WUHDWPHQW
FDXVHV DQ LQFUHDVHG $'& >@ 7KXV WKHUH
PD\EHDOLPLWHGWLPHZLQGRZZKHUHLQFUHDVH
LQ $'& LV D XVDEOH FULWHULRQ IRU WUHDWPHQW
UHVSRQVH )LJ  SDWLHQW  $ PDMRU
FKDOOHQJH IRU ': 05, LV WKH ODFN RI
VWDQGDUGL]DWLRQ RI DFTXLVLWLRQ PHDVXUHPHQW
DQG DQDO\VLV DQG WKH IDFW WKDW WKHUH DUH QR
LQWHUQDWLRQDOO\ DFFHSWHG GHILQLWLRQV IRU
UHVSRQVH RQ ': 05, )XUWKHUPRUH WKH
WKUHVKROG RI FKDQJHV LQ $'& FRUUHVSRQGLQJ
ZLWK D WUXH WUHDWPHQW HIIHFW KDV QRW EHHQ
HVWDEOLVKHG 5HSURGXFLELOLW\ VWXGLHV KDYH
VKRZQ WKDW $'& PD\ YDU\ ZLWK XS WR 
EHWZHHQ FRQVHFXWLYH ': 05, H[DPLQDWLRQV
>@ :H WKHUHIRUH GHILQHG UHVSRQGHUV DV
SDWLHQWVZLWKDQ$'&LQFUHDVHRI!DW7S
,Q WKH RQO\ UHVSRQGLQJ SDWLHQW DW 7S ZLWK
OHVV WKDQ  LQFUHDVH LQ $'& DW 7S D
GHFUHDVH LQ 05,DVVHVVHG WXPRXU YROXPH RI
! ZDV REVHUYHG 7KXV HDUO\ ODUJH
UHGXFWLRQLQWXPRXUYROXPHPD\KDYHPDVNHG
DQ LQFUHDVH LQ $'& %\ WKH XVH RI WKHVH
FULWHULD FKDQJH DW 7S FRUUHFWO\ SUHGLFWHG
WUHDWPHQW UHVSRQVH DW 7S LQ DOO SDWLHQWV
7DQJHWDOUHFHQWO\UHSRUWHGWKDWWKHODUJHVW
GLIIHUHQFHLQ$'&FKDQJHEHWZHHQUHVSRQGHUV
DQG QRQUHVSRQGHUV ZDV REVHUYHG DIWHU RQH
ZHHN LPDWLQLE WUHDWPHQW PHGLDQ $'&
LQFUHDVHRIDQGIRUWKHUHVSRQGHUV
DQG QRQUHVSRQGHUV UHVSHFWLYHO\ ,Q WKH
FXUUHQW VWXG\ D PHGLDQ LQFUHDVH IRU
UHVSRQGHUVZDVPHDQDIWHUGD\V
RILPDWLQLEWUHDWPHQW
*URZWK SDWWHUQ DQG ELRORJLFDO
KHWHURJHQHLW\ RI *,67V DQG WKHLU YDULDEOH
UHVSRQVHWRLPDWLQLEWUHDWPHQWFKDOOHQJHWKH
LQWHUSUHWDWLRQRILPDJHVIURPWKHVHSDWLHQWV
,QGHSWKNQRZOHGJHRIWKHSK\VLFDOSULQFLSOHV
XQGHUO\LQJ LPDJH LQIRUPDWLRQ LV HVVHQWLDO IRU
HYDOXDWLRQ RI WUHDWPHQW UHVSRQVH ,Q FDVHV
ZKHUH WXPRXU LV LQWHUPL[HG ZLWK EHQLJQ
WLVVXH DQG WKH WXPRXU FRQVLVWV RI VHYHUDO
WLVVXH FRPSRQHQWV )LJ  SDWLHQW  LPDJH
YDOXHV REWDLQHG IRU WKH HQWLUH OHVLRQPD\EH
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 /LYHU PHWDVWDVLV ZKLWH DUURZ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DG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WUHDWPHQW DF DQG DIWHU  GD\V RI LPDWLQLE WUHDWPHQW GI 5HGXFWLRQ LQ DWWHQXDWLRQ RQ &7 DQG RI 689PD[ RQ ))'*
3(7&7$'&FKDQJHGIURPYDOXHV UHIOHFWLQJSHULSKHUDO VROLG WXPRXUDQGFHQWUDOQHFURVLV LQWRYDOXHV LQGLFDWLQJSHULSKHUDO
QHFURVLVDQGFHQWUDOILEURVLV6WDEOHGLVHDVHZDVREVHUYHGDWPRQWKIROORZXSLPDJLQJ0LFURVFRSLFH[DPLQDWLRQRIDQHHGOH
ELRSV\IURPWKHOLYHUSULRUWRLPDWLQLEWUHDWPHQWVKRZHGDPRGHUDWHO\FHOOXODU*,67PHWDVWDVLV7KHELRSV\ZDVSRVLWLYHIRU
&'DQG'2*RQLPPXQRKLVWRFKHPLVWU\1RSRVWWUHDWPHQWWXPRXUWLVVXHZDVDYDLODEOHIRUH[DPLQDWLRQ
 
RI OLPLWHG FOLQLFDO YDOXH DV WKH UHVSRQVH WR
WUHDWPHQW PD\ EH GLIIHUHQW IRU GLIIHUHQW
FRPSRQHQWV ,VRODWHGXVHRIPHDQ$'&FRXOG
PDVN WLVVXH KHWHURJHQHLW\ DQG EHPLVOHDGLQJ
)LJ  SDWLHQW  +LVWRJUDP DQDO\VLV PD\
LQFUHDVH WKH SUHGLFWLYH RXWFRPH RI $'&
PHDVXUHPHQWV )XUWKHUPRUH TXDOLWDWLYHO\
DVVHVVPHQW RI ': 05, XVLQJ KLJK E YDOXH
LPDJHV PD\ GHWHFW IRFDO DUHDV RI UHVLGXDO
WXPRXU>@
689 DQG $'& PHDVXUH GLIIHUHQW
SK\VLRORJLFDO SURSHUWLHV EXW VRPH GHJUHH RI
FRUUHODWLRQPLJKWEHUHDVRQDEOH:KHUHDV689
LV D VHPLTXDQWLWDWLYH PHWKRG IRU WKH
FDOFXODWLRQ RI DFWLYLW\ XSWDNH UHIOHFWLQJ
JOXFRVH PHWDEROLVP $'& LV D TXDQWLWDWLYH
PHDVXUHPHQW RI WKH %URZQLDQ PRWLRQ RI
ZDWHUPROHFXOHV LQ WLVVXH UHIOHFWLQJ FHOOXODU
GHQVLW\ 'LUHFW FRPSDULVRQ RI DEVROXWH
YDOXHV KRZHYHU GRHV QRW VHHP WR
DSSURSULDWH 3UHYLRXV VWXGLHV KDYH IRXQG D
VLJQLILFDQW LQYHUVH FRUUHODWLRQ EHWZHHQ 689
DQG$'&LQUHFWDOFDQFHU>@KHDGDQGQHFN
FDQFHU >@ QRQVPDOO FHOO OXQJ FDQFHU >@
DQGDOVRLQ*,67>@1RFRUUHODWLRQEHWZHHQ
689PD[ DQG $'& ZDV IRXQG LQ WKH SUHVHQW
VWXG\ LQFOXGLQJ D OLPLWHG QXPEHU RI SDWLHQWV
DQGDUHODWLYHO\VKRUWREVHUYDWLRQWLPH
,Q FRQFOXVLRQ DOO SDWLHQWV FRXOG EH FRUUHFWO\
LGHQWLILHGDWDQHDUO\VWDJHE\WKHXVHRI':
05, DQG 05, YROXPHWU\ LOOXVWUDWLQJ WKH
SRWHQWLDO RI WKLV WHFKQLTXH IRU PRQLWRULQJ
WUHDWPHQW UHVSRQVH LQ *,67V IROORZLQJ
LPDWLQLE WKHUDS\ 7KHVH ILQGLQJV PXVW
KRZHYHU EH FRQILUPHG LQ ODUJHU SURVSHFWLYH
VWXGLHV ZLWK VSHFLDO HPSKDVLV RQ WKH
HVWDEOLVKPHQW RI RSWLPDO WLPHSRLQW IRU
LPDJLQJDQGWUHDWPHQWUHVSRQVHFULWHULD

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:HZRXOGOLNHWRWKDQNSK\VLFLVW/LQH$XVODQG
5HIVXP IRU DGYLFHV DQG WKH ELRHQJLQHHUV RI
7KH'HSDUWPHQWRI1XFOHDU0HGLFLQHIRUWKHLU
KHOS LQ SHUIRUPLQJ WKH VWXG\ 7KLV VWXG\
UHFHLYHG ILQDQFLDO VXSSRUW IURP 7KH
1RUZHJLDQ 5DGLXP +RVSLWDO 5HVHDUFK
)RXQGDWLRQ
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